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Abstract 
 
Regeneration of human central nervous system (CNS) neurons is limited due to the 
inhibitory environment that forms post injury known as the glial scar.  Reactive astrocytes 
within the glial scar produce both inhibitory and permissive extracellular matrix molecules 
(ECM) into the local environment.  Chondroitin sulfate proteoglycans (CSPGs) are a 
component of the ECM which have been shown in vitro and in vivo to inhibit neurite 
regeneration.  Physiologically relevant in vitro models of the glial scar are essential in 
developing new therapeutics and understanding the cellular processes that underpin neural 
regeneration.   
In this study human pluripotent stem cells were differentiated using the highly potent and 
stable synthetic retinoid EC23.  A concentration dependent profile of the action of EC23 
on stem cell differentiation was determined, furthermore, the mechanisms for the enhanced 
biological activity of EC23 were investigated.  
This study used the well described small molecule EC23 to form aggregates of neural 
progenitors which were characterised and used in a two dimension (2D) and three 
dimension (3D) model of neurite outgrowth.  
Next, the neurite outgrowth substrate was manipulated to represent the inhibitory ECM of 
the glial scar using the CSPG Aggrecan.  The presence of Aggrecan inhibited neurite 
development and was used to assess small molecules that could enhance outgrowth in 2D 
and 3D. Small molecule modulators of; rho-associated protein kinase (ROCK); retinoic 
acid receptor β2; glycogen synthase kinase 3β and protein tyrosine phosphatase σ were 
shown to at least partially enhance neurite outgrowth on Aggrecan in 2D and 3D.   
Furthermore, the bacterial enzyme Chondroitinase ABC was used to cleave chondroitin 
sulphate glycosaminoglycan side chains (GAG) from Aggrecan to further aid neurite 
outgrowth in this model.  In addition a 2D and 3D co-culture system was developed using 
the human astroglioma cell line U118MG and human stem cell-derived neural progenitors 
described previously.  This model demonstrated inhibition of neurite outgrowth by 
U118MG which could be overcome by ROCK inhibition.   
This thesis describes the development of a novel model of neurite outgrowth using human 
stem cell-derived neurons.  The model described was used to investigate Aggrecan induced 
neurite inhibition and to investigate pathways involved in neural regeneration.   
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CHAPTER 1 INTRODUCTION 
 
Combining recent advances in developmental biology, synthetic chemistry and 
bioengineering will aid the translation of basic biology into potential clinical therapeutics, 
creating more physiologically relevant models of pathophysiological states.  
Developmental biology encompasses the understanding of stem cell differentiation and the 
processes that define cell lineage commitment. There are many advantages of using stem 
cell-derived tissue over adult tissue, including:  human stem cells can produce large 
numbers of human specific somatic cells; particular stem cells are ethically more 
acceptable than the use of animals and the manipulation of stem cells in vitro allows for 
more control over the tissue that forms that animal derived cells. 
Synthetic chemicals that specifically target key developmental pathways in stem cells are 
an important tool for investigating the initial steps of stem cell commitment and guiding 
the cells to form the desired tissue.  Finally, stem cell-derived tissues can be combined 
with enabling technology to create more physiologically relevant models of disease states 
such as spinal cord injury.  
The vitamin A metabolite all-trans retinoic acid (ATRA) is a modulator of cell 
differentiation in vivo and in vitro.  Understanding the regulation and physiological role of 
ATRA in vivo guides its use during the derivation of stem cell-derived tissue, in particular 
neural tissue.  ATRA induces neural commitment in stem cells both in vitro and in vivo in 
a concentration and temporal dependent manner. Understanding the role of these 
parameters throughout the differentiation process will help produce more physiologically 
relevant in vivo models of neural development.  
This study involves the development, characterisation and application of novel 
technologies to investigate the process of neural differentiation in health and disease.  We 
have investigated the role of synthetic retinoid agonists on modulation of stem cell-derived 
neural differentiation.  We have subsequently applied neural models and have developed to 
investigate neurite inhibition in the spinal cord glial scar.  This Chapter provides a review 
of the primary literature and work leading up to this project.  
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1.1 THE CENTRAL NERVOUS SYSTEM 
 
The two major organs that make up the central nervous system (CNS) are the spinal cord 
and the brain.  The role of the CNS is to receive and coordinate information from the 
peripheral nervous system resulting in a response that is dependant on the stimulus and 
information recieved.  Sensory information received at the level of the spinal cord is sent to 
and interpreted by the brain via afferent nerve fibres.  
Both the spinal cord and the brain are contained within the meninges, which are split into 
three layers:  Dura mater, arachnoid mater and pia mater.  The space between the 
arachnoid and pia mater is filled with cerebral spinal fluid (CSF) produced by the choroid 
plexus of the brain.  The role of the structures that encase the brain is to provide 
mechanical protection, basic local immunity and help regulate cerebral blood flow. 
Spinal Cord  
The spinal cord is usually around 40-50 cm in length and 1.5 cm in diameter and extends 
from the medulla in the brain to the second lumbar vertebrae.  The spinal cord is separated 
into four distinct levels cervical, thoracic, lumbar and sacral.  A cross section of the spinal 
cord reveals distinct areas; white matter at the periphery containing an area of grey matter 
with a central CSF filled lumen contained by ependymal cells. The grey matter contains 
cell bodies of neurons and glia in a H like shape and is separated into four main areas: 
dorsal horn, lateral horn and ventral horn.  
Surrounding grey matter are the axons of myelinated and unmeylinated neurons and makes 
up the white matter. Ascending and descending fibres lie within the white matter. 
Ascending white matter tracts send this information for higher CNS processing.   
Descending tracts regulate voluentary movment, posture, balance and nociception. The 
spinal cord receives information from sensory peripheral neurons that enter the spinal cord 
via the dorsal root ganglion (DRG).  The DRG lying outside the CNS contain cell bodies 
of peripheral sensory neurons. DRG cells are used throughout developmental and 
neurobiological research as a model of neurite outgrowth and regeneration [4, 10]. Models 
of spinal cord development have helped elucidate key mechanisms of regeneration and 
understanding the anatomy of the spinal cord and associated neural grouping helps 
functional regeneration in this system [1]. 
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Brain  
The brain is the most complex organ in the human body and consists of around 38 billion 
glia and neuronal cells [11].  The brain has a lot of functional reserve and can adapt 
remarkably well to insult, but until relatively recently was not thought to regenerate in any 
way [12].  Recent studies have demonstrated that the function of parts of the brain requires 
plasticity, which is a type of neural regeneration and strengthens the approach to 
overcoming neural injury by regeneration [13].   
The basic anatomy of the brain is described blow each structure with a different and 
conserved function. During development this complex organ is under the tight control of 
cues that define positional identity, neural subtype specificity and hence regenerative 
capacity. 
Forebrain 
The forebrain is responsible for many of the higher intellectual functions associated with 
human life including speech and thought.  This part of the brain also controls voluntary 
movement and sensory integration.  Within the forebrain lies the telencephalon containing 
cerebral hemispheres and the diencephalon which lies within it the thalamus, 
hypothalamus, epithalmus and subthalmus which are important in endocrine regulation and 
control many bodily functions such as hunger, thirst, blood pressure/temperature and 
pleasure. The development of these highly regulatory structures is as influenced by 
environmental factors as it is genetic and evolutionary indicating at the highly adaptive and 
complex functions these serve [14]. 
Midbrain 
The midbrain has a variety of very important functions for life.  The structure lies between 
the forebrain and the hindbrain and connects the cerebral hemispheres to the cerebellum.  
A number of structures within the midbrain influence motor function including the 
dopaminergic producing cells in the substantia nigra and the reticular formation.  Cranial 
nerves in the midbrain control eye movement, lense shape and pupil diameter. A well-
described disease of the midbrain is Parkinson’s disease, which affects the dopamine 
producing cells in the substantia nigra. Development of this structure is under the 
regulation of the transcription factor Otx2, regulation of Otx2 in the developing brain is 
highly regulated and under the influence of multiple gene enhancers and positions the 
midbrain-hindbrain boundary [15, 16]. 
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Hindbrain 
The hindbrain is a highly patterned structure and development is under the regulatory 
control of multiple transcription factors.  As is described later in this Chapter, HOX genes 
regulate hindbrain rhombomere segmentation and development.  The Hindbrain is made up 
of the medulla oblongata and the pons.  Information is relayed from the spinal cord to the 
brain via the medulla oblongata, which is also involved in maintaining heart muscle 
contractions and breathing rate. The pons has multiple functions including connecting the 
cerebral cortex with the cerebellum and controlling cranial facial nerve signalling, both 
sensory and motor. 
Tight control and early specification of the distinct areas of the CNS is an important factor 
during development.  Understanding the processes that occur to form these structures and 
disease pathologies that are related to their development is important in treating congenital 
disease.  
1.1.1 Development of the central nervous system 
 
Folding of the neural plate during early embryonic development results in neural groove 
formation, which is followed by closure of each of end forming a tube.  Failure of neural 
tube closure results in a number of well-known neural tube defects.  Stem cells within the 
neural tube differentiate into neural and glial progenitors and are under the influence of 
morphogens produced either by the notochord, ectoderm or flanking somites.  The relative 
concentration of the morphogens; retinoic acid, BMP and SHH to the developing stem cell 
influences the progenitors and mature cells that develop.  As is discussed later in this 
chapter the anterior-posterior and dorsal-ventral positional identity of developing cells in 
the neural tube defines their functional identity [17]. 
Understanding the role of morphogens in neural development has aided or understanding 
of disease pathologies affecting the CNS and helped elucidate in vitro methods of stem cell 
differentiation for use in developmental and regenerative medicine studies.  
Figure 1-1 is a schematic that shows the major structures of the neural tube after closure.  
The flanking somites produce retinoic acid, which is thought to act via paracrine signalling 
to regulate neural tissue development.  In combination with morphogens from the 
notochord and ectoderm, retinoic acid guides specific neural development in particular 
motor neuron subtype specificity. 
5 
 
 
 
Retinoic acid is produced by somites flanking the developing neural tube [18]. Paracrine 
signalling by retinoic acid in developing cells of the neural tube is concentration dependant 
and regulates anterior-posterior identity.  Furthermore, signalling has also been shown to 
fine tune dorsal-ventral neural subtype and functional activity of mature neurons [19]. 
Therefore the structures surrounding the neural tube are essential for correct CNS 
development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific genes that control downstream events regulating neural subtype differentiation 
must also be regulated in a concentration dependant manner to provide tight control over 
neural development at each level of the developing neural tube. A group of highly 
conserved genes that are differentially expressed along the anterior-posterior and dorsal-
ventral axis and have been associated with neural subtype selectivity are HOX genes [20, 
21].  
HOX genes are discussed in detail later in this chapter, however, HOX gene regulation by 
retinoic acid produced by flanking somites is an important level at which neural 
progenitors begin to develop and become defined along the anterior-posterior and dorsal 
ventral axis[22]. Figure 1-2 is a schematic showing relative 5’ to 3’ HOX gene expression 
Retinoic 
acid 
Retinoic 
acid 
Ectoderm 
Somites 
Notochord 
Neural tube 
Figure 1-1 Schematic of the developing neural tube.  Retinoic acid is produced by the somites 
shown in yellow.  Paracrine activity of retinoid acid acts on developing cells of the CNS to form 
the anterior-posterior axis and influence neural subtype development via HOX gene expression. 
The overlying neuro-ectoderm produces the morphogen BMP that acts on the neural tube and the 
notochord produces Shh which also influences neural subtype development. 
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along the gene cluster and its relationship to anterior-posterior development of the neural 
tube.  Note that more 5’ HOX genes are expressed in the more posterior developing tissue. 
 
 
 
 
 
 
 
 
In addition retinoic acid signalling and HOX gene expression profile have been shown to 
influence developing neural progenitors specifying neural subtype at each level of the 
developing CNS.  In combination with other transcription factors, such as PAX6, HOX 
gene expression and hence, retinoic acid signalling help to tightly define sub populations of 
neuron. Cross regulation between transcription factors often make it difficult to determine 
which gene is under the direct influence of retinoic acid one indication is a retinoic acid 
response element in the coding gene [23]. 
 
 
 
 
 
 
 
Figure 1-2 Schematic shown the anterior-posterior expression of HOX genes in the 
developing human embryo.  Notice the 3’ and 5’ anterior-posterior patterning. Retinoic acid 
produced by the somites shown in figure regulates the expression of HOX genes in the CNS and 
influences development. Figure adapted from [7]. 
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CNS progenitor cells 
In vivo progenitor cells develop in domains that are defined by chemical cues produced by 
the local embryonic environment.  CNS progenitors are an important factor in neural 
regeneration with the potential of local implantation and repopulation of damaged neural 
tissue.  These cells can also be used to create a permissive environment for neural 
regeneration and have been demonstrated to aid functional neural tissue regeneration [24]. 
Understanding the chemical cues and genetic markers of these cell types is important for in 
vitro production of neural progenitors from embryonic or induced pluripotent stem cells for 
use in regenerative medicine.  Two major types of CNS progenitor are described below: 
Neural stem cells 
Neural stem cells have the potential to develop into neurons, astrocytes and 
oligodentrocytes, the three main cell types in the CNS.  These cells are described further in 
this Chapter however it is important to note that the majority of cells in the CNS are 
derived from a small population of neural stem cells.  These cells are directed by chemical 
cues into different lineages with a wide range of functions.  In addition a number of 
precursor cells are maintained in areas of the CNS providing them with plasticity.  Another 
type of neural progenitor cell found within the CNS is the NG2 cell, which has a function 
in adult neural functionalization and homeostasis. 
NG2 glia 
These cells are oligodendrocyte precursor cells and a subpopulation of astrocyte, they are 
evenly distributes throughout the CNS.  These cells are defined by expression of the 
proteoglycan NG2 on their surface membrane.  NG2 glia have multiple functions in the 
CNS and are found in both myelinated and unmyelinated areas of the brain. NG2 cells are 
closely associated with synapses and the NG2 protein is inhibitory to axonal regeneration 
indicating at a diverse role of these cells in the CNS. Upon differentiation into 
oligodendrocytes NG2 precursor cells up regulate myelin associated antigens and down 
regulate NG2 [25].  These cells seem to descend from ventral CNS domains developing in 
the presence of Sonic hedgehog (Shh) and that migrate expressing Olig1/2 in the pMN 
domain and NKX2.2 in the p3 domain (these domains are described later in this Chapter). 
NG2 begins to be expressed after commitment to these ventral neural progenitors and 
migration into the spinal cord [26].  
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Mature CNS cells 
Broadly the different type of neural tissue in the CNS can be grouped into:  Glia and 
neurons.  Gial cells can be further divided into astrocytes, and oligodendrocytes each with 
a distinct function and related pathophysiology.   
The highly specialised nature of a neuron facilitates the rapid transmission of an electrical 
signal from neuron to neuron or from a neuron to target tissue.  The general function of a 
neuron is the same between subtypes.  Subtype specificity comes from differences in 
targets for example motor neurons have a highly specialised neuro-muscular junction, 
whereas other neurons may synapse to post-synaptic membranes as you would expect to 
see in the brain.  Furthermore, the neurotransmitter that is released at the pre-synaptic 
membrane upon arrival of an electrical impulse also varies.  Broadly neurons in the CNS 
can be classified into either motor or interneurons. 
Neurons  
Motor neuron 
Motor neurons are generally multipolar with a single long axon extending from the cell 
body that can transmit an impulse either from the cortex to the spinal cord or from the 
spinal cord to muscle cells.  These neurons tend to have multiple dendrites emanating from 
the cell body allowing for the integration of many input signals. 
Sensory and motor neuron connections are extremely specific and act to highly co-ordinate 
motor output and behaviour.   Directed differentiation of motor neurons has been shown to 
be involved in development of these connections, however, even what is even more 
regulated is the development of sensory-motor neuron connections via a local environment 
specific mechanisms.  Neural circuit connections and neural regeneration have been shown 
to be highly regulated by local environmental factors defined by patterning of the CNS 
[27]. These studies and many more describe how early patterning of the CNS defines 
neural subtype development and highly specific targeted innervation of tissue.   
Interestingly the spatial distribution of CNS neuron clusters reflects that of the spatial 
distribution of the main limb muscle groups [28]. 
Interneuron 
Interneurons are found within the brain and spinal cord of the CNS, this type of neuron are 
generally short and relay information within the CNS via two axons.  They can be both 
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inhibitory (producing the neurotransmitter GABA) and excitatory (producing glycine or 
acetylcholine).  A number of different types of interneurons are found throughout the brain 
and spinal cord, each with a unique function and phenotype.   It is thought that interneuron 
diversity is the result of post-mitotic interactions.  Furthermore, the genetic profile of each 
progenitor results in specific migration resulting in experience directed differentiation and 
functionalization at different areas of the brain and spinal cord.  Transcription factor 
expression and regulation during development of this type of neuron is particularly 
important and helps specify neural subtype and function. For a review on this topic see 
Kessaris, N et al (2014) [29] . 
Glial cells 
Glial cells can be thought of as the support cells of the CNS, they are closely associated 
with neurons and regulate many functions including: local environment homeostasis, 
neurotransmitter turnover, neural repair and early neural migration.  Neurons rely upon 
glial cell for a number of functions, however, as is described in later in this Chapter one 
type of glial cell, the astrocyte can be activated to inhibit neural repair.  The two broad type 
of glial cell are astrocytes and oligodendrocytes their role within the CNS is described 
below [30]. 
Astrocytes 
Astrocytes are a star shaped cell that is closely associated with neurons in the CNS.  
Astrocytes express the intermediate filament GFAP and are involved in providing 
mechanical support, synaptic stability, and nourishment through storage and processing of 
substrates, regulate neural development and phagocytose debris within the CNS.   The 
microstructure of the CNS is created by astrocytes making them important for correct 
patterning of the CNS. 
Oligodendrocytes 
Neurons are myelinated by Oligodendrocytes, myelination allows for rapid signal 
transduction over relatively large distances.  The electrical signal is rapidly passed between 
gaps in the myelin created by oligodendrocytes called nodes of Ranvier. The myelin 
sheaths that wrap around axons provide multiple functions to facilitate and optimise signal 
transduction in the CNS. Multiple pathologies are associated with loss of axon myelination 
for example multiple sclerosis, indicating at the importance of these cells in the CNS. 
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Understanding the biology behind myelination of axons by oligodendrocytes and disease 
pathologies that affect myelination is an important factor when trying to regenerate 
functional neurons in the CNS. 
 
1.2 RETINOIC ACID AND EMBRYONIC NEURAL DIFFERENTIATION 
 
Indirect evidence for the role of ATRA in CNS development and maturation has come 
from a number of different experimental methods.  Initially ATRA was implicated to have 
a role in CNS development through vitamin A deprivation studies.  Studies on pigs and 
chickens demonstrated that vitamin A deficiency resulted in signs of motor neuron disease 
and in some cases loss of eye development [31].  It soon became apparent that a deficiency 
in vitamin A resulted in a multitude of developmental defects of the spinal cord and CNS, 
including- Hydrocephalus, Spina bifida and Anopthalmia.  Maden, M et al (1996) [32] 
used a Vitamin A deficient (VAD) quail to investigate developmental defects resulting 
from VAD, the study demonstrated that RA deficiency caused a reduction in the number of 
neurons within the neural tube and those that were produced did not show normal neurite 
outgrowth or correct neurite guidance.  Following the elucidation that retinoic acid was the 
major biologically active metabolite of vitamin A investigation into the presence of 
retinoic acid in the spinal cord began. McCaffery, P.J  et al (1994) [33] demonstrated in 
mice that retinoic acid was present in the spinal cord and hindbrain of the developing 
embryo and that the levels of retinoic acid correlated with the amount of RALDH present 
in the tissue.  The expression profiles of both RALDH and CYP26 enzymes were 
characterised by Reijntjes, S et al (2005) [34] in normal and VAD quail. The expression of 
RALDH2 was seen in the motor neurons and limb level spinal cord of normal quail, 
however, this expression was lost in VAD quail, indicating a positive regulatory role of 
retinoic acid on RALDH2 expression. However, the expression of RALDH2 did not 
correlate to retinoic acid signalling in the same tissue suggesting a paracrine role of 
retinoic acid during CNS development.  
1.2.1 Dorsal-ventral neural patterning of the spinal cord  
 
There are distinct differences in the type of neuron that form along the dorsal ventral (DV) 
axis of the spinal cord. Neural subtypes arise through cellular interaction with a multitude 
of external transcription mediators. One of the main signalling pathways involved in 
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modulating ventral spinal cord development is Sonic hedgehog (Shh), which acts with 
retinoic acid to direct neural progenitors into cells with a motor neuron phenotype. 
Shh acts as a morphogen to regulate the expression of transcription factors involved in 
establishing distinct DV neuroprogenitor domains.  Shh is produced by the notochord and 
forms a concentration gradient with high levels ventral and low dorsal.  At defined 
concentrations of Shh, homeodomain-containing transcription factors are either induced or 
repressed, the combination of transcription factors at each level along the DV axis marks a 
domain of neuroprogenitor cells.   The five progenitor domains are termed vp3, pMN, vp2, 
vp1, vp0 and pD and are expressed ventral-dorsal respectively [9, 35].  Each progenitor 
domain gives rise to functionally different neurons e.g. pMN form ventral motor neurons. 
The pMN progenitor is defined by the combinational expression of the transcription factors 
PAX6, OLIG2 and NKX.6 and the motor neurons formed from further differentiation of 
these progenitors defined by MNR2 and Hb9 expression. Figure 1.1 shows the overlapping 
expression domains of two classes of transcription factors I and II and how these can be 
used to identify neural progenitor domains along the DV axis [9]. 
The two groups of transcription factors- class I and class II are under the regulation of Shh 
signalling.  Class I genes are repressed by Shh and class II induced, however, class I and II 
also cross regulate forming distinct combinations of transcription factors in each progenitor 
domain.  RA is integral to defining distinct progenitors along the DV axis and has an 
important role in motor neuron differentiation.  RA is produced by the somites adjacent to 
the developing neural tube; furthermore, there is an important interaction between FGF and 
RA signalling during neural development.  For the correct development of ventral neural 
subclasses RA is required to inhibit FGF8 signalling, failure to do so results in down 
regulation of markers of ventral neuroprogenitor domains such as Pax6.  FGF signalling 
inhibits the expression of both Class I and Class II transcription factors and has been 
shown to down regulate RALDH2 expression in paraxial mesoderm.  However, RA 
signalling inhibits FGF expression and subsequently allows Shh regulation over Class I 
and Class II genes [36].  Furthermore, RA has been shown to induce the expression of 
Class I transcription factors such as PAX6 and NKX.  Interestingly, PAX6 and NKX2.2 are 
required to prevent the expression of transcription factors that inhibit the bHLH containing 
transcriptional repressor OLIG2. OLIG2 is required for motor neuron differentiation 
through indirect regulation of Mnx and LIM proteins [37], indicating a role of PAX6 
expression in motor neuron differentiation. 
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Differentiation of each neuroprogenitor into specialised neural tissue is incomplete without 
directed neurite outgrowth and functional synapse formation with target tissue.  Much of 
the characterisation of functional neurons comes from the neurotransmitters released from 
the synapse and provides a good link between developmentally discrete neuroprogenitors 
and their ultimate function in the central nervous system.   
Manipulation of stem cells in vitro provides important insights into neural development 
and subtype selectivity, furthermore, the different stages of development can be utilised in 
disease models of the CNS.  
 
 
 
 
Figure 1-3 Dorsal/ventral transcription factor expression. A diagram representing the 
transcription factor domains along the DV axis and which class I and class II transcription factors 
are influenced by Shh. The interplay between opposing transcription factors determines the ventral-
dorsal neural progenitor pool that develops, each pool of progenitors along the DV axis is shown as 
a different colour. . The black lines show genes that are induced by Shh and their influence on each 
progenitor domain.  Blue lines show the expression of genes inhibited by Shh and their DV level of 
expression.  The genes respond differently to different concentrations of Shh.  Figure adapted from 
Lee et al (2001) [9]. 
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 1.3 RETINOIC ACID AND ANTERIOR-POSTERIOR EMBRYONIC PATTERNING 
 
Movement and expansion of the transient epiblast through the primitive groove results in 
the formation of three germ layers- endoderm, mesoderm and ectoderm, this is the process 
of gastrulation. Cells during gastrulation are highly migratory and are in constant dynamic 
flux.  Gastrulation is an important stage during development and results in the formation of 
an anterior-posterior axis (AP)- a process that is directly affected by ATRA signalling [38]. 
Of the three germ layers the ectoderm gives rise to the neural crest, the neural tube and the 
epidermis.  The mesoderm forms a number of different structures including the notochord 
and somites which are integral to post gastrulation organogenesis and neurulation. Finally, 
the endoderm forms the epithelia of the digestive and respiratory systems and some 
digestive organs.  Each of the germ layers and the independent cell niches that arise within 
them are derived from embryonic stem cells making up the epiblast.  Axis formation of the 
three germ layers is important to ensure proper cellular development and tissue function.  
An insight into the role of transcription factors in the process of AP-axis formation came 
from mutagenesis screens in Drosophila melanogaster. Mutations in some of the genes 
screened revealed ectopic expression of body appendages, such as the ectopic expression 
of legs in place of antennae or duplication of a wing segment, demonstrating a change in 
positional identity of cells developing in a particular area of the developing embryo.  The 
genes found to be responsible for these positional changes in Drosophila were termed 
HOM-C and were found on two clusters; antennapedia and bithorax. The expression of 
each gene was temporal and spatially restricted along the AP axis and the expression of 
each gene was determined by its position within the cluster, an effect known as co-linearity 
[39]. 
A similar set of evolutionary conserved homeobox-containing transcription factors were 
discovered in humans, termed HOX genes.  HOX genes are a family of 39 nuclear 
transcription factors split into four clusters- A, B, C and D [40].  Paralogs of each gene are 
found between clusters and each paralogue is given a number from 1-13.  The temporal 
expression of each gene is dependent on its spatial arrangement in the cluster, which is 
directly regulated by retinoic acid [41-43].  
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HOX genes 
Multiple developmental studies have demonstrated that the expression of 3’ HOX genes is 
associated with tissue of anterior fate, whereas 5’ HOX genes provide posteriorisation cues 
to migrating cells and developing tissue.   Formation of the AP axis was hypothesised to 
involve an external environmental factor; a diffusible morphogen was suggested to 
regulate the expression of HOX genes in a concentration dependent manner.   Multiple 
studies have demonstrated that retinoic acid can alter the expression of HOX genes and 
retinoic acid signalling results in posteriorisation of developing tissue, therefore it is 
widely accepted that retinoic acid is involved in the expression of many of the HOX genes 
and can act to induce expression through a concentration gradient [42, 44, 45]. 
Furthermore, many 3’ HOX genes contain a RARE and are sensitive to low levels of 
retinoic acid.  There are a number of theories about how retinoic acid induces co-linear 
expression in HOX genes, it has been hypothesised that retinoic acid may bind to RARE in 
the promoter of each HOX gene with different affinities and therefore induce each gene 
with different potencies, however, this require each HOX gene promoter to have a RARE, 
but RARE in many of the HOX genes have not been described [23]. A second theory is that 
the products of 3’ HOX genes act to regulate later HOX genes 5’ of the cluster.  This is 
supported by much of the information known about HOX genes to date, however, there is 
still much unknown about the targets of HOX genes and how they interact. Figure 1-4 
shows diagrammatically the four clusters of HOX genes, their associated sensitivity to 
retinoic acid and their anterior-posterior expression domains. 
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Further, evidence for the role of retinoic acid in AP patterning came from detailed analysis 
of rhombomere segmentation and how retinoic acid affects the AP axis within the 
hindbrain. A normal hindbrain consists of 7 rhombomeres each have a unique positional 
identity, identified through cell surface and gene expression markers.  In the VAD quail 
expansion of anterior restricted rhombomeres is increased, resulting in an enlargement of 
the anterior segments, whereas the posterior rhombomeres are truncated [43, 46]. This fits 
in with the concentration dependent effects of retinoic acid, indicating that retinoic acid 
signalling results in posteriorisation and without ATRA signalling an anterior fate is 
adopted. This effect has been shown to be concentration dependent with progressive loss of 
the posterior hindbrain markers as ATRA is reduced.  Models other than VAD have 
utilised methods of reducing endogenous production of retinoic acid through null 
mutations in RALDH or through the application of RAR antagonist.  RALDH null 
mutations are essentially equivalent to a VAD phenotype; RAR antagonists require a 
specific temporal application demonstrating the temporal expression of RAR during 
development. HOX genes have a defined barrier of expression for each of the 
rhombomeres e.g. HOXB1, which is the only HOX gene found in rhombomere 4. Vitamin 
   D11 
RA Sensitivity 
Figure 1-4 HOX gene clusters and their relative sensitivity to retinoic acid.  The 39 HOX 
genes are arranged into 4 clusters A-D, each cluster contains up to 11 HOX genes, with paralogs of 
genes between clusters.  The spatial arrangement of each gene within the cluster determines its 
temporal expression pattern, which is influenced by retinoic acid signalling. 
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A treatment results in loss of this defined domain and an expansion of rhombomere 3 
indicating posteriorisation, conversely in VAD animals, there is an enlargement of anterior 
rhombomeres 3 and 4 and a reduction in markers of rhombomere 5 and 6 essentially 
posterior rhombomeres are lost and replaced by more anterior cells [43], these studies 
underline the temporal and concentration dependent role of ATRA during development.  
HOX genes and differentiation 
The ability of HOX genes to control axis formation can be used to define areas of the 
developing embryo, the HOX code of any particular developing tissue defines its position 
within the embryo but it also ultimately determines how the cell will differentiate. The 
position of the cell within the embryo determines which signalling molecules are present 
and importantly the concentration they are present at [44]. The teratogenic effects of 
retinoic acid are partly due to its regulation over HOX genes that control AP patterning.  
HOX genes themselves regulate a vast range of transcriptional mediators and genes 
however, retinoic acid controls initial HOX gene expression, hence, aberrant expression of 
HOX genes results in disordered development and differentiation [47]. 
Human embryonal carcinoma (hEC) stem cells are an efficient and ethically acceptable 
way of investigating the development of human tissue and the role of retinoic acid in this 
development (see Section 1.6).  In vitro experiments demonstrated that in the embryonic 
carcinoma stem cell line NTER2.cl.D1, a model thought to represent the primitive 
ectoderm, retinoic acid induced a concentration dependent expression of HOX genes from 
each of the four chromosome clusters in a co-linear manner [48]. A study by Mavilio, F. et 
al (1988) [49] initially demonstrated that retinoic acid specifically induced differentiation 
and HOX gene expression in NTERA2.cl.D1 EC cells, which was not induced by the 
compounds hexamethylenebisacetamide or bromodeoxyuridine.  Furthermore the effect of 
retinoic acid was shown to be dependent on the use of the specific EC cell line 
NTERA2.cl.D1, making this an excellent model for investigating the role of HOX genes in 
cell differentiation. Following on from this study Simeone, A et al (1990) [50] showed that 
retinoic acid induced a sequential activation of HOX genes on cluster 2 (HOXB) and 
activation depended on concentration of and length of exposure to retinoic acid.   Further 
studies exemplified this model to investigate the regulation of HOX genes during neural 
specific development and co-linear expression [41].  
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The expression of HOX genes in this model of differentiation is directly associated with the 
early stages of differentiation [48, 50].  Furthermore, the induction of HOX genes has been 
implicated in the specific differentiation of human embryonic stem cells, with HOX genes 
serving as markers of cell lineage identity [51].  This suggests that HOX genes may be 
involved in some key aspects of cellular differentiation that are not merely an indirect 
consequence of AP patterning.  
1.4 RETINOIC ACID 
1.4.1 Storage and metabolism of retinoic acid 
 
Retinol (vitamin A) is an essential fat soluble nutrient obtained from the mammalian diet in 
the form of β-carotene or pre-formed retinyl esters [52].   Retinol can be derived from a 
number of food sources such as meat, vegetables and other Vitamin A fortified foods.  
Vitamin A and its derivative group of compounds retinoids consist of four isoprenoid units 
and contain five carbon double bonds.  In vivo the biological effects of vitamin A are 
solely due to either the aldehyde or carboxylic acid derivatives, more specifically, 11-cis 
retinal and all-trans retinoic acid (ATRA) respectively. Investigation into the ability of 
ATRA to compensate for rats deficient in vitamin A has shown that although the rats will 
develop with no obvious defect, they are blind and cannot reproduce. These results indicate 
that retinoic acid alone cannot completely compensate for vitamin A deficiency and is not 
the only vitamin A metabolite responsible for its biological actions [53]. Understanding 
how vitamin A is absorbed, metabolised, stored and transported in vivo is important in 
rationalising treatment of disease relating to the biological activity of vitamin A and its 
derivatives.  Furthermore, elucidating the biologically active components of vitamin A will 
aid synthetic development of analogues based around these molecules.     
Within the intestinal lumen retinyl esters are converted into retinol and along with β-
carotene enter the enterocytes via passive diffusion [54]. Once within the enterocytes β 
carotene is enzymatically converted to retinol.  Retinol is then re-esterified by 
lecithin:retinol acetyltransferase and packaged into chylomicrons for transport within the 
lymphatics [55].  Hydrolysis of the chylomicron by lipoprotein lipase enzymes bound to 
epithelial surfaces results in chylomicron remnant formation.  The chylomicron remnant 
associates with APOE, targeting the remnant to hepatic stellate cells for storage as retinyl 
palmitate, with some remnants associating with lipoprotein receptors on target tissues [56].   
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Once in the liver release and transport of all-trans retinol (ATR) is though association with 
serum retinol binding protein (RBP).  Quadro, L et al (1999) [57] demonstrated that 
although RBP is required to mobilise retinol from liver stores it is not needed for 
accumulation of retinol in the liver.   RBP transports ATR to target cells or tissues and 
associates with a multi-transmembrane domain protein known as STRA6.  There is 
evidence to suggest that the ability of STRA6 to facilitate ATR uptake is dependent upon 
RBP binding and internalisation, furthermore, tissue expression of STRA6 is in agreement 
with the developmental, visual, reproductive and CNS roles of retinol derivatives [58]. 
Once within the cell cytoplasm intracellular control over the biological activity of retinol 
and its derivatives is essential to prevent unregulated biological activity. 
1.4.2 Control over the cellular activity of retinoic acid 
 
Cellular control over the biological effects of all-trans retinoic acid (ATRA) is important to 
ensure a tissue specific response.  Localised production and paracrine activity is controlled 
by enzymes that regulate production and degradation of retinoic acid at the receptor ligand 
binding site.  Furthermore, transport of intracellular ATRA by the cellular binding proteins 
can guide the bioactive molecule to either the nuclear receptors or catabolising enzymes, 
resulting in tight control over activity depending on the regulation of these proteins.  This 
results in the formation of a bioactive gradient of ATRA without the need for a 
concentration gradient. 
Cellular retinoic acid binding protein 
Conversion of intracellular retinol to ATRA occurs through a number of oxidation and 
hydrolysis steps.  The first step is rate limiting and results in the formation of all-trans 
retinal through enzymatic activity of retinol dehydrogenase (RODH or ADH).  Retinal is 
then converted irreversibly to all-trans retinoic acid by a family of retinaldehyde 
dehydrogenase enzymes (RALDH1, RALDH2 and RALDH3) [59]. Once formed retinoic 
acid binds one of two proteins found within the cytoplasm, cellular retinoic acid binding 
protein I or cellular retinoic acid binding protein II (CRABP I and II).  The role of CRABP 
I is to facilitate retinoic acid oxidation. The affinity of CRABP I for RA is higher than 
CRABP II, however, RA induces the expression of CRABP II resulting in a positive 
feedback loop and increased binding to CRABP II.  CRABP II has been shown to directly 
influence RAR signalling by actively channelling RA into the ligand binding pocket, 
indirect evidence for this process came from over expression of CRABP II in a mammary 
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carcinoma cell line. Over expression resulted in an increased sensitivity of the carcinoma 
to RA signalling [60]. CRABP II has been detected within the cell nucleus, however, it was 
found that this was cell type specific and exclusion from the nucleus has also been 
reported, indicating a possible role of CRABP II in cell specific sensitivity to retinoic acid 
[61].  
CRABP I is a known regulatory protein of retinoic acid signalling and targets RA for 
metabolism [62]. Metabolism of ATRA is an important step in controlling its biological 
activity, however, some oxidation products have been shown to have biological activity 
similar to ATRA. Reijntjes, S et al (2005) [34] demonstrated that the oxidation products 4-
oxo-RA, 4-OH-RA and 5,6-epoxy-RA could up-regulate CYP26A1 in the neural tube of 
quail, probably through RAR α.   Furthermore, these products were able to rescue the 
effects of VAD in quail if provided at the correct stage of development indicating a 
possible developmental role for these products. 
Cytochrome P450 and retinoic acid metabolism 
The metabolising enzymes that oxidise retinoic acid are part of cytochrome P450 family 
26. Three isomers of CYP26 enzymes that are known to be involved in retinoic acid 
metabolism are CYP26A1, CYP26B1 and CYP26C1 [63-65]. The expression of each 
enzyme during development is spatially and temporally distributed, resulting in dramatic 
variations in retinoic acid concentration throughout the embryo regulating cell 
development.  
Inhibition of this family of enzymes through the use of the imidazole- Liarozole fumarate 
(R85246) has been shown to increase the bioavailability and enhance the biological 
activity of ATRA [66-68].  Liarozole is a nonspecific inhibitor of several cytochrome P450 
enzymes including CYP26. The group of compounds that are being developed to modulate 
this pathway are known as retinoic acid metabolism blocking agents (RAMBAs).  Work on 
enhancing retinoic acid potency and action has many applications in stem cell biology and 
disease treatment.  Understanding retinoid metabolism may open up valuable areas of 
research aimed at enhancing the potency and specificity of its actions.  Figure 1-5 shows 
the oxidation sites on ATRA and the potential bioactive molecules that are produced and 
may act to bind alternative retinoic acid receptors (RAR) to ATRA. 
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1.4.3 Retinoic acid receptors and signalling 
 
RAR are nuclear-ligand activated transcriptional regulators.  The three RAR are: α, β and 
γ; each RAR group contains isoforms arisen through gene splicing and differential 
promoter usage and are shown in Figure 1-6. Crystallographic imaging demonstrated that 
consistent with most other nuclear steroid receptors RAR consist of five distinct regions 
(A-F), understanding the structure and function of each region is key to receptor binding 
selectivity.  Regions A and B contain the ligand independent activation function (AF1), 
region C contains the DNA binding domain (DBD) and is composed of two zinc finger 
Figure 1-5 Oxidation products of all-trans retinoic acid.  The cytochrome P450 enzyme family 
26 oxidises ATRA to form a number of different products.  Some of the products may have the 
same biological activity as ATRA in vivo. It is not well known how biologically relevant each 
oxidation product is or if their presence is an artefact of in vitro culture.  
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domains, two alpha helices and a COOH terminal extension.  The core of the DBD is 
composed of the two alpha helices crossing at right angles to each other [69].  Region D 
forms a hinge between regions C and E, where region E contains the ligand binding pocket 
and the ligand dependent activation function (AF-2). Regions C and E are the most 
conserved domains between species demonstrating the importance of conserved DNA 
binding and ligand activation in development and reproduction.  Knowledge of the 
structure of each RAR will aid in the development of subtype selective synthetic retinoids 
[70]. 
Gene Isoforms Human 
Chromosome 
RAR α α1, α2 17q.21.1 
RAR β β1, β2, β3, β4 3p24 
RAR γ γ1, γ2 12q13 
 
Figure 1-6 RAR isoforms and their chromosomal locations  [71].  Importantly, RARβ1/3 and 
RARβ2/4 are transcribed via the same promoter, differences in their structure and overall function 
arise from splice variants of the receptor. 
The RARs signal through heterodimerisation with another nuclear receptor; the retinoid X 
receptor (RXR). As with RAR there are three RXR receptors α, β and γ, however, in 
contrast to RARs they can regulate gene transcription through homodimerisation or by 
forming a heterodimer with a nuclear orphan receptor such as receptors from the 
peroxisome proliferator-activated receptor (PPAR) family.  Imaging studies demonstrate 
that the ligand binding pocket of RAR and RXR are significantly different giving them 
different ligand specificities.  RAR has an I shaped binding pocket and RXR an L shaped 
pocket. Due to the shape of ATRA it can only bind the I shaped RAR pocket, whereas the 
ATRA isomer 9-cisRA can act as a ligand for both RAR and RXR.  The role of 9-cisRA 
signalling in vivo is unclear as it has been difficult to isolate endogenous 9-cisRA. 
However, in vitro 9-cisRA is found and is involved in the retinoid signalling pathway 
suggesting that 9-cisRA is a product of in vitro isomerisation of ATRA and not thought to 
be involved in the biological effect of vitamin A in vivo [70].  Understanding the stage 
specific effect of ATRA signalling in vivo will aid its use in in vitro developmental studies.   
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1.5 IN VITRO NEURAL DIFFERENTIATION 
 
The process of neural differentiation in vitro closely resembles that during neural 
development in vivo as determined by the expression of gene profiles, neural tube-like 
structures and functional neurites.  Producing large numbers of neurons in a defined and 
reproducible manner is a major advance in neuroscience and has aided high throughput 
drug screening using human neural progenitors and neurons. To investigate neural 
development and neurite outgrowth undifferentiated cells capable of forming 
neuroprogenitors are required, these are often mouse or rat foetal derived brain neural 
progenitors or embryonic stem cells. The advantage of using pluripotent stem cells as 
opposed to the more committed foetal progenitors is the enhanced control over the age and 
specificity of the neurons that develop, furthermore, human stem cells produce human 
specific tissue, which is directly relevant to human development.  
1.5.1 Human embryonic stem cells  
 
Human embryonic stem cells are derived from the inner cell mass of a blastocyst and can 
be cultured in vitro for investigating the molecular processes that direct differentiation, in 
particular the mechanisms by which human embryonic stem cells can be induced to form 
specific neural subtypes.      
Pluripotent embryonic stem cells are defined by their high expression of the transcription 
factors OCT4 and NANOG, cell surface expression of the proteins SSEA3/4, TRA-1-60 
and high telomerase activity. Under defined conditions these cells are immortal, dividing 
unrestricted and without morphological change [72].  
hES cells can be characterised by their ability to form teratomas in immuno-compromised 
mice or by functional incorporation into the early inner cell mass of a blastocyst. Both 
result in complex tissue formation and a multitude of differentiated cells of all three germ 
layers. Importantly, the teratoma mass formed from implantation of pluripotent stem cells 
retain a stem cell niche allowing for maintenance of the teratoma through serial 
transplantation of this sub set of cells [73].   
Manipulation of hES cells in vitro has helped elucidate the mechanisms behind inducing 
differentiation, maintenance of pluripotency and cellular development.  Many methods of 
inducing human embryonic stem cells have been described in the literature, most of which 
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involve the use of small molecules to induce cell signalling that ultimately leads to the 
stem cells committing to a cell lineage [74, 75].  The stem cell will become an early 
progenitor. In the case of neurons, stem cells lose the expression of OCT4 and NANOG and 
begin to express PAX6 and NESTIN, as well as showing characteristic neural rosette 
morphology.  Terminal differentiation of stem cell-derived neurons is characterised by β 
III Tubulin expression, NF200 and neural subtype markers such as HB9 for motor neurons 
[76] and NKX2.2 for interneurons [77].  Finally functional activity can be determined by 
synapse formation and electrophysiological measurements [78].  
1.5.2 Embryonal carcinoma stem cells 
 
The malignant counterpart of hES is the human embryonal carcinoma stem cell (EC cells) 
derived from the stem cell niche of a malignant germ cell tumour.  EC cells can form 
complex teratomas when grafted into immune-compromised mice and have the ability to 
be incorporated into the inner cell mass of a mouse blastocyst.  Interestingly these cells do 
not seem to be cancerous under the conditions found within the inner blastocyst.   The use 
of human embryonic stem cells in developmental research is particularly limited due to 
ethical and availability constraints; however human EC cells circumnavigate these 
problems and represent an ideal model of human embryonic development for basic 
research. There are many similarities between ES and EC cells such as the ability to 
maintain them in an undifferentiated, self-renewing state.  Furthermore, there is a growing 
body of literature defining the conditions required for directed differentiation of both cell 
types into functional cells from all three germ layers.   
Pioneering studies by Strickland, S et al (1978) [79] demonstrated retinoic acid (RA) 
induced endodermal differentiation in a murine EC cell line.  However, it was later 
demonstrated that the ability of RA to induce endodermal differentiation was dependent on 
the EC cell used.  In vivo many of the murine EC cells were capable of differentiating into 
cells of all three lineages; however, in vivo these cells were more limited in their lineage 
potential. Studies by Jones-Villenuvive, E.M (1982) [80] demonstrated that the murine P19 
EC cell could be induced to differentiate into cells with a neuronal phenotype by treatment 
with RA.  These cells could be purified and were characteristic of ectoderm. The 
concentration of RA used in these studies was important to ensure a high yield of neurons 
within the culture. Much of the initial work on directing differentiation of EC cells was 
done using mouse EC or ES cells; however, it is difficult to say with confidence that 
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human ES or EC cells would respond in the same way.  Therefore to continue using EC 
cells in research it was important to derive a human cell line. Initially many of the hEC 
cells derived were unresponsive to retinoic acid and few differentiated into cells with a 
neuronal phenotype [81]. This may be a consequence of the carcinoma origin of the cells, 
as it would be evolutionary beneficial if the ability of differentiation was lost in these cells, 
therefore their ability to differentiate does in many instances not completely reflect that of 
hES cells. 
In 1970 the human EC stem cell TERA2 was derived from the lung metastasis of a male 
germ cell tumour.  In 1984 Andrews, P et al (1984) [82] used a xenograft to form a 
teratoma in nu/nu mice using the TERA2 cell line and subsequent isolation of single cell 
clones revealed a subset of cells that expressed high levels of the surface proteins SSEA3/4 
and TRA-1-60.  Further characterisation of the cells revealed more similarities of the clone 
to hES cells including high levels of OCT4 and telomerase expression [83].  It was 
determined that the TERA2 clone, NTERA2/D1 was induced to differentiate upon retinoic 
acid treatment.  A small proportion of the cells formed were neurons and the rest fibroblast 
like epithelial cells. Subsequent work on this EC cell line was directed at developmental 
neuroscience and basic differentiation mechanisms.  
Przyborski, S.A (2000) [84] used a modern technique to derive a TERA2 EC stem cell 
clone that expressed high markers of stem cell specific glycoproteins.  Deriving hEC stem 
cells from different sources has provided scientists with tools that have varying strengths 
and weaknesses.  The application of a modern isolation technique provided a TERA2 clone 
that would be independent of NTERA2.cl.D1 and likely have a different karyotype and 
response to retinoids and other small molecules. The method used involved 
immunomagnetic sorting of cells expressing high levels of the stem cell marker SSEA3 
from an early passage of the TERA2 parent lineage, this was unlike NTERA2.cl.D1 that 
was passed through a nude mouse. SSEA3 specific antibodies were used to separate 
differentiated cells of the TERA2 from the small stem cell niche.  The TERA2.cl.SP12 EC 
cell was demonstrated to have high levels of SSEA3, TRA-1-60 and was induced to 
differentiate upon RA treatment.  The NTERA2.cl.D1 and TERA2.cl.SP12 EC cells are 
similar in many respects providing a model of human retinoic acid induced neural 
differentiation. 
TERA2.cl.SP12 hEC stem cells were originally induced to form neurites by retinoic acid in 
a mono-layer culture. This provided a network of neurites for studying the protein and 
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genetic regulation of stem cell differentiation by retinoic acid.  Aggregates of the cells 
were also shown to differentiate and express neural and astrocytic markers after 14 days 
retinoic acid treatment [85, 86].  Recent functional data demonstrated the neurons derived 
from TERA2.cl.SP12 were electrically active [87] further exemplifying these cells as a 
model of neural development.  Other uses of the cells involve investigating the process of 
neural differentiation manipulating this process in vitro [88-90]. 
Retinoic acid has been used for many years to induce differentiation of the EC cells 
described above, however, a major difference between in vitro and in vivo retinoic acid 
signalling is the isomerisation of ATRA in vitro under ambient conditions.  It is unknown 
exactly how much of an effect the isomerisation of ATRA will have on the results obtained 
during an experiment; it is known that the actual concentration of ATRA within culture 
will change as ATRA isomerises.  Furthermore, the isomer of ATRA, 9-cisRA may have 
unwanted effects on cellular response.  Therefore the reproducibility of ATRA treatment 
and the concentration dependent effects associated with ATRA will be affected in vitro by 
the instability of the compound [91]. 
1.6 LIMITATIONS OF RETINOIC ACID IN VITRO 
 
Isomerisation and metabolism in cell culture results in the need for high experimental 
ATRA concentrations.  The instability of retinoids is inherent in the five unstable 
conjugated double bonds, additionally ATRA degrades into a number of other compounds 
that have an unknown biological activity [90].  
The ATRA isomer, 9-cisRA may have unwanted effects on cellular response and 
differentiation. Therefore the reproducibility of ATRA treatment and the concentration 
dependent effects associated with ATRA will be affected in vitro by the instability of the 
compound,  this was highlighted in an article by Murayama, A et al (1997) [91].  A number 
of small molecule analogues have been designed and synthesised aim at overcoming the 
inherent instability of ATRA and to probe the biological process regarding retinoic acid 
signalling in vitro and in vivo.  
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1.7 SYNTHETIC RETINOIC ACID ANALOGUES 
 
Advances in the design of small molecules and a better understanding of retinoic acid 
receptors and their isotype have aided the development of a large range of synthetic 
analogues.  Elucidating the processes regulated by retinoic acid specifically during neural 
commitment will aid understanding of many disease mechanisms that arise from 
abnormalities in the signalling pathway. 
An understanding of the structure-function relationship of retinoid analogues is important 
to gain the desired response.  It is also necessary to understand the system which the 
retinoids will be applied to. The biological outcome may be dependent on the expression 
retinoic acid receptor subtypes.  A general retinoid structure is shown in Figure 1-7 the 
structure consists of a large hydrophobic unit, a linker unit and a polar terminus. Structural 
modification of the hydrophobic unit has been exemplified by the TTNPB series and leads 
to alterations in potency. Furthermore, removal of methyl groups from this unit to reduce 
oxidative metabolism was demonstrated to reduce activity. To bind and activate either the 
RXR or RAR receptor the polar terminus must be capable of interacting with the bottom of 
the ligand binding pocket (LBP). This interaction acts to anchor the retinoid to the LBP.  
Finally, modifications to the linker unit provide selectivity of receptor binding of RXR and 
RAR as well as RAR isotype selectivity.  
 
 
 
 
 
 
 
 
 
Hydrophobic 
Unit 
Polar  
Terminus 
Linker  
Unit 
Figure 1-7 General retinoid structure.  When designing retinoids three main units are to 
be considered these are:  The hydrophobic unit, the linker unit and the polar terminus.  
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The synthetic analogue of ATRA – EC23 has been developed to be resistant to oxidation 
and as such provides a novel model to assess the role of metabolites on stem cell 
differentiation and the role of metabolising enzymes on the potency of ATRA [89, 90, 92].  
EC23 is a highly potent photostable arotinoid which contains active methyl groups on the 
hydrophobic unit.  The active methyl groups provide maximal potency and the presence of 
a stable linear triple bond ensures RAR selectivity.  The aromatic ring prevents oxidative 
metabolism, all together these modifications account for the enhanced potency of EC23 
over ATRA and other retinoid analogues [93].  
Structure-function relationship 
One specific example of structure activity relationships and the effect on the biological 
outcome is in the small molecules EC19 and EC23 [89, 94, 95].  These studies describe the 
differences in biological activity of the retinoid analogues EC19 and EC23.  A subtle 
difference in the position of the carboxylic acid group between EC19 and EC23 did not 
alter the shape of the molecule but resulted in a large difference in the observed potency.  
This was possibly a result of reduced receptor binding or differential receptor activation.  
Figure 1-8 shows the molecular structures of EC19 (meta isomer) and EC23 (para isomer). 
 
 
 
 
 
 
Recently, data regarding the role of the synthetic retinoid EC23 on stem cell 
differentiation, neural commitment and receptor subtype activation has shown that the 
potency of this small molecule is much greater than its natural counterpart – ATRA.  Due 
to its stability in culture, potency and the increasing knowledge of this compound in stem 
cell differentiation, the use of EC23 to develop neurite outgrowth models is an attractive 
alternative to ATRA.  
 
EC23 EC19 
Figure 1-8 Molecular structures of EC19 and EC23.    
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1.8 CURRENT MODELS OF NEURITE OUTGROWTH  
 
Assessing neurite outgrowth in vitro can be achieved using a number of different models.  
It is necessary to use the model which best resembles neurons in the natural in vivo 
environment.  This is important when investigating neurite regeneration and the role of 
glial scar proteins in neurite outgrowth.  Peripheral and central nervous system neurites 
will respond differently to extracellular cues [96, 97].  In addition, the developmental age 
of the neuron is important as studies have demonstrated an ability of some embryonic 
neurons to overcome the inhibitory environment of the glial scar [98].  Furthermore, 
species differences when using the models for potential therapeutic drug discovery should 
be recognised.   
1.8.1 Cerebellar Granular Neurons 
 
Cerebellar granular neurons (CGN) are a primary cell representative of CNS neurons and 
are used to investigate neurite outgrowth in vitro.  CGN neurons represent a highly 
homogenous population of brain CNS neurons and are the most abundant neuron in the 
brain.  These neurons are most often isolated from post-natal rat cerebellum [99].  Radio, N 
et al (2010) [100] used rat CGN in a high throughput screen of compounds that may affect 
neurite outgrowth.  The study showed using a comparison with PC12 neurites that different 
neural cell models are differentially responsive to chemical treatment and highlighted the 
fact that reduced cell viability was often associated with a loss in neurite outgrowth – 
indicating a toxic effect on the neurites, as opposed to a role in neurite outgrowth 
regulation.  Another study that investigated neurite outgrowth from CGN was described in 
Ahmed, I et al (2006) [101].  This study demonstrated the role of Rho GTPase in neurite 
outgrowth from CGN. Overall many studies have used this model to investigate neurite 
outgrowth from primary CNS neurons. 
1.8.2 Dorsal Root Ganglia 
 
Another well characterised model of neurite outgrowth is dorsal root ganglia (DRG) 
derived neurons.  DRG are derived from neural crest cells during development and migrate 
to the periphery. DRG can be isolated from vertebrates of a number of species, including 
rat, mouse and chicken.  DRG neurites have been used to demonstrate the neurite 
enhancing ability of both retinoic acid and NGF and are ideal for myelination and co-
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culture studies.  The axons that form spread as a halo around a central aggregate and the 
length of the neurites is between 1-3 mm, making quantification of neurite length relatively 
straight forward.  The age and method of derivation of DRG determines how the 
developing neurites will respond to their environment.  Furthermore, it is becoming more 
clear that the age and method of purifying DRG cells determines how the cells will 
respond to their environment, making the route of isolation particularly important when 
designing a specific study [102].  More recently, DRG neurons have been used to 
investigate neural regeneration and models of spinal cord injury [103].     
1.8.3 SH-SY5Y 
 
The cell line SH-SY5Y is a human clone of the bone marrow derived neuroblastoma SK-
N-SH established in 1970 (ATCC).  The cells can be differentiated with retinoic acid, 
responding more to 9cis-RA than all-trans-RA, however, this was not likely through RXR 
homodimer signalling [104, 105]. The cells are mainly used to investigate retinoic acid 
induced neural differentiation [106] and have been used to investigate GDNF induced 
peripheral neurite outgrowth [107].  
1.8.4 PC12 
 
The PC12 cell line is derived from a rat adrenal medulla neuroendocrine tumour known as 
a pheochromocytoma.   The cells are induced to terminally differentiate upon neurite 
growth factor (NGF) treatment and become cholinergic-like neurons [108]. The model is 
used to investigate neural differentiation and neurite outgrowth and to determine the role of 
NGF and retinoic acid signalling during neural development.   Cosgaya, J.M et al (2001) 
[109] demonstrated the cross regulation between NGF signalling and retinoic acid 
sensitivity in PC12 cells during neural differentiation via a Ras dependent mechanism. 
Furthermore, Scheibe, R.J (1992) [110] demonstrated that retinoic acid signalling could 
increase the sensitivity of PC12 cells to NGF by up-regulating the specific NGF receptor.  
This demonstrates a fundamental link between NGF, retinoic and neural commitment and 
neurite outgrowth, making this model good for investigating these links.  It is important to 
realise that this model represents a peripheral neuron and the length of neurites that 
develop are small making quantification difficult.  
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1.8.5 Embryonal carcinoma stem cells 
 
The malignant counterpart of embryonic stem cells is the embryonal carcinoma stem cell 
(hEC) – and has been described earlier.  Two hEC stem cell lines have been derived 
independently and are termed, NTERA2.cl.D1 and TERA2.cl.SP12, both cell lines can be 
induced to differentiate into neurons by all-trans retinoic acid.  Models of neurite 
outgrowth using both cell lines have been described.  Initially the stem cells were 
differentiated and the neural progenitors induced to form neurites on either Poly-D-Lysine 
(P-D-L) and/or Laminin/Matrigel™ substrates.  Tegenege, M.A et al (2011) [111] studied 
a rapid 14 day aggregate differentiation method to induce human neurite outgrowth from 
NTERA2.cl.D1.  The study demonstrated migration of individual neurites from the 
differentiated aggregate when placed on P-D-L and Matrigel™.   Neurite outgrowth from 
each neuron could then be measured under different conditions.  The neurites expressed the 
neural specific antigen TUJ-1 and outgrowth was regulated by cAMP dependent signalling.  
Similar to NTERA2.cl.D1, the TERA2 clone SP12 could be induced to differentiate into 
neurons with high efficiency.  The cell line has been used to investigate neural 
differentiation and as a model system for investigating neurite outgrowth [112].  Due to the 
often limited differentiation potential of hEC stem cell the yield of neural progenitors is 
high.  This makes the cells useful for investigating human neurite outgrowth in an efficient 
and ethically acceptable way.   
1.8.6 Embryonic stem cells 
 
Neural differentiation from human embryonic stem (hES) cells offers the ability to produce 
high numbers of defined neural subtypes for use in neural differentiation and neurite 
outgrowth studies.  Due to the low yield and culture heterogeneity of embryonic stem cell 
differentiation few studies have used hES cells to investigate neurite outgrowth.   Although 
hES and other species of embryonic stem cells can be induced to form axons, 
quantification and high throughput screening of compounds using these cells is still in the 
early stages of research. Ma W et al (2008) [113] measured neurite number and neurite 
length from differentiated hES cells grown on a variety of extracellular matrix substrates 
and determined neurite outgrowth differences – neurites grown on Laminin produced the 
most outgrowth.  However, the total length and difference between substrates was very low 
making the accuracy of this study limited.  Laminin induced a maximum outgrowth of 90 
µm, whereas Fibronectin and Collagen induced a length of 40 µm.  Lin, L et al (2006) 
31 
 
 
 
[114] used a mouse embryonic stem cell model to investigate neurite outgrowth, large 
numbers of neurites were produced from aggregates of neural progenitors, however; again 
the neurites that formed were short, control cultures extended neurites to around 100 µm.  
Therefore, although hES cells are an attractive model of human neural development and 
outgrowth, optimisation of neurite outgrowth must follow the optimisation of neural 
differentiation for high throughput screening to be beneficial and outcompete other models 
that are easier to quantify and have less ethical issues.  
1.8.7 Induced pluripotent stem cells 
 
A relatively recent advance in the use in stem cells for neural development and neurite 
outgrowth comes from the ability to derive stem cells from human somatic cells.  Inducing 
somatic cells such as fibroblasts in the skin to become pluripotent and have the ability to 
form any one of the three germ layers – mesoderm, ectoderm or endoderm, has 
revolutionised disease modelling and potential therapeutics from stem cells [115].  
Induction of pluripotency can be achieved through multiple methods however each method 
is a different way of inducing the expression of pluripotency genes in non-pluripotent cells.  
The number and type of pluripotency genes required depends on the starting cells used. 
Chang, T et al (2011) [116], measured neurite outgrowth from an iPSCs derived from the 
fibroblasts of a patient suffering with the genetic motor neuron disorder spinal muscular 
atrophy (SMA).  Differentiation of the iPSCs into neurons demonstrated a reduction in 
motor neuron formation and neurite outgrowth abnormalities.  Therefore, the use of iPSCs 
in this instance may be beneficial at screening for patient specific compounds that can 
enhance neurite outgrowth in a genetic disease state.  
1.8.8 3D models of neurite outgrowth 
 
Using the cells described above multiple studies have focussed on making the models of 
neurite outgrowth more physiologically relevant.  By combining neural progenitors with 
functionalised or biomimetic scaffolds 3D models of neurite outgrowth can be developed.  
Numerous methods have been used to produce 3D neurite outgrowth and these usually 
require the presence of a permissive extracellular matrix protein such as Laminin [117].   
Aligning the scaffolds can also achieve directed neurite outgrowth for use as conduits. 
These models are often used in conjunction with animal spinal cord injury to demonstrate 
32 
 
 
 
the ability to enhance outgrowth [118].   The cell line of choice is often DRG explants as 
they extend long neurites from an aggregate making quantification easier.  Multiple studies 
have used aligned polymers to guide the neurites, however, as with 2D growth only one 
surface of the developing neurite is exposed to the ECM [119-121].  Furthermore, many of 
these studies involve co-culture with supportive cells such as Schwann or astrocytic cells 
that can enhance neurite outgrowth and aid regeneration. 
Other 3D neurite outgrowth assays use gels or hydrogels that are composed of ECM 
molecules that promote outgrowth such as collagen and Laminin [96, 122].  The neurites 
form inside the gel, these models are difficult to quantify.  Small molecule treatment and 
manipulation of neurite outgrowth often requires functionalization of the scaffold making 
high throughput screening difficult due to the time required to optimise production [123, 
124].  Balgude, A.P et al (2001) [125] investigated the effect of stiffness of an agarose 
hydrogel on neurite outgrowth from DRG. The study demonstrated that as the % of 
agarose in the gel increased from 0.75 % to 2 % there was a decrease in neurite outgrowth 
length. The study also described the change in growth cone from 3D to 2D, where the 3D 
growth cone was more spherical as opposed to the flattened 2D growth cone seen in many 
studies.  
Other scaffolds made from porous biomaterials provide the most 3D like culture with the 
neurites in contact with each surface of the scaffold.  The scaffold can be functionalised 
rapidly via coating with ECM proteins and cell media can be supplemented with test 
compounds.  Multiple studies have used this method to induce 3D neurite outgrowth [112, 
126]. Hayman, M.W et al (2005) [112], demonstrated using a porous polystyrene scaffold 
that neurites from differentiated TERA2.cl.SP12 EC cells will grow in 3D, furthermore, 
coating the scaffold with a combination of Laminin and P-D-L enhanced neurite outgrowth 
better than coating with P-D-L alone. Interestingly, this study demonstrated that P-D-L 
coating was required for neurites to attach to the scaffold and Laminin was then used to 
enhance neurite outgrowth from neuroprogenitors.  The study also demonstrated the ability 
of this scaffold to be coated easily with ECM molecules that regulate neural differentiation.   
In vitro models of neurite outgrowth will be useful when investigating disease pathologies 
that affect neurite development.  In addition, by modelling the pathophysiological states in 
vitro, screens of small molecules can be tested for their ability to overcome inhibition of 
neurite outgrowth. These models important are tools to aid studies into the molecular 
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processes that occur under different disease conditions or inhibitory environments such as 
those that develops through spinal cord injury.  
1.9 SPINAL CORD INJURY 
 
Traumatic spinal cord injury (SCI) is a life changing and debilitating event that affects 
approximately 12,000 people every year in the United States, with around 273,000 people 
living with the disability.  The causes of traumatic injury can be the result of a range of 
events including but not exclusively: Road traffic accidents; sport; violence and falls; with 
road traffic accidents accounting for 36.5 % of all SCI events [127].  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cervical nerves 
 C1-C8 
Thoracic nerves 
 T1-T12 
Lumbar nerves  
L1-L5 
Sacral nerves and coccygeal nerve  
(S1-S5, C0) 
Figure 1-9 Levels of human spinal cord and injury.  The level of spinal cord injury determines the 
extent of paralysis and loss of function for the patient.  Injury to cervical nerves results in potential 
functional loss of all muscles including those that control breathing.  Injury to thoracic level nerves 
(T1-T12) can result in loss of innervation to the legs and/or the trunk.  Lumbar level injury (L1-L5) 
results in loss of sensation in the hip and legs with varying patterns of sensation.  Injury to the sacral 
nerves causes loss of perineum sensation [3].  Figure adapted from Hoa et al (2009) [8].  
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The level of paralysis caused by traumatic spinal cord injury is determined by the area of 
the spine that is damaged.  Injury to anterior spinal cord cervical level segments often 
results in full or partial quadriplegia.  As the level of spinal cord injury becomes more 
posterior the resulting paralysis is reduced as the brain receives input from the undamaged 
neurons.  To aid diagnosis and treatment a classification of the level of spinal cord injury is 
categorised into five levels these are [128]: 
Category A: Complete spinal cord injury – no motor or sensory function in the sacral 
segments S4-S5 
Category B: Incomplete spinal cord injury – sensory function is preserved below the level 
of injury including sacral segments S4-S5 however, motor function is not preserved. 
Category C: Incomplete spinal cord injury with preserved motor function below the site of 
trauma – motor function is defined by more than half of the key muscle s having full range 
of movement against gravity and an active muscle grade less than 3.  
Category D: Incomplete spinal cord injury with preserved motor function below the site of 
trauma – motor function is defined by at least half of key muscles having full range and 
active muscle grade 3 or more. 
Category E: Normal – motor and sensory function is normal.  This does not rule out spinal 
cord injury.  
Traumatic spinal cord injury has had some high profile backing particularly from 
celebrities most notably the actor Mr C Reeve (1952-2004).  Christopher sustained injury 
to his cervical spinal cord after falling from a horse in 1995, paralysing him from the neck 
down.  
Research into the treatment of traumatic spinal cord injury has taken a number of different 
approaches recently, including the use of stem cell-based therapies to induce neural 
regeneration; bio-engineering scaffolds to aid neural growth and technology to facilitate 
the independence of patients that have suffered the disability. Understanding the glial scar, 
the mechanisms by which neural regeneration is inhibited and ways of overcoming the 
inhibition will be necessary for the development of future therapeutics.  
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1.10 THE GLIAL SCAR 
 
Traumatic spinal cord injury (SCI) as was described in the previous section can result in 
total or partial paralysis.  Although the cause and effect of the disability are well described 
treatments remain largely incomplete and in the most severe cases aim solely to sustain 
life.  
Hu, R et al (2010) [129], used an in vivo rat model of chronic spinal cord injury to 
demonstrate glial scar and cavity formation by the activation of astrocytes. The resultant 
scar inhibited axon formation after 4 weeks post-injury.  Some regeneration was 
demonstrated for 1-2 weeks post injury, underlining the regenerative potential of these 
neurites.  These data demonstrate the potential of an ideal time window for therapies to 
prevent the loss of axonal processes post SCI.  Understanding the process of scar formation 
and the mechanisms behind axon inhibition will directly influence the development of new 
therapeutics in the area.  
1.10.1 Development of the glial scar 
 
The scar that forms after chronic spinal cord trauma is composed of four distinct areas – 
glial scar, glial limitans, fibrotic scar and the cavity (Figure 1-10).  Each area inhibits 
neurite regeneration either mechanically or biochemically.  The cavity of the scar is fluid-
filled and the thickness of the scar around the cavity is different rostral and caudally, 
making the level of neurite inhibition and regeneration heterogeneous [129].  Surrounding 
the cavity is a fibrotic scar, which comprises fibroblasts and segmented collagen creating a 
mechanical barrier to neurite outgrowth.  Around this zone is a limiting boundary of glial 
cells that marks the transition into the glial scar – an area that is composed of reactive 
astrocytes and large deposition of extracellular matrix proteins.  The glial scar is highly 
inhibitory to axonal development and neurite regeneration [130, 131]. 
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Reactive astrocytes  
Chronic damage to the spinal cord results in glial scar and cavity formation predominantly 
produced by the activated response of astrocytes at the site of injury.  Astrocytes are 
abundant in the CNS and post SCI the local astrocytes are thought to be activated by TGF 
β undergoing genetic and morphological changes to become reactive [132].  Reactive 
astrocytes are characterised by high GFAP levels, a star shaped phenotype under 
histological analysis and the production of ECM into the area of injury – they retain their 
unique domains upon activation [132].  Since ‘reactive astrocytes’ compose a large cellular 
component of the glial scar and are thought to be responsible for producing inhibitory 
chondroitin sulphate proteoglycans they have been investigated in multiple studies as a 
potential target for SCI therapies[133-136]. In addition to reactive astrocytes that are 
proximal to the lesion site, migratory astrocytes and astrocytes derived from stem cells, 
other cell types also respond to SCI.  Cells such as neuron-glial antigen 2 progenitors 
(NG2), ependymal cells and meningeal cells undergo trans differentiation to become 
Figure 1-10 Schematic detailing the structure of a chronic traumatic spinal cord injury 
scar.  Four distinct areas of the scar interact with developing neuritis either mechanically or via 
receptors to inhibit neurite regeneration.  These include a cavity, fibrotic scar, the glial limitans 
and the glial scar.  Figure adapted from Yuan et al (2013) [6].  
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reactive astrocytes and contribute to scar formation [137-139].  Furthermore, it was 
demonstrated by Hirsch and Bahr (1999) [140] that the axon inhibitory properties of 
meningeal cells in the glial scar is much more potent than inhibition by the inhibitory 
environment produced by reactive astrocytes. This was a likely result of increased keratin 
sulphate expression and a decrease in expression of the neural cell adhesion molecule 
(NCAM) in activated meningeal cells. 
Scar extracellular matrix 
After traumatic SCI TGF β signalling causes reactive gliosis, the astrocytes become 
reactive and begin producing large amounts of extracellular matrix proteins into the site of 
injury to form a scar.  The large spinal processes of astrocytes create a lattice which bind 
the ECM proteins together and mechanically inhibit neurite outgrowth and regeneration 
[132].  It is now largely accepted that the ECM molecules that are excreted by reactive 
astrocytes are inhibitory to neurite regeneration, induce neurite retraction and growth cone 
collapse.  A major inhibitory ECM protein family that has been widely studied are the 
Chondroitin sulphate proteoglycans (CSPG) [141], CSPGs have been shown to be up-
regulated in the glial scar [142, 143] inhibit neurite outgrowth in vitro and their removal in 
vivo results in partial neural regeneration [144] - CSPGs provide an inhibitory environment 
to neurite regeneration in the chronic injured spinal cord.  
Chondroitin sulphate proteoglycans 
CSPGs are a family of proteoglycan molecules that have attached negatively charged 
repeating disaccharide units or glycosaminoglycan (GAG) [135].  CSPGs have varying 
numbers of GAG chains bound to a protein backbone; the number of side chains affects the 
biological activity.  Chondroitin sulphate regulates CSPG attachment to proteins in the 
ECM controlling activities such as axonal guidance and path finding.  The lectican family 
of CSPG consist of four glycoproteins -Brevican, Neurocan, Versican and Aggrecan, all of 
which are expressed in CNS tissue.  Aggrecan was thought to be restricted to cartilage 
expression, where Neurocan, Versican and Brevican regulate neural development and 
plasticity in the CNS [2].  However, it has been demonstrated that Aggrecan is also an 
integral structural protein in the CNS making up part of the perineuronal nets in the brain 
and helping define glial boundaries.   All four of the CSPGs are composed of the N-
terminal G1 domain and the C-terminal G3 domain, in addition Aggrecan has a short G2 
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domain near to the C-terminus and some keratin sulphate chains in the N-terminus of the 
molecule (Figure 1-11). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Up regulation of CSPGs in the glial scar is inhibitory to neurite outgrowth and this is due 
to the glycosaminoglycan side chains attached to each protein back-bone.  The number of 
potential GAG chains is highest for Aggrecan with around 120 binding sites per molecule 
which decreases to 20 for Versican, 7 for Neurocan and 3 for Brevican [2].  Therefore, it is 
likely that the inhibitory potential of Aggrecan is greater than that for the other CSPGs.  
Evidence for the inhibitory potential of CSPG on neurite outgrowth came from studies on 
DRG and cerebellar granular neurons [145, 146], which demonstrate a preferential growth 
on Laminin ECM than on CSPG or keratin sulphate proteoglycan.  Aggrecan has been 
used in multiple models of the glial scar to investigate the role of CSPGs as culturing 
neural progenitors on an Aggrecan substrate potently inhibits neurite outgrowth [98, 147].   
Aggrecan Versican Neurocan Brevican 
G3 G2 G1 
Figure 1-11.  Domain structures of the four lecticans – Aggrecan, Versican, Neurocan and 
Brevican.  All four lecticans contain the G1 and G3 domains in addition Aggrecan contains a G2 
domain and additional keratin sulphate chains (green).  Figure adapted from Yamaguchi, Y 
(2000) [1, 2].  
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CSPG receptors  
Until relatively recently the glial scar and especially the matrix of astrocytic processes 
were thought to provide mechanical inhibition to neurite outgrowth and regeneration, 
however, using modern molecular biology it has been possible to establish that two protein 
tyrosine phosphatase receptors regulate receptor mediated inhibition of neurite outgrowth 
and regeneration [148]. 
The two receptors that have been characterised are the protein tyrosine phosphatase (PTP) 
σ receptor [149] and a leukocyte common antigen related protein tyrosine phosphatase 
(LAR) [150].  A schematic showing the general structure of both enzymes is described in 
Figure 1-1-12. Shen, Y et al (2009) [1] demonstrated in a cell free assay the binding of 
PTPσ receptor to CSPGs, furthermore, the receptor bound to Neurocan on astocytic cells 
and was shown in a knockout DRG system to significantly reduce neurite outgrowth. 
Similarly, Fisher, D et al (2011) [148] showed LAR activation by CSPGs in a non-
neuronal assay using COS-7 cells and that inhibition of neurite outgrowth in cerebellar 
granular neurons was by LAR in an AKT and RhoA dependent mechanism. These two 
studies describe the role of these receptors in the inhibition of neurite regeneration after 
spinal cord injury.  
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Figure 1-1-12. Structure of protein tyrosine phosphatase receptors. The transmembrane 
receptor has two intracellular protein tyrosine phosphatases multiple extracellular Fibronectin type 
III like domains and multiple immunoglobulin like domains.  
 
1.11 MODELLING THE GLIAL SCAR 
 
Modelling the glial scar in vivo and in vitro have distinct individual advantages however, 
both aim to either elucidate the mechanisms of CNS injury and neural regeneration with 
the objective to better understanding targets for regenerative therapies. The glial scar 
model used will depend on the hypothesis being tested and the complexity of the model 
should mirror the biological environment required to test the hypothesis.  In vivo models 
have much more complexity surrounding the biological response to CNS injury compared 
to in vitro neural models, this allows for whole system dependent hypothesis to be tested.  
In vitro assays provide more specific answers to biological questions and help elucidate 
key biological mechanisms.  One major advantage of using in vitro over in vivo models is 
Protein tyrosine phosphatase 
Fibronectin type III like 
domain 
Immunoglobulin like domain 
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the potential to test human neural regenerative potential in vitro.  Some of the current 
models of the glial scar are discussed below in context with their use in the literature. 
 
1.11.1 Current in vivo models of the glial scar  
 
The majority of in vivo spinal cord injury and glial scaring models use either rats or mice 
with injury to the spinal cord in these models performed under anaesthetic and usually via 
a transection, hemisection or contusion injury [151].  It is thought that the rat glial scar that 
forms after injury best recapitulates that seen in the human situation, due to the large cavity 
that develops as opposed to mouse where the lesion site is composed of a dense 
accumulation of fibrous connective tissue [152].  An advantage of using mouse models is 
the ability to knock out whole genes to determine their effect on glial scar formation and 
neural regeneration. Schreiber, J et al (2013) [153] used a mouse knockout of tenascin-C to 
investigate the role of this ECM molecule on glial scar formation and neurite regeneration.  
This model was useful since in vitro tenascin-C had both neurite promoting and inhibitory 
effects. The study demonstrated that this molecule regulated inflammation post-injury; was 
involved in regulating the composition of the glial scar ECM and resulted in the facilitation 
of neurite regeneration.  
In vivo studies on rats have been used to demonstrate the up-regulation of CSPGs after 
both cervical and thoracic hemisection, it was shown that chondroitinase ABC could be 
used to create a permissive environment for DRG transplantation and neurite outgrowth 
into the scar [154].  Furthermore, Chan, C.C et al (2007) [155] demonstrated that the 
known small molecule ROCK inhibitor Y-27632 could regulate CSPG production in vivo, 
however, required an in vitro model to discern effects on neurite outgrowth.  These studies 
demonstrate in whole systems that the glial scar inhibits neurite outgrowth, furthermore, 
this inhibitory environment has the potential to be overcome by developing neurites.    
Although physiologically these models are relatively close to human neurons and will act 
in a similar way upon injury, there will be subtle differences that may affect the way the 
neurons respond to treatment, making translation from in vivo models to clinical treatments 
difficult.  Furthermore, using whole animals to study spinal cord injury may make the basic 
biological mechanism and interactions between cells in the injured spinal cord difficult to 
elucidate due to the complex interaction between systems.  Ethically animal usage is under 
a lot of pressure to reduce failed experimentation and wastage. This makes it difficult to 
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complete high throughput screening of potential therapeutic compounds using animal 
models due to wastage and expense.  
 
1.11.2 Current in vitro models of the glial scar 
 
In vitro modelling of the glial scar utilises the neurite outgrowth model cells described 
earlier.  Neurite outgrowth can be manipulated by altering growth media supplementation 
or culture substrate.  By altering the extracellular matrix the neurites develop on, a model 
of neurite inhibition can be developed. Through supplementing the culture media or 
treating the culture substrate methods of enhancing neurite outgrowth and overcoming 
neurite inhibition can be investigated.  The major advantages of in vitro models is the 
ability to perform high throughput screening of test compounds and investigate biological 
mechanisms between individual proteins or cell types and neurite regeneration.  
Manipulating the coating substrate that DRG, CGN and hEC derived neurons are induced 
to form neurites on is useful for investigating the interaction between neurite development 
and the ECM.  Jin, Y et al (2011) [156] used 1 mm strips of filter paper saturated in CSPGs 
to investigate the lentiviral expression of Chondroitinase ABC and its ability to induce 
neurite outgrowth from chick DRG on the inhibitory CSPG substrate.  Similar methods 
have been described using CGN [157, 158] and hEC derived neurites [159].  These models 
utilise a relatively simple 2D method of coating a substrate and investigating its effect on 
neurite length and number.  Enhancing outgrowth on the 2D inhibitory substrate using 
small molecules and other compounds are potential therapeutics for spinal cord injury.  
Using human stem cell-derived neural progenitors is an efficient way to investigate human 
neurite regeneration in 2D on an inhibitory substrate.  Regulation of ROCK activity, 
integrin stabilisation and enzymatic degradation of CSPGs GAG side chains have all been 
demonstrated in 2D models of the glial scar [155, 160, 161].  
In addition to in vitro 2D models of the glial scar, some 3D culture systems are also 
investigating the interaction between developing/regenerating neurites and molecules that 
make up the glial scar ECM.  The translation to a 3D model is more physiologically 
relevant to the in vivo situation and the use of human stem cell-derived neurons can 
enhance the physiological relevance. 3D models often utilise ECM coated scaffolds or 
functionalised scaffold that can be used to either investigate neural regeneration or act as 
conduits to overcome the inhibitory glial scar environment.  It has been demonstrated that 
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co-culture with other cell types in 3D enhances neural regeneration in vivo; furthermore, 
directed neurite outgrowth by 3D scaffolds will aid functional recovery [120, 162].  Few 
3D models have investigated the molecular mechanisms of the neural-glial scar interaction 
and this is likely a result of the difficulty in quantifying 3D neurite outgrowth. 
1.12 PATHWAYS INVOLVED IN NEURITE REGENERATION 
1.12.1 Rho associated protein kinase (ROCK) inhibition  
 
As described earlier neuronal signalling through the PTPσ or LAR receptors by CSPG 
molecules in the CNS results in loss of neurite outgrowth and neurite retraction.  The 
cellular signalling cascade that follows receptor signalling activated mediators such as 
RhoA and P160 ROCK, which induce changes in gene expression and cytoskeletal 
architecture [148, 163-165].    
Monnier, P.P et al (2003) [158] demonstrated using embryonic day 6 chick retinal explants 
that CSPGs inhibit neurite growth in vitro and this can be overcome by inhibition of 
ROCK signalling.  Inhibition of ROCK was achieved using the synthetic inhibitor Y-
27632. This work demonstrated nicely up-regulation of CSPG in the damaged spinal cord 
and inhibition of neurite outgrowth via ROCK activation.  Other studies used human EC 
derived neurons, DRG neurons, rat cerebellar neurons and optic nerve neurons to 
demonstrate the same process [159, 166].  ROCK inhibition can be achieved directly by Y-
27632 treatment or through up regulation of cAMP and RhoA inhibition using C3 
transferase.  Either way, inhibition of this signalling cascade at multiple levels was 
demonstrated to overcome at least partially, neurite outgrowth inhibition induced by 
CSPGs.  
It is thought that ROCK acts by phosphorylating collapsing response mediator protein-2 
(CRMP-2), destabilising it and inhibiting its positive effect on neurite outgrowth. CRMP-2 
is found at high levels in developing neurites in the CNS.  Phosphorylation of CRMP-2 
results in growth cone collapse and neurite retraction, whereas overexpression enhances 
neurite outgrowth [167] making this protein a promising target for neural regeneration. 
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1.12.2 Retinoic acid receptor β  
 
In the regenerating newt limb a small molecule diffuses from the regenerating limb mass 
(blastema) to provide guidance and outgrowth signals to neurons in the spinal cord.  
Dmetrickhuk, J.G (2005) [168] demonstrated that a bead containing retinoic acid could 
provide similar neuronal outgrowth cues to neurons as that seen in vitro with a blastema. 
Furthermore, this effect is inhibited by the RAR β receptor antagonist LE135 indicating 
that retinoid signalling within the regenerating limb of a newt may be involved in neurite 
outgrowth from the spinal cord in vivo.  
The neurotropic factor NGF β , is used routinely to induce neurite outgrowth in a number 
of in vitro models of neurogenesis from primary cell lines (DRG) and neuroblastoma cells 
(PC12), providing evidence that neurotrophins may be involved in the initiation, stability 
and subsequent outgrowth of developing/regenerating axons.  Recent studies have 
implicated retinoic acid (RA) as a downstream target of NGF β signalling. So, P.L et al 
(2006) [169] demonstrated that DRG from RAR β null mice treated with 0.1 μM RA for 3 
days did not form as many NF200 expression neurites than wild type DRG and those that 
did form were significantly shorter.  This implicated RAR β signalling in neurite 
outgrowth; furthermore, RAR β null DRG cells treated with 20 ng/ml NGF β had a 
reduction in the average length of neurite compared to wild type DRG, suggesting that 
NGF β acts at least partially through RAR β.  NGF β is known to act upstream of RAR and 
has been shown to induce expression of RAR β [109] further implicating RAR β in the 
ability of NGF β to induce neurite outgrowth. The induction of RAR β expression and 
subsequent neurite outgrowth may be in part due to NGF β inducing the production of 
enzymes involved in the production of RA. 
As described previously retinoids are essential for proper embryonic axis formation and 
CNS development.  The role of retinoid in neurogenesis is complex owing to the three 
retinoic acid receptors RAR α, RAR β and RAR γ and their respective isoforms. It is 
known that the receptors have some functional redundancies; however, many of the effects 
seen in cells treated with retinoic acid are a direct response to activation of a specific RAR 
subtype.  Piu, F et al (2005) [170] treated NTERA2/D1 EC cells with 10 μM RA or one of 
three RAR β selective agonists for 7 days, the cells were then fixed and stained for Gap43 
expression.  The author concluded that the cells were differentiating in response to the 
RAR β selective compounds, however, the undifferentiated control also expressed Gap43 
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immunostaining and the extensions seen after 7 days in the EC cells were not characteristic 
of developing neurites and no further maturation of the neurons was performed.  It has 
been recently demonstrated that at least 12 days of continuous ATRA treatment is required 
for neuronal differentiation in NTERA2.cl.D1 EC cells [171]. 
In neuroprogenitor cells such as primary DRG and neuroblastoma the RAR β2 isotype has 
been strongly implicated in neurite outgrowth [169].  Up regulation of rat RAR β2 in DRG 
has been shown to induce neurite outgrowth and functional regeneration of synapses when 
co-cultured with spinal cord in vitro [172].  Elevated RAR β2 expression has been detected 
in injured rat cerebral cortex which is further induced in the presence of an RAR β2 agonist 
[173] indicating that the receptors required for axonal regeneration are present.  Corcoran, 
F et al 2000 [174] utilised receptor specific agonists of RAR β, α and δ to show that NGF 
and NT-3 dependent DRG neurons require synergistic signalling through RAR β2 and 
neurotropic factors for maximum neurite outgrowth. Conversely signalling through RAR γ 
can inhibit neurite outgrowth via down regulation of RAR β2 
Studies utilising newly developed RAR β agonists such as CD2019 demonstrate the ability 
of small lipophilic retinoid analogues to diffuse and affect damaged neurons in vivo [173]. 
Although ATRA acts as an agonist for RAR β2 and will induce neurite outgrowth, gene 
expression is heterogeneous and nonspecific agonists of the RAR may not be optimum for 
neuritogenesis as many of the other RAR have been implicated in genes not associated 
with neuronal differentiation or maturation.  Furthermore, RAR β selective agonists have 
been shown to induce motor neuron lineage commitment in a neuroprogenitor cell line in a 
concentration dependent manner and induce neurite outgrowth in these cells.  However, to 
maintain mature neuronal differentiation signalling through RARα is required [175]. 
Investigation into the ability of compounds such as NGF β and RAR selective retinoid to 
enhance neuritogenesis can be difficult due to the ability of developing neurons to form 
multiple axons.  In vitro neurogenesis often results in a spaghetti type structure making it 
difficult to determine the length or origin of any one neurite (Figure 1.6.2). This makes 
determining any effect on neuritogenesis almost impossible.  Some in vitro cell systems are 
better than others and often rely on a low density of neuroprogenitor cell such as PC12 or 
rat cerebella granular cell as were described earlier. 
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1.12.3 Glycogen synthase kinase 3β 
 
The role of AKT inhibition and subsequent GSK3β inhibition has been shown to play at 
least a partial role in the inhibitory effect of CSPGs on neurite outgrowth [148].  It was 
demonstrated by Alabed, Y.Z et al (2010) [176] that GSK3β inhibition, inhibited neurite 
outgrowth from DRG neurons, and this was likely at least an effect of collapsing response 
mediator protein-4 (CRMP4) inhibition. Furthermore, multiple studies have described the 
requirement of GSK3β in axonal polarity at the growth cone [177, 178].  These studies 
demonstrate that GSK3β signalling is required for neurite outgrowth; however, there is 
some evidence to suggest the opposite effect is true, where GSK3β activation resulted in 
loss axonal outgrowth.  Wang, Y et al (2012) [179] demonstrated in rat cortical neurons 
that GSK3β signalling induced growth cone collapse and neurite retraction via repulsive 
guidance molecule-a (RGM-a) dependent pathway.  RGM-a signalling caused CRMP-2 
phosphorylation ultimately resulting in neurite retraction.  The study demonstrated that 
although there was no evidence for phosphorylation of CRMP-2 by GSK3β, inhibition of 
GSK3β resulted in loss of RGM-a activity which was shown to be directly responsible for 
the destabilisation of CRMP-2 and loss of outgrowth. 
Due to the pleiotropic effect of signalling effectors such as GSK and the cross regulation 
between PI3K, AKT and GSK3β it is not surprising that the role of the GSK signalling 
cascade is dependent on the model used to investigate the relationship.  It is likely that both 
studies are correct and that GSK3β signalling is part of a complex signalling pathway and 
the outcome on neurite growth depends on other factors as well.  
1.12.4 Chondroitinase ABC treatment  
 
Inhibition of neurite outgrowth in human neurites is induced by CSPGs present in the glial 
scar.  The molecular pathway that induces loss of outgrowth is dependent on the binding of 
glycosaminoglycan (GAG) side chains attached to the proteoglycan backbone, to receptors 
on the growth cone of regenerating or developing neurites. Molecules or enzymes that 
prevent binding or activation of this receptor will ultimately prevent down stream 
signalling of ROCK and as was discussed earlier it is likely neurite outgrowth mediators 
such as CRMP-2 will not be disrupted.  
The bacterial enzyme Chondroitinase ABC is known to cleave chondroitin sulfate GAG 
from CSPGs and make glial scar explans permissive to neurite outgrowth [141]. Other 
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evidence came from treating the extracellular matrix produced by reactive astrocytes with 
Chondoritinase, again making the environment permissive to neurite outgrowth [180].  
More recently,Vahidi, B  et al (2008) [157] demonstrated using a microfluidic device using 
strips of the CSPG – Aggrecan, that rat cortical neurons can grow into the inhibitory 
Aggrecan environment after the Aggrecan strips are treated with chondroitinase ABC for 
30 minutes. 
It is thought that in vivo, Chondroitinase treatment to an injured spinal cord can aid 
regeneration via a number of mechnaisms, including inhibition of the downstream 
signalling associated with GAG receptor binding (ROCK etc), freeing up Laminin in the 
extracellular matrix to allow integrin binding [181], liberating growth factors in the glial 
scar bound in the CSPG matrix [182] and finally there is some evidence to suggest CSPGs 
can modulate inflammation in the glial scar [183]. 
The enzyme is not present in humans, but can be isolated from cultures of Proteus 
Vulgaris, furthermore, lentivirus vectors can be use for targetted expression of the enzyme 
to developing/regenerating neurites aiding their regeneration in the inhbitory glial scar 
environment [156]. 
It is likely that a therapy to aid the regeneration of neurons in the inhibitory glial scar will 
involve multiple methods described above including Chondroitinase treatment and small 
molecule modulation of signalling pathways.  
1.13 CONCLUSIONS  
 
In conclusion, as our understanding of the glial scar increases, more physiologically 
relevant models can be developed and used to investigate small molecule modulation and 
enhancement in the inhibitory environment.  Using human stem cell-derived neurons in a 
model of the glial scar is necessary for enhancing the physiological relevance.  This review 
described the role of retinoids in development and neural differentiation highlighting key 
signalling pathways and limitations in the use of retinoids.  Knowledge of the retinoid 
pathway and small molecules that can specifically target key receptors involved in retinoid 
induced neural differentiation will enhance the yield and subtype selectivity of stem cell-
derived neurons. 
Translating the advancement in stem-cell differentiation protocols and tools into usable, 
relevant models of the glial scar will require knowledge of the interaction between 
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components of the scar and the neuron.  As 3D models become increasingly important for 
investigating these interactions combining current advances in biomaterials, stable retinoid 
analogues and knowledge of the glial scar is necessary for studying human neurite 
outgrowth in a 3D inhibitory glial scar like environment. 
1.13.1 Project Aims 
 
This project aims to build upon current knowledge of small molecule induced stem cell 
differentiation, investigating the role of structure-function relationships during the 
induction of stem cell differentiation and neural commitment.  Furthermore, this project 
aims to create a novel model of human neurite outgrowth, by combining small molecule 
tools with modern bioengineering to produce an efficient model of the glial scar that is 
physiologically relevant.  The model will be used to investigate novel signalling pathways 
that can enhance neurite outgrowth in the inhibitory environment of the glial scar. 
1.13.2 Project Objectives 
 
 Investigate small molecule induced neural differentiation from human pluripotent 
stem cells. 
 Develop a model of human neurite outgrowth in conventional 2D culture and use 
this model to investigate small molecules that can overcome the glial scar. 
 Develop a novel 3D model of the glial scar using human stem cell-derived neurons 
and use this model to investigate small molecules that can enhance neurite 
outgrowth in 3D. 
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CHAPTER 2 MATERIAL AND METHODS 
 
2.1 CELL CULTURE 
2.1.1 TERA2.cl.SP12 embryonal carcinoma stem cells 
 
The human embroynal carcinoma stem cell line TERA.cl.SP12 is a subclone isolated from 
TERA-2 embryonal carcinoma cells by Stefan Przyborski (Durham University) [84].  The 
TERA-2 cell line was originally isolated from a human lung metastasis of a primary 
embryonal carcinoma in the testis  [184]. 
Adherent mono-layer culture maintenance and passaging 
TERA2.cl.SP12 EC cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, high glucose, Lonza BE12 614F) supplemented with 10 % foetal calf serum 
(Sigma 10270), 2 mM L-glutamine (Lonza BE17 605F) and 100 active units of Penicillin 
and Streptomycin (Lonza DE17 602F). Cells were incubated at 37 °C in a 5 % CO2 
humidified atmosphere. Cells were propagated in T75 plasma treated tissue culture flasks 
(NUNC 353136) and passaged every 3-4 days when the cells reached 95 % confluence. 
Passaging of the cells was by dislodging the cells using x 5 acid washed glass beads 
(Fisher Scientific G/0300/50) in 3 ml fresh culture media.  Cells were then split 1:3 and re-
seeded in a T75 cell culture flask in 20 ml fresh media and incubated.  
Creating a single cell suspension 
A single cell suspension was achieved by the following procedure: Cell culture medium 
was aspirated and the cells were washed once with 3 ml of sterile PBS to remove excess 
medium. Cells were then incubated with 3 ml 0.25 % trypsin/2 mM EDTA (Sigma T4049-
100 ml) for 2-3 minutes. Detached cells were visualised under a x 10 objective using a 
light microscope, attached cells were dislodged by short sharp blows to the side of the 
culture flask. Once all of the cells were detached they were transferred to a 15 ml falcon 
tube containing 6 ml culture medium to inhibit trypsin. Cells were then pellet by 
centrifugation at 800 rpm for 3 minutes and the supernatant aspirated. A single cell 
suspension was then produced by re-suspension of the pellet in 1 ml medium using a 1 ml 
pipette. Cells could then be counted using a haemocytometer before reseeding at an assay 
dependent concentration.   
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Storage of TERA2.cl.SP12 
Storage of TERA2.cl.SP12 grown as an adherent monoculture was at -140 °C in FBS 
supplemented with 10 % DMSO (Sigma D8418).  Cells were split 1:3 from a 95 % 
confluent T75 and re-suspended in freezing medium, cells were then slowly frozen.  
Thawing of cells was performed rapidly from -140 °C in a 37 °C water bath.  Cells were 
then transferred into a 15 ml falcon tube (Fisher) containing 10 ml of warm TERA2.cl.sp12 
maintenance media.  Cells were centrifuged at 800 rpm for 3 minutes and the DMSO 
containing media was removed by careful aspiration into 20 % Trigene. Cells were then re-
suspended in 10 ml of fresh media and seeded into a T25 and incubated at 37 °C in a 5 % 
CO2 humidified atmosphere for 2-3 days before passaging into a T75 1:1.  
Suspension culture maintenance and passaging 
For suspension culture 1.5 x 106 cells were re-suspended in 20 ml of normal maintenance 
media and incubated overnight in an untreated 90 mm bacteriological Petri dish (Fisher).  
Cells were left to aggregate overnight before the addition of any experimental compounds.  
Replacement of media and passaging of aggregates could be achieved by transferring the 
suspension into a 50 ml falcon tube and leaving the aggregates to settle for 10 minutes.  
After 10 minutes the old media was carefully aspirated. Fresh maintenance media was 
added and the aggregates re-suspended by swirling the media.  Aggregates in suspension 
were then placed in a fresh 90 mm bacteriological Petri dish by gentle pouring and 
incubated overnight at 37 °C in a 5 % CO2 humidified atmosphere.  
Differentiation of mono-layer TERA2.cl.SP12 EC cells by EC23 
 Day 1 
Confluent cells in a T75 were re-suspended using the previously described procedure, 
counted using a haemocytometer and seeded onto tissue culture plastic at 12,000 cells/cm2 
in warm (37 °C) Dulbecco’s modified Eagle’s medium (DMEM, high glucose, Lonza 
BE12 614F) supplemented with 10 % foetal calf serum (Sigma 10270), 2 mM L-glutamine 
(Lonza BE17 605F) and 100 active units of Penicillin and Streptomycin (Lonza DE17 
602F). Cells were incubated at 37 °C in a 5 % CO2 humidified atmosphere for 24 hours.  
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Day 2 
Dilute a 10 mM stock of EC23 using DMSO to give a stock of 0.1 mM which can be used 
in differentiation studies: 
MW= 332 g  
Known amount= 10 mg 
332 g in 1000 ml= 1 M 
 
3.32 g in 1000 ml = 10 mM 
0.01/3.32= X/1000 
X=3.01 ml of DMSO. 
For 0.1 mM to use for stem cell differentiation take 10 µl of 10 mM stock and add this to 
990 µl of molecular biology DMSO (mix well using a 1 ml pipette).  
To differentiate the mono-layer of TERA2.cl.SP12 use 0.1 µM EC23.  Add 50 µl of 0.1 
mM stock to 50 ml of maintenance media described on day 1 to get a concentration of 0.1 
µl.  Carefully aspirate the old media from the cells and replace the new media down the 
side of the flask ensuring the cells are not washed off by the media.  
Maintain the cells at 37 °C in a 5 % CO2 humidified atmosphere for 21 days changing the 
media as described above ever 3-4 days. 
Differentiation of aggregated TERA2.cl.SP12 EC cells by EC23 
Day 1 
For suspension differentiation 1.5 x 106 cells were re-suspended in 20 ml of Dulbecco’s 
modified Eagle’s medium (DMEM, high glucose, Lonza BE12 614F) supplemented with 
10 % foetal calf serum (Sigma 10270), 2 mM L-glutamine (Lonza BE17 605F) and 100 
active units of Penicillin and Streptomycin (Lonza DE17 602F were incubated at 37 °C in 
a 5 % CO2 humidified atmosphere for 24 hours in an untreated 90 mm bacteriological Petri 
dish (Fisher).   
Day 2 
After 24 hours to prevent disaggregation EC23 is added directly to the 24 hour old 
maintenance media added at day 1.  Make up a 0.1 mM stock of EC23 as described in the 
mono-layer differentiation procedure. Using a 200 µl pipette add 20 µl of 0.1 mM EC23 to 
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the 20 ml of media containing the aggregates.  Gently swirl to distribute the compound.  
Incubate at 37 °C in a 5 % CO2 humidified atmosphere for a further 21 days changing the 
media every 4 days by transferring the suspension into a 50 ml falcon tube and leaving the 
aggregates to settle for 10 minutes.  After 10 minutes aspirate the old media being careful 
to leave the aggregates as sediment.  Add 20 ml of fresh maintenance media containing 20 
µl of 0.1 mM EC23 to the falcon tube and gently swirl to break up the cell aggregate 
clump.  Pour carefully into a fresh 90 mm Petri dish under sterile conditions.  
2.1.2 U-118MG Human Glioblastoma/Astrocytoma cells 
 
U-118MG (ATCC® HTB-15™) cells are an adherent cell line derived from a grade III 
human brain glioblastoma.  Cells have mixed morphology and comprise of astrocytoma 
and glioblastoma cells.  The cells mostly have a characteristic fibroblastic shape and are 
tumorigenic in nude mice.    
Adherent mono-layer maintenance and passaging of U-118MG 
U-118MG cell line were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
high glucose, Sigma) supplemented with 10 % foetal calf serum, 2 mM L-glutamine and 
100 active units of Penicillin and Streptomycin. Cells were incubated at 37 °C in a 5 % 
CO2 humidified atmosphere. Cells were propagated in T75 plasma treated tissue culture 
flasks (NUNC) and passaged ever 3-4 days when the cells reached 95 % confluence. 
Passage of the cells was 1:3 – 1:6 and by the following procedure:  Aspirate media from 
the flask and wash cells in 3 ml 0.25 % trypsin/2 mM EDTA briefly, aspirate and replace 
with 3 ml 0.25 % trypsin/2 mM EDTA for 3 minutes to remove the cells from the plastic.  
After 3 minutes was any loosely adherent cells with 5 ml of fresh media and place all 8 ml 
containing the U-118MG in a 15 ml falcon tube.  Pellet the cells at 800 rpm for 3 minutes, 
re-suspend in 3 ml of fresh maintenance media and split the cells into the appropriate T75 
flasks containing 15 ml of fresh media making sure the cells are re-suspended.  
Storage of U-118MG CELLS 
U-118MG cells were stored at -140 °C in complete growth medium 95 %, DMSO 5 %. A 
single cell suspension of U-118MG was produced as previously described and split 1:3 for 
storage at -140 °C.  Thawing of cells was performed rapidly from -140 °C in a 37 °C water 
bath.  Cells were then transferred into a 15 ml falcon tube (Fisher) containing 10 ml of 
warm U-118MG growth media.  Cells were centrifuged at 800 rpm for 3 minutes and the 
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DMSO containing media was removed by careful aspiration. Cells were then re-suspended 
in 10 ml of fresh media and seeded into a T25 and incubated at 37 °C in a 5 % CO2 
humidified atmosphere for 2-3 days before passaging into a T75 1:1.  
2.1.3 Small molecules 
 
Throughout this thesis a number of different small molecules have been used to probe 
cellular processes during differentiation and to manipulate cell signalling pathways.   
Stock solutions of each small molecule were aliquot and stored at -80 °C to avoid loss of 
compound integrity by free/thaw cycling. An example of the calculation used to determine 
the volume of vehicle required for a 10 mM stock of the small molecule EC23 is shown 
below.  This calculation as then used for all of the other small molecules using in this study 
by altering the molecular weight, known mass and required concentration. 
Stock solutions 
 
Example EC23-  
 
MW= 332 g  
Known amount= 10 mg 
332 g in 1000 ml= 1 M 
 
3.32 g in 1000 ml = 10 mM 
0.01/3.32= X/1000 
X=3.01 ml of DMSO. 
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COMPOUND STRUCTURE MOLECULAR 
WEIGHT (g) 
SUPPLIER 
EC19 
 
332.44 
CHEM DEPT 
www.dur.ac.uk 
EC23 
 
332.44 
TOCRIS 
www.tocris.co.uk 
4011 
ATRA 
 
300.44 
SIGMA 
www.sigmaaldric
h.com 
R2625 
AH61 
 
322.19 
CHEM DEPT 
www.dur.ac.uk 
Methylated 
EC19 
 
347.44 
CHEM DEPT 
www.dur.ac.uk 
Methylated 
EC23 
 
347.44 
CHEM DEPT 
www.dur.ac.uk 
55 
 
 
 
AC261066 
 
353.41 
TOCRIS 
www.tocris.co.uk 
4046 
XAV 939 
 
312.31 
TOCRIS 
www.tocris.co.uk 
3748 
Y-27632 
dihydrochlorid
e 
 
320.26 
TOCRIS 
www.tocris.co.uk 
1254 
PTP IV 
inhibitor 
 
608.6 
CALBIOCHEM 
www.merkmillipo
re.co.uk 
540211 
Purmorphami
ne 
 
520.6 
CALBIOCHEM 
www.merkmillipo
re.co.uk 
540220 
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2.2 FLOW CYTOMETRY 
 
Flow cytometry was used to determine the level of cell surface antigens on live cells using 
fluorescent antibodies.  Quantification of fluorescence was used to determine the overall 
expression of an antigen in a cell population and determine its regulation under different 
experimental conditions.  Use of this technique gave date on the % of positive cells in a 
population that expressed a particular antigen and the intensity of the positive signal.  
Quantification using this technique is highly specific and can be used to determine both the 
up-regulation and down regulation of cellular antigens.  
2.2.1 Sample preparation 
 
Cells for flow cytometric analysis were seeded at 300,000 cells in a T25 tissue culture 
flask.  Single cell suspensions of TERA2.cl.sp12 cells for flow cytometry were created as 
described previously using trypisinsation.  Cells were re-suspended in 1 ml blocking buffer 
(0.1 % Bovine serum albumin in PBS) centrifuged at 800 rpm for 3 minutes and counted 
using a haemocytometer. A volume of blocking buffer up to 200 µl containing 150,000 
cells was added to each well of a flat-bottomed 96 well untreated flow cytometry plate. An 
example pro-forma is shown in Figure 2.3.1.1. The 96 well plate was then centrifuged at 
800rpm for 3 minutes to pellet the cells. Any excess cells not used in the study were lysed 
in RLT buffer (Lysis buffer, Quiagen – contains Guanidine Isothiocyanate) and stored at -
80 °C for real time PCR (see section on RT-PCR). 
Cells were re-suspended with 50 μl of the appropriate primary antibody in blocking buffer 
(0.1 % BSA in PBS) and incubated on ice for 1 hour. The cell pellets were pipette mixed 
with a 200 µl pipette tip at least 10 times to ensure a single cell suspension. Primary 
antibodies used and their dilutions are shown in                    Table 2-1. Antibodies were 
diluted from a stock with blocking buffer. 
Antibody  Dilution  Supplier  
SSEA3  1 in 5  DSHB  
TRA-1-60  1 in 10  ABCAM 
A2B5  1 in 20  ABCAM  
P3X  1 in 10  P.Andrews. 
University of 
Sheffield 
                   Table 2-1. Primary antibodies used in flow cytometry. 
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After incubation 100 μl of blocking buffer was added to each well and the plate centrifuged 
at 800 rpm for 3 minutes. The supernatant was then removed into the sink and cells washed 
by re-suspension in 100 μl blocking buffer followed by centrifugation at 800 rpm for 3 
minutes, this was repeated a further twice to ensure removal of all excess primary 
antibody.  
The cells were then incubated with an anti-mouse IgM secondary antibody diluted 1:50 
(Sigma) in blocking buffer for 1 hour in the dark. After incubation cells were washed 3 
times as described above and re-suspended in 200 μl blocking buffer for flow cytometric 
analysis on the Millipore GuavaCyte Plus Flow cytometer. 
 (www.millipore.com/flowcytometry) 
2.2.2 Flow cytometric analysis 
 
Prior to analysis quality control was performed on the flow cytometer to determine if a 
calibration was required using Guava Check (Millipore, 4500-0020). The quality control 
used beads with known size, shape and fluorescence to determine a % coefficient of 
variance (CV). As with most automated assays the % CV should be less than 5 %. 
Debris and clumps of cells were removed from the data set using both forward and side 
scatter gates.  Side scatter gating removed debris and forward scatter clumps of cells, this 
ensured that the fluorescence detected was from individual cells.  An example histogram of 
the fluorescence detected and data produced by the flow cytometer is shown in Figure 2-1. 
Using a third gate for intensity the percentage of positive cells can be measured, the gate is 
shown as a red line on the graph anything within this range is counted as positive, this 
should be consistant throughout experimental assays.  In this example the green line is a 
negative control, the purple line shows a partial increase in the number of positive cells and 
the black line is almost completely positive for the antigen being measured.    
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Figure 2-1 A histogram showing cell count number against green fluorescence intensity for 
three distinct samples using flow cytometry.  The red line gates for positive cells and 
determines the percentage of each population expressing the antigen above this fluorescence 
threshold.  
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2.3 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR) 
 
Relative quantification of cellular mRNA expression can be used to determine the changes 
that occur under different experimental conditions on the expression of specific genes. 
Using fluorescence resonance transfer tagged primer probes specific for a gene of interest 
can be used to give relative fold change in gene expression between two individual cell 
populations.  
2.3.1 RNA extraction (Qiagen kit) 
 
To lyse the cell pellets 350 μl of lysis buffer (RLT) was added and immediately vortex for 
30 seconds. Cell membranes were disrupted via aspiration with a 21 G needle 5 times and 
placed into a new RNase free Eppendorf tube. Cell lysate was then stored at -80°C for a 
maximum of 2 weeks prior to RNA extraction.  
To isolate cell lysate RNA samples were thawed on ice and one volume of 70% molecular 
biology ethanol was added to each sample. The sample and any precipitate was transferred 
to a labelled RNeasy spin column and kept on ice. Spin columns were then centrifuged at 
10000 pm for 15 seconds and the flow through discarded, samples were kept on ice. The 
column was then washed with 350 μl RW1 wash buffer, centrifuge at 10,000 rpm for 15 
seconds and the flow through discarded. The next step was to remove any genomic DNA 
within the column. 
DNA digestion  
From the RNase-free DNase kit (Qiagen 79254) 10 μl of DNase stock was added to 70 μl 
of RNase-free buffer (RDD) and place directly onto the easy spin column. The column was 
then left at room temperature for 15 minutes. 
After DNA digestion the following wash steps were performed: 
Add 350 μl RW1 wash buffer to the column, spun at 10000 rpm for 15 seconds and the 
flow through discarded.  Next 500 μl RPE was buffer (containing molecular biology 
Ethanol) was added to the column and centrifuged at 10000 rpm for 15 seconds and the 
flow through discarded finally, complete the wash steps by adding 500 μl RPE and 
centrifuge at 10000 rpm for 2 min. To remove any excess RPE buffer and importantly 
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ethanol replace the collection tube and centrifuge at full speed for 2 min.  The column now 
contains purified RNA. 
The RNeasy spin column was then placed in a RNA collection tube and 40 μl RNase free 
water added directly to the column and the water was left to penetrate the easy spin column 
membrane for 3-5 min. The column was then centrifuged at 10000 rpm for 1 minute to 
remove dissolving the RNA into solution. The flow through now contains isolated RNA – 
Do not discard. To increase yield and concentration the flow through was pipette back onto 
the easy spin column and centrifuged at 10000 rpm for 1 minute. The pellet of RNA can be 
stored at -80°C prior to analysis. 
Purity of RNA  
Using the nanodrop measure the absorbance of the RNA at 280, 230 and 260 nm. The ratio 
260/280 is an indicator of the level of protein contamination in the sample. The 260/230 
ratio is a further measure of purity. The values for both ratios should be between 1.8 and 
2.2 for pure RNA. RNA isolated in this study was measured using these parameters.  
RNA integrity  
Make up 50 x Tris Acetate EDTA using the following protocol: 
 To make up 0.5 M  EDTA (Sigma  EDS) initially add 93.05 g to 400 ml deionized 
water and pH 8.0.  After all of the EDTA powder is dissolved top up the final 
volume to 500 ml.  
 To make a 50 x stock of Tris Acetate EDTA weight out 242 g Tris base (Fisher BP 
152-1) and dissolve in 750 ml deionized water.  
 Add 57.1 g of glacial acetic acid and 100 ml of 0.5 M EDTA (pH 8.0) and adjust 
the solution to a final volume of 1 L. 
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To make up a 1% Agarose gel for electrophoresis dissolve 1 g Agarose (Fisher BP 160-
100) into 100 ml and heat for 2 minutes in an 800W microwave or until Agarose in fully 
dissolved.  After the gel begins to cool add 0.5 µg/ml Ethidium Bromide (Sigma E-1510) 
and gently swirl.  Pour the gel into the electrophoresis chamber and allow to set (place the 
comb in the gel before it sets).  Into well 1 add 6 µl of RNA ladder and into the other wells 
add the test samples (test samples should be diluted with 6 x loading buffer (Promega, 
C1881) to a total volume of 6 µl and contain around 500 ng RNA).   
 
Figure 2-2. Intact ribosomal RNA bands. A 1% TAE agarose EtBr gel separating RNA. 
500ng RNA was ran at 100 V. The figure shows intact rRNA, 28S rRNA has around double the 
staining intensity of 18S, which is another good indicator of intact RNA. 
 
 
 
 
 
 
 
 
62 
 
 
 
2.3.2 Reverse Transcription 
 
Conversion of isolated mRNA into copy DNA (cDNA) is required for real-time PCR 
analysis. Each reverse transcription reaction can convert up to 2 µg of mRNA.  
Quantification of mRNA was done using the Nanodrop and the volume of water containing 
2 µg of mRNA was calculated.  As the reaction mixture is at 2 x concentration and the 
reaction reagents make up 10 µl, a total of 2 µg of mRNA in 10 µl molecular biology water 
was the maximum volume and concentration permissible (lower concentrations of mRNA 
could be reverse transcribed in the same volume).  Make up a stock of reaction mixture for 
n + 1 where n is the number of reactions.  
Figure 2-2 lists the reaction reagents in the reaction mixture and Table 2-3 the heat cycle 
required for the reaction to proceed using the Biometra Thermocycler. It is assumed that 
the reaction goes to completion and all 2 µg of mRNA is converted to cDNA. 
 
Component  Volume/reaction μL  
10 X RT buffer  2.0  
25 X dNTP mix (100mM)  0.8  
10 X RT Random primers  2.0  
Multiscribe reverse transcriptase  1.0  
Nuclease-free H2O  4.2  
                       Table 2-2. Reverse transcription master mix reaction components. 
 
 
 1 2 3 4 
Temperature  25  37  85  4  
Time  10 min  120 min  5 sec  ∞  
Table 2-3 Thermocycle time and temperature settings for reverse transcription 
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2.3.3 FAST RT-PCR 
 
Real time PCR is a method to determine the relative change of a particular gene of interest 
under different cellular conditions.  The use of fluorescence energy resonance transfer is 
used to either quench a reported fluorophore or allow detection of its energy.   The level of 
fluorescence changes as the number of gene sequence copies increases giving a 
stereotypical sigmoidal curve which can be used to determine the starting number of 
mRNA sequences (Figure 2-3).   
 
Figure 2-3 Sigmoidal graph representing the relationship between the amount of cDNA 
produced during a PCR reaction and cycle number. The graph goes through a lag phase, 
exponential increase, linear relationship and then as the reaction saturates the amount of cDNA 
tails off.  Whereas convention semi-quantitative PCR measures towards the end of the reaction RT-
PCR uses the linear phase to extrapolate and determine a relative quantity. 
 
Note:  The Applied Biosystems software calculates the relative change in expression and 
presents this in graphical form. 
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To set up a real-time PCR reaction using TaqMan master mix and TaqMan primer-probe 
sets: 
The concentration of each stock cDNA sample after reverse transcription was 2000 ng in 
20 µl. For RT-PCR each sample was performed in triplicate and each assay contained 50 
ng of cDNA (0.5 µl of 2000 ng stock).  
All TaqMan gene assays were purchased at 20 x concentration from Applied Biosystems. 
Upon arrival assays were diluted 1:2 with molecular biology waster aliquot (50 µl) and 
stored at -20 °C prior to use.  
Make up a stock reaction mixture for each gene to be assayed containing the assay (20 x) 
and the TaqMan mater mix (2 x):  For example for 13 assays the stock reaction mixture 
would contain 13 µl Gene expression assay and 130 µl of 2 x TaqMan Fast Universal 
Master mix (Invitrogen 4352042).  In the bottom of each well 11 µl of reaction mixture 
was added. 
In separate tubes dilute the cDNA samples so that 9 µl of molecular biology water contains 
50 ng of DNA. Adding 9 µl of cDNA to the reaction mixture gave a total volume of 20 µl.  
For example the cDNA stock for 13 samples would contain 7.5 µl cDNA and 110.5 µl 
Molecular Biology Water, 9 µl of cDNA was then added to the side of each well and kept 
on ice.  
Table 3 shows the components and volume of reagents in each well.  An example pro-
forma for the 96 well RT-PCR plate can be found at the back of this document.  
Each well contained the following constituents: 
Reagent Volume/well (µl) 
TaqMan Gene Expression assay (20x) 1 
TaqMan Fast Universal Master mix (2x) 10 
cDNA 0.5 
Water 9 
Total 20 
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A 96 well plate was loaded with each assay and was centrifuged at 2000 rpm for 2 minutes 
prior to the reaction removing any bubbles in the well.  Prior to centrifugation and analysis 
the plates were kept in a cradle to prevent the bottom of the well being contaminated.  A 
thin film of plastic was used to cover the plate tightly to prevent any evaporation loss 
during the heating step of the PCR reaction. Fast Real-Time PCR reaction was done using 
the Applied Biosystems 7500 Fast RT-PCR analyser.  The heating steps of the PCR 
reaction were: 
Sample volume: 20 µl per well 
Stage 1:  Increase temperature of plate to 95 °C 
Stage 2:  (95 °C for 0:03 seconds then at 65 °C for 0:30 seconds) repeat process for 40 
cycles. 
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Gene AB code Interrogated 
Sequence 
(gene bank) 
Reporter 
HOX B1 Hs00157973_m1 X16666.1 FAM 
HOX B6 Hs00255831_s1 AK292200.1 FAM 
HOX B9 Hs00256886_m1 AK056123.1 FAM 
HOX D1 Hs00707081_s1 AF241528.1 FAM 
HOX D4 Hs00429605_m1 AK313885.1 FAM 
HOX D8 Hs00251905_m1 BQ429720.1 FAM 
HOX A1 Hs00939046_m1 AK308067.1 FAM 
HOX A5 Hs00430330_m1 BC013682.1 FAM 
HOX A6 Hs00430615_m1 BC069497.1 FAM 
OCT4 Hs03005111_g1 BC117435.1 FAM 
NANOG Hs02387400_g1 AB093576.1 FAM 
RAR β2 Hs00977143_m1 AF157483.1 FAM 
GAPDH 4333764F 402869 FAM 
NESTIN Hs00707120_s1 AB073350.1 FAM 
PAX6 Hs00240871_m1 AB209177.1 FAM 
HB9 Hs00907365_m1 AF107457.1 FAM 
ISL1 Hs00158126_m1 AK290742.1 FAM 
NKX2.2 Hs00159616_m1 BC075092.2 FAM 
NGF Hs01113193_m1 BC032517.2 FAM 
NGFR Hs00609977_m1 AK303278.1 FAM 
PTPΣR Hs00370080_m1 AB209333.1 FAM 
LAR  Hs00892965_m1 AB177857.1 FAM 
ITGB1 Hs00559595_m1 AK291697.1 FAM 
HOX C4 Hs00205994_m1 X07495.1 FAM 
OTX 2 Hs00222238_m1 AB593057.1 FAM 
Table 2-4. Fast Real-time PCR primer probe sets.  Primer probes are either inventoried from 
Applied Biosystems or made to order. The AB code provides online information about the assay.  
Assay details can be found at https://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/PCR/real-time-pcr/real-time-pcr-assays.html  
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2.3.4 Sample 96 well pro-forma for real time PCR 
 
Example PCR plate lay out for 3 samples and 4 genes (A-D): 
Sample 1: Control 
Sample 2:  Treatment group 1 (T1) 
Sample 3: Treatment group 2 (T2) 
No template control (NTC) : No cDNA 
  1 2 3 4 5 6 7 8 9 10 11 12 
A  NTC NTC  NTC   Control Control   Control T1   T1  T1 T2   T2  T2 
B  NTC NTC  NTC   Control Control   Control T1   T1  T1 T2   T2  T2 
C  NTC NTC  NTC   Control Control   Control T1   T1  T1 T2   T2  T2 
D  NTC NTC  NTC   Control Control   Control T1   T1  T1 T2   T2  T2 
E                         
F                         
G                         
H                         
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2.4 HISTOLOGY AND IMMUNOSTAINING 
 
Fixation of samples 
After treatment cells were washed carefully with PBS and fixed with 4 % 
paraformaldehyde (PFA) for 30 minutes on ice. Cells were then washed 3 times with PBS 
to remove excess PFA.  
n.b. Fixed cells can be stored in PBS for 2 weeks prior to staining. 
Fixation and histological sectioning of wax embedded tissue and 3 dimensional cell culture 
is a powerful tool for understanding structural changes during 3D development and 
regulation in a 3D environment.  Thin sections of tissue can be used to give a 
representative sample of 3D culture, with thicker sections used for confocal microscopy 
and 3D structural imaging.  
2.4.1 Preparing wax embedded Alvetex®Scaffold and aggregate sections 
 
Cells grown in Alvetex®Scaffold were fixed in 3.8 % PFA overnight and then washed in 
PBS three times prior to embedding.  The embedding protocol consisted of: 
Dehydration through a series of ethanol washes – 30, 50, 70 (containing 1 % crystal 
violet), 80, 90, 95 and finally 100 % each for 15 minutes.  Crystal violet (Sigma C3886) 
was added to aid sectioning of cells on the scaffold.  
After dehydration cells were transferred to histoclear for 15 minutes and then 1:1 
wax:histoclear at 60 °C for 30 minutes followed by a final incubation at 60 °C in wax.  
Embedding into cassettes should be done on half scaffolds and left overnight to solidify.  
Sections of scaffold can be cut at between 6 and 50 µm for histochemical analysis of the 
tissue.  
2.4.2 Haematoxylin & Eosin( H&E) staining 
 
The following protocol is used for H & E staining of paraffin embedded sections of both 
Alvetex®Scaffold and fixed cell tissue.  
1. Deparaffinise in Histoclear (National diagnostics HS-200) for 5 minutes 
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2. Transfer into Absolute (100  %) ethanol for 2 minutes 
3. Rehydrate in 95 % ethanol, 70 % ethanol and distilled water for 1 minute each 
4. Stain in Mayers Haematoxylin (Sigma MH532-1L) for 5 minutes 
5. Wash in Distilled water for 30 seconds 
6. Blue the nuclei in Alkaline alcohol for 30 seconds 
7. Dehydrate in 70 % ethanol and 95 % ethanol for 30 seconds each 
8. Stain in Eosin solution ( Sigma HT 110232- 1L) 
9. Dehydrate in 95 % ethanol twice for 10 seconds each 
10. Absolute ethanol for 15 seconds 
11. Absolute ethanol for 30 seconds 
12. Clear in Histoclear for 3 minutes 
13. Clear in Histoclear for 3 minutes 
14. Mount in DPX (Fisher D/53 19/05) add glass coverslip and allow to dry 
2.4.3 Immunohistological staining 
 
Immunofluorescent staining of paraffin sections may require antigen retrieval, individual 
antibody requirements were referred to.  A general protocol is shown below: 
1. Deparaffinise sections in Histoclear for 5 minutes 
2. Hydrate through 100, 90 and 70  % ethanol for 2 minutes each 
3. Retrieve antigens by placing slides in 200 ml 1 x citrate buffer (pH 6) and 
microwave (800 W) for 2 x 3 minutes 
4. Open the microwave door and leave to stand for 3 minutes 
5. Microwave for 3 minutes 
6. Leave to stand outside the microwave for 20 minutes 
7. Wash in 1 X PBS (3 x 10 minutes) 
8. Treat slides with 0.1 % TX-100 for 10 minutes 
9. Block slides with 1 % new-born goat serum, 0.1 % Tween-20 in PBS on ice for 1 
hour 
10. Add primary antibody in blocking buffer at 4 °C in a humidified chamber for 16 
hours 
11. Wash 3 x 10 minutes in blocking buffer 
12. Add secondary antibody + DAPI in blocking buffer and incubate in a dark, 
humidified chamber for 1 hour 
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13. Wash in 3 x 10 minutes blocking buffer 
14. Mount in Vectashield (Vector labs H-1000) and seal coverslip with nail varnish 
15. Store slides in a dark place until visualisation 
2.4.4 Immunocytochemistry  
 
Fixed cells were permeabilised with 1 % Triton X-100 in PBS for 10 min and blocked for 
30-60 min on ice (Blocking buffer- 1 % goat serum, 0.01 % Tween in PBS). Blocking 
buffer was then removed and the primary antibody added for 1 hour gently rocking. 
Antibodies used are shown in Table 2-5 and were diluted in blocking buffer. 
Antibody  Dilution  Supplier  Code 
Anti β III tubulin 
Rabbit IgG  
1 in 600 Covance  MMS 435P 
Anti PAX6 1 in 100 ABCAM AB 5790 
Anti HB9 1 in 50 ABCAM AB 79541 
Anti CSPG 1 in 100 ABCAM AB 11570 
Anti Cytokeratin 8 1 in 500 Ab59400 ABCAM 
Table 2-5. Primary antibodies used in immunocytochemistry 
Cells were then washed in blocking buffer for 15 minutes gently rocking, this was repeated 
three times to remove excess primary antibody.  The secondary fluorescent antibody was 
then added, which was specific for the primary antibody used.  
Table 2-6 lists the secondary antibodies used in this study and their dilutions. Samples 
were incubated with secondary antibody for 1 hour which required light protection and 
gentle rocking. 
 
Table 2-6. Secondary antibodies used in immunocytochemistry 
 
 
Antibody  Dilution  Emitted 
wavelength nm  
Selectivity  Code 
Alexaflour 488 
(Invitrogen) 
1 in 600  495  Mouse IgG/Rabbit 
IgG  
R37120/R37116 
Anti IgM –FITC 
(Sigma) 
1 in 50 FITC Mouse IgM SAB4700348 
Cy3 (Jackson 
Labs) 
1 in 600  546  Rabbit IgG  200-162-037 
Hoechst 33342  
(Invitrogen) 
1 in 1000  Blue   H21492 
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2.5 WESTERN BLOT ANALYSIS 
2.5.1 Sample collection and protein extraction (Igepal) 
 
Protein was purified from cell pellets for each assay condition using igepal lysis buffer (1 
% igepal (Sigma, I8896), 50 mM Tris-HCl [pH 8.0], 150 mM NaCl. 1 mM MgCl2 and a 
protease inhibitor (Roche Diagnostics).  Cell pellets were left on ice in lysis buffer for 30 
minutes and then centrifuged at 15000 rpm for 5 minutes.  The supernatant containing 
purified protein was transferred to a fresh tube and stored at -140 °C until required.  A 
Bradford based assay was used to determine protein concentration using spectroscopy (see 
below): 
Standard curve: 
Make up 1 mg/ml BSA (Sigma, A2153) stock solution. 
Dilute the required concentration of BSA to 1 ml molecular biology water. For example:  0 
µg/ml (1 ml water), 1 µg/ml (1 µl BSA stock and 999 µl water), 5 µg/ml (5 µl BSA stock 
and 995 µl water), 10 µg/ml (10 µl BSA stock and 990 µl water), 20 µg/ml (20 µl BSA 
stock and 980 µl water) and 50  µg/ml (50 µl BSA stock and 950 µl water) as shown in 
Figure 2-4. 
Figure 2-4 Standard curve for protein quantification using a Bradford assay.   The R2 values 
demonstrates the correlation between the two parameters, the closer to 1.0 the more correlated the 
parameters are.  
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Bradford Assay: 
Add 2 µl of protein sample to 998 µl molecular biology water and add 250 µl Bradford 
Reagent (Sigma, B6916).  Leave for 10 minutes and then measure absorbance 595 nm.  
Compare your absorbance value to a standard curve to provide protein quantification for 
your sample. To get a protein quantification of sample per µl the quantity measured is 
divided by 2.  
2.5.2 SDS-Polyacrylamide Gel Electrophoresis 
 
Samples were loaded on to a 12-well, 1 mm thick NuPage 4-12 % Bis-Tris pre-cast gel 
(Invitrogen) and ran at 100 V in Invitrogen’s XCell SureLock Mini-Cell and system. 
Samples comprised on 75 µg/µl protein per sample in a total volume of 20 µl.  Sample 
comprised – 4 µl 4x Gel Loading Dye + 2 µl Reducing Agent + H2O. 
2.5.3 Western Blot 
 
Electrophoresed samples were blot on Hybond – LFP membrane (GE Healthcare) at 30 V 
for 1 hour.  Blots were then blocked overnight in 5 % dried milk powder and 0.1 % Tween-
20 in Tris-Buffered Saline at 4 °C.  
Primary antibody solution consisted of: 1 in 5000 mouse beta-actin Ab (Sigma) and 1/2500 
rabbit TUJ-1 Ab in 5 ml blocking buffer.  The blots were incubated for 1 hour at room 
temperature on a roller. 
Following incubation with primary antibody a 2 x rinse with 0.1 % Tween-20 in PBS was 
performed followed by a 2 x 5 minutes wash. 
Secondary antibody solution consisted: 2 µl CY3-labelled anti mouse secondary and 2 µl 
CY5-labelled anti rabbit secondary.  Blots were incubated in the dark for 1 hour at room 
temperature on a roller. 
Following incubation samples were rinsed 3 x in 0.1% Tween 20 in PBS followed by 4 x 5 
min washes and 3 x rinse with PBS. 
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Blots were left to dry in the dark at room temperature overnight between two sheets of 
blotting paper and imaged on the FLA-3000 Fluorescent Image Analyser. The CY3 label 
was detected via 532 nm laser excitation and the CY5 detected by 633 nm laser excitation. 
2.6 SUMMARY OF ANTIBODIES USED  
 
 
 
 
 
 
 
 
2.7 STATISTICAL ANALYSIS 
 
Paired samples were assessed for statistical differences using students paired T-test. 
Comparison between the mean of two groups of multiple samples was performed using 
ANOVA. 
Error between samples was assessed by standard error mean values except for real time 
PCR where error is shown as standard deviation from the mean.  
2.8 MICROSCOPY 
2.8.1 Light microscope 
 
Leica ICC50 High definition camera mounted onto a Leica microscope with objectives: x5, 
x10, x20 and x40 
 
Antibody Dilution Code Supplier 
SSEA3 1 in 5 MC-631 DSHB 
TRA-1-60 1 in 10 Ab16288 ABCAM 
A2B5 1 in 20 Ab53521 ABCAM 
P3X 1 in 10  P.Andrews University of 
Sheffield 
Anti β III tubulin 
Rabbit IgG 
1 in 600 MMS 435P Covance 
 
Anti PAX6 1 in 100 AB 5790 ABCAM 
Anti HB9 1 in 50 AB 79541 ABCAM 
Anti CSPG 1 in 100 AB 11570 ABCAM 
Alexaflour 488 1 in 600 R37120/R37116 Invitrogen 
Anti IgM –FITC 1 in 50 SAB4700348 Sigma 
Cy3 1 in 600 200-162-037 Jackson Labs 
Anti Cytokeratin 
8 
1 in 500 Ab59400 ABCAM 
Table 2.7. Details of the antibodies used throughout this thesis.  Antibodies and their suppliers 
are shown alongside recommended dilutions for applications detailed earlier in the thesis.    
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2.8.2 Fluorescence Microscopy  
 
Leica DFC 310FX with digital camera DMI 3000B.  Objectives x5, x10, x20, x40. Filters: 
DAPI and 488 nm 
Nikon DIAPHOT 300 fluorescence microscope with camera DMX 1200.  Objectives x4, 
x10, x20, x40. Filters DAPI, 488 nm and 650 nm 
Leica SP5 Confocal Laser Scanning Microscope SP5 
For confocal microscopy on Alvetex®Scaffold:  Follow the immunocytochemical staining 
procedure on whole scaffold, ensuring the secondary antibodies used are compatible with 
the lasers of the confocal microscope.  
After staining place the scaffold on a glass slide and add a drop of VectaShield (Vector 
labs H-1000) and mount with a glass cover slip ensuring the side to be imaged is against 
the coverslip. Seal using nail varnish.  
Laser Lines (nm) excitatory:  405/458/478/488/494/514/543/594/633 
Filters (emission):  Fully tuneable 
Lenses:  10x HCX PL APO CS, 20x HCX PL APO oil UV, 40x HCX PL APO Oil UV, 
63x HCX PL APO Oil UV 
Images were taken at a 100 Hz laser rate with a resolution of 1500/1500 and Z-stack slices 
of 1 µm.  
2.9 EQUIPMENT USED 
 
Water- Milli-Q 0.22 μm filtered de-ionised water 
Slide dryer – Thermo Scientific 
Centrifuge- Eppendorf 5412R, 5810R 
Pipette tips--1-10 μl RNase/DNase free tips, 10-100 μl RNase/DNase free tips, 20-200 μl 
RNase/DNase free tips, 100-1000 μl RNase/DNase free tips, glass pastettes.  
Imaging- Digital camera DXM1200, Leica ICC50 High definition camera, Leica DFC 
310FX with digital camera DMI 3000B 
Balance- AND EK-200g d=0.01g 
Thermocycler- Biometra thermocycler 
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Spectrophotometer- Nanodrop 1000 
pH meter- HANNA instruments H12210 
Water Bath-Grant (J B Aqua 12 plus) 
Orbital Shaker- Stuarts Scientific (SSM1) 
Tissue culture plastic- NUNC, BD (T25, T75) 
Trans-illuminator- Bio-Rad 
PCR machine- Applied Biosystems FAST 7500 PCR 
CO2 Incubator- SANYO MCO – 18A1C (UV) 
Florescent imager - FLA-3000 Fluorescent Image Analyser 
Flow cytometer - Millipore GuavaCyte Plus Flow cytometer 
Microtome – LEICA RM2125 
Wax embedded – LEICA EG1120 
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CHAPTER 3 DEVELOPING TOOLS TO DISSECT MOLECULAR 
PATHWAYS INVOLVED IN NEURAL DEVELOPMENT 
 
3.1 INTRODUCTION 
 
3.1.1 Retinoic acid and embryonic development 
 
Control over the precise patterning of the central nervous system during embryonic 
development is essential for correct differentiation of neural subtypes [185, 186].  Many 
types of neuron develop at precise locations along the anterior-posterior axis.  A two-step 
mechanism of directing neural cells along the AP axis is responsible for guiding cells to 
develop into the correct neural progenitor at the right position.  The two-step mechanisms 
responsible for this comprise an activating signal that induces cells to become anterior 
neuroectoderm and a posteriorisation of areas to become the CNS and hindbrain. The 
posteriorising signal that cells in the CNS and hindbrain are sensitive to has been shown to 
be retinoic acid.  The action of retinoic acid along this axis occurs in a concentration 
dependent manner, either through control over metabolism and the biological availability 
of RA or via paracrine secretion [187].  
Many genes associated with loss of pluripotency such as OCT4 and NANOG or genes 
associated with specific neural progenitors such as PAX6 contain a RARE in their 
promoter regions and are under the direct transcriptional control of retinoic acid receptors. 
Retinoids can regulate the cell cycle arrest and differentiation in stem cells; furthermore, 
due to the regulation of key neural genes, retinoic acid treatment induces neural 
commitment.  Control over the gene processes that regulate embryonic patterning will in 
part be responsible for the subtype selectivity provided to developing neural cells by RA.   
Part of the role of RA signalling during development is to provide anterior-posterior 
positional identity during neurulation, providing cells with position specific gene 
expression through HOX gene regulation.       
Work into embryonic patterning has been advanced by investigating the developmental 
patterning of the hindbrain [188]; the hindbrain shows very discrete segments along its AP 
axis regulated by genetic ques.  HOX genes have been implicated in the regulation of 
hindbrain segments since their expression is often located at the boundaries between 
segments.  Ectopic expression of HOX genes associated with posterior identity to anterior 
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cells resulted in posteriorisation of anterior hindbrain segments (see Chapter 1 for a review 
of HOX genes).  Posteriorisation of anterior hindbrain and developing embryonic tissue 
can be achieved through the application of retinoic acid indicating a link between retinoic 
acid, HOX genes and AP axis development.  It has been demonstrated recently that many 
of the 3’ HOX genes associated with an anterior fate contain RAREs.  
In a study by Simeone, A et al (2009) [50] retinoic acid (RA) was demonstrated to induce 
the expression of HOX gene mRNA in the human embryonal carcinoma stem cell NT2/D1. 
Regulation of HOX genes by retinoic acid in this model was shown to be time and 
concentration dependent.  Expression of genes on the HOX B cluster was dependent on the 
length of time the cells had been exposed to RA for.  HOX genes at the 3’ end of the 
cluster would were the most sensitive and expression occurred soon after RA treatment (0-
20 hours), as exposure time increased more 5’ genes became expressed.  Indicating a co-
linear expression pattern of HOX B genes Furthermore, expression of the genes 
investigated were shown to be regulated in a concentration dependent manner by RA. 
Other work went on to demonstrate the co-linear, temporal expression of HOX genes on 
the other three clusters [189].  These studies demonstrated the effectiveness of using hEC 
cells and described some fundamental gene regulation by retinoic acid during stem cell 
differentiation and neural lineage commitment.   
As well as control over the anterior-posterior identity of the developing neuroectoderm 
retinoic acid is highly implicated in specific neural subtype commitment and development 
within the spinal cord, specifically along the dorsal-ventral axis. One way retinoic acid 
affects the developing spinal cord through paracrine secretion from flanking somites.  
Transduction of the retinoic acid signal is controlled by a number of different mechanisms, 
including cellular retinoic acid binding proteins, metabolising enzymes and retinoic acid 
receptor number and isotype.  
Furthermore, retinoic acid has been implicated as necessary for mature neural 
differentiation, axon guidance and neural regeneration.  Therefore, when investigating the 
role of retinoic acid in each of these processes it is important to have a model that 
represents the stage of differentiation at which the process is occurring. 
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3.1.2 Retinoic acid and stem cell differentiation 
 
Stem cells have been used for many years to investigate the role of retinoic acid in cell 
differentiation, and in particular neural differentiation. Human stem cells represent a model 
of early development in man that can be induced to undergo lineage commitment and 
maturation for investigations into later developmental processes.  Studying the biological 
mechanisms that underlie initiation of stem cell differentiation; specific lineage 
commitment of stem cells; cellular maturation and finally regeneration after injury, will all 
prove to be useful for many aspects of medicine and cellular biology.  
The use of retinoic acid in stem cell differentiation and development has come from many 
years of work using a variety of in vitro and in vivo models.  There is a close link between 
the role of retinoic acid in the developing embryo and that demonstrated in vitro using 
stem cell models. Retinoic acid is used in animal and cell models to induce posterior 
identity to the developing tissue [190].  It is well documented that retinoic acid acts in a 
temporal and concentration dependent manner in both in vivo and in vitro systems. 
Elucidating the developmental mechanisms behind the role of retinoic acid using animal 
models is difficult due to its pleiotropic action.  Through the use of stem cells, specific 
developmental processes can be investigated in depth using molecular approaches, 
providing a good model for investigating the role of retinoic acid in development.  
Pluripotent embryonal carcinoma stem cells can be derived by multiple methods from 
teratocarinomas [84, 191].  Clones that are derived from the different teratocarcinomas 
exhibit different lineage potential and some require feeder layers for survival [192], never 
the less stem cells derived from teratocarcinomas are recognised as good models for 
investigating stem cell differentiation and embryonic development [193].  
The stem cells used in this study are the human embryonal carcinoma stem cell line, 
TERA2.cl.SP12, isolated from the TERA2 parent lineage, using direct immunomagnetic 
sorting for high expression of the stem cell marker SSEA3. The stem cells express high 
levels of OCT4 and NANOG; do not require a feeder layer; are immortal and importantly 
can be induced to differentiate into neural and glial tissue upon retinoid treatment. 
Accordingly, this model cell system is useful for investigating neural tissue development in 
vitro [84, 86, 194] and has been used extensively throughout this thesis. 
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3.1.3 Limitations of all-trans retinoic acid in cell culture 
 
Most stem cell protocols that require retinoic acid use all trans retinoic acid (ATRA) 
which acts through heterodimersiation of RAR-RXR receptors to induce gene transcription 
[56].  As described earlier it is known that the concentration of ATRA in culture is a key 
determinant of the genes that are transcribed.  One limitation of the use of ATRA is that it 
is isomerised at ambient temperature and in natural light; isomers of ATRA such as 9-cis-
RA can induce gene transcription by homodimerisation of RXR which affects the overall 
concentration of ATRA in culture and induces heterogeneity and inconsistency into the 
stem cell differentiation protocol [195].  Therefore, when handling ATRA in the 
laboratory, great care must be taken to prevent isomerisation.  However, this is difficult in 
practice due to the nature of cell culture.  
The response of stem cells to retinoic acid induced signalling is dependent on 
concentration both in vitro and in vivo [64, 196]. The cellular concentration of retinoic acid 
in developing neurons determines neural lineage subtype.  Furthermore, retinoic acid 
signalling also regulates anterior-posterior patterning in a concentration dependent manner 
[48, 197], providing positional cues to developing cells.  Variable concentrations of RA 
due to isomerisation and metabolism make investigating these effects difficult in vitro.  
Due to the instability of RA in the laboratory its exact concentration is unknown 
throughout the investigation, adding variability to the assay.  It is also unknown what effect 
the isomerisation products of RA have on stem cell development.   It is required to use RA 
in a dark environment; however, this adds risk to any laboratory procedure and is often 
overlooked.  The replacement of RA with a stable analogue would overcome many of the 
problems associated with RA metabolism. 
The small molecule, EC23, has been developed to overcome the variability introduced by 
ATRA by isomerisation and add consistency and reproducibility to the concentration and 
induction of retinoic acid responsive genes in culture.  EC23 is a stable synthetic analogue 
of ATRA and is not isomerised under normal cell culture conditions.  Work has described 
the ability of EC23 to replace ATRA in stem cell differentiation protocols [95].  
Furthermore, recent evidence demonstrates that EC23 is a pan RAR agonist that is much 
more potent than ATRA and other synthetic analogues of ATRA such as TTNPB [93].  
EC23 exemplifies the ability to design small molecules to use as tools to investigate key 
molecular pathways.    
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3.1.4 Synthetic modulation of signalling pathways 
 
Multiple studies describe work involving the modulation of signalling pathways using 
synthetic small molecules to replace the less consistent natural analogues that are either 
unstable, non-specific or subject to batch variability [198]. EC23 has been described here 
as one example of the use of synthetic molecules, however many differentiation protocols 
utilise a wide range of different small molecules to induce specific neural commitment.  
Sonic hedgehog (Shh) is used in stem cell differentiation protocols to provide 
ventralisation cues to the cells for motor neuron specific differentiation.  As with many 
natural small molecules, Shh is a protein and is subject to large batch variations during 
production, therefore, there are inconsistencies of its activity in culture.  The small 
molecule Purmorphamine is a synthetic modulator of the Shh pathway and has been used 
in many differentiation protocols as a replacement of Shh as it induces more consistent Shh 
activation and has a very narrow range of activity giving a high level of reproducibility 
[199, 200]. Although EC23 has been used in protocols to induce neural differentiation in 
replacement of ATRA, and Purmorphamine has been used in motor neuron differentiation 
protocols to replace Shh, both have not been used in conjunction to induce specific neural 
commitment. The use of multiple synthetic small molecules may increase the yield and 
reproducibility of stem cell differentiation, however, more research is required to 
understand these compounds and how they affect the cell compared to their natural 
counterparts.  
Aims  
This Chapter aims to use synthetic small molecules to investigate the molecular pathways 
involved in retinoic acid induced stem cell differentiation and neural commitment.   It has 
been demonstrated by previous studies that the synthetic retinoid EC23 can induce neural 
differentiation of stem cells in a similar way to ATRA [95]; furthermore, some model 
systems report that EC23 can induce more neurogenic lineage commitment than ATRA 
[95].  EC23 was designed to overcome the practical limitations of ATRA when used in cell 
culture and has provided a model for retinoic acid receptor activation without loss through 
isomerisation; furthermore, it is hypothesised that EC23 will not be metabolised by many 
of the cytochrome enzymes that oxidise ATRA due to its stable structure.  Therefore, EC23 
removes many of the heterogeneous side effects resulting from ATRA instability providing 
a stable and reproducible tool to investigate retinoid activity and consistently induce 
neurogenesis. 
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Retinoid concentration, which is a key modulator of human cellular development, was 
modelled in vitro and the key metabolic, genetic and phenotypical differences of EC23 and 
ATRA activity in stem cells investigated. In addition, the role of subtle structural changes 
of EC23 and its analogue EC19 on stem cell differentiation were assessed through a small 
screen of small molecules aimed at controlling cell fate during differentiation.  Throughout 
this Chapter, retinoid structure, potency and concentration will be discussed and related to 
early neural commitment and late neural phenotype development using the human stem 
cell TERA2.cl.SP12 model of neurogenesis. 
 
Specific Objectives 
 Use TERA2.cl.SP12 EC cells to determine the role of small molecule 
concentration on neural commitment between ATRA and EC23. 
 Use Liarozole to determine the influence of metabolism on the ability of 
ATRA and EC23 to induce stem cell differentiation.  Data can then be used to 
relate HOX expression to potency and determine a minimum concentration for 
neural commitment.  
 Concentration dependent and temporal differences between 9 HOX genes 
located at both 3’ and 5’ on three clusters was used to investigate the 
differences between ATRA and EC23 during early neural commitment. 
 Determine the role of subtle structural differences of EC23 and EC19 on neural 
commitment.  Specifically methylation of each small molecule. 
 Develop a reproducible method of neural differentiation from stem cells using 
synthetic small molecules. 
 Determine the differentiation of specific neural subtype differences between 
EC23 and ATRA in human TERA2.cl.SP12 cells using gene expression 
profiles and synthetic ventralisation by Purmorphamine. 
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3.2 RESULTS 
3.2.1 Investigating the induction of differentiation of human pluripotent stem cells by the 
synthetic retinoid EC23 
 
To investigate the concentration dependent effects of retinoid induced differentiation on 
human pluripotent stem cells, the cell line TERA2.cl.SP12 was treated with serial 
concentrations of EC23 or ATRA from 10 µM – 0.001 µM for a period of 3 or 6 days prior 
to analysis. Due to the enhanced photo-stability of EC23 it was hypothesised that the 
concentration dependent regulation of retinoic acid receptors would be less heterogeneous 
and represents true signalling through these receptors, without side effects from isomers 
that could arise from compound isomerisation during handling of ATRA in cell culture. 
Furthermore, understanding the potency differences between EC23 and ATRA will aid the 
design of future compounds and is useful when planning investigations that require a 
specific response from a narrow retinoid concentration. 
To determine loss of pluripotency by TERA2.cl.SP12 human stem cells a number of cell 
surface phenotype and genetic markers were quantitatively measured after treatment with 
EC23 or ATRA.  Figure 3-1 demonstrates by light microscopy the characteristic shape of 
cells treated with EC23 or ATRA.  Note that following retinoid treatment, cells stop 
proliferating, look less dense and tend not to overgrow in the culture in contrast to 
undifferentiated cultures and DMSO treated control-cells.   
To assess this change quantitatively the percentage of cells that expressed the glycolipid 
stem cell markers SSEA3 and TRA-1-60 was determined on the membrane of the cells by 
flow cytometery in each condition (Figure 3-2).  After 3 days treatment only small changes 
in the expression of SSEA3 or TRA-1-60 were demonstrated by treatment with either 
EC23 or ATRA, with the exception of SSEA3 levels after 10 µM ATRA treatment which 
showed a large decrease in expression.  Loss of SSEA3 expression after 3 days under these 
conditions indicates very early changes occur on the surface of the cells after treatment 
with ATRA, however, no loss of surface antigens were induced by EC23 after just 3 days 
treatment.  After 6 days ATRA induced an almost complete loss of SSEA3 expression at 
10 µM and 1 µM and a substantial loss of TRA-1-60 expression at these concentrations.  
Only small changes in expression were measured below these concentrations. In contrast 
EC23 induced an almost complete loss of SSEA3 expression after 6 days treatment at 
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concentrations of 10-0.01 µM and this was mirrored by a substantial decrease in TRA-1-60 
expression at these concentrations indicating a higher potency of EC23.   
To further investigate early changes of pluripotency induced by EC23 or ATRA the 
relative mRNA expression of the genes OCT4 and NANOG were measured in the same 
cells that were analysed by flow cytometry (Figure 3-3) after 6 days.  The levels of both 
OCT4 and NANOG correlated well with flow cytometry data indicating a loss of gene 
expression induced by 10-1 µM ATRA and 10-0.01 µM EC23.  The relative expression of 
OCT4 and NANOG was more sensitive at measuring the effect of retinoid treatment than 
cell surface glycoprotein expression.  At 0.001 µM EC23/ATRA loss of both NANOG and 
OCT4 was measurable. However, at this concentration little or no expressional change of 
the cell surface glycoproteins SSEA3/ TRA-1-60 was detected.  
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Figure 3-1 Phase microscopy of TERA2.cl.SP12 cells differentiated with EC23 or 
ATRA for 21 days. Cells were cultured with either ATRA or EC23 at 0.001 µM-10 µM 
for 21 days prior to imaging.  Notice the overgrowth that occurs in cultures that do not 
contain retinoid Undifferentiated (A) and DMSO (B).  DMSO was added at 0.1% v/v. 
Cultures were treated with ATRA at 0.001 µM (C), 0.01 µM (E), 0.1 µM (G), 1 µM (I), 
10 µM (K) or EC23 at 0.001 µM (D), 0.01 µM (F), 0.1 µM (H), 1 µM (J), 10 µM (L).  
Arrows show high density cell areas asterisk marks low density cells.  Note the 
heterogeneity within the cultures which is more prominent at low retinoid 
concentrations.  Scale bars: 100 µm. n=3. 
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B 
Figure 3-2 Regulation of stem cell markers during treatment with retinoids. Cell membrane 
expression of SSEA3 and TRA-1-60 in TERA2.cl.SP12 stem cells treated with either EC23 or 
ATRA.  Cells were treated with 0.001, 0.01, 0.1,1 or 10 µM EC23 or ATRA, for 0, 3 or 6 days. 
Live cell flow cytometry was used to measure the percentage of the cell population that expressed 
either SSEA3 (A) or TRA-1-60 (B) under each condition. Loss of expression was induced by both 
ATRA and EC23. Expression changes were detected after just 3 days with ATRA, however, this 
was not demonstrated by EC23.  Since, EC23 showed significant activity at 0.1 µM – 0.01 µM 
compared to ATRA after 6 days,  it appeared that EC23 was active at 100 times lower 
concentration than ATRA. Data represent mean ± SEM, n=3. * p≤0.005** p≤0.0005. Student’s t-
test corrected for multiple testing between compared sample poulations using the Bonifferoni 
correction. 
** 
** 
* 
Compound (µM) 
SSEA3 
TRA-1-60 
Compound (µM) 
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Figure 3-3 Differential regulation of pluripotent stem cell markers in response to 
retinoids. Real time PCR expression of the pluripotency genes OCT4 (A) and NANOG (B). 
TERA2.cl.SP12 cells were exposed to 0.001 µM, 0.01 µM, 0.1 µM, 1 µM and 10 µM EC23 or 
ATRA for 6 days in monoculture. Increasing concentrations of ATRA resulted in a gradual 
loss of expression of both genes with maximal loss associated with 1 µM and 10 µM.  EC23 
showed a similar gene expression profile, however, almost complete loss of expression was 
demonstrated at 0.01 µM, a 100 times lower concentration to ATRA.  Gene profile 
quantification is relative to the level of gene expression in undifferentiated TERA2.cl.SP12 
cultured for 6 days. Data represent mean ± SEM, n=3. 
A 
B 
OCT4 
Concentration (µM) 
NANOG 
Concentration (µM) 
OCT4 
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3.2.2 Investigating the induction of neural commitment of human pluripotent stem cells 
by the synthetic retinoid EC23 
 
To determine the role of concentration and potency of EC23 at inducing neural 
commitment, the neural specific cell surface glycoprotein A2B5 was measured using 
flow cytometry under the same experimental conditions as previously described.  Cells 
were treated with 10-0.001 μM EC23 or ATRA for 3 and 6 days prior to flow 
cytometric analysis.  An increase in A2B5 expression is indicative of early neural 
commitment and a percentage population of cells expressing the surface glycoprotein 
is a good indicator of the differentiation inducing potential of the small molecules 
being investigated.  Figure 3-4 shows that as with loss of pluripotency ATRA induces 
neural commitment at 10 μM and 1 μM after 6 days, any concentrations below this did 
not induce a significant amount of neural commitment indicated by A2B5 expression.  
EC23 induced an increase in A2B5 expression at concentrations from 10 µM - 0.01μM 
after 6 days.  Note that after 3 days only changes in the highest ATRA concentration 
was measured indicating that EC23 acts slower than ATRA even though it as a higher 
overall potency. 
To determine the genomic level neural commitment induced by EC23 under these 
conditions and assess more sensitively the early changes that are occurring during 
induction of differentiation, the mRNA level of PAX6, a transcription factor associated 
with neural commitment, was measured using real time PCR.  PAX6 contains a RARE 
in its promoter this is an ideal candidate to investigate any differences between the 
retinoids. Data on gene transcription events that occur during differentiation was used 
to determine similarities and differences between ATRA and EC23 at the genetic level 
(Figure 3-5). Figure 3-5 shows data from day 3 and day 6 of retinoid treatment of the 
relative change in quantity of PAX6 mRNA compared to the undifferentiated control.   
As with the induction of A2B5 expression, EC23 does not induce a measurable PAX6 
response in the cells after 3 days treatment.  In contrast, as was demonstrated by A2B5, 
treatment with a high concentration of ATRA induced neural commitment and this is 
seen at the genomic level by high levels of PAX6 expression after 3 days of 10 µM 
ATRA treatment. 
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After 6 days continuous treatment a peak of PAX6 expression was demonstrated at 0.1 
μM EC23 which tails off either side of this concentration, indicating an optimal dosage 
for inducing PAX6 in this model by EC23 and potential optimal concentration for 
specific neural subtypes.  ATRA induced a peak of PAX6 expression at 10 μM which 
reduced with concentration in a dose dependent manner.  
Immunocytochemical staining of Pax6 protein demonstrates high levels at 0.1 μM 
EC23 or 10 μM ATRA only (Figure 3-6).  Note that Pax6 seems to be located in areas 
of high cell density indicating heterogeneity within the cultures which may result in 
sub-optimal neural differentiation and variation in the cell population across the 
culture dish.  
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Figure 3-4 Regulation of neuronal marker A2B5 during treatment with retinoid. Cells were 
treated with 0.001, 0.01, 0.1,1 or 10 µM EC23 or ATRA, for 0, 3 or 6 days. Live cell flow cytomery 
was used to measure the percentage of the cell population that expressed A2B5 under each 
condition. Loss of expression was induced by both ATRA and EC23, however, EC23 was active at 
100 times lower concentration than ATRA.  Expression changes were detected after just 3 days with 
ATRA, however, this was not demonstrated by EC23. High levels of A2B5 are indicative of 
commitment to the neural lineage by differentiating stem cells. Data represent mean ± SEM, n=3.     
*p≤0.005 Student’s t-test corrected for multiple testing between compared sample poulations using 
the Bonifferoni correction. 
Compound (µM) 
* 
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Concentration (µM) 
Concentration (µM) 
Figure 3-5 Differential regulation of PAX6 expression demonstrating concentration dependent 
neural commitment by exposure of human pluripotent stem cells to retinoids.  TERA2.cl.SP12 
cells in monoculture were exposed to 0.001 µM, 0.01 µM, 0.1 µM, 1 µM or 10 µM for 3 days (A) 
or 6 days (B) respectively and PAX6 gene expression was measured by real time PCR.  Expression 
at day 3 for both compounds was low, except for 10 µM ATRA which indicated an early response 
at this concentration.  Each concentration of EC23 induced a small increases in expression after 3 
days, indicating a lag in the induction of neural differentiation compared to ATRA at high 
concentrations. This correlated with flow data for A2B5 (Figure 3.4) and SSEA3 (Figure 3.2) at day 
3 where similarly high concentrations of ATRA induced changes in expression not seen by EC23.  
After 6 days treatment ATRA induced a concentration dependent response in gene expression as 
concentration increased so did PAX6 expression; in contrast maximal expression in cells treated 
with EC23 was at 0.1 µM which reduced as concentration either side of this concentration, 
indicating a potential regulatory feedback effect on PAX6 expression not seen by ATRA due to the 
toxic when a higher than 10 µM concentration is used.  Data represent mean ± SEM, n=3. 
 
PAX6 3 Days 
6 Days 
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Figure 3-6 Differential regulation of nuclear protein Pax6 in response to retinoids. 
Immunocytochemistry demonstrates concentration dependent expression of Pax6 by EC23 and 
ATRA.  TERA2.cl.SP12 cells were exposed to 0.1 µM, 1 µM and 10 µM EC23 (B,D,F) or ATRA 
(C,E,G) for 6 days in mono layer culture. Nuclear staining of Pax6 was seen in all cultures in areas of 
high density (DAPI shown in blue).  Maximum expression of Pax6 was shown at 10 µM ATRA (C) 
and 0.1 µM EC23 (F) which correlated with real time PCR data shown in Figure 3.5. The low level 
nuclear staining at high concentrations of EC23 and the low expression at 0.1 µM ATRA also 
correlate with gene expression data. Pax6 indicates commitment to neural differentiation and is 
specific for more ventral neural subtypes. Notice Pax6 is expressed highly in high density areas of cell 
nuclei. Arrows indicate areas of nuclear Pax6 staining Scale bars: 50 µm. n=3. 
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In a more extensive commitment of retinoid-induced cell differentiation, cells were 
cultured for 21 days in the continued presence of 10-0.001 µM EC23 or ATRA.  After 21 
days the cells were fixed in 4 % PFA and stained for the neuronal cytoskeletal protein β III 
Tubulin and the non-neuronal protein Cytokeratin 8. Figure 3-7 shows 
immunocytochemical staining of the neural specific cytoskeletal protein, β III Tubulin, at 
three concentrations of ATRA:  0.1 μM, 1 μM and 10 μM.  This data demonstrates neural 
differentiation at all three concentrations. However, at 0.1 μM ATRA the amount of neural 
differentiation is visibly reduced.   Comparing gene expression data, flow cytometric data 
and immunocytochemical morphology and protein expression data it is evident that 0.1 μM 
ATRA was sufficient to induce neural commitment in a sub set of the stem cells.  It is 
important to note that SSEA3, TRA-1-60 and A2B5 expression was not changed at this 
concentration, however, OCT4 and NANOG mRNA expression was reduced.  This 
indicates a possible advantage of mRNA analysis over cell surface glycoprotein expression 
measurement when screening for compounds that induce differentiation of stem cells.  
Stem cells treated with EC23 for 21 days produced cells with a characteristic neural 
phenotype from (10-0.01 µM EC23).  To quantify the level of neural protein in each 
culture and a western blot was performed on the highest expressing cultures. Figure 3-8 
shows protein quantification of β III Tubulin on protein from cells treated with 10, 1 or 0.1 
µM EC23 or ATRA from 21 days.  Notice the low level of protein expression in both the 
untreated control and low concentration of ATRA treated cultures. Co-staining for the non-
neuronal protein Cytokeratin 8 (Figure 3-9) demonstrated a heterogeneous culture of 
neuronal and non-neuronal cells in the 0.1 µM ATRA treated cells as demonstrated by the 
large flat epithelial like cells.  In contrast very few large epithelial like cells were seen in 
EC23 treated cultures. Undifferentiated and DMSO treated controls became over confluent 
and cells died indicating they continued to proliferate and did not differentiate.  
Furthermore, cells treated with 0.01 μM ATRA or 0.001 μM EC23 did not survive to 21 
days culture, the cells that became over confluent, lifted off the cell culture plastic 
substrate and such cultures were terminated.        
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Figure 3-7 Neural differentiation of cells treated with EC23 and ATRA.  Cells were treated 
with 10 µM, 1 µM, 0.1 µM and 0.01 µM EC23 (A,C,E,G) or ATRA (B,D,F). Cells treated with 
0.001 µM EC23, 0.001 µM ATRA and 0.01 µM ATRA died by over proliferation (H).  Due to the 
nature of the cells decreasing the starting density to prevent cells becoming over confluent was not 
possible.  The stem cell phenotype of the cells are density dependent and at low densities 
spontaneously differentiate into epithelial like cells. In the presence of retinoid the cells stop 
proliferating and express neuronal markers.  Cells were exposed to each concentration for 21 days, 
fixed in 4 % PFA and stained for the pan-neural epitope TUJ-1(Red) and DAPI (Blue). Neural 
differentiation was demonstrated at each concentration of EC23, ATRA induced neurite 
differentiation to a concentration of 0.1 µM. Note the reduction in neural development in cultures 
exposed to low levels of ATRA compared to EC23. Scale bars: 50 µm. n=3. 
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Figure 3-8 Regulation of neural proteins by retinoid treatment. Western blot analysis was used 
to quantify the protein expression of β III Tubulin in TERA2.cl.SP12 (A) cells treated with 10, 1 or 
0.1 µM EC23 or ATRA for 21 days. Densitometry measurement of protein expression (B). 
Significantly higher levels were seen in retinoid treated groups than the undifferentiated controls.  
Levels were higher consistently in EC23 treated cultures. Data represent mean ± SEM, n=3.* 
p≤0.005 Student’s t-test corrected for multiple testing between compared sample poulations using 
the Bonifferoni correction. 
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Figure 3-9 Non-neural differentiation of cells by EC23 or ATRA.  Cells were treated with 0.001 
µM, 0.01 µM, 0.1 µM. 1 µM or 10 µM EC23 (A,C,E,G) or ATRA (B,D,F) for 21 days. Cells 
treated with 0.001 µM EC23, 0.001 µM ATRA and 0.01 µM ATRA died by over proliferation (H).  
Due to the nature of the cells decreasing the starting density to prevent cells becoming over 
confluent was not possible.  The stem cell phenotype of the cells are density dependent.  After 
treatment cells were fixed in 4 % PFA and stained for the cytoskeletal protein cytokeratin 8 (Green) 
and DAPI (Blue). Non-neural differentiation indicated by cytokeratin 8 positive areas of large flat 
epithelial like cells was demonstrated at 0.1 µM ATRA. Note the higher expression of cytokeratin 8 
staining and plaque formation in cultures exposed to low levels of retinoid (dashed lines). Scale 
bars: 50 µm.n=3. 
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3.2.3 Determining the role of metabolism on the potency of EC23 and neural commitment 
of human pluripotent stem cells. 
 
Cytochrome P450 inhibiting compounds, known clinically as retinoic acid metabolism 
blocking agents or RAMBA’s, are used to enhance the biological potency of endogenous 
retinoic acid. The use of RAMBA agents is predominantly for increasing the endogenous 
activity of retinoic acid in skin disease [62].  One relatively recently developed RAMBA is 
Liarozole hydrochloride [62].  In this section it was hypothesised that the enhanced 
potency of EC23 seen over ATRA is due to EC23 not being metabolised and hence is 
available to bind receptors constantly even at low concentrations. In contrast, ATRA would 
be metabolised by a group of cytochrome P450 enzymes family 26, and lose the ability to 
induce gene transcription by retinoic acid receptors.   
Due to the presence of low levels of endogenous retinoic acid in FBS, an initial screen to 
determine if incubation with Liarozole alone was sufficient to enhance the biological effect 
of endogenous retinoic acid resulting in stem cell differentiation (Figure 3-10). In addition 
it is known that DMSO can induce differentiation if at high enough concentration (around 
1 %) therefore it was important to determine the effect of Liarozole on the potency of 
DMSO in this model.  Figure 3-10 demonstrates that the addition of 10 µM Liarozole 
dissolved in DMSO 0.1 % v/v did not induce any changes in SSEA3, TRA-1-60 or A2B5 
expression compared to the undifferentiated control, furthermore, no change in cell 
expression of SSEA3, TRA-1-60 or A2B5 was measured in cells treated with Liarozole in 
DMSO 0.2 % v/v (control). The higher percentage of DMSO in the control (0.2 % v/v) 
accounts for the DMSO used to dissolve EC23 or ATRA as well as Liarozole.   
To assess the role of retinoid metabolism on potency of retinoids to induce stem cell 
differentiation, TERA2.cl.SP12 cells were treated with three concentrations of ATRA that 
did not induce differentiation, 0.001 µM, 0.01 µM and 0.1 µM for 6 days with and without 
10 µM Liarozole (Figure 3-11).  After 6 days a significant and large change in the 
expression of SSEA3, TRA-1-60 and A2B5 was seen in cells treated with 0.01 µM and 0.1 
µM ATRA with the addition of Liarozole, indicating loss of pluripotency and neural 
commitment with higher potency than ATRA alone. There was some enhancement of 
biological activity at 0.001 µM ATRA plus Liarozole compared to the ATRA only control.  
To determine if the enhanced potency demonstrated by EC23 was due to its resistance to 
metabolism TERA2.cl.SP2 stem cells were treated with 0.001 µM (an inactive 
concentration of EC23), 0.01 µM and 0.1 µM EC23 with and without Liarozole.  Markers 
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of pluripotency and neural commitment were then assessed by flow cytometry (Figure 
3-12).  The levels of each of the markers assessed, SSEA3, TRA-1-60 and A2B5 were not 
altered by the presence of Liarozole, indicating that the potency of EC23 was not affected 
by inhibition of metabolising enzymes.   
 
 
 
 
 
 
Figure 3-10 Application of Liarozole alone does not influence cell phenotype.  TERA2.cl.SP12 
cells were exposed to Liarozole and Liarozole plus 0.1 % DMSO as a control for subsequent 
experiments using Liarozole.  Expression of the cell surface markers SSEA3, TRA-1-60 and A2B5 
did not change with the addition of Liarozole or Liarozole plus 0.1 % DMSO compared to untreated 
controls. This demonstrates the inability of any endogenous ATRA in the cell culture media at 
inducing differentiation with the addition of Liarozole.  Data represent mean ± SEM, n=3. 
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Figure 3-11 Addition of Liarozole enhances the activity of ATRA. Flow cytometric analysis of the stem cell markers SSEA3 (A), TRA-1-60 (B) and the pan-neural 
marker A2B5 (C).TERA2.cl.SP12 cells were exposed to ATRA at concentrations of  0.001 µM, 0.01 µM or 0.1 µM with and without the presence of 10 µM Liarozole 
hydrochloride for 6 days.  At 0.001 µM and 0.01 µM ATRA no change in the expression of each cell surface marker was measured, with only small changes at 0.1 µM.  
The addition of Liarozole hydrochloride resulted in an almost complete loss of SSEA3, a much reduced expression of TRA-1-60 and high levels of A2B5 expression at 
0.01 µM and 0.1 µM, indicating enhancement of potency. Only small changes in expression were seen at 0.001 µM with Liarozole. These data suggest the role cytochrome 
P450 enzymes in the regulation of ATRA in this system. Data represent mean ± SEM, n=3.  
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Figure 3-12 Addition of Liarozole does not change the activity of EC23. Flow cytometric analysis of the pluripotency markers SSEA3 (A), TRA-1-60 (B) and the pan-
neural marker A2B5 (C).TERA2.cl.SP12 cells were exposed to EC23 at concentrations of  0.001 µM, 0.01 µM or 0.1 µM for 6 days with and without the presence of 10 
µM Liarozole hydrochloride.  Differentiation was demonstrated at 10 µM by loss of SSEA3, TRA-1-60 and expression of A2B5, no change in the number of cell surface 
markers were seen at 1 µM and 0.1 µM. Data suggest that EC23 is not metabolised by enzymes from the CYP 450 family, specifically EC23 is unlikely to be metabolised 
by CYP 26 enzymes. No statistically significant differences were shown between groups. Data represent mean ± SEM, n=3. 
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To further investigate the role of metabolism on the activity of ATRA and EC23, and to 
determine if metabolites of ATRA have a role in inducing neural differentiation a pulse 
and refresh experiment was performed.  In this experiment, cells were pulsed with either 
0.1 µM EC23 or ATRA (Figure 3-13) or 1 µM EC23 or ATRA (Figure 3-14) for 1 minute, 
1 hour, 1 day or added continuously.  After pulsing with the compound the cells were 
washed in PBS and fresh media without retinoid was added, cells were then incubated to 6 
days prior to flow cytometry of SSEA3, TRA-1-60 and A2B5.  
EC23 induced differentiation in the stem cells after just 1 minute incubation at 0.1 µM, the 
level of differentiation increased with incubation time.  Only small changes in 
differentiated were demonstrated by 0.1 µM ATRA.  At 1 µM EC23 induced an almost 
complete loss of SSEA3 and TRA-1-60 expression by the cells at each of the incubation 
times and this was accompanied by high levels of A2B5 expression.   In contrast only 
continuous exposure to 1 µM ATRA induced the same level of changes in the cell surface 
markers as EC23. Finally Liarozole was added to a pulse of ATRA or EC23 to determine if 
a pulse of ATRA or EC23 that was previously inactive could be enhanced (Figure 3-15).  
No change in potency of EC23 was observed at 0.1 µM pulsed for 1 hour in the presence 
of 10 µM Liarozole, however, pulsing for 1 hour with 1 µM ATRA in the presence of 
Liarozole did result in an enhanced activity.  
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Figure 3-13 A single pulse of 0.1 µM EC23 is sufficient to induce differentiation.  TERA2.cl.SP12 cells were treated with 0.1 µM EC23, 0.1 µM ATRA or 0.1 % 
DMSO for 1 minute, 1 hour, 1 day or continuously.  After treatment cultures were maintained for 6 days in fresh media.  Quantification of the stem cells surface proteins 
SSEA3 (A) and TRA-1-60 (B) as well as the neural marker A2B5 (C) by flow cytometry showed if the cells were differentiating. In all cases EC23 induced a loss of 
SSEA3 and TRA-1-60 expression and an increased expression of A2B5.  The change in cell surface markers induced by EC23 at this concentration was lower in the pulsed 
experiments than in continuous exposure.  Data represent mean ± SEM, n=3. * p≤ 0.05 using Student’s paried t-test. 
 
Dosage time Dosage time 
Dosage time 
* 
* 
102 
 
 
 
 
 
 
 
A B 
C 
Figure 3-14 A single pulse of 1 µM EC23 is sufficient to induce differentiation.  TERA2.cl.SP12 cells were treated with either 1 µM EC23, 1 µM ATRA or 0.1 % 
DMSO for 1 minute, 1 hour, 1 day or continuously.  After treatment cultures were maintained for 6 days in fresh media.  Quantification of the stem cells surface proteins 
SSEA3 (A) and TRA-1-60 (B) as well as the neural marker A2B5 (C) by flow cytometry showed if the cells were differentiating. In all cases EC23 induced a loss of 
SSEA3 and TRA-1-60 expression and an increased expression of A2B5. The affect seen by ATRA was much less pronounced at any of the pulsed times indicating 
metabolism and loss of activity in these cultures.  Data represent mean ± SEM, n=3. * p≤ 0.05 using Student’s paired t-test. 
Dosage time Dosage time 
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Figure 3-15 An ineffective pulse treatment of ATRA can be enhanced by Liarozole treatment.  
TERA2.cl.SP12 cells were treated with 1 µM ATRA or 0.1 µM EC23 for 1 hour with and without 
10 µM Liarozole.  The cells were then maintained in fresh cell culture media for 6 days.  Flow 
cytometric analysis of the cell surface markers SSEA3 (A), TRA-1-60 (B) and A2B5 (C) was used 
to determine if the cells were differentiating.  There was a significant enhancement of the activity of 
ATRA with the addition of Liarozole, however this was not demonstrated with EC23. Data 
demonstrates the effect of metabolism on the potency of ATRA.  Data represent mean ± SEM, n=3. 
* ≤0.05 using Students paired t-test. 
* 
* 
* 
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3.2.4  Enhancing the potency of synthetic retinoids by incorporation of a methyl group 
 
The small molecule EC23 was developed alongside the small molecule, EC19.  EC19 and 
EC23 have a similar structure; however the carboxyl group on EC19 is at the meta-
position, compared with EC23 where it is in the para-position (Figure 3-16).  
 
 
Figure 3-16 Molecular structures of EC19 and EC23.  Both EC19 and EC23 contain a highly 
stabilising triple bond and no oxidation sites. 
 
EC23 can induce consistent neural differentiation in human stem cells, whereas EC19 
treatment resulted in large flat epithelial like cells with very few neurons [95]. The 
differential response between EC19 and EC23 may suggest activation of alternative 
receptors in this model.  The structure activity relationship between retinoids has been 
studies extensively and is apparent naturally.  The cis configuration of at the 9 carbon 
position in 9-cis-RA confers a differential response in neuroblastoma cells compared to all-
trans RA. Another analogue of ATRA, TTNPB is very similar to the structure of EC23 and 
contains a cis-bond isomerisation and can induce enhanced apoptosis in some cell models. 
TTNPB is similar in potency to EC23; however, EC23 has been shown recently to result in 
higher RAR binding [93]. 
As with EC23, TTNPB is not metabolised demonstrated by Liarozole models [201]. In this 
section it was hypothesised that 3-methylation of EC19 and EC23 may affect their 
biological activity.  The addition of a 3-methyl group to TTNPB resulted in a decrease in 
RAR activity and increased RXR activity suggesting either a possible increase in TTNPB 
metabolism [202] or a change in ligand binding to the receptor.  Investigating the role of 
carbon 3 methylation on change in receptor selectivity/metabolism and stem-cell 
differentiation will provide useful insights when designing synthetic compounds in the 
future to induce specific receptor activity. In this section biological activity of 3-carbon 
EC19 EC23 
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methylated EC19 and EC23 was investigated in TERA2.cl.SP12. The structures of 
methylated EC19 and EC23 are shown in Figure 3-17, due to the rigidity of the triple bond 
in EC19 and EC23, addition of the methyl group should not interfere with the 
conformation and thus not affect interaction with the ligand binding pocket (LBP) of the 
RARs and hence, biological activity. 
 
           
 
  
Figure 3-18 shows flow cytometric data of TERA2.cl.SP12 cells treated with either EC19 
or methyl-EC19 (MeEC19).  As has been demonstrated previously that EC19 did not 
induce a marked change of SSEA3, TRA-1-60 or A2B5 at 10, 1 or 0.1 µM, indicating a 
low activity in this system.  Methylation of EC19 resulted in a marked increase in 
biological activity at 10 µM, as indicated by a loss of SSEA3 and TRA-1-60 expression 
and an increase in A2B5 positive cells.  At the lower concentrations 1 µM and 0.1 µM no 
significant difference was shown.   
To assess if methylation of EC23 resulted in a change of the potency of the molecule, 
active and inactive concentrations of EC23 were investigated using flow cytometry. There 
was no change in potency at either the active concentrations 0.1 µM or 0.01 µM or the 
inactive concentration tested 0.001 µM (Figure 3-19), suggesting EC23 already induced a 
maximal response regardless of the methyl group. 
Real time PCR was used to determine if the enhanced activity demonstrated by methyl 
EC19 at 10 µM was also demonstrated in an enhanced neural progenitor commitment 
through the gene expression analysis of PAX6. Figure 3-20 demonstrates that 10 µM 
MeEC19 MeEC23 
Figure 3-17 Chemical structure of methylated EC19 and EC23.  Compounds are identical to 
EC19 and EC23, however, contain a methylated  3 carbon which will not affect the shape of the 
molecule.  
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ATRA, EC23, MeEC23 and MeEC19 induce expression of PAX6, ATRA induced the 
highest expression and MeEC19 the lowest.  No expression was detected in EC19 treated 
cells, indicating an enhancement of EC19 activity by addition of the methyl group.  
To assess if the addition of a methyl group to either EC19 or EC23 resulted in an increased 
metabolism of either of the compounds 10 µM Liarozole hydrochloride was added to 
concentrations of EC19 (Figure 3-21), MeEC19 (Figure 3-22) and MeEC23 (Figure 3-23) 
that were ineffective at inducing changes in expression of SSEA3, TRA-1-60 and A2B5.  
As was shown previously, ATRA can be enhanced though synergistic activity with 
Liarozole (Figure 3-11), any metabolism as a result of the addition of the methyl group will 
be inhibited by Liarozole.  The data demonstrated that methylation of EC19 and EC23 did 
not appear to change its metabolism in this model.  Furthermore, EC19 was not enhanced 
by Liarozole, suggesting it also is not metabolised similar to EC23 and its lower potency 
may be due to sequestering effects or poor receptor binding affinity/alternative receptor 
binding.  
Understanding the structure activity relationship of retinoic acid analogues is important for 
compound design directed at control of cell differentiation.  The large array of RAR and 
RXR receptor isotypes and growing knowledge of the role different heterodimers during 
development makes designing small molecules capable of specific RAR or RXR subtype 
selectivity important for future research into retinoids and their biological activity.  
In summary this study has described how subtle chemical modifications can alter the 
biological activity of synthetic retinoids without affecting the overall conformation of the 
molecule.  Hence, the addition of a methyl group to EC19 resulted in a small increase in 
RAR LBP affinity.  
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Figure 3-18 Concentration dependent differentiation of TERA2.cl.SP12 cells by 3-Methyl EC19 (MeEC19) and EC19.  Cells were treated with either 10 µM, 1 µM or 
0.1 µM MeEC19 or EC19 for 6 days. Using flow cytometric analysis the number of cells expressing the cell surface markers SSEA3 (A), TRA-1-60 (B) or A2B5 (C) were 
quantified.   No change in expression was seen at 0.1 µM or 1 µM of both EC19 and MeEC19 compared to an untreated control.  There was no change of the cell surface 
markers demonstrated by 10 µM EC19.  However, MeEC19 induced differentiation of the cells at 10 µM as demonstrated by a loss of SSEA3 and TRA-1-60 expression and 
an increase in A2B5 expression.  These data indicate that methyl EC19 shows enhanced biological activity over EC19. Data represent mean ± SEM, n=3. * p≤0.01 Students  
t-test.  
Concentration (µM) Concentration (µM) 
Concentration (µM) 
* 
* 
* 
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Figure 3-19 Concentration dependent differentiation of TERA2.cl.SP12 cells by Methyl EC23 (MeEC19) and EC23.  Cells were treated with either 0.1 µM, 0.01 
µM or 0.001 µM MeEC23 or EC23 for 6 days. Using flow cytometric analysis the number of cells expressing the cell surface markers SSEA3 (A), TRA-1-60 (B) or 
A2B5 (C) were quantified.   Very little change in expression was seen at 0.001 µM of both EC23 and MeEC23 compared to an untreated control.  At the higher 
concentrations 0.01 µM and 0.1 µM both MeEC23 and EC23 induced differentiation as demonstrated by a loss of SSEA3 and TRA-1-60 expression and an increase in 
A2B5 expression.  These data show that addition of a methyl group to EC23 does not appear to influence its biological activity. Data represent mean ± SEM, n=3. 
Concentration (µM) Concentration (µM) 
Concentration (µM) 
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Figure 3-20 PAX6 expression is enhanced by methylation of EC19. TERA2.cl.SP12 cells were 
treated with 10 µM ATRA, EC23, methyl EC23 (MeEC23), methyl EC19 (MeEC19) and EC19 for 
6days.  The mRNA expression of PAX6 was measured using real-time PCR and gave a representation 
of any enhancment of potency after methylation.  Methylation of EC19 induced a 24 times significant 
increase in PAX6 expression in this model compared to EC19. No change in activity was seen by 
EC23. Data represent mean ± SEM, n=3. *  p≤0.05 Students t-test. 
 
  
 
 
 
 
 
PAX6 mRNA 
PAX6 mRNA expression 
Concentration (10µM) 
* 
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Concentration (µM) Concentration (µM) 
Concentration (µM) 
Figure 3-21 Addition of Liarozole to cells treated with EC19 does not appear to change the activity of EC19. Flow cytometric analysis of the pluripotency markers 
SSEA3 (A), TRA-1-60 (B) and the pan-neural marker A2B5 (C). TERA2.cl.SP12 cells were exposed to EC19 at concentrations of 0.1 µM, 1 µM or 10 µM for 6 days 
with and without the presence of 10µM Liarozole hydrochloride.  The addition of Liarozole to each concentration did not enhance the potency of EC19.  No statistically 
significant differences were shown between groups Data represent mean ± SEM, n=3. 
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Figure 3-22 Addition of Liarozole to cells treated with MeEC19 does not appear to change the activity of MeEC19. Flow cytometric analysis of the pluripotency 
markers SSEA3 (A), TRA-1-60 (B) and the pan-neural marker A2B5 (C). TERA2.cl.SP12 cells were exposed to MeEC19 at concentrations of 0.1 µM, 1 µM or 10 µM for 
6 days with and without the presence of 10 µM Liarozole hydrochloride.  Differentiation was demonstrated at 10 µM, no change in the number of cell surface markers 
were seen at 1 µM and 0.1 µM. The addition of Liarozole to each concentration did not enhance the potency of MeEC19. No statistically significant differences were 
shown between groups. Data represent mean ± SEM, n=3. 
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Figure 3-23 Addition of Liarozole to cells treated with MeEC23 does not appear to change the activity of MeEC23. Flow cytometric analysis of the pluripotency 
markers SSEA3 (A), TRA-1-60 (B) and the pan-neural marker A2B5 (C). TERA2.cl.SP12 cells were exposed to MeEC23 at concentrations of 0.001 µM, 0.01 µM or 0.1 
µM for 6 days with and without the presence of 10 µM Liarozole hydrochloride.  Differentiation was demonstrated at 0.1 µM and 0.01 µM, however no change in the 
number of cell surface markers were seen at 0.001 µM.  No statistically significant differences were shown between groups .The addition of Liarozole to each concentration 
did not enhance the potency of MeEC23.  Data represent mean ± SEM, n=3. 
Concentration (µM) Concentration (µM) 
Concentration (µM) 
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3.2.5 Modulation of embryonic anterior-posterior patterning genes during stem cell 
differentiation using synthetic small molecules 
 
Regulation of developmental patterning by a group of genes known as HOX genes is key to 
the correct differentiation of neural subtypes through environmental cues.  HOX genes 
contain a DNA binding homeobox which is conserved among different species.  Human 
HOX genes are located on four different chromosomes and consist of 39 genes clustered 
into four distinct regions; A, B, C and D.  Regulation of HOX genes is developmentally 
conserved and requires a morphogenic stimulus. Mammalian HOX genes are thought to 
pattern the anterior-posterior axis via co-linear expression; co-linear expression means that 
due to the proximity of the HOX genes on each cluster the expression of each gene along 
the A-P axis is determined by its position in the cluster i.e. HOX genes 3’ in the cluster are 
expressed in the anterior developing embryo, whereas 5’ HOX genes are only expressed in 
the posterior developing embryo.  The hypothesis behind the ability of these genes to be 
expressed in this way is due to a concentration gradient of retinoic acid.  Many of the 3’ 
HOX genes are able to induce the expression of HOX genes more 5’.  In addition 3’ HOX 
genes usually contain a RARE, therefore retinoic acid is thought to regulate HOX gene 
expression directly and hence, anterior-posterior patterning and differentiation.  It was 
demonstrated in vitro that retinoic acid can induce temporal and concentration dependent 
co-linear expression of HOX genes.  For a detailed review see Chapter 1.  
This section is aimed to investigate the regulation of HOX genes in a temporal and 
concentration dependent manner by ATRA.  Furthermore, using the synthetic ATRA 
analogue EC23, it was hypothesised a more consistent, reproducible and accurate 
concentration/activity could be achieved and give a better understanding as to the 
regulation of HOX genes by RARE activation.  
Initially 9 genes were chosen to be investigated, including HOX A1, 5, 6 B1, 6, 9 and D1, 
4, 8.  These represent HOX genes at both the 3’ and 5’ ends of three clusters of genes.  It is 
known that HOX A1, B1, D1 and D4 all contain RARE.  Relative expression of each gene 
to the untreated control was measured by real time PCR at 72 and 144 hours treatment to 
assess temporal regulation.  To determine concentration dependent regulation and co-
linearity in our model, TERA2.cl.SP12 cells were treated for 72 and 144 hours with five 
different concentrations of both EC23 and ATRA.  The concentrations used were: 0.001 
µM, 0.01 µM, 0.1 µM, 1 µM and 10 µM.  Furthermore, it was demonstrated earlier in this 
Chapter using real time PCR and flow cytometry which of the retinoid
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concentrations induce neural differentiation. (Figure 3-24 - Figure 3-29).  
The expression of HOX genes induced in our stem cell model by each concentration of 
EC23 or ATRA for 72 hours is shown for cluster A in Figure 3-24, cluster B in Figure 3-25 
and cluster D in Figure 3-26.   The HOX genes on cluster A after 72 hours of induction by 
EC23 or ATRA demonstrated concentration dependent expression.  ATRA did not induce 
the expression of HOXA1, A5 or A6 to high levels in cultures treated with 0.001 µM, 0.01 
µM or 0.1 µM.  High levels of HOXA1 and HOXA5 were demonstrated at both 1 µM and 
10 µM treatment; however, HOXA6 even at 10 µM did not induce a large increase in 
relative expression, indicating a co-linear relationship between these genes. In contrast the 
expression of all genes A1, A5 and A6 were induced by EC23 at 0.001 µM - 10 µM in a 
concentration dependent manner.  The level of maximal expression was lower than that of 
ATRA treated cultures, however, EC23 induced more expression at the lower 
concentrations investigated. The low expression levels seen are typical of EC23 after 72 
hours.  
Regulation of HOX genes on cluster B demonstrated less fold change in the 3’ genes 
compared to that of HOXA.  However, in contrast to HOXA1, the 3’ gene HOXB1 was 
induced maximally after 72 hours by a low concentration of EC23 – 0.01 µM.  Expression 
was demonstrated at 0.001 µM, peaked at 0.01 µM and reduced with EC23 concentration. 
HOXB1 increased with dose in cells treated with ATRA indicating a differential response 
of HOXB1 to EC23 and ATRA.  Very little change in expression of HOXB6 was 
demonstrated after 72 hours induction by EC23 or ATRA.  However, HOXB9 was induced 
maximally by 1 µM EC23 and ATRA and remained at high levels to 10 µM of each 
compound; little or no change in expression was demonstrated at the low concentrations 
tested for HOXB9 (Figure 3-25). 
The three HOX genes from cluster D measured were D1, D4 and D8.  The genes analysed 
on cluster D were demonstrated to be regulated in a concentration dependent manner. Data 
in Figure 3-26 demonstrates that EC23 induced maximal HOXD1 expression at 0.1 µM 
which decreased either side on this concentration a similar pattern was produced with 
PAX6 expression.  Regulation of HOXD4 and HOXD8 by EC23 after 72 hours was 
minimal.  With only a small peak demonstrated at 1 µM for both HOXD4 and HOXD8.  In 
contrast ATRA induced a direct increase of HOXD1 with concentration; however 
expression levels did not reach that of 0.1 µM EC23.  High levels of both HOXD4 and 
HOXD8 were induced in similar pattern; the transcript was almost completely absent from 
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0.001 µM – 0.1 µM.  A steep increase of expression was demonstrated at 1-10 µM in 
ATRA treated cultures. 
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Figure 3-24 Regulation of HOXA1, A5 and A6 concentration dependent expression induced by EC23 or ATRA.  TERA2.cl.SP12 cells were treated with 0.001 µM, 
0.01 µM, 0.1 µM, 1 µM or 10 µM for 3 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXA1 (A), HOXA5 (B) and 
HOXA6 (C) was measured.  Data demonstrates a similar dose response at each concentration for each gene assayed for the individual compounds.  EC23 induces changes 
in expression at a lower concentration, however, does not reach the level of change demonstrated by high concentrations of ATRA.   The relative changes measured were 
highest in the more 3’ genes assayed –HOXA1 and A5. Data represent mean ± SEM, n=3. 
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Figure 3-25 Regulation of HOXB1, B6 and B9 concentration dependent expression induced by EC23 or ATRA.  TERA2.cl.SP12 cells were treated with 0.001 µM, 
0.01 µM, 0.1 µM, 1 µM or 10 µM for 3 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXB1 (A), HOXB6 (B) and 
HOXB9 (C) was measured.  Data demonstrates a peak of HOXB1 expression by both EC23 and ATRA at low concentrations, however, the relative change is more 
pronounced with EC23, negligible changes in expression are demonstrated in HOXB6 with both compounds.  A comparable increase in expression of HOXB9 is 
demonstrated between EC23 and ATRA at high concentrations.  There seems to be a concentration dependent co-linearity between HOXB1 and HOXB9 at this time point. 
Data represent mean ± SEM, n=3. 
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Figure 3-26 Regulation of HOXD1, D4 and D8 by EC23 and ATRA is concentration dependent.  TERA2.cl.SP12 cells were treated with 0.001 µM, 0.01 µM, 0.1 µM, 
1 µM or 10 µM for 3 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXD1 (A), HOXD4 (B) and HOXD8 (C) was 
measured.  Data demonstrates a peak of HOXD1 expression by 0.1 µM EC23, however ATRA induces a linear dose response.   ATRA induced a large increase in the 
relative expression of HOXD4 and HOXD8 at 1 µM and 10 µM. In comparison HOXD4 was induced by EC23 at each concentration tested, however to a much lower level 
increase than the maximum induced by ATRA.  EC23 induced HOXD8 expression at 1 µM and 10 µM but levels were much lower than ATRA.  Similar expression 
patterns were demonstrated between HOXD4 and HOXD8 possibly indicating a link between their regulation. Data represent mean ± SEM, n=3. 
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After a further 72 hours of treatment with EC23 or ATRA at 0.001 µM - 10 µM mRNA 
expression was determined of the 9 HOX mRNA transcripts described previously.  Again 
the genes were from three HOX gene clusters A, B and D, and represented 3’ and 5’ genes 
within each cluster. 
The expression of HOXA1 was induced at the lowest concentration of both EC23 and 
ATRA (Figure 3-27).  EC23 induced much more expression in the cells at low 
concentrations than ATRA, however, ATRA induced similar levels at 1 µM to EC23 but 
higher levels at 10 µM then EC23.  Although relative to ATRA HOXA5 was induced to 
low levels by EC23, the overall relative change from base line was high, indicating some 
level of regulation, however, much higher levels of HOXA5 were induced by 10 µM 
ATRA in comparison to EC23.  The same pattern as HOXA5 was seen with HOXA6 and 
however, the relative increase in transcript number was much less. This may be due to the 
downstream regulation of HOXA6 by HOXA5 indicating co-linear expression.  Increasing 
the time of treatment may well induce much higher levels of 5’ HOXA6.  
Genes on the HOXB cluster measured were HOXB1, HOXB6 and HOXB9 which are spread 
from 3’ to 5’ along the cluster. Data demonstrate that this cluster is highly regulated by the 
concentration of both EC23 and ATRA (Figure 3-28).  HOXB1 was expressed highest at 
0.001 µM and 0.1 µM EC23 and ATRA, indicating a highly sensitive RARE within the 
promoters, since increasing the concentration further resulted in a decrease in expression a 
negative feedback mechanisms may be in place. HOX B6 was induced by 0.01 µM-10 µM 
EC23 with peak expression at 0.1 µM and ATRA induced expression maximally at 1-10 
µM.  The 5’ HOXB9 gene which would be expected to be least responsive to retinoic acid 
stimulation was expressed at high levels by 1-10 µM EC23 and ATRA, with little or no 
expression at lower concentrations. The three genes investigated on HOXB are induced by 
EC23 by concentration dependent regulatory mechanisms. Finally, the regulation of genes 
HOXD1, D4 and D8 from the HOXD cluster, after 6 days treatment demonstrated a pattern 
similar to that after 3 days treatment, with both EC23 and ATRA. However, the level of 
relative expression was much higher after 6 days.  This indicated that the number of 
transcripts increases in a temporal manner; however, the relative change is not greater in 3’ 
genes than 5’ genes.  This may be since there is a low level of 3’ HOX gene expression in 
undifferentiated cells making any relative change from base line less pronounced.  Due to 
the concentration effects on HOX genes by retinoids described here it is likely that 
regulation of HOX genes is through concentration dependent regulation, in addition to a 
co-linear temporal response.  
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Figure 3-27 Regulation of HOXA1, A5 and A6 concentration dependent expression induced by EC23 or ATRA.  TERA2.cl.SP12 cells were treated with 0.001 
µM, 0.01 µM, 0.1 µM, 1 µM or 10 µM for 6 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXA1 (A), HOXA5 
(B) and HOXA6 (C) was measured.  Increased expression of HOXA1 was seen at all concentrations of ATRA and EC23 with a gradual increase with concentration, 
higher levels were induced at concentrations of 0.001 µM, 0.01 µM and 0.1 µM EC23 than ATRA. HOXA5 and HOXA6 showed a similar pattern of expression at 
each concentration of ATRA and EC23, however the expression of both was induced much higher with ATRA than EC23 at 1 µM and 10 µM.    Data represent mean 
± SEM, n=3. 
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Figure 3-28 Regulation of HOXB1, B6 and B9 concentration dependent expression induced by EC23 or ATRA.  TERA2.cl.SP12 cells were treated with 0.001 µM, 
0.01 µM, 0.1 µM, 1 µM or 10 µM for 6 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXB1 (A), HOXB6 (B) and 
HOXB9 (C) was measured.  Both EC23 and ATRA induced a shift in expression between 3’ HOXB1 to more 5’ HOXB6 and HOXB9.  Similar patterns of expression were 
seen between EC23 and ATRA for HOXB1 with high levels induced at the lowest concentrations.  Some differences were observed between EC23 and ATRA at inducing 
HOXB6 expression, EC23 induced much higher levels than ATRA at 0.01 µM and 0.1 µM.  The 5’ HOXB9 gene was only expressed at 1 µM and 10 µM of both ATRA and 
EC23, similar pattern of expression was demonstrated between ATRA and EC23.  These data clearly demonstrate a difference in concentration induced expression from 3’ 
to 5’ HOX genes on cluster B. Data represent mean ± SEM, n=3. 
Concentration (µM) 
Concentration (µM) Concentration (µM) 
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Figure 3-29 Regulation of HOX D1, D4 and D8 by EC23 and ATRA is concentration dependent.  TERA2.cl.SP12 cells were treated with 0.001 µM, 0.01 µM, 0.1 µM, 
1 µM or 10 µM for 6 days.  RNA was extracted and purified and using real time PCR the relative expression change of HOXD1 (A), HOXD4 (B) and HOXD8 (C) was 
measured.  Data demonstrates a large peak of HOXD1 expression by 0.1 µM EC23, however ATRA induces a linear dose response with much a much lower fold increase.   
ATRA induced large a large increase in the relative expression of HOXD4 and HOXD8 at 1 µM and 10 µM. In comparison HOXD4 was induced by EC23 at each 
concentration tested excluding 0.001 µM, however to a much lower level increase than the maximum induced by ATRA.  EC23 induced HOXD8 expression at 0.1 µM, 1 
µM and 10 µM but levels were much lower than ATRA.  Similar expression patterns were demonstrated between HOXD4 and HOXD8 possibly indicating a link between 
their regulation. Data represent mean ± SEM, n=3. 
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3.2.6 Synthetic modulation of the dorsal-ventral axis during neural differentiation 
 
The homeodomain containing gene PAX6 has been demonstrated to be involved in neural 
subtype specification of hindbrain, spinal cord V1 interneuron and somatic motor neurons.  
Interneuron and motor neurons develop in the ventral part of the CNS [203, 204], therefore 
morphogens that provide ventral position identity to developing neural stem cells will 
express markers of interneuron or motor neurons. As described earlier EC23 and ATRA 
induce the expression of PAX6 mRNA in stem cells that differentiate into neurons, 
furthermore, the concentration of each retinoid appears to influence the level of PAX6 
expression in the cell population.  It is unknown how retinoic acid concentration affects 
ventral neural subtype identity. 
In this model ventral specification signals are provided to cells via the morphogen sonic 
hedgehog (Shh). Sonic Hedgehog is produced by the notochord in the developing neural 
tube and acts in a concentration dependent way to specify either NKX2.2 interneuron fate 
or ISL1+ motor neuron identity. 
This study aimed to use a single concentration of the synthetic Shh agonist Purmorphamine 
(1 µM) from day 6 to induce ventralisation of differentiating TERA2.cl.SP12 stem cells. 
Using the neural subtype specific markers ISL1, HB9 and NKX2.2 to monitor specific 
ventral neural commitment varying concentrations of retinoid were investigated for their 
influence on ventral subtype identity.  
Initially cells were treated with either 0.1 µM, 1 µM or 10 µM EC23 or ATRA for 6 days.  
At day 6 a single 1 µM concentration of Purmorphamine was added to the culture to 
ventralise the cells.  Cultures were maintained for a further 8-22 days. The expression 
profile of PAX6 mRNA (Figure 3-30) was typical of that expected during differentiation.  
As before, EC23 induced a peak expression of PAX6 at 0.1 µM at day 6, but reduced from 
day 14-21 to levels similar to that induced maximally by 1 µM EC23.  Only low levels of 
PAX6 expression were induced throughout by 10 µM EC23.  ATRA induced PAX6 
expression maximally after 6 days in cells treated with 1 µM and 10 µM but by day 14-21 
expression reduced to levels induced by 0.1 µM ATRA.  These data suggest for neural 
differentiation a reduction in PAX6 is necessary.  It may be however, that those 
concentrations of EC23 that maintain a higher level after 14-21 days induce commitment 
of different neural subtypes than the lower levels of expression.  
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Low mRNA levels of the motor neuron marker HB9 were detected throughout the culture 
period up to 28 days at each concentration.  EC23 demonstrated very little variability in 
expression between concentrations, whereas ATRA induced maximal expression at 10 µM 
(Figure 3-31).  After 14 days 0.1 µM and 10 µM treated cells were stained for HB9 protein 
(Figure 3-32) only low nuclear expression was detected, however, more immune-reactivity 
was seen in cells treated with retinoid and Purmorphamine than Purmorphamine alone.  
Since HB9+ cells can give rise to both interneuron and motor neurons the relative mRNA 
expression of two more markers specific for either motor neuron identity (ISL1) or V1 
interneuron (NKX2.2) was measured at each 0.1-10 µM EC23 or ATRA treated cells after 
21 days.  
Data demonstrates a differential expression of both NKX2.2 and ISL1 expression dependent 
on the concentration (Figure 3-33).  Only high concentrations of ATRA and EC23 induced 
ISL1 expression in the cells, this is in contrast to NKX2.2 where cells treated with 0.1 µM 
of EC23 or ATRA induced a higher level of expression than at 10 µM.  A similar pattern 
was also demonstrated at 1 µM EC23, indicating that retinoid signalling may influence 
interneuron and motor neuron fate.  
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Figure 3-30 Regulation of PAX6 gene expression during TERA2.cl.SP12 cell differentiation 
with EC23/ATRA and Purmorphamine. Monolayer cultures of TERA2.cl.SP12 cells were 
treated with 0.1 µM, 1 µM and 10 µM EC23 (A) or ATRA (B) for 21 days.  At day 6 
Purmorphamine was added to the culture media and continued to day 21.  Arrows mark point at 
which Purmorphamine is added to the culture media. mRNA expression was measured at day 0, 
6, 14 and 21. Data demonstrate the loss of PAX6 expression as the cells differentiate past day 6. 
Data represent mean ± SEM, n=3. 
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Figure 3-31 Regulation of HB9 gene expression by real-time PCR during TERA2.cl.SP12 
differentiation by EC23/ATRA and Purmorphamine. Monolayer cultures of TERA2.cl.SP12 
cells were treated with 0.1 µM, 1 µM and 10 µM EC23 (A) or ATRA (B) for 28 days.  At day 6 
Purmorphamine was added to the culture media and continued to day 28.   mRNA expression was 
measured at day 0, 6, 14, 21 and 28. Arrows mark point at which Purmorphamine is added to the 
culture media. Data demonstrate increasing level of HB9 expression throughout differentiation 
indicating a ventral phenotype of the differentiating neurons. Data represent mean ± SEM, n=3. 
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Figure 3-32 HB9 expression in TERA2.cl.SP12 cells during differentiation.  Cells were treated 
for 14 days with 1 µM Purmorphamine (B) or EC23 (C)/ATRA (D) for 6 days followed by the 
addition of 1 µM Purmorphamine for a further 8 days.  Cells were stained with a HB9 specific 
antibody.  Some nuclear staining for HB9 was detected in the cultures containing either ATRA or 
EC23 however not in the Purmorphamine only control. n=3. 
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Figure 3-33 Concentration dependent regulation of gene expression associated with ventral 
neural progenitors in TERA2.cl.SP12 cells differentiated with EC23/ATRA and 
Purmorphamine.  TERA2.cl.SP12 cells were treated with 0.1 µM, 1 µM and 10 µM EC23 or 
ATRA for 21 days. At day 0 the undifferentiated cells were given a relative quantity of 1.0.  From 
day 6, 1 µM Purmorphamine was included in the culture media. Expression of ISL1, a motor neuron 
associated gene was maximally expressed at 10 µM of both EC23 and ATRA.  In comparison the 
ventral interneuron marker NKX2.2 was expressed maximally at 0.1 µM by both compounds and 
decreased as concentration was increased.  Data represent mean ± SEM, n=3. 
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3.3 DISCUSSION 
 
Directed differentiation of pluripotent stem cells is necessary to advance areas of cell 
biology and regenerative medicine.  As the understanding of how external signals affect 
stem cell fate the focus of using the stem cell-derived neurons for investigating disease and 
developmental pathways becomes more physiologically relevant. Furthermore, there is 
scope for direct implantation of specific neural subtype progenitors to treat disease such as 
Parkinson’s. Differentiating human stem cells into a neural progenitor fate using small 
lipophilic molecules is an attractive method of achieving a high yield of neural progenitors 
and mature neurons from stem cells for use in such application.   
Modulation of know developmental pathways can influence cell fate decisions, synthetic 
small molecules that engage with these pathways can be designed to be more potent, stable 
and more specific, guiding cells more efficiently and accurately.  Designing small 
molecules that affect biological signalling pathways in this way requires knowledge of the 
compound and its effects in multiple stem cell systems.  In addition the combination of 
small molecules both temporally and synergistically will no doubt be required to facilitate 
the most specific and optimum neural differentiation of human stem cells for regenerative 
medicine.   
3.3.1 Induction of differentiation and neural commitment by EC23 and ATRA 
 
Loss of pluripotency induced by EC23 and ATRA 
 
The cell surface antigens globoseries stage specific embryonic antigen 3 (SSEA3) and 
Keratin-sulfate-associated-glycoprotein surface marker (TRA-1-60) have been 
demonstrated to be specific for an undifferentiated cell phenotype in both hES and hEC 
cells [82, 205-207].  Furthermore, SSEA3 has been used to separate the undifferentiated 
hES and hEC stem cell niche from a population of differentiated heterogeneous cells, 
indicating the specificity of this cell surface antigen for pluripotency [84, 207].  As well as 
cell surface markers, expression of certain genes have also been used to separate 
pluripotent and committed cells – both OCT3/4 and NANOG are well documented for their 
ability to determine pluripotency.  
The results from this study demonstrate that as published previously, ATRA induces down 
regulation of both SSEA3 and TRA-1-60 in the EC cell TERA2.cl.SP12 at concentrations 
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of 10 μM and 1 μM over 6 days of treatment [95], however, at concentrations of 0.1-0.001 
μM the differentiation capability of ATRA is significantly reduced  (Figure 3-2).   
The cell surface antigens SSEA3 and TRA-1-60 are good overall markers of an 
undifferentiated phenotype, however, due to the post-translational processing required 
prior to expression of these proteins at the cell surface, small changes in pluripotency 
induced by low levels of retinoid may not be detected until after 6 days. Therefore, to 
assess more accurately the effect of low concentrations of ATRA and EC23 on 
TERA2.cl.SP12 differentiation the relative mRNA levels of transcription factors OCT4 and 
NANOG was determined using RT-PCR (Figure 3-3). OCT4 and NANOG are well 
described in the literature as ‘gate keepers’ of the pluripotency phenotype, their expression 
is required to maintain and induce pluripotency therefore a suppression of their expression 
is indicative of differentiation [208].  The results from this study demonstrate that both 
EC23 and ATRA induce suppression of the transcription factors OCT4 and NANOG at 10 
μM and 1 µM, however, below these concentrations ATRA induces only moderate 
suppression, whereas, EC23 induces a high level of suppression up to 0.01 μM, indicative 
of its high potency. 
The data in this section agree with published data on EC23 and ATRA. Both can induce 
neural differentiation of stem cells.  Both ATRA and EC23 have been shown to induce 
differentiation of TERA2.cl.SP12 EC cells and Human embryonic stem cells [90, 92].  
This study investigated the concentration dependent role of EC23 and ATRA during 
differentiation of TERA2.cl.SP12 and although EC23 has not been demonstrated to be 
active at the concentrations used in this study below 1 µM there was a differential effect 
observed with concentration.  It is well documented in the literature that retinoic acid 
signalling in vivo acts via concentration dependent mechanisms [31, 34], therefore 
understanding these effects in vitro with the synthetic analogue of ATRA, EC23 was 
important for its characterisation.  It has been shown recently that EC23 induces RAR 
activation in a concentration dependent manner which is different to ATRA and other 
molecules.  Firstly, EC23 induces a much higher activation than many other retinoids 
including similar synthetic analogues of ATRA such as TTNPB and secondly, EC23 has 
maximal receptor activation at 0.1 µM, fitting in well with data described in this thesis 
[93].  
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Neural differentiation induced by EC23 and ATRA 
 
The EC cell TERA2.cl.SP12 is a well characterised model of in vitro neural differentiation 
and has been shown in multiple studies to differentiate into mature neurons through 
treatment with ATRA.  The cell line is thought to represent pluripotent cells of the early 
ectoderm, hence, differentiates into CNS neurons, Glial cells and neural-epithelia [84].  To 
determine the effect of concentration on neural lineage commitment the percentage 
expression of a cell surface antigen, A2B5 was determined in cells treated with 
concentrations 0.001-10 μM ATRA for 3 and 6 days.  
Monoclonal antibodies raised against the glycoside antigen A2B5 has been described in 
many models as a marker of early neural commitment and is thought to be a marker of 
neural progenitor cells [85, 209].  High levels of A2B5 expression is demonstrated on the 
cell surface membrane of Oligodendrocyte progenitors and neural stem cells, furthermore, 
A2B5 antibodies can be used to isolate neural stem cells from animal tissue.  In this study 
expression of A2B5 was indicative of neural commitment and was used to determine the 
activity of small molecules aimed at inducing neural lineage differentiation.   As with what 
was seen with the loss of pluripotency markers, ATRA induced the highest percentage 
expression of A2B5 at 10 μM and this decreased with concentration (Figure 3-4).   In 
contrast EC23 induced high levels of A2B5 expression at concentrations from 0.01 µM-10 
µM, again exemplifying the enhanced potency of EC23. These data are in broad agreement 
with previously published data on EC23 [89, 90].  
PAX6 is a pan-neuronal marker, expression of PAX6 in vivo is found throughout the spinal 
cord [210] and during retinal neural progenitor development [211]. PAX6 expression is 
found in discrete areas of the CNS and provides ventral positional cues to developing 
neural cells induced through controlled feedback between SHH and BMP signalling [203, 
212].   In combination with other transcription factors such as OLIG2 and ISL1, PAX6 can 
be used to distinguish neuroprogenitor cells and their potential differentiation fate [213, 
214]. 
In this study PAX6 mRNA levels were measured in the same cells used for flow cytometry 
at day 3 and 6 of EC23 or ATRA supplementation.  As expected a concentration dependent 
increase was observed in cells treated with ATRA after 6 days, a 5 times increase in 
expression was measured between 10 μM and 1 μM indicating that ATRA induced neural 
commitment in the TERA2.cl.SP12 EC cells as described in previous publications. The 
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concentration-activity relationship demonstrated by ATRA linear, indicating as more 
receptors were activated the more PAX6 mRNA was transcribed. 
In contrast to the relationship of concentration observed with EC23 expression with the 
antigens SSEA3, TRA-1-60 and the transcription factors OCT4 and NANOG, the 
expression of PAX6 gene transcription was optimum at 0.1 μM.  This may reflect a 
negative feedback loop that occurs with high concentrations of retinoid signalling, 
however, due to the effect of high concentrations of ATRA on cell survival it is not 
possible to demonstrate this with ATRA.  Protein levels of PAX6 observed by 
immunocytochemical staining after 6 days treatment with 10, 1, or 0.1 µM, EC23  or 
ATRA demonstrated high expression at 0.1 µM EC23 and 10 µM ATRA (Figure 3-6).  
Furthermore, the expression of translational products was located at areas of high cell 
density, representing areas most likely to become neuronal, this effect of cell density has 
been observed recently [171].  High levels of PAX6 mRNA are indicative of good neural 
commitment during the early stages of differentiation.  Maintaining high levels provides 
positional cues to developing neural progenitors to form ventral neural subtypes.  Although 
it is difficult to determine that the observed differences in PAX6 expression at each of the 
retinoid concentrations will result in a different phenotype it does suggest that the cells 
with high PAX6 expression would be more likely to become motor neurons than cells with 
an initially low PAX6 mRNA level [215, 216]. 
This section described how EC23 and ATRA induce a similar response in TERA2.cl.SP12 
EC cells at 10 μM and 1 μM.  The response indicates neural differentiation of the cells that 
has been described by Christie, V.B et al (2008) [95]. The biological effect of EC23 
remains high at the concentrations of ATRA which showed limited biological activity.  
Furthermore, EC23 can induce mature neuronal differentiation at much lower 
concentrations than ATRA demonstrating a correlation between potency during initiation 
of differentiation and maturation of the neural progenitor cells into neurons. Whether or 
not EC23 signalling is required throughout the complete neural differentiation protocol is 
unknown; however, it is likely that as with ATRA a minimum of 12 days treatment is 
required [171].  In addition these results suggest that treatment with concentrations of 10 
μM and 1 μM EC23 may not be optimum in TERA2.cl.SP12 for inducing neural lineage 
commitment, this is supported by flow cytometry data published by Christie V,B et al 
(2008) [95] demonstrating an enhanced effect of EC23 at 1 μM compared to 10 μM (0.1 
μM was not tested). The expression of PAX6 mRNA in this study demonstrates the most 
striking increase at an individual concentration.  The decrease in PAX6 mRNA expression 
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at concentrations above 0.1 μM may be a result of negative feedback pathway not normally 
seen with ATRA.  
Neurite formation and the morphology of differentiated neurons were assessed after 21 
days culture in TERA2.cl.SP12 EC cells treated with 0.01, 0.1, 1 and 10 μM EC23 or 
ATRA.  Staining fixed cells for the cytoskeletal protein, β III Tubulin demonstrated neurite 
formation by cells differentiated with 0.01-10 μM EC23 and 0.1-10 μM ATRA (Figure 
3-7).  Cells treated with 0.01 μM ATRA and 0.001 μM EC23 and ATRA became over 
confluent and were disposed.  To visually assess the heterogeneity between concentrations 
and compounds a non-neuronal cytoskeletal protein was also stained for, cytokeratin 8 
staining demonstrated that at low concentration of ATRA there was in increase in 
epithelial like plaques (Figure 3-9).  Quantification of β III Tubulin protein using western 
blot from cells treated with 0.1, 1 and 10 μM EC23 or ATRA for 21 days demonstrated a 
higher level of neural protein in EC23 treated cultures.  A robust and reproducible method 
for inducing neural differentiation from TERA2.cl.SP12 cells by EC23 is included in 
Chapter 2 (Methods) and can be used to investigate many of the molecular processes that 
occur during stem cell differentiation in vitro.  
In summary this section demonstrated the ability of EC23 to induce neural differentiation 
of human stem cells with greater potency than its natural analogue ATRA.  Therefore, the 
use of this stable synthetic molecule is useful as a replacement for ATRA, however, the 
concentration that it is used should be considered if used for comparative studies with 
ATRA. 
3.3.2 Testing the role of metabolism as a mechanism to explain the apparent increased 
potency of EC23 during EC cell differentiation 
 
ATRA is oxidised by the cytochrome P450 family 26 group of enzymes, the oxidisation 
products are either excreted, have less biological activity or are further metabolised.  
Therefore, this process reduces the bioavailability of ATRA and hence, reduces the effects 
of low concentrations.  This section aims to investigate the role of retinoic acid oxidation 
on the increased potency of EC23 and determine if the loss of biological activity 
demonstrated in Section 3.1 with low concentrations of ATRA can be rescued by inhibiting 
this process.   
To investigate the role of retinoid metabolising enzymes on EC23 induced differentiation 
the cytochrome P450 enzyme (CYP) family 26 (CYP26), was inhibited using the pan CYP 
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inhibitor, Liarozole Fumarate.  Studies have demonstrated that Liarozole can enhance the 
effects of low concentration of retinoid in mouse EC and mouse limb bud cells, 
presumably through inhibition of ATRA metabolism [66, 217].  ATRA is oxidised by the 
family of CYP26 enzymes into the products of metabolism shown in Figure 1.3, therefore, 
inhibition of this process should increase the amount of ATRA available to bind the RAR.  
Many of the ATRA oxidation products have been shown to have biological effects [218], 
however, there has been no data relating to treatment of human EC cells with Liarozole 
and the effect of Liarozole on increasing the ability of low concentrations of ATRA to 
induce neural differentiation.    
Figure 3-9 demonstrates the effect of Liarozole on TERA2.cl.SP12 differentiation through 
flow cytometric analysis of SSEA3, TRA-1-60 and A2B5. Cells were treated with 10 μM 
Liarozole for 6 days with and without 0.1 % DMSO v/v, to assess the effect of Liarozole 
alone on the stem cells.  There was no change in expression of the cell surface 
glycoproteins after 6 days compared to the undifferentiated control.  Preliminary studies 
demonstrated that consistent with Liarozole concentrations used in the mouse F9 
teratocarcinoma cell line.  In the study 1-10 μM Liarozole inhibited CYP26 activity 
sufficient to demonstrate increased ATRA response [66], importantly Liarozole was not 
shown to have any retinoid like properties. 
The effect of Liarozole on the potency of ATRA and EC23 
 
In Figure 3-11, 10 μM of Liarozole induced an enhancement of EC cell differentiation at 
concentrations of ATRA that were shown previously to have little or no effect on 
pluripotency. Flow cytometry of EC cells treated with 0.01 μM and 0.1 μM ATRA 
demonstrated suppression of SSEA3 and TRA-1-60.  Furthermore, at these concentrations 
expression of A2B5 was enhanced, indicating neural lineage commitment in these cells.  
Treatment with Liarozole enhances the activity of ATRA at these concentrations and the 
enhancement results in similar activity (as assessed by these markers) to EC23, alone.  
These data also indicates that metabolites of ATRA are unlikely to contribute to the 
differentiation inducing potential of ATRA, since prevention of oxidation products results 
in an enhanced potency of ATRA.  As has been described by the use of clinically and in 
models of ATRA potency, the addition of Liarozole results in enhancement of the 
biological activity of ATRA [62, 66]. This is the first time Liarozole has been shown to 
enhance the biological activity of ATRA in human stem cells.  This model can be used to 
assess other retinoid analogues for the effect of metabolism on their biological activity. 
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This model was therefore also used to assess the role of metabolism on the biological 
activity of EC23.  Stem cells were treated with 0.01, 0.1 and 0.001 µM EC23 for 6 days.  
The cells were then analysed as described previously for cell surface glycoproteins 
indicative of loss of pluripotency and neural commitment. As was known previously 
treatment with EC23 induced differentiation at concentrations 0.01 and 0.1 μM and this 
was the same with and without Liarozole (Figure 3-12). However at 0.001 μM a 
concentration that did not induce differentiation in these cells, no enhancement was 
detected in the presence of Liarozole. This may suggest that EC23 is not oxidised by 
CYP26 and hence, inhibiting this group of enzymes did not contribute to any elevated 
intracellular binding of receptors.  This correlated with structural data since the compound 
structure of EC23 is predicated not to have any of the oxidation sites found in ATRA. 
The synthetic retinoid TTNPB has been demonstrated to have 1000 fold greater potency 
than ATRA and this increased potency is in part due to its resistance to metabolism and 
greater availability to bind RAR [201]. Therefore, it is likely that the increased potency of 
EC23 is due to its resistance to metabolism in this cell model. These data also suggest that 
the oxidation products of ATRA are not involved in the initiation of differentiation of hEC 
cells, as inhibition of their production enhances this process.  
This section demonstrated that EC23 was not metabolised by cytochrome P450 enzymes, 
however, the biological activity of ATRA was enhanced by Liarozole indicating 
metabolism, as expected. Since inhibition of ATRA metabolism in the stem cells resulted 
in an enhancement of neural differentiation, it can be deduced that metabolites of ATRA 
do not contribute to the differentiation process.  Furthermore, these data suggest the 
potency of EC23 may be due in part to its resistance to metabolism. 
Pulsing of EC23 and ATRA 
 
Since EC23 was demonstrated not to be metabolised by CYP enzymes it was hypothesised 
that a single dose pulse of EC23 would be sufficient to induce differentiation in the 
TERA2.cl.SP12 stem cells. A pulse of EC23 would remain within the cell cytoplasm, 
bound to cellular retinoic acid binding proteins and be constantly activating the retinoic 
acid receptors in the nucleus.  It was unknown if the sequestering proteins, namely cellular 
retinoic acid binding protein (CRABP I) I would be in high enough concentration to 
prevent differentiation.  Induction of the CRABP I, II and the cellular retinol binding 
protein I (CRBP  I) by 10 µM EC23 has been demonstrated by Maltman, D et al (2009) 
[219], other proteins that were shown to be up-regulated by EC23 by neural specific 
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differentiation were Profilin and phosphorylated Stathmin which was similar to levels 
induced by 10 µM ATRA.    Tongue, J.R. et al (2012) [171] indicated that a single dose of 
ATRA for ≤ 3 days in a similar EC cell line NTERA2.cl.D1 (a different TERA2 clone) 
was in-sufficient to induce large expressional change in the mRNA of the neuronal 
markers PAX6 and NEUROD1 – cells were maintained to 12 days after the initial ATRA 
dose.  Data from this study also showed that OCT4 and NANOG were still highly 
expressed in cells treated with ATRA for 1 day, furthermore, up-regulation of 
Endomesodermin  a trophoblast and endoderm marker was detected in cells pulsed for ≤ 3 
days indicating a differential lineage commitment in these cells similar to treatment with 
the small molecule EC19.  Maximal A2B5 and PAX6 expression was induced after a 12 
day pulse of 10 µM ATRA treatment in NTERA2 EC cells which resulted in a high yield 
of neurons after 21 days similar to continuous supplementation with ATRA.  Significantly 
lower neuronal yield of neuron was detected after a pulse of 6 days ATRA, even though 
stem cell markers were highly decreased and neural specific mRNA expression was 
increased significantly.  
In this study cells were pulsed for 1 minute, 1 hour and 1 day or continuously by 0.1 µM or 
1 µM, EC23 or ATRA.  Cells were exposed to the compounds in cell culture media for the 
time required, washed in PBS once and cultured to 6 days in fresh media.  As has been 
described earlier, cells were then analysed using live cell flow cytometry for the cell 
surface glycoprotein, SSEA3, TRA-1-60 and A2B5 (Figure 3-13 and Figure 3-14).  The 
data from this section demonstrated that at 0.1 µM or 1 µM ATRA, continuous treatment 
was required for cell glycoprotein changes after 6 days which correlates well with 
published data [171].  In contrast EC23 induce significant expressional changes in SSEA3, 
TRA-1-60 and A2B5 after just 1 minute exposure to 1 µM and 1 hour exposure to 0.1 µM.  
Providing further evidence that EC23 is not metabolised in these cells and constitutively 
activates RAR signalling inducing cell differentiation.   
The solvent DMSO is used to dissolve synthetic small molecules for transport across the 
cellular membrane, however, may affect cellular differentiation of both hES and hEC cells 
affecting the overall outcome when investigating specific small molecules and 
concentrations.  Smith, S.C. et al 1987 [220] demonstrated that aggregation of the 
embryonic carcinoma stem cell line P19 and treatment with 1 % DMSO for 5-6 days 
results in endodermal differentiation into epithelial and cardiac tissue.  A comparison 
between the effect of 1 % DMSO treatment and retinoic acid treatment in hES aggregates 
demonstrated a differential regulation of haematopoietic markers through Wnt dependent 
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signalling [221].  Although in these studies on hEC and hES cells the concentration of 
DMSO is around 10 x higher than that used throughout this thesis it may be that even small 
levels of DMSO can reduce the level of neural differentiation in TERA2.cl.SP12.  The 
pulse effect of EC23 would be a suitable method for decreasing DMSO exposure; 
however, data showing terminal neural differentiation after 1 minute pulse would be 
required.  
In this section the resistance of EC23 to metabolism was utilised to reduce the exposure of 
stem cells being differentiated to DMSO.  Pulsing the cells with EC23 for one minute was 
sufficient to induce neural differentiation in this model.   This was not demonstrated for 
ATRA.  A minimum concentration and time of exposure was required for EC23 to induce 
differentiation.  With further phenotypical data the pulse effect of EC23 may lead to an 
additional improvement to the optimised protocol in both hEC and hES cells.  
3.3.3 Enhancing the potency of synthetic retinoids by incorporating a methyl group 
 
The relationship between retinoid structure and biological activity is exemplified by the 
differential regulation of stem cell differentiation by the small molecules EC19 and EC23 
[95].  The small change in chemical structure between EC19 and EC23 seemed to affect 
the receptor specificity of the molecules, making EC19 apparently less active than EC23.    
Development of panels of retinoid analogues has aided research and discovery into the 
retinoic structure-activity relationship, however, the model system use to investigate the 
cellular effects of each retinoid analogue is important [70].  For example, although EC19 is 
relatively inactive in TERA.2.cl.SP12 EC cells its receptor specificity and activity may be 
highly potent at inducing – for instance P19 endodermal differentiation.  Recent insights 
have been available from receptor binding assays of retinoid analogues and provide a 
standardised method of investigating structure-activity relationships for RAR activity [93, 
222].   
Previous studies have demonstrated that methylation of the synthetic retinoid analogue 
TTNPB results in a 90° twist in conformation (Durham University, Chemistry Dept- 
Unpublished data); the twist allows the retinoid to access the L-shaped retinoid X receptor 
(RXR) which is not possible with the native TTNPB compound.  Methyl-TTNPB takes on 
a more 9cis-RA conformation and activates biological signalling characteristic of RXR 
signalling [223].  In this part of the study a methyl group was added to the 3-Carbon 
position of both EC19 and EC23.  Due to the inherent stability of the structure of EC19 and 
EC23 methylation would not change the conformation of the structures.  Data in this 
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Chapter demonstrate that methylation of EC23 does not alter its activity; however, 
methylation of EC19 seems to increase its activity at high concentrations, inducing both 
genetic and cell surface expression of neuronal markers.  The observed enhancement in 
EC19 activity after methylation may be the result of enhanced RAR binding.  
3.3.4 Regulation of anterior-posterior patterning genes 
 
The role of retinoids in establishing the anterior-posterior axis has been hypothesised to 
involve a gradient of retinoic acid activity such that genes responsible for conferring 
anterior positional identity are highly sensitive to retinoic acid signalling and hence, 
respond to low levels of retinoic acid. The converse is true for genes that confer posterior 
identity; hence retinoic acid treatment is generally used to induce posterior identity during 
cellular development.  In the case of HOX genes there exists a concentration dependent and 
co-linear expression of the 39 genes in response to retinoic acid.    
Aberrant expression of HOX genes has been shown to be induced by retinoic acid and 
leads to alterations in the anterior-posterior axis of the developing embryo, which 
inevitably results in altered differentiation of cells relating to their position along the AP 
axis.  Alterations in HOX gene expression is one cause of the teratogenic effects seen with 
retinoic acid signalling and emphasises the importance of correct RA signalling during 
development [47]. 
Simeone A et al (1991) [48, 50] demonstrated through semi-quantitative analysis, that 
retinoic acid could induce co-linear and concentration dependent expression of HOX genes 
in the embryonic carcinoma stem cell NTERA2.cl.D1. The study detailed the time 
dependent regulation of HOX signalling in stem cells treated with retinoic acid.   This 
provided a unique model to investigate the effect of retinoic acid on the expression of these 
genes and their role in embryogenesis.  Little is known about how synthetic retinoids affect 
the expression of HOX genes and the role of concentration on HOX gene regulation.  
In addition to in vitro modelling of HOX gene regulation, numerous animal models have 
utilised modern labelling techniques to investigate the barrier of HOX gene expression 
during development. Amirthalingam, G. et al (2009) [224] used whole-mount chick 
embryo in-situ hybridization to establish that flanking somites can up-regulate HoxB4, 
regulating the anterior patterning of the neural tube through a retinoic acid dependent 
mechanism.  Furthermore, HoxB4 is associated with dorsalisation of neural tube via BMP4 
signalling. This study demonstrate the regulation of one HOX gene by retinoic acid in vivo 
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and its ability to regulate-at least in part the developmental patterning of the chick neural 
tube [224].  
Regulation of HOX genes by EC23 and ATRA 
 
This study aimed to investigate the ability of the synthetic retinoid EC23 to regulate the co-
linear, concentration dependent and temporal expression of HOX genes in the EC cell 
TERA2.cl.SP12 and compare the expression profiles to that of ATRA. Of the 39 HOX 
genes present on four clusters, 9 genes were assayed, the HOX genes chosen were from 
throughout the clusters of A, B and D, representing 3’ and 5’ genes some with known 
RARE and some without direct retinoic acid transcriptional regulation.   
Cells were treated for 72 and 144 hours with either EC23 or ATRA.  After 72 hours many 
of the genes were only expressed at low levels relative to the undifferentiated control.  The 
concentration dependent changes that occurred after 72 hours were mirrored at 144 hours 
but at higher fold change indicating a temporal induction.  The small increased in HOX 
gene expression after 72 hours may have only been measured due to the highly sensitive 
nature of the assay.  In less sensitive assays many of the 5’ HOX genes that demonstrated 
some expression after 72 hours may have not shown any expression and be assumed un- 
responsive at that time point or retinoid concentration [41, 48, 50].  This may detract from 
the overall picture as to how ATRA regulates HOX gene expression, since many of the 
small changes in HOX gene mRNA may be due to biological variation and not represent 
retinoid acid signalling.  Furthermore, the pattern of expression at 72 hours and 144 hours 
were similar in each of the genes investigated and did not clearly demonstrate temporal co-
linear expression.  This may have been a result of the time points used, since after 72 hours 
many of the genes were being expressed making it hard to determine if any one gene was 
induced before the other.  Therefore, a much early time point would be required to 
determine if, for instance the 3’ HOXB1 gene at 0.01 µM was expressed before the more 5’ 
HOXB6 gene at the same concentration. 
Due to the increased potency of EC23 signalling and the high yield of neural cells formed 
from differentiating TERA2.cl.SP12 EC cells with EC23, elevated levels of expression of 
any of the HOX genes may relate to increased neurogenesis  
As the concentration of ATRA decreased its apparent biological activity also decreased 
when measuring HOX gene levels.  Relative expression of 3’ and 5’ HOX gene mRNA 
reduced, with only HOXA1 being expressed greater than 50 times the undifferentiated 
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control at 0.1 μM and 0.01 μM ATRA.  In comparison five HOX genes were induced by 
0.1 μM EC23 to greater than 50 times the control. The genes that are consistently elevated 
during the concentrations of EC23 and ATRA that are capable to induce highly efficient 
neural differentiation in this model are: HOXA1, D4, D8 and A5.  Each is known to contain 
a RARE in their promoter sequence and so their expression is directly induced by retinoic 
acid signalling.  Furthermore, there is evidence to suggest some of the HOX genes are 
directly involved in the process of cellular differentiation. 
HOXA1 
It has been demonstrated that HOXA1 mRNA expression in mouse EC cells, requires 
RARγ signalling, however, there is also a reduction in expression when RARβ2 is knocked 
out, interestingly RAR α knockouts have no change in HOXA1 expression [225, 226]. 
Therefore, the higher RQ of HOXA1 induced by EC23 at 10 μM, 1 μM and 0.1 μM may be 
due to increased signalling through RAR γ or RAR β2.  As described earlier HOXA1 has 
been shown to be required for neural differentiation in mouse ES cells. 
HOXD4 
As was seen with PAX6 the maximum expression of HOXD4 induced by EC23 was at 0.1 
μM and interestingly PAX6 has been implicated in regulation of HOXD4 through binding 
to its neural enhancer.  Therefore, the peak of PAX6 mRNA at 0.1 μM EC23 may explain 
the increase of HOXD4 mRNA at this concentration [227], and could be involved in 
differentiation of the hEC cells into neural progenitors.  
HOXA5 
At even lower concentration i.e. 0.01 μM EC23 induced the expression of HOXA5 to levels 
much higher than that at 0.1 μM, the levels of expression were similar to that seen at 10 
μM and 1 μM. It has been demonstrated that RAR β is required for the expression of 
HOXA5 and HOXA5 is implicated in growth inhibition and apoptosis of breast cancer cells 
[228].  The same property of growth inhibition is demonstrated in hEC cells since 
treatment with retinoic acid results in loss of cell proliferation; however, this may not be a 
result of HOXA5 transcription.  
HOXD8 
Little is known about HOXD8, however, the results shown in this study suggest that it is 
likely involved in maintaining neural lineage commitment.  Furthermore, HOXD8 has been 
demonstrated to be induced by retinoid acid during neuroblastoma differentiation. Further 
suggesting its involvement in neurogenesis [229].  
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The induction of neurogenesis induced by retinoic acid and the high relative expression of 
HOXA1, A5, D4 and D8 in this model suggest that these transcription factors, at least in 
part are involved in the initial process of differentiation.  
The schematic in Figure 3-34 demonstrates the concentration of EC23 required to induce a 
maximal response in most of the HOX genes tested in this study.  With the exception of 
HOXD1 and HOXD4 expression as this was maximal at 0.1 µM and may represent 
activation via an alternative RARE to that of the other HOX genes. It was interesting to 
demonstrate the concentration dependent and temporal associated with HOX gene 
expression and these data demonstrate that both the concentration of retinoic acid and the 
exposure time is important to determine the extent of expression. 
 
 
 
Figure 3-34 Concentration of EC23 required to induce HOX gene expression.  Schematic 
demonstrates visually the position of each HOX gene used in this study in each chromosome 
cluster. The concentration required of EC23 to induce expression of each gene is also depicted.  
Note the sensitivity of each HOX gene to EC23 decreases as the genes become more 5’ providing a 
regulatory role of EC23 in HOX gene expression and AP patterning.  Low concentrations of EC23 
induced the expression of more 3’ genes as concentration increased the expression of 5’ genes were 
induced. Schematic describes day 6 HOX gene expression data. 
 
Concentration of EC23 
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Regulation of the anterior-posterior developmental axis is complex and requires numerous 
mechanisms to ensure correct positional identity of developing cells.  It is known that HOX 
genes are directly involved in regulating such positional identity and control both A-P axis 
and in some cases D-V axis development.  The role of retinoic acid in inducing the co-
linear expression of HOX genes is still being investigated.   
Temporal regulation of HOX genes was through to be a result on co-linearity, where 
activation of 3’ HOX genes can, via a positive feedback loop induce the expression of more 
5’ genes on the same cluster; hence, a domino like effect would ensue.  Data from this 
Chapter suggest that although HOX gene expression does increase with time i.e. from 0-72 
and 72-144 hours, differential regulation is due to retinoid sensitivity and retinoid 
concentration and not an effect of co-linear activation.  It may be that earlier time points 
would be more likely to demonstrate co-linear activation of HOX genes in this model and 
may be more evident after a single pulse of EC23/ATRA. 
HOX regulation of mature neural differentiation 
The role of HOX genes and retinoic acid concentration in stem cell and neural 
differentiation is complex and the outcome of multiple signals working in positive and 
negative feedback loops.  There are, however, some key regulatory pathways that link 
HOX gene expression, retinoic acid and neural differentiation.  Neuronal column 
organisation is responsible for motor neuron organisation which regulates differential 
peripheral muscle innervation.  The mechanisms that give rise to the different motor 
column groups involve numerous signalling pathways and specific gene expression 
profiles.  Distinct HOX-C homeodomain protein clusters are expressed at different levels 
of the developing motor neuron columns. The lateral motor column (LMC) neurons can be 
distinguished from other groups by their expression of the retinoic acid producing enzyme 
Retinaldehyde dehydrogenase 2 (RALDH), implicating a role for retinoic acid (RA) in the 
development of LMC, or a paracrine effect of RA on surrounding developing tissue [230].  
Furthermore, the co-expression of multiple HOX genes is associated with the development 
of specific LMC specification and is likely to offer some functional redundancy [231].  A 
recent study has implicated the expression of the 3’ HOXB1 gene with inducing a more 
dorsal neural phenotype, as measured by a decrease in NKX2.2 expression in embryonic 
stem cells forced to express HOXB1.  Data from this Chapter suggests that NKX2.2 does in 
fact negatively follow the expression of HOXB1.  No NKX2.2 expression was detected at 
the lowest concentrations of EC23 or ATRA tested, however, since these provided the 
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highest up-regulation of HOXB1 it is likely very low levels of NKX2.2 would be detected  
[232]. 
The data presented in this thesis suggest a concentration dependent regulation of HOX 
gene expression with little emphasis on temporal expression.  Furthermore, HOX genes are 
regulated in a retinoic acid receptor subtype specific manner, this is apparent since EC23 
induced differences in the expression of the HOX genes investigated compared to ATRA, 
suggesting simple RARE activation is not sufficient to induce a co-linear cascade response. 
These data further exemplify EC23 as a replacement for ATRA, removing much of the 
heterogeneity in the use of ATRA and provide insights into HOX gene regulation during 
neural differentiation in TERA2.cl.SP12 EC cells. Furthermore, HOXB1 has been shown to 
regulate CRABP I and II expression in mouse ES cells controlling hindbrain neural 
differentiation and patterning [51].     
3.3.5 Synthetic modulation of the dorsal-ventral axis during neural differentiation 
 
Neural subtype differentiation can be enhanced using specific small molecules for key 
molecular signalling pathways.  As has been discussed in this Chapter the replacement of 
ATRA with EC23 enhances neurogenesis in our model. Other small molecules can be used 
as replacements for proteins that affect other signalling pathways associated with neural 
differentiation for example, Purmorphamine.  Purmorphamine is a synthetic Shh pathway 
agonist that can be used as a replacement for the recombinant Shh protein in stem cell 
differentiation protocols for motor neuron differentiation [213].  In this study the addition 
of Purmorphamine to the cell culture media was used to investigate the concentration 
dependent role of retinoic acid on the motor neuron markers HB9 and ISL1, and the 
interneuron marker NKX2.2. As with previous studies, Purmorphamine treated cultures 
expressed transcriptional markers characteristic of ventral spinal cord neural progenitors 
[77, 213]; however, the relative expression of NKX2.2, ISL1 and HB9 was dependent on 
the concentration of either EC23 or ATRA when used in conjunction with Purmorphamine. 
Data demonstrated that retinoic acid concentration regulated the expression of the motor 
neuron marker ISL1 and the ventral interneuron marker NKX2.2, indicating the ability of 
retinoic acid to determine neural subtype. The role of retinoic acid in motor neuron 
specificity and spatial regulation along the dorsal ventral neural tube was demonstrated by 
Wilson, L. et al (2004)  [233] using VAD quail model.   
These data showed in an in vitro model of neural differentiation that not only is retinoid 
concentration an important factor for inducing differentiation, but it is also involved in 
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directing the neural progenitor cells into specific ventral neural subtypes. Used in 
combination with an optimal ventralisation signal from Purmorphamine directing neural 
subtypes will benefit from the use of stable retinoic acid analogues such as EC23. Further 
work on the role of retinoic acid in neural subtype selectivity should look at the functional 
development of the mature neuron and any differences observed. 
3.3.6 Conclusion 
 
This Chapter has described a model of human neurite differentiation using the synthetic 
small molecule EC23.  EC23 was used alongside its natural analogue ATRA and a 
concentration dependent regulation of stem cell differentiation was demonstrated.  Due to 
the inherent instability of ATRA, the need for a more robust and reproducible protocol for 
stem cell differentiation is advantageous.  This has been evidenced throughout this Chapter 
by the concentration dependent role of RAR activation was discussed in relation to neural 
differentiation.  Stable and potent retinoid analogues are necessary for the controlled 
regulation of RAR activation by refined concentrations.  A method for inducing mono-
layer neural differentiation using EC23 can be found in Chapter 2 (Methods) and uses 
concentration data obtained from the work in this thesis to determine optimal conditions of 
differentiation.  
EC23 is around 100 times more potent than ATRA and was shown using a novel method 
with the CYP26 inhibitor Liarozole to be resistant to metabolism.  Differentiation 
protocols require the continuous exposure of ATRA currently; this means that the vehicle 
DMSO is also present continuously.  Since EC23 is resistant to metabolism it was shown 
that a single pulse of EC23 was sufficient to induce loss of pluripotency markers.  
The structure activity relationship between synthetic small molecules was then investigated 
further.  Previous studies demonstrated the addition of a methyl group resulted in a 90° 
change in angle and enhanced biological activity in a synthetic analogue of ATRA.  To 
investigate this, a 3Methyl group was added to EC23 and the relatively inactive EC19.  
Addition of this group resulted in enhancement of EC19 however; no increase in activity 
was demonstrated by EC23, as it is likely inducing the maximal response.  Furthermore, 
3methylation did not increase the metabolism of each small molecule.  
To investigate the regulation of anterior-posterior patterning in a concentration dependent 
manner by EC23 9 HOX genes were assayed at 5 concentrations of both EC23 and ATRA.  
EC23 was used as a tool to probe the specific concentration dependent effect of RARE 
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activation, since it will not be metabolised or isomerised in vitro and thus have a constant 
concentration within the cell cytoplasm.  Data demonstrated a concentration dependent 
response to retinoic acid and the response was dependent on the position of each HOX 
gene on the chromosome cluster.   
There has been evidence to suggest that retinoic acid is not only required for neural 
development and anterior-posterior patterning but is also necessary for correct dorsal-
ventral patterning in the neural tube.  To investigate the ventralising molecule, 
Purmorphamine was added to the neural differentiation protocol. Three concentrations of 
ATRA and EC23 were then investigated for changes in the ventral markers NKX2.2, HB9 
and ISL1.  Data demonstrated that retinoid concentration was important for the subtype 
selectivity of motor neurons determined by either ISL1 or NKX2.2 expression.   
Controlling the subtype identity of neurons is important for relating in vitro models to the 
in vivo cell.  The neural subtypes that can be formed by stem cells interact with different 
targets and are functionally different.  For instance motor neurons target muscle tissue and 
utilise acetylcholine as the neurotransmitter whereas neurons in the mesencephalon are 
likely dopaminergic and are associated with multiple actions.   
Robustly controlling neural subtype differentiation will aid the development of specific in 
vitro models of disease which can be used in a reproducible mode for drug discovery.  
Utilising potent, selective and stable small molecules will aid the development of these 
robust, reproducible and efficient human neural models.   
The next Chapter of this thesis will build upon the use of small molecules in neural 
differentiation and investigate the role of retinoid signalling in neurite outgrowth. 
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CHAPTER 4 INVESTIGATING NEURITE INHIBITION BY HUMAN 
STEM CELL-DERIVED NEURONS IN CONVENTIONAL 2D CELL 
CULTURE 
 
4.1 INTRODUCTION 
 
4.1.1 Application of a stem cell model of human neuritogenesis 
 
Using stem cells to produce large amounts of human neurons in a reproducible and 
consistent manner is beneficial for studying the process of human neurite outgrowth in 
vitro. Human stem cell-derived neurons are an important source of human specific tissue.  
As was demonstrated in Chapter 3 differentiation of the human EC stem cell line 
TERA2.cl.SP12 using synthetic small molecule analogues of ATRA can result in highly 
neurogenic differentiation of TERA2.cl.SP12.  Using human neural tissue derived in this 
way is both ethically and biologically efficient; differentiation of the stem cells can be 
controlled using defined protocols and specific receptor agonists.  In this Chapter the stem 
cell-derived neurons discussed in Chapter 3 will be used as a human in vitro model of 
neurite outgrowth. 
Modelling neurite outgrowth and investigating the processes that result in loss of neurite 
regeneration in the damaged central nervous system (CNS) is important for discovering 
key molecular and biochemical processes that can be targeted for therapeutics.  The glial 
scar that forms after CNS injury is the result of a dynamic response termed “reactive 
gliosis” [135].  This process is initiated by loss of tissue architecture in the CNS and 
normal tissue boundaries ultimately resulting in the formation of a glial scar. 
4.1.2 Glial Scar 
 
Traumatic injury to the central nervous system (CNS) and spinal cord results in the 
development of a structure known as the glial scar.  The glial scar comprises of both 
cellular and extracellular matrix components (ECM) and consists of molecules that are 
permissive or inhibitory to neurite regeneration. The ratio between inhibitory and 
permissive components of the scar determines to what extent regeneration occurs, towards 
the centre of the scar inhibitory molecules dominate over the permissive ECM which 
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results in neurite retraction and an environment inhibitory to neurite growth [234]. 
Overcoming this inhibitory environment is a major focus for regenerative therapeutics 
aimed at CNS regeneration.  The evolutionary advantage of rapid scar formation is through 
repair of the blood-brain barrier and infection prevention [235], however, due to medical 
advances scaring is to an unnecessary extent. A major cellular component of the glial scar 
is the reactive astrocyte, astrocytes become activated by TGF-β signalling post-injury 
[236].  Activation results in a morphological change to the astrocyte and an increase in the 
secretion of extracellular matrix proteins such as Laminin, Collagen IV and Fibronectin 
which are permissive to neurite regeneration and act as a matrix for neurite outgrowth.  In 
addition to the secretion of permissive molecules chondroitin sulphate proteoglycans 
(CSPG) which are strongly inhibitory to neurite outgrowth and regeneration are produced 
and make up a large part of the scar.  The dynamic process of astrocyte activation and glial 
scar formation is known as “reactive gliosis” [134]. 
 
Until recently it was thought that CSPGs represented a physical barrier to neurite 
regeneration however, recent studies have shown that CSPGs act through at least two 
protein tyrosine phosphatase (PTP) receptors PTPσ and LAR [150]. Activation of PTPσ 
and LAR on the growth cone has been shown to induce neurite retraction and inhibit 
regeneration of damaged axons [150]. The three main CSPG’s that activate these receptors 
and are present within the glial scar include: Aggrecan, Neurocan, Brevican, Phosphocan 
and Versican which make up the lectican family of hyaluronan-binding CSPG’s.   
 
The major ligand for the LAR and PTPσ receptors is the glycosaminoglycan (GAG) side 
chain that is found attached to the protein backbone of CSPG’s [237].  Removal of the 
GAG side chains through enzymatic cleavage demonstrates a loss of CSPG induced neurite 
retraction both in vivo and in vitro [141].  Furthermore inhibition of downstream signalling 
elements involved in the signal transduction of PTPσ or LAR transduction has been 
demonstrated to be sufficient to overcome neurite outgrowth inhibition by CSPG. ROCK 
inhibitors and cAMP analogues were shown to overcome both CSPG and Myelin 
associated neurite retraction; there is also evidence to suggest that activation of the RAR β2 
receptor can result in neural regeneration [238]. Due to the non-specific effects of these 
modulators it is important to determine new ways of overcoming receptor mediated neurite 
retraction and inhibition of neurite outgrowth for use in treatments of acute and chronic 
CNS damage. 
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One focus of neural regeneration research is the role of the CSPG- Aggrecan in the glial 
scar.  Aggrecan is normally associated with avascular cartilage but is up-regulated after 
traumatic injury to the CNS. Aggrecan inhibits axon regeneration through a number of 
mechanisms, including activation of ROCK [239] and inhibition of integrin receptor 
activation – a key receptor for Laminin binding and initiation of axon formation [240].  
The effect of Aggrecan can be overcome by chondroitinase ABC treatment, ROCK 
inhibition and integrin stabilisation [160, 240].  The key mechanisms of how human 
neurites respond to Aggrecan and the molecular pathways involved in neurite retraction are 
still relatively unknown.  Basic models of neurite outgrowth and regeneration will help 
pinpoint the role of Aggrecan in the glial scar and help determine new ways of enhancing 
neural regeneration. 
4.1.3 Models of Neurite outgrowth and Regeneration 
 
The most utilised models of neurite outgrowth for in vitro research of neural regeneration 
currently are rat dorsal root ganglion cells (rDRG) [4] or embryonic cortical cultures [241]. 
These models can be induced to form long neurites which are relatively simple to quantify.  
Other models such as PC12 rat pheochromocytoma [242] or N1E-115 [243] cells also form 
neurites and have been developed into commercial neurite outgrowth kits, however the 
length of the neurites that form are relatively short making it difficult to assess any changes 
in length accurately.  DRG neurons are heterogeneous and their activity not only depends 
on the way they were isolated, but the growth factors and morphogens present during the 
experiment [174, 244].  Although rDRG is a good model of neurite outgrowth, it is of 
peripheral sensory nervous system origin [245] and therefore represents a different neural 
subtype to that found within the CNS.  The major disadvantage of all of these models is 
their non-human origin; furthermore, the exact stage of the neural progenitor is unknown 
making it difficult to relate the regenerative potential of the neurons to the developmental 
stage, which is a key advantage of human stem cell-derived neurons. 
Human neural progenitors are commercially available; however, as with many models of 
neurite outgrowth the ability to accurately quantify any change in neurite length or number 
is difficult due to the heterogeneity of the cells that develop and the network of neurites 
that forms. Alternative methods of producing human neurons for use in neurite outgrowth 
studies have been developed using human embryonal carcinoma stem cells [159]. hEC 
stem cells can be differentiated using the same techniques as hES cells, however their use 
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in research is less restricted.  Furthermore, many hEC stem cells are limited in their lineage 
potential resulting in a highly reproducible, defined method of producing different cell 
types.  Current models for studying neurite outgrowth are reviewed in Chapter 1.  
4.1.4 Small molecule regulation of stem cell differentiation 
 
Protocols to induce neural differentiation of human stem cells often include the morphogen 
ATRA and as discussed earlier there are many limitations of the use of ATRA.   Synthetic 
analogues of ATRA have been demonstrated to overcome many of these limitations and 
enhance the consistency of both the molecule in culture and its concentration [89, 95].  
The small molecule analogues of ATRA, EC23 and AH61 were chosen to investigate the 
advantage of using synthetic retinoid that are more stable and potent when ATRA in the 
neural differentiation protocol to produce neurons for use in neurite outgrowth models.  As 
discussed earlier EC23 is well defined in its genetic and phenotype effect on stem cells and 
this has also been demonstrated for AH61 [246]. 
Aim 
This Chapter aims to develop a unique, highly reproducible, highly neurogenic model of 
human neurite outgrowth using stem cells differentiated using the potent synthetic 
retinoids, AH61 and EC23.  This model will be optimised alongside ATRA and used to 
investigate the molecular mechanisms that undergo CSPG-induced neurite inhibition and 
regeneration. Recent studies have implicated the CSPG- Aggrecan in neural growth cone 
collapse and neurite retraction in the glial scar  [247] the effect of Aggrecan in this model 
will be investigated.   
In this section a 2 dimensional (2D) approach for assessing human neurite outgrowth and 
modulation of neurite outgrowth by CSPGs has been used.  The 2D model utilises 
conventional tissue plastic to grow neurites from aggregates of differentiated human stem 
cells.  Neurites form on a single plain as a halo around the aggregate meaning only one 
membrane surface of the neurite is in contact with the tissue culture plastic substrate. 
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Specific Objectives 
 Develop a reproducible model of human neurite outgrowth using the synthetic 
small molecules AH61 and EC23 and compare neurite outgrowth with cells 
differentiated with conventional ATRA.  
 
 Using this defined model of human neurite outgrowth  investigate CSPG induced 
neurite inhibition 
 
 Investigate small molecules that can overcome neurite inhibition in response to the 
CSPG-Aggrecan 
 
 Investigate neurite inhibition in a neural/glial co-culture model. 
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4.2 METHODS 
4.2.1 2 Neurite outgrowth assay: performed on 2D conventional cell culture plastic. 
 
TERA2.cl.SP12 embryonal carcinoma stem cells passage < 35 were cultured as described 
in Chapter 2. 
 
Prior to starting the differentiation procedure ensure: 
 Good stocks of untreated 90 mm Petri Dishes (Fisher Scientific FB51504) 
 At least 200 µl of 0.1 mM EC23(Reinnervate) in molecular biology grade DMSO 
(Sigma Aldrich D8418) 
 1 x 500 ml bottle of DMEM (Lonza BE12-614F) containing 10 % FBS(Sigma 
Aldrich), 5 mM L-glutamine(Lonza BE17-605F) and penicillin/streptomycin 
(Lonza DE17 602F) (DMEMFGP) 
 Access to a class I laminar flow  microbiological safety cabinet 
 0.25% trypsin/2 mM EDTA (Sigma Aldrich T4049) 
 
To begin the differentiation procedure a single cell suspension of TERA2.cl.SP12 EC cells 
is needed.  A single cell suspension was achieved as described in Chapter 2. Cells were 
counted using a haemocytometer as described in Chapter 2. 
 
For differentiation of cells as aggregate follow the steps below: 
1. Add 1.5 x 106 TERA2.cl.SP12 EC cells to 20 ml DMEMFGP and leave overnight 
to initiate cell aggregation 
2. After 24 hours aggregation add 20 µl of a 0.1 mM EC23 stock directly to the media 
and gently swirl  
3. After 4 days treatment with a final concentration of 0.1 µM EC23 place the media 
containing aggregates into a 50 ml Falcon tube for 15 minutes allowing the 
aggregates to settle – this must be done in a sterile environment 
4. Using an aspirator, supernatant leaving the pellet of aggregates in the bottom of the 
Falcon tube.  
5. Add 20 ml of DMEMFGP and 20 µl of 0.1 mM EC23.   
6. Gently swirl and place in to a fresh 90 mm untreated bacteriological Petri dish 
7. Repeat steps 3-7 every 3-4 days or when required 
8. After 21 days aggregates are differentiated and capable of forming neurites 
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4.2.2 Coating conventional 2D tissue culture plastic for neurite outgrowth studies 
 
Materials required: 
1 mg/ml Engelberth-Holm-Swarm murine sarcoma membrane (Sigma Aldrich L2020) 
5 mg Poly-D-lysine (Sigma Aldrich P7405) 
500 ml PBS without calcium and magnesium (Lonza 13E17-512F)  
 
Coating procedure: 
1. Add 5 ml of PBS without Ca++, Mg++ to 5 mg of Poly-D-lysine in a sterile 
environment and gently swirl to dissolve.   
2. Dilute 500 µl of 1mg/ml P-D-L solution and 500 µl of 1 mg/ml Engelberth-Holm-
Swarm murine sarcoma membrane into 49 ml of PBS. To create 50 ml of 10 µg/ml 
Laminin/P-D-L solution working stock. 
3. Add 150 µl to each well of 48 well tissue culture treated plastic and seal lid with 
Parafilm. 
4. Leave coating at room temperature overnight. 
5. After 24 hours remove excess coating solution and wash 3 x with PBS and store in 
PBS prior to use – use within 12 hours.  
 
4.2.3 To induce neurite outgrowth from cell aggregates differentiated with 0.1 µM EC23 
for 21 days 
 
Materials required: 
Laminin/P-D-L coated 48 well tissue culture plastic (Beckton Dickinson 353078) 
10 mM 5’fluoro 2’ deoxyuridine (Sigma Aldrich F0503) 
10 mM Uridine (Sigma Aldrich U3003) 
1 mM Cytosine β-D arabinofuranoside (Sigma Aldrich C1768) 
DMEMFGP 
Paraformaldehyde (Sigma Aldrich P6148) 
100 µm tissue culture filter (Fisher Scientific 22363549) 
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Neurite outgrowth procedure: 
1. Filter differentiated aggregates through a 100 µM filter and rinse with fresh 
DMEMFGP do not discard neurospheres in filter. 
2. Backwash aggregates in filter (>100 µm in size) with 10 ml fresh media w/o EC23 
into a new 90 mm bacteriological Petri dish, swirl to distribute. 
3. Make up 50 ml of DMEMFGP containing 1 µM Cytosine Arabinosine, 10 µM 
5’Fluoro 2’ Deoxyuridine and 10 µM Uridine. 
4. Remove PBS from Laminin/P-D-L coated tissue culture plastic 
5. Using a 200 µl pipette take up 30 µl of media containing 1-2 neurospheres and 
expel into a Laminin/P-D-L coated tissue culture plastic well and repeat for each 
well 
6. Add 500 µl of DMEMFGP containing mitotic inhibitors and culture at 37 °C, 5 % 
CO2 in a humidified atmosphere for 10 days (do not change the media during this 
time, as this affects neurite growth).  
7. For cell fixation, after 10 days remove all culture media and add 200 µl of 4 % PFA 
for 1 hour.  After fixation wash once with PBS and store at 4 °C prior to analysis 
 
4.2.4 Aggrecan coating 
 
For neurite outgrowth inhibition studies follow the procedure as above, however, when 
coating perform the following additional steps: 
1. Dissolve 1 mg Aggrecan from bovine cartilage (Sigma Aldrich) in 1ml PBS w/o 
Ca++, Mg++. 
2. To make up the inhibitor coating solution place 19 ml of 10 µg/ml Laminin/P-D-L 
solution (made as described above) into a new 50 ml Falcon tube and add 1 ml of 1 
mg/ml Aggrecan solution.   
3. Add 150 µl of solution containing: 50 µg/ml Aggrecan, 10 µg/ml Laminin and 10 
µg/ml P-D-L to each well of 48 well tissue culture plastic and seal with Parafilm 
for 24 hours. 
4. Follow the above procedure for neurite outgrowth studies involving Aggrecan 
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4.2.5 Chondroitinase ABC pre-treatment in 2D 
 
Chondroitinase ABC enzyme buffer and dilution: 
Chondroitinase ABC (Sigma Aldrich C3667), from Proteus vulgaris was reconstituted with 
1 ml 0.1 % BSA (Sigma Aldrich A7906) giving a concentration of 5 units/ml.  Stock 
solution was diluted in enzyme buffer to 0.15units per well in. Enzyme buffer consisted of: 
 0.02 % BSA 
 50 mM TRIS pH8  
 60 mM Sodium acetate (Sigma Aldrich) 
 PBS w/o Ca++, Mg++ 
Treatment of Aggrecan coated plastic with Chondroitinase ABC: 
1. Tissue cultured plastic was coated with Aggrecan, P-D-L and Laminin as described 
above 
2. Wash coated plastic with PBS x 3 
3. Add 150 µl of either Chondroitinase buffer (control) or buffer containing 5units/ml 
enzyme 
4. Incubate for 1 hour at 37 °C, 5 % CO2 
5. After 1 hour incubation wash 3 x with PBS and follow the above procedure for 
neurite outgrowth from differentiated TERA2.cl.SP12 aggregates.  
4.2.6 2D U118MG astroglioma/neural co-culture 
 
1. For neural/glial co-culture at day 14 aggregate differentiation begin culture of 
U118MG cells in 2D as described in Chapter 2. 
2. Coat 48 well tissue culture plastic with 10 µg/ml Laminin/P-D-L as described 
above  
3. Filter and backwash neurospheres as described above for neurite outgrowth study at 
day 21 
4. For co-culture add 5,000 U118MG cells in 500 µl DMEMFGP containing mitotic 
inhibitors to each test well 
5. Take 1 neurosphere in 30 µl media and add to each well as necessary 
6. Add 500 µl of DMEMFGP containing mitotic inhibitors and culture at 37 °C, 5 % 
CO2 in a humidified atmosphere for 10 days (do not change the media during this 
time, as this affects neurite growth).   
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7. Fix cells for 1 hour in 4% PFA and wash 3 x in DPBS.  
 
4.2.7 Aggrecan ELISA 
 
Protein was purified and quantified as described in Chapter 2.  Briefly, protein from 1 x 
106 U118MG cells were purified using an IGEPAL method and quantified using the 
Bradford assay (for details see Chapter 2). 
For the Aggrecan ELISA the following method was followed: 
BlueGene Human Aggrecan (AGC) Elisa Kit (AMSBIO, AMS.E01A0413) utilised a 
sandwich enzyme immunoassay technique to quantify AGC in total protein samples.  The 
kit used a microtiter plate pre-coated with a monoclonal antibody specific for AGC. A 
polyclonal anti-ACG antibody conjugated to horseradish peroxidase (HRP) was used to 
report any binding to the monoclonal antibody in the microtitre plate. A colour change was 
detected using a 450 nm microplate reader. 
 
Sample preparation 
 Bring all kit components and samples to room temperature 
 Dilute 10 mL of wash solution (100 x) with 990 ml of deionized or distilled 
water to prepare 1000 mL of 1 x wash solution.  
 Assay procedure: 
1. Add 50 µL of standards or samples to the appropriate well in the antibody 
pre-coated Microtitre Plate.  Add 50 µL PBS in the blank control well. 
Standards used were 0, 2.5, 5.0, 10, 25 and 50 ng/ml Aggrecan.  For the 
sample under investigation 50 ng of purified U118MG protein were added 
to the test well. 
2. Dispense 5 µL of Balance Solution into 50 µL specimens, mix well.  
3. Add 100 µL of Conjugate to each well (but do not add to blank control 
well).  Pipette up and down 10 x to mix. (n.b Mixing well in this step is 
important). Cover and incubate the plate for 1 hour at 37 °C 
4. Wash the micro titre plate using manual washing technique. This must be 
repeated five x and blot dried by short sharp downward movements onto a 
156 
 
 
thick piece of tissue paper (n.b. blot dry until no liquid is left on the tissue 
paper). 
5. Add 50 µL Substrate A and 50 µL Substrate B to each well including blank 
control well, subsequently.  Cover and incubate for 10-15 minutes at 37 °C 
(Avoid sunlight) 
6. Add 50 µL of Stop Solution to each well including blank control well. Mix 
well.  
7. Determine the Optical Density (OD) at 450 nm using a microplate reader 
(BioTek, ELx800) immediately.  
4.2.8 Neurite quantification 
 
Neurite number 
Digital images (Tiff files) of neurite outgrowth to be counted were opened using Image-J 
(http://rsbweb.nih.gov/ij/).  Using the magnification option in Image-J a section of neurites 
stained for β III Tubulin (TUJ-1) (Green) were magnified.  Using the multiple count option 
individual neurites were marked at the growth cone.  To move to another area of the 
aggregate the scroll option in Image-J was used.  Each mark had a number assigned the last 
neurite to be marked gave the number of neurites around the aggregate.  Figure 4-1 shows 
an example of magnified neurites being counted using Image-J software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Quantification of the number of neurites using Image-J.  
Image- J was used to magnify the individual neurites and count neurite growth 
cone/ends of neurites for quantification.  
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Neurite length quantification 
Using the Leica advanced fluorescence software (hhtp://www.leica-
microsystems.com/products/microscope-software/life-sciences/las-af-advanced-
flourescence/) traces of individual neurites could be drawn.  Using the statistical option 
exportation of data into Microsoft Excel could be achieved.  The length of each free drawn 
line could then be averaged in Microsoft Excel.   Note:  It is important to ensure the correct 
magnification is chosen when taking the image in this software to ensure the correct 
neurite length is calculated.  Figure 4-2 shows an example of neurite length quantification 
using Leica AF software.  Image A shows un-traced neurites stained for TUJ-1 (Green), 
Image B shows traced neurites using Leica AF software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2  Neurite length quantification using Leica AF software.  Image A shows un-
traced neurites stained for β III Tubulin (TUJ-1) (Green), Image B shows traced neurites using 
Leica AF software. Numbers on traces can be used to identify individual neurite length and the 
number of neurites measured.  
A B 
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4.3 RESULTS 
 
4.3.1 Induction of neurogenesis in cell aggregates by synthetic small molecule 
 
As described in the previous Chapter, to study human neurite outgrowth and differentiation 
a 2D monolayer protocol was developed.  The technique resulted in high levels of neurite 
outgrowth and neural tissue development as demonstrated in Chapter 3, Figure 3.2.  Using 
this highly neurogenic model would prove difficult to determine any subtle length or 
number changes in neurite under experimental conditions, due to the complete network of 
neurites that form.  Accordingly this was not an appropriate method of differentiation to 
assess neurite outgrowth.   
An alternative differentiation protocol utilised suspension aggregates of TERA2.cl.SP12 
cells and has been shown previously to be neurogenic [85]. It has been reported that the 
incorporation of a high concentration of retinoic acid into the differentiation protocol of 
human stem cells can result in an enhancement of neurite outgrowth from differentiated 
embryoid bodies [248]. However, the consistency and reproducibility of neurite outgrowth 
from each aggregate was low and often resulted in complex neural networks that were 
difficult to quantify for change in length or number. Figure 4-3  shows in a simple 
schematic the difference between 2D monolayer neurite outgrowth and development of 
neurite from an aggregate in 2D. 
 
 
 
 
 
 
 
 
 
Figure 4-3. Neurite outgrowth from mono-layer or aggregate derived 
differentiation protocols. Schematic depicting the difference between a mono-
layer network of neurites (A) and a central focal point of neural origin derived from 
aggregate neural progenitors (B). Neurites are depicted in green and nuclei in blue. 
A B 
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Figure 4-4 Monolayer and aggregate culture of the human EC cell TERA2.cl.SP12. Cells 
were maintained in a monolayer (A) and differentiated as an aggregate (B). The close cell contact 
demonstrated in culture (A) is necessary to maintain the TERA2.cl.SP12 stem cell phenotype.  
Cells were transferred to form cultures as aggregates (B) when the differentiation protocol was 
followed. Cells were left to aggregate overnight on non-adherent plastic (B) prior to retinoid 
treatment. Image (B) demonstrates the typical structure of an aggregate differentiated for 21 days 
with 0.1 µM EC23. Scale bars: (A) 50 µM (B) 250 µM. 
The commercial synthetic retinoid EC23 and the novel retinoid analogue AH61 both 
induce highly potent neural commitment in a variety of cell models and have been shown 
to be significantly more potent than ATRA [246] [95].  EC23 has been described 
throughout Chapter 3, however, the synthetic retinoid AH61 has not been used so far.  
AH61 was discovered to potently induce neural differentiation of TERA2.cl.SP12 in a 
screen of compounds performed as part of a PhD thesis [246].  Data from this thesis 
indicated that AH61 was very similar to EC23 in potency in mono-layer cultures, however, 
no data was described about its effect on aggregates of TERA2.cl.SP12 hEC stem cells. 
In this study the enhanced activity of these compounds was exploited to induce neural 
differentiation from stem cell aggregates and assess the potential for neurite outgrowth. 
Initially TERA2.cl.SP12 hEC stem cells were grown and maintained as a monolayer to no 
more than passage 30.  Aggregates were formed by transferring a single cell suspension of 
the cells into an untreated bacteriological Petri-dish in normal growth media.  After 24 
hours ATRA or synthetic retinoid was added to the media. 
Figure 4-4 shows the difference in cell contact between monolayer and aggregate culture. 
Notice that the aggregate method results in a 3D-like spherical structure.  The 
concentration of any small molecule within the culture media would have to diffuse 
throughout the aggregate to gain access to the cells in the centre.  It is therefore important 
that small lipophilic molecules such as retinoids are used and aggregates are not allowed to 
become too large to ensure differentiation is complete throughout the aggregate 
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Aggregates of TERA2.cl.SP12 cells were initially differentiated for 14 days by media 
supplementation with AH61, ATRA or EC23 at 10, 1 or 0.1µM.  To investigate structural 
differences between aggregates treated by each compound and concentration, H & E 
stained histological sections of day 14 neurospheres were imaged (Figure 4-5).  High 
concentrations of each small molecule resulted in the formation of neural rosettes and the 
development of structures within the aggregate.  Aggregates were relatively small in size 
which may be a consequence of the dehydration process during wax embedding. 
Interestingly the aggregates differentiated by AH61 were much larger than those treated 
with ATRA or EC23. 
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Figure 4-5 Internal aggregate structure demonstrates neural rosette formation and 
heterogeneous cell patterning after 14 days differentiation. Aggregates were differentiated with 
EC23 (A,B,C), ATRA (D,E,F) or AH61(G,H,I) at 10 µM, 1 µM or 0.1 µM respectively, for 14 
days.  Differentiated aggregates were then fixed, embedded, sectioned and stained with 
Haematoxylin & Eosin. Staining demonstrates structural similarities between each compound, after 
14 days neural rosettes have developed in the highest concentrations used, however these structures 
are not seen at the lower concentration used.   Large structures can be seen within the aggregates 
many representing neural rosettes (arrows). 
10µM 1µM 0.1µM 
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Sections of cell aggregates differentiated for 14 days were analysed to determine how the 
concentration of each small molecule influences neural commitment. Sections of each 
aggregate for each treatment group were immuno-stained for Nestin, TUJ-1 and nuclei.  
Nestin is indicative of neural progenitor formation and represents early neural 
commitment.  Cells that express Nestin are usually proliferating neuroprogenitor cells; in 
contrast TUJ-1 expression in neural tissue indicates a more committed neural phenotype, 
representative of later stages of neural development.  Figure 4-6 shows aggregates stained 
and sectioned after 14 days treatment with EC23.  A high concentration of EC23 induced 
the highest level of TUJ-1 expression, as would be expected, at the lowest concentration of 
EC23 high levels of Nestin and low expression of TUJ-1 was visualised, indicating early 
neural commitment characteristic of the lag time prior to EC23 eliciting a cellular 
response.  In contrast ATRA induced low levels of both Nestin and TUJ-1 expression at 
each concentration, with the highest levels of Nestin and TUJ-1 expression at 10 µM 
(Figure 4-7). 
The ATRA analogue AH61 was shown to be highly potent at inducing neural commitment 
in 2D monolayer cultures of TERA2.cl.SP12 [246].  Neural protein expression after 14 
days indicated that AH61 induced TUJ-1 and Nestin to high levels at 10 µM and 1 µM, 
poor expression of Nestin and TUJ-1 was seen at 0.1 µM.  These results so far indicate that 
differentiation of aggregates for 14 days induced both TUJ-1 and Nestin expression in 
TERA2.cl.SP12 human stem cell, the level and proteins expressed were determined by the 
type of small molecule used and its concentration. 
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Figure 4-6 Expression of neural proteins in TERA2.cl.SP12 aggregates after differentiation 
for 14 days with EC23.  Differentiated aggregates were fixed and embedded prior to sectioning 
and staining for the neural proteins, Nestin (Green) and β III Tubulin (TUJ-1) (Red). The data 
shown is DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged flourescence (J,K.L) at 10 µM, 
1 µM and 0.1 µM.  Nuclei were stained with DAPI (Blue).  Aggregates were positive for both 
Nestin and β III Tubulin (TUJ-1).  Higher β III Tubulin (TUJ-1) expression was visible in 
aggregates differentiated at 10 µM. The lowest concentration of EC23 0.1 µM had visibly higher 
levels of Nestin expression than β III Tubulin (TUJ-1) indicating that the cells represent early 
neural progenitors.  Scale bars = 250 µm. n=3 
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Figure 4-7 Expression of neural proteins in TERA2.cl.SP12 aggregates after differentiation 
for 14 days with ATRA.  Differentiated aggregates were fixed and embedded prior to sectioning 
and staining for the neural proteins, Nestin (Green) and β III Tubulin (TUJ-1) (Red).  The data 
shown is DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged flourescence (J,K.L) at 10 µM, 
1 µM and 0.1 µM. Nuclei were stained with DAPI (Blue).  Aggregates were positive for both 
Nestin and β III Tubulin (TUJ-1).  High levels of Nestin were present at 10 µM  EC23.  Low levels 
of β III Tubulin (TUJ-1) was expressed throughout all three concentrations. These cells were in the 
early stages of neural commitment. Notice the central area of aggregates E, and H do not express 
typical neruonal markers.  This is likely due to non-neuronal lineage commitment or cell death. 
Scale bars = 250 µm. n=3 
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Figure 4-8 Expression of neural proteins in TERA2.cl.SP12 aggregates after differentiation 
for 14 days with AH61.  Differentiated aggregates were fixed and embedded prior to sectioning 
and staining for the neural proteins, Nestin (Green) and β III Tubulin  (TUJ-1) (Red).  The data 
shown is DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged flourescence (J,K.L) at 10 µM, 
1 µM and 0.1 µM.  Nuclei were stained with DAPI (Blue).  Aggregates were positive for both 
Nestin and β III Tubulin (TUJ-1).  High levels of β III Tubulin (TUJ-1) were present at 1 and 10 
µM  AH61. Very high levels of Nestin are observed at 1 µM.  Low expression of β III Tubulin 
(TUJ-1) and Nestin was observed at 0.1 µM, indicating a direct developmental response in the cells 
depending on the concentration of AH61 used. Scale bars: 250 µm. n=3 
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It was hypothesised that increasing the differentiation of TERA2.cl.SP12 with each of the 
compounds from 14 to 21 days would result in an aggregate that contained more mature 
neural progeny than at 14 days.  Increasing the time period of cell differentiation appears to 
result in a more mature neural phenotype. Under such conditions it would be predicted that 
cell aggregates may express more β III tubulin and a reduced level of Nestin.  Furthermore, 
cells may act differently when encouraged to form neurites. Initially the internal structural 
differences of each aggregate under each condition were assessed. Figure 4-9 provides 
evidence to suggest a differential response between the length of differentiation and the 
potency of the retinoid used to induce differentiation.  Each aggregate was approximately 
the same size after 21 days.  Furthermore, the perimeter and spherical nature of each 
aggregate was more clearly defined than that at 14 days.  In some cases aggregates 
contained large internal structures with a characteristic neural rosette shape indicative of an 
early neural progenitor phenotype.  The neural rosette structures were mainly seen in 
aggregates treated with the least potent retinoid or concentration i.e. 0.1 µM AH61 and 
ATRA, and the higher concentrations of EC23 10 µM and 1 µM.  Interestingly, the internal 
structure of aggregates differentiated with each concentration of EC23 was much more 
heterogeneous than the high concentrations of ATRA or AH61, indicating a differential 
effect across the aggregate by EC23. 
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Figure 4-9 Internal aggregate structure demonstrates neural rosette formation and 
differential cell patterning after 21 days differentiation. H & E staining of aggregates 
differentiated with EC23(A,B,C), ATRA (D,E,F) or AH61(G,H,I) at 10 µM, 1 µM or 0.1 µM 
respectivly for 21 days. Histological analysis demonstrate structural similarities between each 
compound, after 21 days neural rosettes have developed in many of the lower concentrations used. 
Some non-rosette like structures also formed in the synthetic compounds 0.1 µM EC23 and 1 µM 
and 0.1 µM AH61. The overall shape and size of the aggregates are more consistent between 
compounds indicating structural limitations of the aggregates. Arrows show internal neural rosette 
structures. n=3. 
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The neural rosette structure observed within some of the differentiated cell aggregates is 
characteristic of neural progenitor formation [5].  The progenitors are generally able to 
develop into the three main types of neural cell – oligodendrocyte, neuron and astrocyte 
however this was not tested. 
Neural rosettes have a characteristic radial-columnar structure and express neural specific 
cytoskeletal proteins such as Nestin and β III Tubulin.  H & E staining so far has 
demonstrated the presence of neural rosettes in some aggregates, suggesting neural 
progenitor formation, aggregates without rosettes may be non-neuronal or more developed 
neural tissue.  Figure 4-10 demonstrates a high magnification image of a neural rosette 
from TER2.cl.SP12 EC cells differentiated by 1 µM EC23 for 21 days. 
 
Figure 4-10 Neural rosette structure characteristic of neuroprogenitors differentiation from 
stem cells.  Development of neural rosettes are characteristic of neuroprogenitor formation.  
Rosettes have a radial arrangement of columnar cells and express proteins associated with neural 
development [5].  TERA2.cl.SP12 EC cells were differentiated for 21 days by 1µM EC23 and 
stained with H& E.  The white line marks the approximate outer edge of the neural rosette. Scale 
bar: 50 µm. 
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Figure 4-11 Expression of neural proteins in TERA2.cl.SP12 aggregates after differentiation 
for 21 days with EC23.  Differentiated aggregates were fixed and embedded prior to sectioning and 
staining for the neural proteins, Nestin (Green) and β III Tubulin (TUJ-1) (Red). The data shown is 
DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged flourescence (J,K.L) at 10 µM, 1 µM and 
0.1 µM.   Nuclei were stained with DAPI (Blue).  Aggregates were positive for both Nestin and β III 
Tubulin (TUJ-1).  Higher β III Tubulin (TUJ-1) expression was visible in aggregates differentiated 
at 10 µM. The lowest concentration of EC23 0.1 µM had visibly higher levels of Nestin expression 
than β III Tubulin (TUJ-1) indicating that the cells represent early neural progenitors. Notice the 
central area of aggregates E, and H do not express typical neruonal markers.  This is likely due to 
non-neuronal lineage commitment or cell death.   Scale bars : 250 µm. n=3 
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Figure 4-12 Expression of neural proteins in TERA2.cl.SP12 aggregates after 
differentiation for 21 days with ATRA.  Differentiated aggregates were fixed and embedded 
prior to sectioning and staining for the neural proteins, Nestin (Green) and β III Tubulin (TUJ-1) 
(Red).  The data shown is DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged 
flourescence (J,K.L) at 10 µM, 1 µM and 0.1 µM.  Nuclei were stained with DAPI (Blue).  
Aggregates were positive for both Nestin and β III Tubulin (TUJ-1).  High levels of Nestin were 
present at 10 µM  ATRA.  Low levels of β III Tubulin (TUJ-1) was expressed throughout all 
three concentrations. These cells were in the early stages of neural commitment. Notice the 
central area of aggregates D, and G do not express typical neruonal markers.  This is likely due 
to non-neuronal lineage commitment or cell death.  Scale bars : 250 µm. n=3. 
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Figure 4-13 Expression of neural proteins in TERA2.cl.SP12 aggregates after differentiation 
for 21 days with AH61.  Differentiated aggregates were fixed and embedded prior to sectioning and 
staining for the neural proteins, Nestin (Green) and β III Tubulin (TUJ-1) (Red).  The data shown is 
DAPI (A,B,C), Tuj-1 (D,E,F), Nestin (G,H,I) and merged flourescence (J,K.L) at 10 µM, 1 µM and 
0.1 µM.   Nuclei were stained with DAPI (Blue).  Aggregates were positive for both Nestin and β III 
Tubulin (TUJ-1).  High levels of β III Tubulin (TUJ-1) were present at 1 and 10 µM  AH61. Very 
high levels of Nestin were expressed at 1µM, low expression of β III Tubulin (TUJ-1) and Nestin 
was observed at 0.1 µM, indicating a direct developmental response in the cells depending on the 
concentration of AH61 used. Notice the central area of aggregate D does not express TUJ-1 
however, nestin is expressed indicating a proliferative neural progenitor.  Scale bars : 250 µm. n=3 
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4.3.2 Neurite Outgrowth from differentiated neurospheres using synthetic retinoids 
 
Evidence suggests that the cell aggregates are neurogenic and clearly resemble the 
structure typical of a neurosphere. Aggregates of cells differentiated in suspension for 14 
or 21 days expressed a combination of Nestin and TUJ-1 indicating neural commitment, 
however, the apparent stage of differentiation depended on the compound, concentration 
and length of time used to differentiate the cells.  To further differentiate the cells and 
induce neurite formation the aggregates from each treatment group were placed onto a 
Laminin and P-D-L coated substrate.  Each of the aggregates adhered to the substrate and 
neurites developed from the central sphere.  In this part of the differentiation process 
retinoid was not included in the media; however, to control any excess cell by 
proliferation, mitotic inhibitors were added throughout this part of the protocol. 
Aggregates differentiated for 14 days regardless of the concentration or compound used 
lost the integrity and smooth border of the aggregate (Figure 4-14).  Many cell nuclei 
migrated away from the aggregate and formed individual neurites.  More cells remained in 
the central aggregate when differentiated with AH61, however, the aggregate began to 
disperse.  Such cell migration and loss of aggregate integrity resulted in difficulty of 
quantification of any change in length or number of neurites, as with 2D mono-layer 
differentiation.  The migratory ability of the cells may be in part the result of early neural 
commitment and high Nestin levels typical of neuroprogenitors.   Although most of the 
treatment groups resulted in such cell dispersal, this was more pronounced when using 
lower concentrations of ATRA.  In contrast many more cells were maintained as a central 
sphere when differentiated with synthetic retinoids EC23 or AH61. 
Increasing the length of the differentiation period from 14 to 21 days resulted in a more 
consistent aggregate structure and size.  Furthermore, an apparent increase in TUJ-1 
staining indicated the formation of more mature, differentiated neural cells.  Transfer of the 
aggregates differentiated under each condition for 21 days to a Laminin/P-D-L substrate 
for 10 days resulted in a distinct halo of individual neurites projecting from a central 
sphere of cell nuclei (Figure 4-15). Quantification of the number of neurites that developed 
from the aggregate under each condition revealed differences between the potency of 
compound and the number of neurites that developed.  The highest number of neurites 
developed from aggregates that were differentiated with 10 µM and 1 µM ATRA, AH61 or 
0.1 and 1 µM, EC23.  The lowest number of neurites that formed was from 0.1 µM ATRA 
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and 10 µM EC23 differentiated cells. It became apparent that for a consistent model of 
neurite outgrowth that can be quantified consistently the cells would need 21 days 
differentiation with a potent or concentrated level of retinoid. 
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Figure 4-14 Neurite outgrowth from aggregates differentiated for 14 days.  Aggregates of 
TERA2.cl.SP12 EC cells were differentiated for 14 days in the presence of ATRA (A,D,G), EC23 
(B,E,H) or AH61 (C,F,I) at 10, 1 or 0.1 µM respectively.  After 14 days the aggregates were placed 
onto tissue culture plastic coated with 10 µg/ml Laminin/P-D-L for 10 days in the presence of 
mitotic inhibitors.  After 10 days aggregates were fixed in 4% PFA and stained for β III Tubulin 
(TUJ-1) (Green) and DAPI (Blue).  The structural integrity of the aggregate was not maintained as 
many cells migrated away from the neurosphere. Migrating cells formed individual neurites on the 
Laminin/P-D-L substrate.  More migration from the central spehre was seen by low levels of ATRA 
than the same concentration of AH61 or EC23.  This indicated a more mature 14 day differentiated 
neural progenitor or a different type of progentiro has developed. Some non-tuj-1 expressing cells 
also migrated from the aggregate. Scale bars: 500 µm. n=3. 
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Figure 4-15 Induction and quantification of neurite outgrowth from human pluripotent 
stem cells after 21 days treatment with ATRA, EC23 or AH61. Aggregates of TERA2.cl.SP12 
were incubated with either ATRA (A,D,G), EC23 (B,E,H) or AH61 (C,F,I) at 0.1 µM, 1 µM or 
10 µM respectively for 21 days.  Aggregates were plated onto Laminin/P-D-L for 10 days and 
stained for the pan neuronal antigen β III Tubulin (TUJ-1). The number of neurites that developed 
from each aggregate depended on the concentration of compound used.  Neurites were quantified 
by magnification and counting using Image-J software.  Interestingly an increase in 
differentiation time to 21 days resulted in a loss of cell migration from the aggregate, maintaining 
a tight sphere.  Scales Bars:  500 µm. Data represent mean ± SEM, n≥3. * p≤0.005 Student’s t-
test corrected for multiple testing between compared sample poulations using the Bonifferoni 
correction. 
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It was decided not to take AH61 any further into the study, since much less was known 
about its biological effect on TERA2.cl.SP12 and due to constraints on production, AH61 
was less available than EC23 which was purchased having undergone quality control 
procedures, making the compound more reliable and consistent for large scale studies.  
Furthermore, due to its highly neurogenic activity, stability and the genetic profiles known 
about its mode of action, EC23 was selected to be used in this model of neurite outgrowth. 
Since 0.1 µM EC23 induced the optimum level of neural differentiation this was chosen as 
the concentration to use throughout the rest of this thesis.   
To further characterise the neural cell types that develop from treatment with 0.1 µM EC23 
a number of genetic CNS markers were assessed. Figure 4-16 shows the gene profiles of 
developing aggregates treated with 0.1 µM EC23 for 0, 7, 14 and 21 days.  The relative 
quantity of the gene PAX6, indicative of neural commitment [203], OTX2 a gene 
associated with anterior forebrain CNS development [249] and HOXC4 which is associated 
with posterior CNS development, were measured [250].  The profiles expressed by the 
cells represented neural commitment into ventral posterior CNS.  OTX2 levels decreased 
with time and this was concomitant with an increase in HOXC4.  As expected there was an 
initial peak of PAX6 and this was maintained at a high level throughout differentiation 
indicating potential ventral progenitor development as observed previously (Chapter 3).  
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Figure 4-16 Transcriptional profiling of genes associated with neural commitment, forebrain 
development and caudal CNS development. Data shows relative real time PCR expression of the 
genes PAX6 (A), OTX2 (B) and HOXC4 (C).  Aggregates of TERA2.cl.SP12 cells were exposed to 
0.1 µM EC23 for 0, 7, 14 and 21 days.  A peak of PAX6 expression was seen at day 7 this was 
reduced at day 14 and the lower level maintained to day 21, indicating neural commitment.  
Expression of the CNS forebrain marker OTX2 decreased to almost undetectable levels after 
treatment with EC23, however the posterior CNS gene marker HOXC4 gradually increased to around 
90 fold compared to the undifferentiated control. Suggesting aggregates develop into posterior CNS 
neural progenitors. Data represent mean ± SEM, n=3.  
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4.3.3 Regulation of retinoid receptors during induction of stem cell differentiation 
 
The regulation and modulation of receptors involved in neural commitment and 
development is important for determining the responsiveness of cells to particular 
extracellular ligands and ultimately for directing neural specificity.   
The retinoic acid receptor β2 has been demonstrated to be involved in numerous 
developmental stages of neurogenesis, including neural commitment [251], neurite 
outgrowth [174, 252] and neural differentiation [238].  Since our model of neurite 
outgrowth will be assessing the role of RAR β2 in key molecular pathways involved in 
neurite regeneration it was important that the receptor was expressed in the differentiated 
cells.  Figure 4-17 demonstrates the rapid up regulation of RAR β2 mRNA induced by 
EC23 treatment. Furthermore, the expression was sustained throughout the differentiation 
process. These data provide information as to the predicted responsiveness of the cells to 
agonists of this receptor, of which EC23 is thought to be one [93]. The rapid up-regulation 
of RAR β2 mRNA is likely to be in part a positive feedback response induced by EC23. 
Figure 4-17 Regulation of gene expression profile of the retinoic acid receptor β2 during 
induction of stem cell differentiation.  Aggregates of TERA2.cl.SP12 cells treated with 0.1 µM 
EC23 were lysed after 0, 7, 14 and 21 days for gene expression analysis by real time PCR. High 
levels of the receptor was induced and maintained throughout the differentiation protocol. This 
indicates a link between neural differentation and neural maintenance with the retinoic acid 
receptor. Data represent mean ± SEM, n=3 
RARβ2 
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The NGF receptor is a trans-membrane receptor often referred to as p75NTR   and transmits 
the signal for neurotropic factors from the neurotrophin family of molecule such as nerve 
growth factor β (NGF β) and brain-derived neurotropic factor (BDNF) [253].  
NGFR receptor or p75 is involved in neural differentiation in a number of cell models such 
as SH-SY5Y [254], PC12 [255] and rat DRG [256].  Furthermore, NGF expression is 
associated with development of CNS neurons, commitment to neural tissue, regeneration 
and sustained adult nervous system function [253].  The stages of development, 
regenerative potential and neural subtype are important in discerning the expression of the 
NGF receptor [257-259]. 
NGFR signalling directly affects RAR β expression and hence many of the downstream 
affects associated with this signalling [109].  Treating cell aggregates with a NGFR 
receptor agonist did not affect neurite outgrowth, however, understanding the temporal 
expression of this receptor may give insight into the type of neuron that will develop. 
To further assess the expression of receptors involved in neural differentiation and 
commitment, the relative mRNA expression level of nerve growth factor receptor (NGFR) 
and its ligand NGFR β were measured in the aggregates at 0, 7 14 and 21 days after 
treatment with 0.1 µM EC23.   
The expression of NGFR β mRNA increased with time as the stem cells differentiated, 
indicating a possible response to ligands of the receptor.  The expression in the 
neuroprogenitors may not correspond to that in the neurons and requires further analysis.  
There was an initial peak in NGF β mRNA which may be responsible for the increased 
receptor expression however, there was no sustained production of NGF β mRNA 
suggesting supplementing the media of developing aggregates may induce a response.   
These data suggest a developmental role of NGFR β in the stem cell aggregates which may 
be exploited to further direct the neuroprogenitors, or prime them for neurite outgrowth.  
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Figure 4-18  Regulation of NGFR receptor and NGFR β mRNA expression in aggregates 
treated with EC23. TERA2.cl.SP12 cells were treated with 0.1µM EC23 for 0,7,14 and 21 days. 
At each time point the mRNA expression of NGFR and NGFβ was determined relative to the 
undifferentiated aggregate.  The mRNA expression of NGFR increased rapidly to around 3.5 fold 
the undifferentiated control and was miantained throughout the differentiation protocol.  The 
mRNA expression of the NGFR ligand NGFβ peaked initially, however, rapidly reduced to basal 
levels indicating no sustained release of this protein from the cells. Data represent mean ± SEM, 
n=3. 
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4.3.4 Application of stem cell derived neurogenic culture model 
In the previous Sections a defined model of neural progenitor development and neurite 
outgrowth has been described. This model utilises a well described cell line used in 
neurobiological research and a highly stable well characterised small molecule that is 
analogous to natural ATRA.  Using these tools a robust and reproducible model of human 
neurite outgrowth has been developed that is highly neurogenic and neurite outgrowth is 
easy quantifiable. 
This model can now be applied to investigate human neurogenesis in health and disease 
specifically in regard to robust neurite outgrowth; however, there are differences to be 
aware of. The neurites that form from the differentiated aggregate on Laminin and P-D-L 
have not undergone damage as would have occurred in neurons after traumatic CNS injury 
and represent neurite outgrowth similar to that which may be seen during embryogenesis.  
It is known that as a consequence of CNS injury, genes associated with early embryonic 
neurite outgrowth are up regulated [260]. Some regeneration is demonstrated in the CNS 
post-injury which is characterised by growth cone formation and extension of the neurite, 
however, much of the outgrowth is perpendicular to the direction of the damaged spinal 
nerves, indicating an inhibitory environment within the glial scar.  Growth cone formation 
is indicative of embryonic development and neural regeneration after injury.   
Developmental programmes that are switched off in the mature neuron become activated 
once more in an effort to recover the lost neuronal tissue.  It is important to understand 
why these neurites do not fully re-innervate the CNS and work out ways of enhancing the 
regeneration to aid recovery.  The model developed herein represents an early stage of 
neural development that recapitulates many aspects of neurons post-CNS injury, thus 
making the model useful for basic research into enhancing neural regeneration and 
restoration after CNS injury. 
4.3.4 Inhibition of human neurite outgrowth by the CSPG - Aggrecan 
 
Recently direct receptor activation on the membrane of neurites has been associated with 
neurite retraction and inhibition of regeneration induced by chondroitin sulphate 
proteoglycans within the glial scar.  Two of these receptors are protein tyrosine 
phosphatase σ (PTPσ) and the leukocyte common antigen receptor (LAR) also a protein 
tyrosine phosphatase [1, 261].  
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To use our human model neurite outgrowth to assess neural regeneration when grown in an 
Aggrecan rich environment it is essential that these receptors are present in the aggregates 
and developing neurites.  
Figure 4-19 shows the expression of both LAR and PTP σ in the developing aggregates, 
although the fold change is only small, reaching around 2 fold increase from baseline 
mRNA levels, the receptors are expressed at the gene transcription level.  This is 
encouraging since, the next part of this study assessed the effect of ligand interaction of 
each of these receptors on neurite outgrowth.  
Figure 4-19 LAR and PTPSIGMA receptor mRNA expression in TERA2.cl.SP12 EC cells.  
The mRNA of both LAR and PTPSIGMA were expressed in the developing aggregates.  High basal 
mRNA level resulted in only small relative changes over the 21 day differentiation period. High 
basal levels in the aggregates may be indicative of the neural propensity of the cells, or the receptors 
may have an alternative role in undifferentiated stem cells relating to pluripotency. Data represent 
mean ± SEM, n=3. 
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This part of the study aimed to develop a model of the glial scar to simulate neurite 
inhibition.  This will be achieved by altering the substrate of neurite outgrowth by adding 
Aggrecan, an ECM protein up regulated in the glial scar and highly inhibitory to neural 
regeneration.  Initially to assess the effect of concentration, Aggrecan was added to the 
Laminin/P-D-L coating substrate at four concentrations 0 µg/ml, 1 µg/ml, 25 µg/ml, and 50 
µg/ml (Figure 4-20).  Data demonstrates that the addition of Aggrecan reduces the length 
of neurites that form and also the number of neurites in a concentration dependent manner. 
Maximum loss was demonstrated from neurites grown on a 50 µg/ml Aggrecan substrate. 
Throughout the rest of this Chapter Aggrecan was used at a concentration of 50 µg/ml 
which gave the greatest inhibition of neurite outgrowth from the cells and is similar to 
published concentrations used in DRG neurons. 
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Figure 4-20 Loss of neurite outgrowth from differentiated human pluripotent stem cells by 
the addition of Aggrecan to the ECM. Aggregates of neural-progenitors developed from 
TERA2.cl.SP12 cells exposed to 0.1 µM EC23 for 21 days were placed onto a Laminin, P-D-L and 
Aggrecan substrate.  Laminin and P-D-L concentration was kept constant at 10 µg/ml. Aggrecan 
was added at a concentration of 0 µg/ml (A), 1 µg/ml (B), 25 µg/ml (C) or 50 µg/ml (D) to the 
coating solution as described in the methods. Aggregates were placed on the different substrates for 
10 days prior to staining with β III Tubulin (TUJ-1) for quantification.  Measurement of the number 
of neurites in each condition (E) and length of neurites (F) were taken. Data demonstrated that 
incorporation of Aggrecan reduced the number of neurites developing from the aggregate and an 
almost complete loss of neurite outgrowth at 50 µg/ml. Scale Bars: 500 µm. * p≤0.005 Student’s t-
test corrected for multiple testing between compared sample poulations using the Bonifferoni 
correction. 
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4.3.5 Restoration of neurite outgrowth using small molecules 
 
Small molecule analogues of receptor ligands and synthetic mediators of specific 
signalling pathways provide a reproducible method of inducing specific responses in cells 
and are often more potent or induce fewer non-specific side effects due to their enhanced 
specificity for particular pathways. This section focuses on the synthetic modulation of 
signalling pathways involved in the Aggrecan mediated inhibition of neurite outgrowth.  
The experiments performed aimed to investigate known and novel small molecules for 
their ability to overcome Aggrecan-induced neurite inhibition.  Using our human model of 
neurite outgrowth and Aggrecan-induced neural inhibition small molecules representing 
four individual receptor mediated pathways were tested for their ability to revive neurite 
outgrowth when cultured on an unfavourable substrate.  Details concerning work 
performed with the compounds tested are described below. 
4.3.6 ROCK Inhibition and recovery of neurite outgrowth 
 
The commercially available Rho associated protein kinase (ROCK) inhibitor, Y-27632 has 
many applications in stem cell biology and neurobiology.  The small molecule is highly 
specific for p160 ROCK and has a Ki value of 0.14 (TOCRIS Bioscience).  The enzyme 
ROCK activates a downstream modulator RhoA which then affects actin organisation and 
processes such as cell motility, contraction and apoptosis [262, 263].  Furthermore, ROCK 
activation has been implicated in the inhibition of CRMP2 by phosphorylation [167].  
CRMP2 and CRMP4 are known to promote axon formation and inhibition induces growth 
cone collapse in developing neurites.  The inhibition of ROCK and subsequently RhoA has 
been shown to overcome CSPG and Myelin Associated Glycoprotein (MAG) induced loss 
of neurite outgrowth in rat DRG neurons possibly through a CRMP2/4 mechanism [167, 
245].  
Y-27632 
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To investigate how ROCK inhibition affects neurite outgrowth from neurons in our model 
grown on an inhibitory Aggrecan substrate Y-27632 was added to the culture media at 0 
µM, 0.5 µM, 10 µM and 15 µM (Figure 4-22).  Treating the cultures for 10 days with Y-
27632 resulted in recovery of neurite outgrowth from the aggregates on a substrate coated 
with Aggrecan, Laminin and P-D-L. The number of neurites that developed in cultures 
treated with 15 µM Y-27632 was similar to the control; however there was an enhanced 
length induced on the inhibitory substrate by 15 µM Y-27632.  At lower concentrations Y-
26732 induced a reduced enhancement of neurite outgrowth but the effects were apparent 
with just 0.5 µM Y-27632.  In this study an Aggrecan negative control demonstrated good 
neurite outgrowth and an Aggrecan positive culture without Y-27632 supplementation had 
inhibited neurite outgrowth both in neurite length and number. Figure 4-21 shows 
schematically the level at which the small molecule Y-27632 inhibits the signalling 
cascade induced by Aggrecan.  
Figure 4-21.  The small molecule Y-27632 enhances neurite outgrowth in human stem-cell 
derived neurons grown on Aggrecan. Activation of Rho Associated Protein Kinase (ROCK) 
by Aggrecan results in growth cone collapse and neurite retraction in developing axons.  
Inhibition of ROCK by Y-27632 overcomes the effect of Aggrecan by preventing the loss of 
cytoskeletal architecture by ROCK. The schematic demonstrates where in the signalling cascade 
Y-27632 acts. 
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Figure 4-22 Rescue of Aggrecan-induced neurite inhibition by ROCK inhibition.  
Aggregates of TERA2.cl.SP12 EC cells were differentiated with 0.1 µM EC23 for 21 days and 
then placed onto a 10 µg/ml Laminin and P-D-L substrate supplemented with 50 µg/ml 
Aggrecan.  The no Aggrecan control aggregates were grown on Laminin and P-D-L only 
substrate.  Aggregate media was conditioned with the small molecule Y-27632 (TOCRIS), a 
ROCK –P160 inhibitor to investigate the enzymes role in neurite outgrowth under these 
conditions.  Y-27632 was added to the media at 0.5 µM (B), 10 µM (C) or 15 µM (D) for 10 
days. Measurement of the number of neurites in each condition (E) and length of neurites (F) 
were taken. Arrows highlight neurite outgrowth. Recovery of neurite outgrowth was 
concentration dependent with maximal enhancment at 15 µM.  Both neurite length and number 
were increase by Y-27632 treatment. Scale bars: 500 µm. Data represent mean ± SEM, n=3. 
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4.3.7 Neurite outgrowth recovery by retinoid agonist – AC261066 
 
A well described receptor RARβ2, that has been implicated in neural regeneration has been 
discussed earlier.  Agonists of this receptor have been shown enhance neurite outgrowth in 
explants of rat DRG and cortical neurons. Furthermore, the small molecule RAR β agonist 
CD2019 could overcome MAG induced inhibition of rat cerebellar neurons and 
regeneration of lesioned rat spinal cord via PI3K. It was also demonstrated that in the 
regenerating spinal cord RARβ2 was up regulated.  Relatively recently a highly potent 
RARβ2 synthetic agonist, AC261066 was developed and is commercially available [238]. 
AC261066 
 
 
 
The small molecule AC261066 is a potent and selective RARβ2 agonist  the pEC50 = 8.1 
compared to the RARβ1 isotype where pEC50 = 6.4 (TOCRIS Bioscience).  The specificity 
of this small molecule is important when designing drugs since activation of other 
receptors may result in unwanted side affects and in our model may shadow the true action 
of RARβ2. Although this small molecule has not been used in neural regeneration models 
other less potent and less selective agonists have been used and demonstrated receovery or 
enhancment of neurite outgrowth [238] [252].  
Figure 4-24 demonstrates the treatment of our model of neurite regeneration with 
AC261066 on an inhibitory Aggrecan substrate.  Aggregates were treated with 0 µM, 1 
µM, 5 µM and 10 µM for 10 days. Treatment resulted in a partial recovery of neurite 
length and number compared to the control culture grown on a Laminin and P-D-L 
permissive substrate. The optimum concentration of AC261066 for enhancing length and 
number was 5 µM.  Neurons in control Aggrecan cultures were inhibited as was described 
earlier in this Chapter. These data demonstrate for the first time that RARβ2 agonists may 
be a possible treatment for CSPG induced human  neurite inhibition in the glial scar. 
Figure 4-23 shows schematically the level at which the small molecule AC261066 inhibits 
the signalling cascade induced by Aggrecan. This small molecule activates RAR β2 and 
likely acts through more than one mechanism, still yet to be elucidated. 
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Figure 4-23. The small molecule AC261066 partially recovers neurite outgrowth in human 
stem-cell derived neurons grown on Aggrecan. The small molecule AC261066 is a potent 
and specific RARβ2 agonist and is thought to inhibit ROCK activation by acting to supress 
RhoA through a cAMP mechanism [4].  This small molecule acts up-stream of ROCK and so 
may be a more specific modulator of regeneration that ROCK inhibitors. 
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Figure 4-24 Partial recovery of neurite outgrowth by AC261066 treatment.  Aggregates of 
TERA.2.cl.SP12 EC cells were differentiated with 0.1 µM EC23 for 21 days were placed onto a 10 
µg/ml Laminin and P-D-L substrate supplemented with 50 µg/ml Aggrecan.  The no Aggrecan 
control aggregates were grown on 10 µg/ml Laminin and P-D-L only substrate.  Aggregate media 
was conditioned with the small molecule AC261066 (TOCRIS), a potent RAR β2 agonist.  
AC261066 was added to the media at either 0 µM (A)  1 µM (B), 5 µM (C) or 10 µM (D) for 10 
days. The number of neurites (E) and length of neurites (F) were measured.  Recovery of neurite 
outgrowth was concentration dependent with maximal recovery at 10 µM. Only partial recovery 
was demonstrated.  Arrows mark out typical neurites that develop from each aggregate Scale bars: 
500 µm. Data represent mean ± SEM, n=3. 
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4.3.8 Wnt activation and recovery of neurite outgrowth 
 
Signalling through the Wnt pathway controls a wide range of biological processes.  It is not 
surprising that published research has described the role of modulators of Wnt signalling 
on neurite outgrowth and regeneration [167, 176, 245, 264].  What is surprising is that 
research has provided conflicting evidence to suggest that this pathway can both enhance 
neurite outgrowth and inhibit outgrowth under different conditions.  This may be in part to 
the small molecules used to regulate this pathway and their non-specific nature, or more 
likely, due to heterogeneity in many key factors that affect how neurites respond to their 
external environment.  The developmental age of explanted neural tissue, the amount of 
neural damage and the type of neuron/position within the CNS are often unknown and 
affect the regenerative potential of neurons.  The model described in this thesis thus far is 
robust and well characterised.  The age of neurites that develop from stem cells is known. 
Furthermore, processes which are occurring in the neurites that correspond with their stage 
of development are predictable, making this model ideal for comparison between small 
molecule modulators of signalling pathways.  In addition the nature and composition of the 
controlled substrate proteins can be used giving rise to specific effects on the neurites and 
investigating neurite outgrowth under either a permissive or inhibitory environment.  
GSK3 α and β inhibition 
The small molecule CHIR 99021 is a highly selective inhibitor of the enzyme GSK3 
(TOCRIS Bioscience).  Inhibition of GSK3 results in loss of Wnt activated signalling and a 
build-up of β catenin a gene transcription regulator. It is thought that the outcome of GSK3 
signalling is dependent on the amount of GSK3 activity in the developing neurons.   
In this part of the study our model of neurite outgrowth was used to assess the role of 
GSK3 signalling inhibition on neurite outgrowth.  The small molecule was added to the 
neurite outgrowth culture media described in Methods at concentrations of 0.01, 0.1, 1 and 
10 µM for 10 days and the length of neurites measured.  The results demonstrate that 
addition of 1-10 µM CHIR 99021 inhibited neurite outgrowth on a permissive Laminin/P-
D-L substrate (Figure 4-26).   
To investigate the mechanisms by which CHIR 99021 induced loss of neurite outgrowth 
and if activation of P160 ROCK was involved in the inhibition demonstrated by 1 µM,  15 
µM of the small molecule Y-27632 was added to a culture containing 1 µM CHIR 99021.  
Results demonstrate no enhancement of neurite length when cultures were supplemented 
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with Y-27632, possibly indicating loss of neurite outgrowth via a non-ROCK activating 
signalling pathway (Figure 4-27).  Control culture without CHIR 99021 had good neurite 
outgrowth as has been described previously. Figure 4-25 shows schematically the 
inhibition of GSK 3β by the small molecule CHIR 99021 which ultimately resulted in loss 
of neurite outgrowth on a permissive substrate.  
Figure 4-25  CHIR99021 inhibits neurite outgrowth of human stem-cell derived neurites on 
a permissive substrate.  The small molecule CHIR 99021 inhibits GSK 3β and induces loss of 
neurite outgrowth in our model. 
193 
 
 
 
 
  
Figure 4-26 Inhibition of GSK3 results in loss of neurite outgrowth on a permissive substrate.  
Aggregates of the human pluripotent stem cell (TERA2.cl.SP12) were differentiated with 0.1 µM 
EC23 for 21 days.  Aggregates were then grown on a permissive Laminin/P-D-L substrate in the 
presence of mitotic inhibitions (as described in Methods). The no Aggrecan control aggregates were 
grown on Laminin and P-D-L only substrate.  Cultures were treated with CHIR 99021 from day 1 at 
a concentration of 0 µM (A), 0.01 µM (B), 0.1 µM (C), 1 µM (D) or 10 µM (E).  Using LEICA AF 
software neurite length was measured from the neurospheres (F).  Data demonstrate a loss of 
neurite outgrowth from aggregates treated with 1 and 10 µM CHIR99021.  Data represent mean ± 
SEM. * p≤0.05 compared to the control by Students T-test.  Scale bars: 500 µm. 
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Figure 4-27 Inhibition of neurite outgrowth by CHIR 99021 is not overcome by ROCK inhibition. 
Aggregates of the human pluripotent stem cell (TERA2.cl.SP12) were differentiated with 0.1µM EC23 
for 21 days.  Aggregates were then grown on a permissive Laminin/P-D-L substrate in the prese of 
mitotic inhibitions (as described in Methods).  To assess if ROCK inhibition can overcome the affects of 
CHIR99021 15  µM Y-27632 was added to cultures treated with 1 µM CHIR99021 (C).  Control cultures 
without Y-27632 (A) and with Y-27632 (B) had normal neurite length formation.  LEICA AF software 
was used to measure neurite length  from >5 neurospheres (D).  Data demonstrate a loss of neurite 
outgrowth from aggregates treated with 1 µM CHIR99021 and Y-27632 were inhibited compared to 
control cultures.  Data represent mean ± SEM. * p<0.05 Students T-test. Scale bars: 500 µm. 
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The small molecule - XAV 939 is an Axin stabiliser and acts to enhance GSK3β activity 
resulting in β-catenin degradation and increased Wnt signalling.  This small molecule has 
been used in various studies to investigate the role of Wnt signalling. The effect of this 
small molecule would be opposite to that of CHIR 99021 and so would not be expected to 
inhibited neurite outgrowth.   
XAV 939 
 
 
 
 
 
The small molecule was XAV 939 was used to investigate the role of Wnt enhancement on 
neurite outgrowth in our model of Aggrecan induced inhibition.  XAV 939 which is a 
commercially available small molecule from TOCRIS.  In our system XAV 939 was added 
at three concentrations 0.1, 1 and 10 µM to the neurite outgrowth culture media for 10 
days, on an Aggrecan/Laminin/P-D-L substrate.   
Figure 4-29 demonstrates the effect of XAV 939 supplementation on neurite outgrowth on 
an Aggrecan substrate. Neurite number and length was measured under each condition. 
Addition of XAV 939 resulted in a recovery of neurite length and number.  Furthermore, at 
0.1 µM and 1 µM an increase in the migration of cells from the aggregate was observed.  
This may be a non-specific effect of this small molecule resulting in increased cell motility 
an observation that would require further analysis to determine the cells that were 
migrating. Figure 4-28 shows schematically the level at which the small molecule 
XAV939 inhibits the signalling cascade induced by Aggrecan.   
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Figure 4-28.  The small molecule XAV 939 enhances neurite outgrowth in human stem cell-
derived neurons grown on Aggrecan. XAV 939 stabilises the GSK 3β enzyme complex which 
prevents growth cone collapse and neurite retraction on Aggrecan. 
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Figure 4-29 GSK3β stabilisation by XAV 939 can potentially overcome Aggrecan-induced 
neurite outgrowth inhibition.  Aggregates differentiated with 0.1 µM EC23 for 21 days were 
placed onto a Laminin and P-D-L substrate supplemented with 50 µg/ml Aggrecan.  The no 
Aggrecan control aggregates were grown on Laminin and P-D-L only substrate. Aggregate media 
was conditioned with the small molecule XAV 939, a Tankyrase inhibitor.  XAV 939 was added to 
the media at either 0 µM (A), 0.1 µM (B), 1 µM (C) or 10 µM (D) for 10 days and subsequently 
fixed in 4 % PFA.  Neurite number (E) and neurite length (F) were measured for quantification. 
Recovery of neurite length was concentration dependent with maximal recovery at 0.1 µM, however, 
the number of neurites that developed was maximal at 1 µM.  Large colonies of non-neural cells 
migrated from the central sphere at 0.1 µM and 1 µM XAV 939. Arrows show neurites. Asterisk 
marks migrating cells. Scale bars: 500 µm. Data represent mean ± SEM, n=3. 
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4.3.9 PTP IV Inhibition and recovery of neurite outgrowth 
 
The small molecule modulators that enhance neurite outgrowth on an inhibitory Aggrecan 
substrate described so far affect the key signalling pathways involving ROCK, GSK3β and 
RARβ2.  Due to the large biological role of each of these modulators it is likely that in vivo 
applications would result in non-specific side effects that are likely detrimental to the 
organism.  More specific modulators of the receptor-ligand interaction inducing the 
downstream response of Aggrecan may be more suitable for in vivo and clinical 
applications in the future.  One method of influencing the effect of Aggrecan on neurite 
retraction is to inhibit protein tyrosine phosphatase receptor activation [149]. Furthermore, 
it is known that PTPσR signalling regulates NGF by dephosphorylating its receptor TrkA, 
and does so without causing enhanced cell death, ectopically increasing PTPσR  also 
resulted in reduced neurite outgrowth, indicating inhibition of PTPσR a key target for 
enhancing neurite outgrowth [265]. It is known that reducing the activation of PTPσR in 
mouse DRG sensory neurons can overcome CSPG induced neurite inhibition [1].  
Inhibition of PTPσR by the small molecule PTP IV inhibitor has the potential to prevent 
Aggrecan induced neurite inhibition. [266].  
 
PTPIV Inhibitor 
 
 
 
The PTP IV inhibitor is a selective non-competitive, reversible, active site directed 
inhibitor of PTPσ, the intracellular protein tyrosine phosphatase of the PTPσ receptor. The 
IC50 of this inhibitor for PTP σ is 20 µM (TOCRIS Bioscience). Since the GAG side chains 
on Aggrecan bind PTPσR and activate the second messenger system, inhibiting the 
intracellular enzymes of this system will prevent signalling and hence many of the 
downstream responses such as ROCK and RhoA activation which lead to CRMP2 
phosphorylation and growth cone collapse [149].   
Using our model of neurite outgrowth on an Aggrecan substrate, five concentrations of the 
PTPIV inhibitor were tested (0 µM, 0.1 µM, 1 µM, 5 µM and 10 µM).  Cell media was 
supplemented with the compound for 10 days prior to fixation and analysis. Figure 4-31 
demonstrates that both the number and length of neurites were significantly decreased in 
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cultures grown on Aggrecan alone. However, the addition of PTP IV to the cultures 
recovered the length of neurites to that of the control at 1 µM and partially enhanced 
neurite number at each concentration.  The fold increase in neurite length was 3 fold for 
both 10 and 0.1 µM PTP IV inhibition compared to the Aggrecan control length. Maximal 
increase in neurite length was demonstrated by 1 µM with a 4 fold increase. These data 
indicate that this small molecule can be used for overcoming Aggrecan induced neurite 
inhibition in human neurons.  This is the first known report detailing the role of PTP IV 
inhibition on human neurite outgrowth and its potential role in regenerative neurons.  
Figure 4-30 shows schematically the level at which the small molecule PTP IV inhibitor,  
inhibits the signalling cascade induced by Aggrecan, and does so by preventing PTPσR 
activation and downstream signalling. 
 
 
Figure 4-30 The small molecule PTP IV inhibitor enhances neurite outgrowth in human stem 
cell-derived neurons on Aggrecan. The small molecule inhibits activation of the Aggrecan 
receptor enzyme PTPσ on the neurite membrane. Inhibition of the receptor prevents downstream 
activation of the Rho A and ROCK second messengers. 
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Figure 4-31 Inhibition of protein tyrosine phosphatase σ receptor using the synthetic PTP IV 
inhibitor results in enhanced neuritogenesis.  Aggregates of TERA2.cl.SP12 cells were 
differentiated for 21 days by 0.1 µM EC23.  Aggregates were then placed on tissue culture plastic 
coated with 10 µg/ml Laminin and P-D-L and 50 µg/ml Aggrecan.  Loss of neurite outgrowth was 
demonstrated on Aggrecan coated plastic as described earlier.  Cell culture media was supplemented 
with 0 µM (A) 0.1 µM (B), 1 µM (C), 5 µM (D) or 10 µM (E) PTP IV inhibitor.  After 10 days of 
outgrowth the aggregates were fixed in 4 % PFA, stained for DAPI (Blue) and β III Tubulin (TUJ-1) 
(Green) and the neurite length was measured using the Leica AF quantification and tracing software. 
Neurites were counted (F) using Image-J as described in Methods Section. Recovery of neurite 
outgrowth was demonstrated at each concentration of PTP IV inhibition with maximum recovery at 1 
µM (G). Arrows show neurites. Scale bars: 500 µm.  Data represent mean ± SEM, n=3. 
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4.3.10 Chondroitinase pre-treatment and recovery of neurite outgrowth  
 
Another way of targeting PTPσ receptor activation by Aggrecan is to remove the 
glycosaminoglycan side chain from the core Aggrecan protein [267].  The GAG side chain 
as discussed previously is the ligand that interacts and modulates the PTPσ receptor [261].  
Removal of this side chain can be achieved by treating Aggrecan with the bacterial enzyme 
chondroitinase ABC.  Chondroitinase ABC or chondroitin-sulfate (ABC) endolyase can be 
isolated and purified from Proteus vulgaris. The enzyme has been demonstrated 
extensively in chick DRG and mouse models to enhance CNS regeneration after traumatic 
injury [156, 268].  It is unknown if the enhanced regeneration demonstrated by 
chondroitinase treatment is the direct response of GAG cleavage or if cleavage results in a 
secondary immune or vascularisation of the tissue enhancing recovery.  In our robust 
model of neurite differentiation any neurite outgrowth from neurites achieved by the pre-
treatment of Aggrecan by chondroitinase ABC is potentially the direct effect of loss of 
ligand epitope i.e. GAG cleavage. Furthermore, it is unknown if cleavage of GAG on 
Aggrecan by chondroitinase affects human neurites in a similar way to that seen in rodent 
neurons. 
Prior to seeding the differentiated aggregates onto the Aggrecan substrate 0.15 active units 
of enzyme in buffer or enzyme buffer alone was added to the appropriate Aggrecan coated 
test well for 1 hour at 37 °C and then washed x 3 in PBS. After treatment, differentiated 
aggregates were added to each well and cultured for 10 days as described previously. Data 
in Figure 4-33 and Figure 4-34 demonstrate the enhancement of neurite outgrowth from 
aggregates on Aggrecan substrates treated with chondroitinase. Both the number and 
length of neurites were increased compared to the wells treated with enzyme buffer alone. 
The length of neurites that formed were similar to that seen in control Laminin/P-D-L 
cultures reaching around 700 µm and the number of neurites that developed was around 50 
% that of the control cultures. This indicates that there may be an incomplete digestion of 
GAG side chains, resulting in some inhibition of neurite development.   Incomplete 
digestion of GAG side chains may be the result of enzyme saturation; this may be 
compensated by increasing the number of active enzyme units used or by raising the 
incubation time from 1 hour.  Furthermore, it is unknown if free GAG cleaved by 
Chondroitinase can affect these neurites and so an additional PBS wash may overcome the 
incomplete recovery seen in this model. Figure 4-32 demonstrates schematically the level 
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at which Chondroitinase inhibits the ligand-receptor interaction of Aggrecan and PTPσR, 
note that other receptors including LAR will also be inhibited by this method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-32. The bacterial enzyme Chondroitinase ABC inhibits Aggrecan signalling and creates 
a permissive substrate for neurite outgrowth.  Pre-treatment of the Aggrecan coated substrate with 
Chondroitinase ABC resulted in cleavage of glycosaminoglycan (GAG) side chains and decreased 
PTPσ activation.  The resulting effect was decreased ROCK activation and neurite outgrowth was 
permissible.  
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Figure 4-33 Overcoming neurite outgrowth induced by Aggrecan using Chondroitinase ABC pre-treatment.   Negative control neurons were grown on 
Laminin/P-D-L only substrates washed for 1 hour with enzyme buffer and formed large numbers of long neurites, Control (A).  Positive control neurons were 
grown on Laminin/P-D-L plus Aggrecan as described in the Methods Section and were also washed with enzyme buffer (B).  Chondroitinase was added to the 
enzyme buffer and resulted in neurite outgrowth recovery on Laminin/P-D-L plus Aggrecan substrate (C).   Scale bars: 500 µm.  n=3. 
C B A 
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Figure 4-34 Recovery of neurite outgrowth on Aggrecan treated with chondroitinase ABC.  
Tissue culture plastic was coated with 10 µg/ml Laminin and P-D-L in PBS, which is permissive to 
neurite outgrowth.  For inhibition of outgrowth 50 µg/ml Aggrecan was added to the Laminin-P-D-
L coating substrate overnight.  The cultures were then treated with chondroitinase in enzyme buffer 
or enzyme buffer alone, for 1 hour at 37  °C.  The plates were then washed thoroughly to remove an 
excess enzyme or buffer and aggregates differentiated for 21 days by 0.1 µM EC23 were placed 
onto each substrate for 10 days. Pre-treatment with chondroitinase ABC resulted in recovery of 
neurite outgrowth on an inhibitory Aggrecan substrate. Neurites were counted using Image-J 
software (A). Using LEICA AF software the length of neurites were traced and measured (B). Pre-
treatment of chondroitinase ovefcame the inhibitory effect of Aggrecan on neurite length and 
partially restored neurite number. Data represent mean ± SEM, n=3. * p≤0.05 compared to the 
Aggrecan only control by Students t-test. 
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4.3.11 Modelling neuronal/glial interactions in co-culture using conventional 2D 
substrates 
 
The dynamic structure of the glial scar that develops post CNS injury contains both extra 
cellular matrix proteins that modulate regeneration and a cellular component which 
influences the composition of the scar and hence neurite outgrowth.  Post-CNS injury an 
increase in TGF β signalling results in reactive gliosis [6].  Astrocytes in the CNS become 
activated and begin to produce ECM proteins such as Laminin, Fibronectin and some of 
the CSPG’s such as Aggrecan, Brevican and Neurocan [269].  In this part of the study a 2D 
co-culture method was developed to determine the effect of the astroglioma cell line 
U118MG on human neurite outgrowth.   
U118MG is derived from a human brain glioblastoma, for the purpose of this study it is 
used as a model of the reactive astrocyte.  However, like most models this is not perfect 
due to its lack of GFAP expression and cancerous origin, it cannot be directly related to the 
glial scar.  
In Figure 4-35 human U118MG astroglioma cells were seeded at a density of 6000 
cells/cm2 along with 1 neurosphere in each well of a conventional 48 well culture plate.  
The presence of the astroglioma cells prevented neurite outgrowth over 10 days from the 
cell aggregates.  Image A in Figure 4-35 shows the surrounding U118MG nuclei with 
DAPI staining (Blue) and the neurites stained for TUJ-1 (Red). When the cultures were 
grown in the presence of the ROCK inhibitor – Y-27632, neurites formed from the 
aggregate and developed over the U118MG cells.  Therefore, it was determined that the 
U118MG cells induce a receptor mediated inhibition of neurite outgrowth, possibly from a 
cell membrane molecule.  It is known that in the brain glial cells and astrocytes express 
CSPGs, therefore it was hypothesised that the inhibition of neurite outgrowth was due to 
the expression of membrane bound CSPGs. 
To determine if Aggrecan was expressed by the astroglioma cells a total protein ELISA 
was performed for human Aggrecan.  However, no expression was detected in purified 
protein from U118MG lysate (Figure 4-36).  Another CSPG that has been associated with 
glial cells in the brain is Brevican.  Brevican is tightly regulated in the brain and is 
associated with boundaries of neural/glial processes.  It was hypothesised that the 
U118MG may express Brevican on their surface resulting in neurite retraction.  
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Figure 4-37 demonstrates the cell membrane expression and up regulation of Brevican by 
U118MG grown on Laminin and P-D-L in 2D. The addition of Y-27632 or AC261066 
resulted in an increased the level of Brevican membrane expression.   This was backed up 
further by the relative mRNA expression of human Brevican by the cells under the 
different conditions (Figure 4-38).  
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Figure 4-35 Co-culture of human glioblastoma and human neuronal tissue on 2D plastic. The 
glioblastoma cell line U118MG and differentiated TERA2.cl.SP12 aggregates were seeded at the 
same time onto Laminin/P-D-L coated tissue culture plastic.  Approximatly 5,000 U118MG cells 
were seeded in a 48 well plate along with 1-2 aggregates. Cells were maintained for 10 days in 
maintenance media supplemented with mitotic inhibitors.  Fixed cells were then stained for β III 
Tubulin (TUJ-1) (red) and DAPI (Blue). Image A shows inhibition of neurite outgrowth in the 
presence of U118MG (shown as nuclei-Blue).  Image B demonstrates the recovery of neurite 
outgrowth over U118MG cells with the incorporation of 15 µM Y-27632.  Arrows show presence 
of growing neurites. Scal Bars: 100 µm. n=3.  
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Aggrecan ELISA  
Figure 4-36  Aggrecan ELISA standard measurements.  Standard concentrations of Aggrecan 
were measured by ELISA.  The graph demonstrates concentration of Aggrecan ng/ml against optical 
density (OD). Data demonstrates an increase in OD with concentration of Aggrecan.  Note the OD 
from 50 ng of purified U118MG protein was the same as the OD of 0 ng/ml Aggrecan standard 
indicating that the protein extract from U118MG does not contain Aggrecan.  n=1. 
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Figure 4-37 Brevican immunostaining of U118MG cells grown in 2D. No primary antibody 
control (A) and untreated cells (B) did not demonstrate any Brevican staining (green).   Points of 
Brevican staining can be seen on cultures treated with 15 µM Y-27632 (C,E) or 10 µM AC261066 
(D,F) which are located on the membrane of the cell. Indicating a possible mechanism for 
inhibition of neurite outgrowth induced by the presence of these cells. Arrows show neurites. Scale 
bars: 100 µm (A-D), 20 µm (E,F). n=3. 
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Figure 4-38  Relative quantitation of Brevican mRNA in U118MG astroglioma cells. Cells 
were grown on plasma treated only, Laminin coated or Laminin coated plus 15 µM Y-27632 or 10 
µM AC261066.  The mRNA expression of Brevican was measured relative to cells grown on 
plasma treated only substrate using real time PCR.  Data demonstrates the presence of Brevican 
mRNA in the cells and an enhancement of Brevican mRNA in cells grown on Laminin and treated 
with either Y-27632 of AC261066.  Data represent mean ± SEM, n=3.  
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4.4 DISCUSSION 
4.4.1 Differentiation of human stem cells into neurons using an aggregate – based method  
 
Differentiation of human embryonal carcinoma (hEC) stem cells using the aggregate based 
method has been demonstrated to be an alternative approach to mono-layer differentiation 
for neural tissue development in vitro.  hEC stem cell derived aggregates are very similar 
to the embryoid body that forms from aggregates of human embryonic stem cells. 
The cells in this study were TERA2.cl.SP12 human EC cells which are known to 
differentiate into neurons following retinoic acid treatment. Differentiating these cells with 
ATRA in 2D mono-layer culture results in around 10-15 % neural cell differentiation, the 
purity and yield of neural tissue can be enhanced by the aggregate-based differentiation 
method [85]. 
Early stages of retinoic acid treatment results in the up-regulation of Nestin and the 
formation of proliferative neural rosettes. The intermediate filament Nestin was first 
discovered in 1985 from antibodies produced by immunizing mouse with spinal cord 
extract of 15 day old rat embryos. Nestin forms heterodimers with other intermediate 
filaments such as α Vimentin.  The primary role of Nestin is thought to be in regulating the 
intracellular environment and stabilising cell structure, necessary for cell division and 
migration.  Nestin is associated with many areas of the nervous system particularly early 
stages of development both in vitro and in vivo.  Furthermore, Nestin is associated with the 
regeneration of damaged brain and regenerating/proliferating neural progenitors.  As 
development progresses Nestin is replaced with either GFAP expression in glial cells or 
Neurofillaments such as β III Tubulin in neuronal cells. It is therefore suggested for the 
purpose of this study that Nestin is representative of an early neural phenotype.  The 
Neurofillament β III Tubulin is strongly expressed throughout the mature central nervous 
system. In this study aggregates of EC23 treated TERA2.cl.SP12 EC cells expressed the 
cytoskeletal proteins Nestin, an early neural progenitor marker and β III Tubulin a later 
marker of neural commitment. High levels of β III Tubulin from aggregates induced to 
form neurites was indicative of late neural commitment, however, in aggregate sections 
both high levels of Nestin and β III Tubulin were seen indicating a mixed population.  It 
would be interesting to use flow cytometry to quantify the number of Nestin positive and β 
III Tubulin positive cells in aggregates under each retinoid condition, however, 
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disaggregation is difficult due to complex structures and ECM proteins within the 
aggregate. 
In this study aggregates of TERA2.cl.SP12 cells were differentiated with either EC23, 
AH61 or ATRA. The temporal and concentration dependent effects of each small molecule 
were assessed for their ability to induce differentiation. The small molecule EC23 a 
synthetic analogue of ATRA was described in Chapter 4 as a potent inducer of neural 
differentiation in TERA2.cl.SP12.  This is most likely due to its stability in culture and 
EC23 induces a more sustained single concentration effect than ATRA.  AH61 is another 
novel synthetic analogue of ATRA described in detail by A.Henderson’s (2013) [246] 
thesis which induces neural differentiation in TERA2.cl.SP12 EC cells grown as a mono-
layer. In this Chapter the use of stable synthetic small molecules to induce robust and 
consistent differentiation of human stem-cells was investigated as an alternative to ATRA 
Aggregates were differentiated with 10, 1 or 0.1 µM, EC23, ATRA or AH61 for 14 or 21 
days.  The aggregates were then fixed, sectioned and stained with H&E for structural 
imaging or for the neural antigens Nestin and TUJ-1. The results indicate that as with 
previous studies each of the retinoids induced neural rosette formation and neural 
differentiation after 14 days.  Aggregates of TERA2.cl.SP12 differentiated with ATRA for 
14 days has been shown previously to result in neural differentiation [270], agreeing with 
data from this section, furthermore, hES embryoid bodies are also known to form  neural 
progenitors after just 14 days [271].   There was a visible decrease in neural rosette 
formation and Nestin expression in the most potent small molecules after 21 days.  
Furthermore, the aggregates looked more homogeneous in structure after 21 days, longer 
differentiation protocols from 21-28 days have been published in the literature and 
suggests that increasing the length of differentiation results in more mature progenitor 
formation [272]. Some areas in the aggregate did not express TUJ-1 or Nestin indicating 
they may be non-neuronal or represent a heterogeneous population of starting cells.  The 
induction of cytoskeletal proteins associated with neural progenitor formation and 
structures that resemble neural development demonstrates the high neural activity of each 
of these compounds, allowing determination of an optimal concentration and compound to 
be used.  
4.4.2 Development of a robust and reproducible model of neurite outgrowth 
 
Neurite outgrowth from each of the aggregates differentiated using 10, 1 or 0.1 µM, EC23, 
ATRA or AH61 for 14 or 21 days were assessed.  Neuroprogenitors within the aggregates 
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were induced to form axons on a Laminin and P-D-L substrate for 10 days. Induction of 
neurite outgrowth by Laminin is common among many neural progenitor cells and is 
regulated through the Integrin α1β1 receptor heterodimer.  In addition, to prevent the 
division of proliferative cells in the aggregate and loss of the neurosphere mitotic inhibitors 
were added as described in Horrocks, G et al (2003) [85]. Aggregates differentiated for 14 
days in each of the concentration and retinoid groups demonstrate migration of cell bodies 
from the central aggregate. In addition a vast network of neurites formed from each 
aggregate with the exception of 10 µM EC23 where only a few neurites developed.  
Migration of cell bodies from the aggregate is likely due to the early developmental stage 
of the progenitors as would be seen in neural progenitor of the early developing neural 
tube. Migration of developing neuroprogenitors is essential for correct AP and DV 
patterning [35].  High Nestin levels in some of the 14 day aggregates may indicate a high 
migratory potential of the cells, since neural progenitors are known to be migratory [273].    
The formation of neural progenitors after 14 days differentiation has been published 
previously [85].  The time used to differentiate the aggregates was increased from 14 to 21 
days to investigate the temporal dependent effects on neurite outgrowth and any 
differences between the aggregates that may have developed.  In this section our data 
demonstrated that there was a reduction in migration of cell bodies form the central 
aggregate when cells were differentiated for 21 days as opposed to the previous 14 days.  
Furthermore, the length and number of neurites was much easier to quantify as a halo of 
individual neurites formed around a central point of origin.  Staining of DAPI (Blue) and 
neurons (TUJ-1, Green) clearly separated the two primary structural aspects of the neuron. 
There was also a clear effect of retinoid concentration on neurite number, high 
concentrations of EC23 and low concentrations of ATRA induced fewer neurites than the 
converse.  This concentration affect is likely due to the initiation of neural development 
within the aggregate.  Retinoid concentration has been demonstrated to be highly 
regulatory over the differentiation of mouse ES cells; low concentrations of ATRA around 
0.001 µM and 0.01 µM were associated with an increased level of mesoderm and 
epidermal markers [196]. In our aggregate-based model concentration had a similar 
differential effect, the low concentrations of ATRA induce poor neural commitment and 
neurite outgrowth suggesting an alternative germ layer developed, however, the high 
concentration of EC23 also induced a similar low level neural commitment and neurite 
outgrowth, possibly due to complex feedback mechanisms involving Pax6 as was 
discussed in Chapter 3.  
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In light of the published data and research described so far in Chapters 3 and 4 the most 
optimised and described method of neurite outgrowth for studying neural development 
would involve the differentiation of TERA2.cl.SP12 EC cells with 0.1 µM EC23.  This 
concentration and cell line were chosen to be taken forward in this study to investigate the 
molecular mechanisms involved in neurite regeneration (see Methods Section for the 
standard operating procedure). To further classify the neurons that were developing in this 
model a number of anterior-posterior gene markers and receptors were also assessed. 
Anterior-posterior axis specification of neural tissue in the CNS is regulated by 
morphogens from the Wnt, BMP, FGF and RA family of small molecules [213, 274-276]. 
The morphogen that signals to the cells and ultimately determines their fate depends on 
their anatomical location in the CNS. Initially the anterior-posterior axis of the neural tube 
is formed and results in the development of distinct forebrain, midbrain, hindbrain and 
spinal cord structures.  The development of each structure is regulated by a distinct pattern 
of genes induced by combinations of the morphogens described earlier.  In vitro 
development of neural tissue from embryonic stem cells utilises combinations of these 
morphogens and induction of gene markers can be used to determine the subtype of cell 
that will develop [277].  The use of markers to determine the which region of the CNS 
differentiating stem cells are developing into is important for translating in vitro data into 
hypothesis that can be tested in vivo – for instance, small molecule that enhance spinal cord 
regeneration may not have the same effect on neurons in the forebrain.   
To determine genetically the area of CNS cells treated with 0.1 µM EC23 most represented 
a marker of forebrain development, OTX2 which is expressed during development and the 
hindbrain/spinal cord marker HOXC4 were measured using real time PCR.  The results 
indicate a loss of OTX2 mRNA expression in the cells and a temporal dependent increase 
in HOXC4 mRNA expression which indicated a thoracic identity of these cells.  HOXC 
regulation is related to spinal cord development, since HOXC4 is an anterior HOX gene it 
is likely that these cells represent a more hindbrain/anterior spinal cord neuroprogenitor 
cells type [196]. In addition PAX6 mRNA expression was also determined over the 21 
days, this indicated a peak in PAX6 mRNA after 7 days which remained high, PAX6 is 
indicative of ventral neural spinal cord development, PAX6 is also found within the 
forebrain, however, due to the high level of HOXC4 it is likely that the PAX6 expression in 
these cells is representative of a motor neuron or V1 interneuron phenotype [278].  
The data from Figure 4-17 shows that RARβ2 mRNA is sustained at a high level after 7 
days in cells treated with 0.1 µM EC23, after 21 days treatment high mRNA levels likely 
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indicate that the neurites that form from the neurospheres will be responsive to agonists of 
RARβ2.  
The RARβ2 receptor is a common regulator in many neurobiological processes, including 
initiation and sustained neural differentiation of stem cells [251], neurite outgrowth[252], 
axon formation and neurite regeneration [4].  RARβ2 has been demonstrated to be involved 
in anterior-posterior axis formation through the regulation of HOX genes such as HOXD4, 
HOXB4 [279] and HOXA5 [228].  Cross regulation between PAX6, HOXD4 and RARβ2 
are likely key modulators of the response of cells to retinoic acid during the early stages of 
AP axis patterning, since PAX6 has been demonstrated to be highly involved in the 
initiation and maintenance of neural differentiation [280], furthermore both PAX6 and 
RARβ2 are closely involved in the regulation of HOXD4 and various other HOX genes 
[227, 279]. 
In addition to the cross-regulation between RARβ2 and the patterning genes described 
above the neurotropic factor, nerve growth factor and the neurotropic receptor (NGFRR) or 
TrkA are also closely involved in the activation of RARβ2 and hence the downstream 
events that occur [109].  Basal stimulation of RARβ2 expression by NGFR was through a 
Ras dependent mechanism which could be enhanced by retinoic acid treatment in PC12 
cells. NGFRR is expressed both in the CNS and PNS, up-regulation of NGFRR by ATRA 
is associated with cell survival and in some neurons neurite outgrowth is enhanced.  
It has been shown by Maden, M et al (2000) [174], that primary rat DRG neurons are 
induced to form neurites by NGFR treatment express both the RARβ2 receptor and RARγ1 
retinoic acid receptors.  In contrast DRG neurons that do not require NGFR treatment for 
neurite outgrowth which were isolated from a BDNF responsive population express RARβ2 
but not RARγ1 [174].  Since the neurons in this study extend axons without NGFR 
treatment and express RARβ2 it would be interesting to determine the expression level of 
RARγ1 in our model.  Data from Figure 4-18 demonstrates that although the receptor 
mRNA is expressed and increases possibly through retinoic acid dependent mechanisms 
the production of NGFR decreases in expression and therefore NGFR signalling is unlikely 
to affect the development of these cells.   
The neurite outgrowth model described so far has been optimised to produce a high yield 
of neurons in a defined and controlled way; furthermore, the neurites that develop have 
been characterised using gene expression techniques to determine the likely neural subtype 
that they represent in the spinal cord.  The model will now be applied to investigate the 
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inhibition of human neurite outgrowth by the CSPG, Aggrecan and determine small 
molecules that can modulate the process of neurite outgrowth and development. 
4.4.3 Inhibition of human neurite outgrowth by the CSPG Aggrecan 
 
Chondroitin sulphate proteoglycans (CSPGs) are a family of extracellular matrix molecules 
that comprise a core protein with variable numbers of glycosaminoglycan (GAG) side 
chains [281].  
CSPGs are sulphate lecticans which include Neurocan, Versican, Brevican and Aggrecan. 
The C-terminal of the lecticans consists of a C-type lectin, epidermal growth factor and 
regulators of the complement pathway.  The C-type lectin domain of these CSPGs is 
involved in protein-protein interactions, such as binding Fibronectin.  Many of the CSPGs 
found within the central nervous system regulating many neural processes such as 
plasticity and development.  Since the CSPGs have a physiological role in neural plasticity 
and development it is not surprising that their dis-regulation both during embryonic 
development and in the adult CNS is associated with neural pathophysiology.  
CSPG are known to be strongly inhibitory of neural regeneration in CNS neurons.  CSPGs 
are deposited and bind to collagen IV [282] in the glial scar during reactive gliosis, 
deposition of CSPGs and other extracellular matrix proteins is predominantly the role of 
activated astrocytes, characterised by high GFAP expression.  CSPGs exert their affect 
through binding to the protein tyrosine phosphatase receptors σ and F, which are expressed 
on the surface of developing and regenerating neurites.  Receptor activation is through 
binding of CSPG GAG side chains which results in an intracellular signalling cascade [1].  
Signalling through PTP receptors activates RhoA which in turn phosphorylates and 
activates P160 ROCK.   Activation of P160 ROCK results in growth cone collapse and 
axon retraction in neurites through effector molecules such as collapsing response mediator 
protein 2 (CRMP2) [283].  Mixed extracts and in vivo models of spinal cord injury has 
associated CSPGs with neurite inhibition, however, very few studies have investigated the 
effect of individual CSPG subtypes on neurite outgrowth. 
The CSPG, Aggrecan is strongly up regulated in the glial scar post CNS injury.  Few 
studies have directly investigated Aggrecan and neurite outgrowth.  However, Aggrecan 
has been demonstrated to induce loss of neurite outgrowth and regeneration in both in vitro 
and in vivo studies.  Animal models and cells were utilised to investigate the role of 
Aggrecan in this process.  The majority of studies on Aggrecan have involved the use of 
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rat DRG and are focussed on integrin receptor regulation [98] or ROCK inhibition to 
recover outgrowth [284]. 
In this study Aggrecan was added to a permissive Laminin and P-D-L substrate to 
determine its effect on human synthetically derived neuroprogenitor cells and their ability 
to form neurites.  Aggrecan induced a concentration dependent decrease in neurite length 
and number in this model (Figure 4-20).  A high level of compensation can be achieved by 
neurites on a mixture of Laminin and Aggrecan since up regulation of integrin receptors 
can overcome CSPG induced neurite inhibition. This affect is similar to what is 
demonstrated in DRG models of neural regeneration on Aggrecan [98].  Furthermore, the 
presence of Aggrecan or any other CSPG is not sufficient to cause neurite retraction and 
loss of axon regeneration when Laminin is in excess, the ratio between Laminin 
concentration and CSPG concentration which is important and is directly linked to the 
number of integrin receptors on the neurite [234], making recovery of outgrowth possible 
by increasing integrin receptor clustering [160].  High levels of CSPG are required for loss 
of neurite outgrowth which in a glial scar is normally associated closely with origin of the 
scar (epicentre).  Snow, D.M et al (1995) [285] demonstrated that when grown on a 
Laminin substrate, neurites are not affected by soluble CSPG, however, bound CSPG 
inhibited DRG neurite outgrowth.  In contrast there was significant decrease in the rate of 
DRG neurite elongation when Fibronectin was used instead of Laminin.  The ability to 
investigate these processes using Human neurons will provide insight into early 
regeneration and the requirement of permissive ECM proteins in neural regeneration [285].  
The molecular mechanisms involved in the inhibition of neurite regeneration by Aggrecan 
are well known and as described before act through recently discovered protein tyrosine 
phosphatase receptors.  Manipulation of the pathways involved in transmitting the 
Aggrecan signal to a morphological change in cell architecture is currently of interest in 
neural regenerative research.  
4.4.4 Small molecule recovery of Aggrecan induced inhibition of neurite outgrowth 
 
The CSPG, Aggrecan is up-regulated in the glial scar by activated astrocytes that infiltrate 
and attempt to limit further damage by infection.  The scar that forms consists of a network 
of different ECM proteins some permissive and some inhibitory to neurite outgrowth such 
as Laminin and Aggrecan respectively.  Damage and scar formation results in loss of 
neural processes and subsequent paralysis of the injured animal.  Using small molecule 
modulation of the inhibitory signalling pathways that are activated in neurons by the glial 
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scar is an attractive approach enhances recovery of the damaged neurites and aid functional 
recovery.  Multiple small molecules have been investigated in this Chapter, targeting 
known signalling pathways involved in neurite outgrowth.  
Y-27632  
The CSPG Aggrecan has been shown to induce neurite retraction and inhibition of 
regeneration in our model of neurite outgrowth and post-traumatic spinal cord injury in 
vivo.  Aggrecan acts through receptors on the neurite membrane to activate downstream 
signalling by ROCK subsequently resulting in neurite retraction and loss of neurite 
outgrowth.  Activation of the same signalling cascade is known to occur in vivo, providing 
potential targets for inhibitors that can overcome activation of this cascade.   
Recent studies have focussed on inhibiting p160 ROCK using small molecules such as Y-
27632 [155, 164]. Inhibition of ROCK resulted in recovery of neurite outgrowth and 
allowed the neurties to develop on and through inhibitory CSPG substrates.  To determine 
if in our model ROCK inhibition by Y-27632 can overcome Aggrecan induced neurite 
outgrowth inhibition as has been published previously [155]; a concentration profile of Y-
27632 and an assessment of neurite length and number were performed.  The data from 
this study demonstrated that incorporation of Y-27632 to neurites that are inhibited by 
Aggrecan results in enhanced neurite outgrowth both in the length and number of neurites 
(Figure 4-22). This is similar to published data and demonstrates consistency in our model 
and with current literature. Chan, C.C et al (2008) [155] demonstrated that both Aggrecan 
aggregates and monomer inhibited neurite outgrowth from E9 chick DRG cells and Lingor, 
P et al (2007) [159] used an embyonal carcinoma (hEC) stem cell model of human neurite 
outgrowth to demonstrate inhibition by a mixture of CSPG proteins. The hEC cells were 
NTERA2.cl.D1 and were differentiated for 21 days by 10 µM ATRA. Data from this study 
demonstrated 20 % neurite outgrowth from aggregates grown on a 20 µg/ml CSPG 
substrate (with poly-lysine and 20 µg/ml Laminin).  Unlike work in this Chapter, 
NTERA2.cl.D1 cells were differentiated as a monolayer and allowed to aggregate after 
differentiation, however, poor neurite outgrowth was observed in the control cultures, 
partly due to the use of Phalloidin to stain and quantify neurite outgrowth.  Furthermore, 
using this model the group demonstrated recovery of neurite outgrowth on CSPG by the 
treatment of 10 µM Y-27632. The optimised protocol in this Thesis and the use of stable 
small molecules provided a unique method for producing human neurites which 
demonstrated loss of neurite outgrowth specifically induced by Aggrecan and recovery by 
the ROCK inhibitor Y-27632.  
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AC261066 
Multiple articles have demonstrated the role of RAR β2 in developing axons and 
regenerating neurites.  Different methods have been used to enhance or investigate this 
receptor in developing axons including small molecule agonists [238], viral vectors 
containing the gene for RAR β2 [172] and receptor knock out models [286].  Puttagunta, R 
et al (2011) [286] demonstrated in mouse cerebellar granular neurons RAR β2 up-
regulation and retinoid treatment could overcome a specific myelin induced neurite 
inhibition, and this was not seen when the neurites were grown on CSPG.  The reason up-
regulation of this receptor did not overcome CSPG induced neurite inhibition in this study 
may be neuron specific or require a more specific activation of the receptor by small 
molecules that only act on the RAR β2 receptor.  In our study the highly potent RAR β2 
agonist AC261066 was used to enhance neurite outgrowth in our model of Aggrecan 
induced inhibition.  Data demonstrated that the application of AC261066 enhanced neurite 
length and number in our human model (Figure 4-24).  Another way this receptor pathway 
may overcome neurite inhibition by proteins such as Aggrecan is through up regulation of 
the Laminin receptor. It has been demonstrated that in retinoic acid and nerve growth 
factor responsive neurites that neurite outgrowth is enhanced on Laminin through up 
regulation of α1β1 [255, 287], which can be determined in future studies using the model 
described in this Chapter.  
CHIR 99021 and XAV 939 
Since it has been shown that RAR β2 activation acts to activate AKT [238], and it is known 
that AKT can inhibit GSK3β modulating multiple downstream molecules associated with 
neurite outgrowth and cytoskeletal integrity [264] regulation of the GSK, AKT pathway 
was investigated.  Literature suggests that inhibition of GSK3β may enhance neurite 
outgrowth [177, 288], however, there is also evidence to suggest that activating GSK 3β 
pathway/ the WNT pathway can overcome neurite inhibition and enhance regeneration 
[163, 289].  Kawakami, Y et al (2006) [289] demonstrated that Wnt signalling is necessary 
for regeneration axolotl, Xenopus and Zebrafish, furthermore, signalling of this pathway 
can enhance regeneration in these model systems. There is conflicting data as to the role of 
this signalling pathway in neurite regeneration and these will likely be due to differences in 
the models and methods used to investigate the pathway.  
In this study, stabilisation of the GSK 3β enzyme complex via Tankyrase inhibition using 
the small molecule XAV 939 resulted in enhancement of neurite outgrowth on an 
Aggrecan substrate (Figure 4-29).  This small molecule has been shown to enhance the rate 
of myelination after CNS demyelinating injury in mouse spinal cord, indicating at its 
220 
 
 
biological activity and potency, further associating GSK 3β enhancement with regeneration 
[290].  In addition, inhibition of GSK3β post treatment with the small molecule 
CHIR99021 resulted in loss of outgrowth on a Laminin only substrate Figure 4-26, this 
could not be overcome by ROCK inhibition Figure 4-27.  These data agree with multiple 
studies that Wnt signalling is important for enhancing neurite outgrowth and it does so via 
a non-ROCK associated pathway.  Therefore these data suggest in human stem cell derived 
neurons; activation of GSK3beta can overcome Aggrecan induced neurite retraction.  
PTP IV inhibition 
The neural protein tyrosine phosphatase receptor σ for Aggrecan was discussed earlier and 
is known to be one example of how CSPGs influence neurite outgrowth.  Binding of the 
GAG side chain attached to the core protein of Aggrecan to this receptor results in 
activation of a second messenger system involving RhoA and ROCK as described 
previously [1, 149].  It was hypothesised that inhibition of the enzyme PTPσ by the small 
molecule inhibitor  PTP IV could prevent the downstream activation of the second 
messenger that result in growth cone collapse and neurite retraction.  Studies recently have 
associated ROCK inhibition with an increase in astrocyte production of CSPG, thus raising 
the question if the effect of ROCK inhibition on neurite regeneration would be overcome 
by the increased CSPG production in vivo [155].  Using our described model of Aggrecan 
induced neurite inhibition a concentration dependent recovery of neurite length and 
number was demonstrated in the presence of PTP IV inhibition.  Although the PTP IV 
inhibitor inhibits the PTP σ receptor, its selectivity for this specific receptor and potency is 
limited and for therapeutic application would need to be more potent and much more 
selective.  
Chondroitinase ABC 
In addition to small molecule manipulation of receptor signalling pathways initiated by 
Aggrecan, work has recently focussed on utilising a bacterial enzyme that cleaves the GAG 
side chains of CSPGs [267].  Cleavage of GAG results in loss of ligand binding to 
receptors on neurite, facilitating neural regeneration and development.  Most studies have 
utilised animal models of spinal cord injury to investigate the ability of the enzyme 
chondroitinase ABC to overcome inhibition of neurite outgrowth by the glial scar, for 
example Hunanyan, A.S et al (2010) [291] used chronic unilateral hemisection of adult rat 
spinal cord to investigate the rescue of axonal conduction by Chondroitinase ABC 
injections, the enzyme did indeed rescue neurite function in this model.  However, due to 
the many physiological processes that occur during reactive gliosis and neurite 
regeneration it is unknown if the enzyme acts to prevent the biological activity of CSPGs 
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on neurites or if cleavage of GAG from CSPGs induces a secondary response such as 
angiogenesis, which may facilitate removal of CSPG aiding neural regeneration.  Other 
studies have described regeneration of neurites in injured spinal cord after Chondroitinase 
ABC treatment [292], furthermore, since the full effects of CSPGs in the glial scar are not 
fully elucidated it may be that intervention at this level will provide the most regenerative 
therapies. In the model described in this Chapter, although some survival factors will be in 
the serum in the culture medium the model simplifies the investigation of Aggrecan on 
neurite outgrowth.  Enhanced neurite outgrowth in this model is through a direct effect on 
either Aggrecan or the signalling cascade induced by Aggrecan.  Data from this Chapter 
demonstrated that pre-treatment of Aggrecan coated plastic with chondroitinase ABC 
overcame a significant level of neurite outgrowth inhibition induced by Aggrecan (Figure 
4-33).  These data suggest that the role of chondroitinase ABC in regeneration of the spinal 
cord is to prevent CSPG signalling via GAG cleavage, these data do not rule out further 
effects from increased angiogenesis or immune cell chemo taxis.  These results agree with 
previous in vivo studies that demonstrate recovery of neurite outgrowth post-CNS trauma 
by Chondroitinase treatment [267, 269, 293]. 
The study so far has demonstrated how small molecules can be used to interact with 
different parts of the signalling cascade that occurs when neurons are grown on an 
Aggrecan substrate.  By inhibiting or activating different mediators of the cascade a 
reduction of inhibition of the effect of Aggrecan is achieved.  This provides useful data 
into the role of Aggrecan in human neurons after traumatic spinal cord injury.  Figure 4-39 
is a schematic describing the interaction of small molecules and the signalling cascade that 
occurs after during Aggrecan induced neurite inhibition.  
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Figure 4-39 A schematic of Aggrecan induced neurite inhibition and small molecule modulators of the signalling cascade induced. The artificial ECM 
produced by the reactive astrocyte can be simulated using purified protein.  In this schematic different levels of the signalling cascade can be inhibited using enzymes 
and small molecule modulators. Inhibition of the RhoA-ROCK signalling cascade can be achieved through a number of mechanisms such as RAR β2 agonists, 
ROCK inhibitors, Chondroitinase pre-treatment and PTPσ inhibition.  Enhancing GSK 3β signalling using the small molecule XAV 939 also resulted in neurite 
outgrowth on Aggrecan (A), in contrast inhibition of GSK 3β by CHIR 99021 resulted in loss of neurite outgrowth on a permissive Laminin substrate (B). Regulation 
of different parts of the Aggrecan induced signalling cascade by small molecules is a potential therapeutic for spinal cord injury, and may require multiple targets to 
act in synergy depending on the extent of injury.  
 
A B 
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4.4.5 Neural-glial co-culture and neurite inhibition 
 
In vitro co-culture between neural and other cells of the CNS is important for elucidate key 
molecular interactions including enchantment of neural survival and neurite outgrowth or 
inhibitory consequences on neurite development from other cells.  The interaction between 
two cell types may be through contact such as cell membrane associated proteins, or 
through the excretion of proteins/chemical mediators into the matrix surrounding the cells.  
In the case of the ‘reactive astrocyte’, excretion of ECM proteins inhibitory to neurite 
regeneration and survival results an interaction between the two cell types and results in 
sustained damage to the organism.  Model systems to investigate cell-cell interactions after 
often limited by the availability of the cells, media requirements (which must be the same 
for co-culture) an ability to distinguish the cell types and growth rate. 
To model the neural-glial interaction in conventional 2D culture the astroglioma cell line 
U118MG was used in co-culture with the human stem cell-derived neurons. U118MG is a 
human astroglioma and represents a model of human astroglioma cells.  This cell line was 
chosen due to the adherent nature and good growth on Laminin/P-D-L, furthermore, the 
media requirements for both the neural and U118MG cells was the same.   
The astroglioma cell line U118MG was co-cultured with human stem cell derived neurons 
as described in this Chapter.  The presence of U118MG was sufficient to visually inhibit 
neurite outgrowth from human stem cell derived neuroprogenitors, indicating either a 
mechanical barrier to neurite outgrowth or a receptor mediated response; it may be that the 
presence of U118MG mask Laminin epitopes for integrin binding. It was demonstrated 
that by addition of Y-27632 an observable amount of neurite outgrowth was recovered.  
These data indicate a possible receptor mediated inhibitory affect by U118MG on the stem 
cell-derived human-neural cells.  It may be that U118MG cells are representative of a 
‘reactive astrocyte’ like phenotype, this could be demonstrated by determining the protein 
composition of the ECM surrounding U118MG.  It is known that ‘reactive astrocytes’ 
inhibit neurite outgrowth and induce neurite retraction by the production of CSPG’s and 
other ECM proteins [141], if this was also shown in U118MG it would suggest a similar 
mechanisms of neurite inhibition.  Furthermore, it was shown by Chan, C.C et al (2007) 
[155] that ROCK inhibition induced a change in CSPG processing resulting in an increase 
in production of chondroitin sulphate proteoglycans and further loss of neurite outgrowth, 
these affects were overcome by Chondroitinase ABC treatment.  Data from this work 
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demonstrated that ROCK inhibition resulted in a decrease in CSPGs in cell culture media 
or cerebrospinal fluid [155].  Results in this thesis demonstrate that it is likely the 
U118MG cells have CSPGs on their membrane surface, as has been suggested in studies 
on other glial cell lines such as the expression of the CSPG Vesican by U87MG and A172 
[294]. Furthermore, it is known that the proteoglycan Endocan is expressed by U118MG 
and may be responsible for some of the neurite inhibition demonstrated in the co-culture 
model [295]. In this Chapter an increase in CSPG immunoreactivity was demonstrated 
after Y-27632 or AC261066 treatment and this correlated with an increase in Brevican 
mRNA expression. It is likely that combinations of multiple proteoglycans were expressed 
by U118MG, Brevican, has been shown to be produced by high grade astrocytoma cells 
and is involved in invasion of the tumour.  Furthermore, Brevican was expressed on the 
membrane of astrocytoma and was excreted into the ECM [296]. 
A visible increase in CSPG was shown after treatment with Y-27632, but Y-27632 was 
sufficient to stabilise the neuronal cytoskeleton and overcome inhibition of neurite 
outgrowth to some extent even in this highly inhibitory environment.  Up-regulation of 
CSPG protection by Y-28632 is a known phenomenon but does not hinder the neurite 
forming effects of ROCK inhibition [155].  There was no detection of Aggrecan expression 
in protein lysate from U118MG as measured by a specific and quantitative ELISA.  This is 
interesting, however, consistent with the cartilage [297] and peri-neuronal net [298] 
restricted expression of Aggrecan, but it would be expected that ‘reactive astrocytes’ 
express this protein at least to some level consistent with its presence in the glial scar.  
The data from this section demonstrates the co-culture of two individual cell lines; 
however the quantification of this was made difficult due to the presence of the second cell 
line and increased network formation/neurite crossover close to the neural aggregate. As 
this is a model of co-culture it is suggested that more suitable cell types can be used in 
conjunction with our human neurite outgrowth model.    Primary glial/astrocytes cells can 
be derived from animal tissue; however, the species differences may be apparent.  Recently 
Guo, Y et al (2013) [299] used primary rat hippocampal astrocytes in a co-culture model 
with neural stem cells and Shi, M et al (2013) [300] co-cultured rat brain derived glial cells 
with rat hippocampal neurons.  It is also possible to compare astrocytic cells from a glial 
scar and those in a normal physiological environment, however, human tissue is difficult to 
obtain and so the ability to derive neural tissue from stem cells will provide a consistent 
and reliable source of human tissue.  
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4.5 CONCLUSION 
 
This Chapter has described the development of a robust and reliable human neurite 
outgrowth model using human stem cells and synthetic retinoids.  The Chapter exemplified 
the use of EC23 over ATRA and described in detail the neural progenitors that developed 
from using EC23. The temporal and concentration dependent use of these small molecules 
was an important factor throughout this Chapter.  
The defined model of human neurite outgrowth was used to investigate neurite inhibition 
in response to key characteristics of the glial scar that forms post CNS injury.  In this 
model the glial scar CSPG proteins demonstrated inhibition of human neurite outgrowth.  
Furthermore, utilising this system to investigate small molecule modulation of the 
inhibitory effect of the CSPG Aggrecan revealed a number of compounds capable of 
enhancing neurite outgrowth.  Specifically, the inhibition of PTP IV inhibition was found 
to be a novel way of inducing regeneration in this environment. 
Finally, a simple co-culture method was described using human stem cell derived neural 
progenitors and a human astroglioma cell line (U118MG).  Data demonstrated the 
inhibition of neurite outgrowth in the presence of U118MG, which could be partially 
recovered by p160 ROCK inhibition.  
Future work involving the use of this aggregate model of synthetic stem cell differentiation 
will include translation into a more physiologically relevant 3 dimensional (3D) method of 
neurite outgrowth and 3D co-culture, which is discussed in Chapter 5.  
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CHAPTER 5 INVESTIGATION OF NEURITE INHIBITION USING A 
NOVEL 3D MODEL OF SPINAL CORD INJURY 
 
5.1 INTRODUCTION 
 
5.1.1 The developing glial scar 
 
The dynamic structure that develops through a process of reactive gliosis post CNS injury 
and comprises the glial scar has been demonstrated to induce growth cone collapse and 
neurite retraction from CNS neurons.  Furthermore, the physical presence of the scar and 
the inhibitor signals in the extracellular matrix (ECM) results in an environment not 
permissible to neurite regeneration [301] . The scar that forms is made up of a few key 
areas, including the lesion cavity, levels of increasing proteoglycans and the glial limitans 
composed of Reactive Astrocytes and Fibroblasts [302]. The reactive astrocytes produce a 
range of supportive ECM proteins that are both permissive and inhibitory to neurite 
survival and regeneration making the dynamic interplay between the local environment 
and damaged neurons key in neural regeneration studies.  It is the ratio between permissive 
and inhibitory ECM molecules that determines the response of the neurite to its 
environment and ultimately regulates neurite regeneration and functional recovery.  
Furthermore, death of the neurite results in an immune response leading to inflammation, 
secondary destruction and further neurite degeneration induced by myelin fragments such 
as myelin associated glycoprotein (MAG) [260, 303, 304]. 
Although some regeneration can occur in the CNS giving rise to the hypothesis that 
neurons in the CNS have the ability to regenerate, overall the regenerative capability of 
damaged CNS is inhibited by the glial scar [305].  Degeneration of neural tissue results in 
loss of innervation and depending on the level of the CNS at which injury occurs a grade 
of paralysis is likely in the patient.  The regenerative capability of damaged neurons is 
dependent on the local microenvironment.  It is thought that unlike in the PNS the essential 
growth enhancing molecules required to induce the gene profile required for regeneration 
are not present in the CNS [306].  Small molecule modulators of cell signalling may offer 
an attractive method of inducing these genetic responses or can inhibit the inhibitory 
signals provided by the glial scar [307].  The 3D microenvironment surrounding each 
regenerating and degenerating neurite is pivotal to how the neurite responds after injury. 
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Understanding the interaction of developing neurites in this 3D environment may lead to 
advances in treatment at an early stage of injury. 
5.1.2 Stem cells and human neurite outgrowth studies 
 
With the growing knowledge of stem cell biology and enhancements in the manipulation 
of stem cells to form tissue of interest, the ability to use human neurons derived from stem 
cells has made in vitro neurobiology much more relevant to humans.  Furthermore, as 
understanding of neural subtype selectivity, functional neurobiology and neural/non-neural 
interactions develop, more complex assays are available that can answer questions directed 
at specific areas of the nervous system.  Stem cell derived neural progenitors can be 
produced to specifically investigate one neural subtype; furthermore, the age of neuron can 
also be manipulated.  Combining stem-cell differentiated neurons and biomaterials that 
express specific ECM proteins relevant to a particular disease or pathology will result in 
the ability to ask very specific questions in neurobiology.  Although conventional 2D 
culture has been able to elucidate some key pathways of the in vivo system a more 
physiological 3D model system may provide a closer match to that experienced by cells in 
vivo.   
5.1.3 Physiologically relevant neurite outgrowth assays 
 
Development of physiologically relevant model cell systems for investigating small 
molecule modulation of neurite outgrowth and regeneration is necessary to bridge the gap 
between basic biology, therapeutics and clinical treatment.  Utilising relevant and specific 
in vitro cultures that closely represent the in vivo environment is important for reducing 
unnecessary animal usage in research and limiting the number of failures that occur at each 
stage of a clinical trial.  2D stem cell culture has been utilised as a first step in the research 
of small molecules with potential therapeutic application [308].  However, studies have 
suggested that the response of 2D tissue to its environment is far removed from the 
physiological 3D matrix.  There are many limitations of 2D cell culture model systems, 
including a difficulty to co-culture with other cell types, limited 3D structure formation and 
the extra cellular matrix (ECM) is only affective on one linear plane resulting in 
cytoskeletal and architecture changes which would not be representative of the in vivo cell 
shape or function [309-311]. 
The advantage of growing cells in a 3D environment has been exemplified for multiple cell 
systems.  Advantages of 3D over 2D culture include; more physiologically relevant protein 
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and gene expression profiles; robust stem cell differentiation protocols; regulation over 3D 
ECM protein coating and co-culture of different interacting cell types.   
3D cell culture and neurite development models often use gel-based systems such as 
hydrogel and Matrigel™ to create an artificial extracellular matrix microenvironment which 
often utilises Collagen I fibres or mixtures of Laminin, P-D-L and Collagen.  These 
cultures are permissive to neurite outgrowth and allow for the development of neurites.  
Cultures using these models tend to utilise peripheral nervous system neurons such as 
DRG [96] and PC12 cells, as well as neuroblastoma (SH-SY-5Y) [123].  These neural 
models do not recapitulate the in vivo development of CNS neurons.  Few studies have 
used stem cell-derived neuroprogenitors for neurite outgrowth studies in 3D due to the 
complexity of the assay.  In this study the combined use of small molecules, 3D scaffolds 
and stem cells has allowed for a defined, reproducible, physiologically relevant model of 
human neurite outgrowth.  
The scaffold using in this study well described for culturing cells in 3D.  Alvetex®Scaffold, 
a 200 µm thick porous polymer made from styrene monomers.  The scaffold can be treated 
as conventional 2D plastic making 2D/3D cell culture comparisons routine.  (see Chapter 1 
for a review of literature on 3D neurite outgrowth models) .  
Aims  
 
This Chapter aims to translate the 2D neurite outgrowth model described in Chapter IV to 
3D using Alvetex®Scaffold and use this 3D model to investigate inhibition of neurite 
outgrowth by Aggrecan.  Furthermore, this study aims to translate the small molecule 
effectors described in Chapter IV into the more physiologically relevant 3D model.   The 
study will utilise the 3D environment to assess the effect of co-culturing human stem cell 
derived neurons and glial cells. Based on previous reports/review of literature it is 
hypothesised that neurite inhibition by the glial scar observed in vivo can be replicated in a 
novel neuro-glial in vitro model. 
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5.1.5 Specific objectives 
 
 Develop a more physiologically relevant model of neurite outgrowth using a 3D 
scaffold. 
 Create a cell-based assay to investigate the interaction of neurons and glia in 3D. 
 Investigate the small molecule modulation of neurite outgrowth in 3D. 
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5.2 METHODS 
5.2.1 Aligned Scaffold  
 
In collaboration with Dr R Shah, Durham University, Chemistry Dept an Aligned Scaffold 
was produced by the following procedure: 
Polymer solutions for electrospinning were prepared by dissolving polystyrene (Aldrich 
Chemical Inc, USA; Typical Mn -170,000, Typical Mw -170,000, Melt index 2.00 – 4.00 
g/10 min (200°C/5.0 kg, ASTM D1238) in a 3:1 ratio of THF: DMF at a concentration of 
30 % (w/v). The polymer solution was placed in a 10 ml syringe with a blunt metal needle 
(30 Gauge) attached. The syringe was connected to a syringe infusion pump (KDS 100, 
KD Scientific Inc, Holliston, MA01746, USA) which controlled the flow rate (2 ml/hour) 
of the polymer solution and a positive voltage was applied to the needle tip. A high voltage 
power supply (Gamma High Voltage ES 30P, Gamma High Voltage Research, Florida, 
USA) was used to generate the potential difference from 18 kV. The fibres were collected 
on aluminium foil covering the rotating drum collector. The uniform poly(styrene) based 
uniform electrospun scaffold for cell culture was synthesised by layer by layer collection 
method on the rotating drum collector at a speed of 1165 rpm (rotation per minute) at tip-
to-collector distance of 30 cm with total continuous collection time of 40 minutes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Electrospinning rig for producing aligned scaffolds.  
A B 
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5.2.2 Coating of aligned electrospun polymer  
Aligned electrospun scaffolds were carefully peeled off the conductive aluminium mat and 
washed 3 x in 70 % ethanol.  Scaffolds were then coated overnight with 10 µg/ml 
Laminin/P-D-L in PBS.  After 24 hours coating with Laminin and P-D-L scaffolds were 
washed 3 x in PBS and remained in PBS until they were required.  
5.2.3 Neurite outgrowth on Aligned electrospun scaffolds 
Differentiated aggregates were 100 µm filtered and back washed into a fresh Petri dish 
with fresh media prior to seeding onto the Laminin/P-D-L coated scaffold. Aggregates 
were seeded at a density of 10-20 per aligned scaffold and cultured for 10 days in DMEM 
with 10 % foetal calf serum, 2 mM L-glutamine (Sigma,G3126), 100 active units of 
Penicillin and Streptomycin (Invitrogen, 15070-063) and the mitotic inhibitors : 10 µM 
5’fluoro’2’deoxyuridine, 10 µM Uridine and 1 µM Cytosine-arabinoside.  Media was not 
changed.  After 10 days cells were fixed with 4 % PFA for 1 day and then washed 3 x in 
PBS and imaged using confocal microscopy.  
5.2.4 Co-culture using Aligned electrospun scaffolds 
1. For neural/glial co-culture at day 14 aggregate differentiation begin culture of 
U118MG cells in 2D as described in Chapter 2. One confluent flask contains 
around 6 x 106 U118MG cells and takes around 3-4 days to become confluent. 
2. Plasma treat and coat Aligned electrospun scaffold  as described above with 10 
µg/ml Laminin/P-D-L  
3. Filter and backwash neurospheres as described above for neurite outgrowth study at 
day 21 
4. Prior to seeding the differentiated aggregates 1x106 U118MG cells in suspension 
were seeded in 100 µl DMEM:FBS on top of the scaffold and allowed to settle for 
15 minutes at 37 °C .  
5. Take 5-10 neurospheres in 100 µl media and add to each well as necessary 
6. Add 2 ml of DMEMFGP containing mitotic inhibitors (10 µM 
5’fluoro’2’deoxyuridine, 10 µM Uridine and 1 µM Cytosine-arabinoside) to each 
well and culture at 37 °C, 5 % CO2 in a humidified atmosphere for 10 days (do not 
change the media during this time, as this affects neurite growth).  
7. Fix cells for 1 hour in 4 % PFA and wash 3 x in DPBS.  
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5.2.2 3D neurite outgrowth Alvetex®Scaffold assay 
 
The 3D neurite outgrowth assay utilised plasma treated and extracellular matrix (ECM) 
coated Alvetex®Scaffold to create a 3D environment permissible of neurite outgrowth.  
Prior to ECM coating the scaffold plasma treatment was necessary to prime the Scaffold 
making it hydrophilic. 
5.2.3 Plasma treatment of polystyrene scaffolds 
 
Plasma treatment of Polystyrene scaffolds is used to coat the polymer with a layer of 
highly charged oxygen plasma.  Coating is used as a procedure to remove fungal 
contamination and to create a hydrophilic surface for cell adhesion.  
On day 20 aggregate differentiation 12 well inserts of Alvetex®Scaffold were plasma 
treated using the Emitech K1050X Plasma Asher with the following parameters using the 
up and down buttons on the front of the Plasma treater (circled): 
 
 RF power level-40 Watts 
 Ashing time-5 minutes 
 Bleed delay-15 seconds 
 Process Gas-as appropriate 
 Vent valve -Unrestricted 
 Restrict vent time-120 Seconds 
 Pump spin down time -15 Seconds 
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 Vent hold time -0 Seconds 
 Gas shutoff time- 10 Seconds 
 Turbo pumping enabled-0  
After setting the parameters load your plate containing Scaffolds without the lid on and 
press start.  
5.2.4 ECM coating and cell culture 
 
After plasma treatment Alvetex®Scaffold was completely submersed in 10 µg/ml Laminin 
and P-D-L in PBS for 24 hours and then washed 3 x in PBS. This procedure coated the 
Scaffold in the ECM proteins making the hydrophilic scaffold permissive and stimulatory 
of neurite outgrowth.  
5.2.5 Aggrecan coating Alvetex®Scaffold   
 
To make up a 50 µg/ml Aggrecan coating solution, 1 mg of Aggrecan was dissolved in 1 
ml PBS and added to 19 ml of 10 µg/ml (Laminin and P-D-L).  This solution was then 
stored at -20 °C prior to use. 
To coat Alvetex®Scaffold with the above solution follow the steps above but replace the 
submersion step with the Aggrecan coating solution.  
5.2.6 Neurite outgrowth in 3D using Alvetex®Scaffold   
 
Differentiated aggregates were 100 µm filtered and back washed with fresh media prior to 
seeding onto the Laminin/P-D-L coated plastic.  Aggregates were seeded at a density of 
10-20 per scaffold and cultured for 10 days in DMEM with 10 % foetal calf serum, 2 mM 
L-glutamine (Sigma), 100 active units of Penicillin and Streptomycin (Invitrogen) and the 
mitotic inhibitors: 10 µM 5’fluoro’2’deoxyuridine, 10 µM uridine and 1 µM cytosine-
arabinoside.  Media was not changed.  After 10 days cells were fixed with 4 % PFA for 1 
day and then washed 3 x in PBS.  Neurons within and on top of the scaffold were stained 
for TUJ-1 and DAPI and then the whole scaffold imaged using confocal microscopy (488 
and 405 nm excitation) or the scaffold was wax embedded, sectioned and then stained as 
described in Chapter 2. Sections can then be imaged using a fluorescence or confocal 
microscope.  
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5.2.7 3D glial-neural co-culture assay 
 
8. For neural/glial co-culture at day 14 aggregate differentiation begin culture of 
U118MG cells in 2D as described in Chapter 2. One confluent flask contains 
around 6 x 106 U118MG cells and takes around 3-4 days to become confluent. 
9. Plasma treat and coat Alvetex®Scaffold  as described above with 10 µg/ml 
Laminin/P-D-L  
10. Filter and backwash neurospheres as described above for neurite outgrowth study at 
day 21 
11. Prior to seeding the differentiated aggregates 1x106 U118MG cells in suspension 
were seeded in 100 µl DMEM:FBS on top of the scaffold and allowed to settle for 
15 minutes at 37 °C .  
12. Take 5-10 neurospheres in 100 µl media and add to each well as necessary 
13. Add 2 ml of DMEMFGP containing mitotic inhibitors (10 µM 
5’fluoro’2’deoxyuridine, 10 µM Uridine and 1 µM Cytosine-arabinoside) to each 
well and culture at 37 °C, 5 % CO2 in a humidified atmosphere for 10 days (do not 
change the media during this time, as this affects neurite growth).  
14. Fix cells for 1 hour in 4 % PFA and wash 3 x in DPBS.  
5.2.8 Chondroitinase ABC enzyme buffer and dilution 
 
Chondroitinase ABC (Sigma Aldrich C3667), from Proteus Vulgaris was reconstituted 
with 1 ml of 0.1 % BSA (Sigma Aldrich A7906) giving a concentration of 5 units/ml.  
Stock solution was diluted in enzyme buffer to 0.15 units/ml by adding 30 µl stock to 970 
µl buffer, a total of 1 ml was added to each well being treated.  
Enzyme buffer consisted of: 
 0.02 % BSA 
 50 mM TRIS pH8  
 60 mM Sodium acetate (Sigma Aldrich) 
 PBS w/o Ca++, Mg++ 
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Treatment of Aggrecan coated plastic with Chondroitinase ABC: 
1. Alvetex®Scaffold was plasma treated and coated with Aggrecan, P-D-L and 
Laminin as described above 
2. Wash Alvetex®Scaffold  with PBS x 3 after ECM coating 
3. Add 1 ml of either Chondroitinase buffer (control) or buffer containing 0.15 
units/ml enzyme to each well ensuring scaffold is completely submerged 
4. Incubate for 1 hour at 37 °C, 5 % CO2 
5. After 1 hour incubation wash 3 x with PBS and follow the procedure for neurite 
outgrowth from differentiated TERA2.cl.SP12 aggregates.  
 
5.2.9 Primary embryonic mouse cultures 
 
As a collaboration with the University of Reading (Dr B Whalley and Dr I Smith) human 
and mouse neurons grown in 3D using Alvetex®Scaffold coated with Aggrecan.   
Brain dissection from 14-16 day old Swiss mouse embryos 
Recuperation of the Vitellin bag (membrane that surrounds the individual mouse embryos)  
- Soak the abdomen of the mouse with ethanol to sterilize  
- Hold up the skin with the forceps and cut/open the abdominal cavity with scissors 
- Recover the vitellin bag that contains the embryos by cutting away the membrane 
- Place the vitellin bag in a 50 ml falcon tube containing PBS/Glucose 33 mM 
Recuperation of embryos 
- Hold the embryos by the placenta and open the bag with scissors 
- Place the embryos in a petri dish containing PBS/Glucose 33mM 
Decapitation of the embryos 
- Hold the embryos in the middle with forceps, decapitate the embryos by cutting 
behind the head 
- Place the heads in a Petri dish containing a solution of PBS/Glucose 33 mM and 
wash 
- Transfer heads into a new Petri dish containing PBS/Glucose 33 mM 
Stabilisation of the heads under microscopes 
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- Using fine forceps, put an embryo head under the microscope with its eyes facing 
towards the left, so the back of the brain is on the right 
- Stabilize the head by planting the two points of the forceps in the embryo’s eyes, do 
not squeeze too hard 
Liberation of the brain 
- To release the brain, carry out three incisions using fine scissors: one lateral 
incision across the back of the head, about 2 cm of the way up, and one either side 
of that first incision. 
- Release the brain by placing the scissors behind the cortices and gently push 
towards the incision.  
- Place the brain in a new petri dish containing a solution of PBS /Glucose 33 mM 
Dissociation of the cortices 
- Cut out the cerebellum and separate the two hemispheres 
- Remove the striatum 
- Remove meninges with forceps. If needed, use fine scissors to remove them 
Mechanical dissociation of cells 
- Smooth a Pasteur pipette using fire and coat the pipette with sterile Heat inactivated 
FBS 
- Place cortices in a 15 ml sterile falcon tube and add 5 ml PBS/Glucose 33 mM 
- Dissociate cells by slowly and gently pipetting up and down 30-40 times 
- Add PBS/Glucose 33 mM to a final volume of 12  ml 
- Dissociate the cells in this volume 
- Wait  a few minutes for the non-dissociated elements form a deposit 
- Centrifuge at 950 rpm (200 g) for 5  min at room temperature 
- Aspirate supernatant carefully so that the pellet is not disturbed 
- Alvetex®Scaffold in either 48 well or 96 well discs were ethanol wet using 2 x 70 
% ethanol washes and 1x PBS wash.  
- Scaffolds were coated with Aggrecan as described before prior to serum coating. 
- After coating/ethanol wetting the discs were washed in 3 x PBS and 1 x 
DMEM:F12 . 
- Scaffolds were left overnight in DMEM:F12 +  10 % FBS 
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- Freshly dissociated mouse cortical neuroprogenitors were seeded on to 
Alvetex®Scaffold at a concentration of 200,000 cells/cm2 
Freshly dissociated mouse cortical neuroprogenitors were seeded on to Alvetex®Scaffold at 
a concentration of 200,000 cells/cm2 
5.2.10 Primary human neuronal cultures 
 
- 0.5 cm Alvetex®Scaffold discs were ethanol wet using 2 x 70 % ethanol washes 
and 3 x HBSS washes. Circles were not allowed to dry. 
- Scaffolds were the coated with either 1 ng/ml or 10 µg/ml Aggrecan as described 
previously. 
- The scaffolds were then washed 3 x in HBSS (Lonza, BE10-508F) and coated with 
1 x DMEM:F12 (Lonza, BE12-719F). 
- Scaffolds were then incubated at 37 °C until cell seeding, in 10 % Human AB 
donor serum (Labtech, male - HU-490, female - HU-463) made up as 10 % v/v in 
DMEM-F12 with 10 µg/mL gentamicin sulphate (Lonza, BE02-012E). 
- Prior to cell seeding 50 µl NPMM (Lonza kit CC-3329 + 20 ng/ml rh EGF 
(Preprotech AF-100-15) and bFGF (Preprotech 100-18B) was added to each well 
and incubated to equilibrate.    
- P8 human normal mesencephalon neuroprogenitors (originally P1 Lonza, PT-2599) 
were seeded at 15,000 cells/cm2 (96 W) in NPMM.  Media was exchanged 50 % the 
next day and every other day for the next 5 days.  
- Human neurons were differentiated by exchanging 50 % media containing BDNF 
(Preprotech, 450-02) instead of EGF and bFGF. Cells were maintained for 25-35 
days before electrical activity was measured using MEA.  
5.2.11 Multi electrode array (MEA) 
 
- Primary cells were maintained and differentiated as described in 5.2.12 and 5.2.13. 
- Cells were rested on the MEA for 10 minutes 
- Basal MEA recordings were for 10 minutes 
- Drugs were added directly to the MEA for 5 minutes individually with 5 minutes 
rest and 10 minutes basal recording between each drug.  
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- The drugs used were: 20 µM CNQX and 100 µM DLAP5 10 µM tetrodotoxin 
citrate (TTX, ABCAM).  TTX was stored at -20 °C in the appropriate solvent at 
manufacturer’s recommendations. 
- Data was analysed in 300 second blocks and compared for a mean firing rate (Hz). 
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5.3 RESULTS 
 
5.3.1 Neurite outgrowth in 3D 
 
An advantage over other 3D Scaffolds and hydrogels is the ease at which the 
Alvetex®Scaffold matrix can be manipulated.  The scaffold can be coated to contain 
extracellular matrix proteins through the coating procedure described in the Methods 
section.  Coating the scaffold was used to investigate the 3D development of neurite 
outgrowth from stem cell-derived neural progenitor aggregates.   The scaffold was used to 
assess the 3D growth and differentiation potential of neuroprogenitors derived from 
TERA2.cl.SP12 cells treated with 0.1 µM EC23 for 21 days.  Differentiated aggregates 
were placed on a 200 µm thick Alvetex®Scaffold and cultured for 10 days in the presence 
of mitotic inhibitors. The cells were then fixed in 4 % PFA, wax embedded, sectioned and 
stained by H & E to determine the level of penetration of cells into the Scaffold.  H & E 
stained slides also gave an indication to if any neural tissue was present either within the 
aggregate or in the Scaffold. Neural tissue can be distinguished in these cultures by the 
structures that develop such as neural rosettes or highly fibrous cytoplasmic areas.  
Data in Figure 5-2 demonstrates the need for ECM coating Alvetex®Scaffold to ensure 
good cellular penetration and 3D growth.  The Scaffold in Image (A) was plasma treated 
and therefore represented a hydrophilic scaffold, growth of aggregates on the scaffold after 
10 days demonstrated very few cells in 3D and no structural evidence of developing neural 
tissue; there was also loss of aggregate from the surface indicating poor attachment to the 
scaffold.  Therefore further functionalization of the scaffold was necessary to induce 3D 
neurite outgrowth form the neural progenitor aggregates. 
To assess the role of Laminin/P-D-L in 3D neurite outgrowth and maintenance the 
Alvetex®Scaffold was coated in 10 µg/ml Laminin/P-D-L for 24 hours.  Laminin has been 
demonstrated to stimulate neurite outgrowth [287, 312] and P-D-L is often the coating 
choice for enhancing cell adhesion, a combination of both would provide a good ECM 
within the scaffold to support neurite outgrowth and development and has been 
demonstrated to be the optimal coating procedure for neurite outgrowth from embryonic 
stem cells [113].   Coating resulted in an increase of cytoplasmic staining within the 
polymer seen after H & E staining of paraffin embedded sections Figure 5-2 (B). 
Cytoplasmic staining and fibrous development is indicative of neural tissue development, a 
higher magnification image of fibres within the scaffold further indicated at neurite 
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outgrowth in 3D Figure 5-2 (C).  It is known that neural tissue on 2D surface is promoted 
by Laminin coating; this was also indicated from 3D tissue.  
Although cytoplasmic staining of filaments developing from neural progenitors is 
indicative of neurite outgrowth it is possible that these outgrowths were non-neural and so 
to further determine if neurites were developing in 3D using Alvetex®Scaffold when 
coated with Laminin/P-D-L, sections of differentiated aggregates were stained for the pan-
neuronal cytoskeletal antigen TUJ-1.  This antigen is specific for the cytoskeletal protein β 
III Tubulin and is specific for early neurite development.  
Figure 5-3 demonstrates the large amount of neural tissue that forms within the scaffold 
after 10 days (TUJ-1, Green) (D & E).  The large number of neurites in the 10 µm section 
indicated high levels of neurite outgrowth from the aggregates in 3D. Furthermore, notice 
that the aggregate nuclei stained blue remains on top of the scaffold; this is the effect of the 
mitotic inhibitors which disrupt mitosis preventing cell division which would result in loss 
of the aggregate integrity and dispersal of the cells into the scaffold.  A contained 
aggregates makes the assay predominantly focussed on neurite outgrowth with minimal 
cell migration into 3D. Confocal microscopy was used to image the aggregate developing 
on top of the scaffold and the neurites that transit the scaffold and grow on the bottom 
elevation.  Neurite that developed horizontally from the cell aggregate were much shorter 
than in 2D however, these neurite then grew through the scaffold weaving through the 
pores making the total length of neurites around the same as that in 2D.  A large number of 
neurites projected and were imaged on the bottom elevation.  These neurites had woven 
through the scaffold interacting with the scaffold in a 3D manner.   
These data indicate that human neurites can develop in a 3D scaffold when coated in the 
extracellular matrix proteins Laminin and P-D-L.  This model can be used to manipulate 
proteins within the extracellular matrix and determine their influence on 3D human neurite 
outgrowth. 
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Figure 5-2 Attachment of neural aggregates to Alvetex®Scaffold.  TERA2.cl.SP12 cells were 
differentiated with 0.1 µM EC23 for 21 days and placed on an uncoated scaffold, few cells attached 
and there was little evidence of cell penetration and a loss of aggregate was observed. (A). Scaffold 
coated with 10 µg/ml Laminin and P-D-L.  Coating scaffold provided a permissive substrate for 
neurite outgrowth. There is significant evidence of cell attachment, excellent cellular penetration and 
neurite extension into the scaffold (B).  High magnification image of image B demonstrates areas of 
long filaments of cytoskeletal staining indicative of neural processes (light purple) (arrow) (C).  The 
processes emanated from areas of high nuclear staining (dark purple) further indicating at the 
presence of neurites. Data demonstrates the advantage of coating the scaffold with the ECM protein 
Laminin and P-D-L over uncoated Alvetex®Scaffold.  Scale bars: (A,B,)100 µm, (C) 50 µm. n=2. 
 
C 
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Figure 5-3 Extensive neurite outgrowth from neuroprogenitors derived from human stem 
cells grown in Alvetex®Scaffold.  The scaffold was coated with 10 µg/ml Laminin and P-D-L   
TERA2.cl.SP12 aggregates were differentiated with 0.1 µM EC23 for 21 days.  Differentiated 
aggregates were then placed on the scaffold in the presence of mitotic inhibitors for a further 10 
days.  During this time neurites formed within the scaffold, whereas the cell bodies remained on top 
of the scaffold in an aggregate.  This is shown diagrammatically (A).  Sections of wax embedded 
scaffold were stained with TUJ-1(Green) and DAPI (Blue) (D, E) followed by confocal microscopy 
(B, C).  Notice that the cell bodies (Blue) remain outside the scaffold (asterisk).  Dashed line 
indicated approximate top interface of Alvetex®. Arrows mark neurites within the scaffold. Scale 
Bars : (C, D, E)= 50 µm  (B)= 250 µm. n=3. 
B C 
D E 
B C 
D E 
* * 
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5.3.2 Inhibition of neurite outgrowth by Aggrecan 
 
Coating a 3D substrate with ECM proteins provides a more physiologically relevant 
environment for cellular development.  In particular the development of neurites in vivo is 
dependent on extracellular cues that regulate gene expression and neurite migration.  
Guidance of growth cones and neurite outgrowth helps to regulate synapse formation and 
correct tissue innervation [313]. As described previously the ECM proteins Laminin/P-D-L 
are highly inductive of neurite outgrowth and can act to regulate neurite development. 
Coating Alvetex®Scaffold with Laminin and P-D-L resulted in a permissive 3D 
extracellular matrix environment for neurite outgrowth.  Human neurites grow into the 
scaffold when coated with a permissive substrate however; this is not demonstrated when 
the proteins are not present, indicating specific interaction of the neuron with the 3D 
environment.  By changing the proteins that coat Alvetex®Scaffold manipulation of the 3D 
growth substrate of human neurites can be achieved, allowing for both permissive and 
inhibitory environments to be investigated. 
As was discussed in Chapter IV, the CSPG – Aggrecan is inhibitory to human neurite 
outgrowth.  Inhibition of neurite outgrowth and subsequent neural regeneration depends on 
the balance between permissive and inhibitory proteins in the glial scar and this is 
dependent on the stage of the scar, the size of the injury and the distance from the scar 
epicentre. Chapter IV described the concentration dependent effect of Aggrecan on neurite 
outgrowth in 2D.  Almost complete loss of neurite outgrowth was demonstrated in our 
conventional 2D model when 50 µg/ml of Aggrecan was added to 10 µg/ml Laminin/P-D-
L substrate.  In this section Aggrecan was added to the Alvetex®Scaffold coating substrate 
to determine the effect of Aggrecan on 3D neurite outgrowth.  Data in Figure 5-4 
demonstrates that the incorporation of 50 µg/ml Aggrecan to 10 µg/ml Laminin/P-D-L 
resulted in a loss of neurite penetration into the scaffold. Thin sections of the scaffold 
revealed poor neurite outgrowth (D, E) and this was accompanied by a loss of neurites on 
the bottom elevation of the scaffold from neurites that penetrated the whole scaffold. 
Interestingly, the top elevation did not show much loss of outgrowth compared to the 
control, this may be due to the porous nature of the scaffold (B), allowing neurites to 
develop in areas of low Aggrecan concentration, the growth of some neurites through the 
scaffold in (C) may be indicative of heterogeneous coating and reflects the concentration 
dependent nature of the effect of Aggrecan on neurite outgrowth.  These data indicate that 
the use of stem cell-derived human neuroprogenitor aggregates in a 3D model of neurite 
outgrowth can be used to investigate the role of Aggrecan in the inhibition of neurite 
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outgrowth and subsequent enhancement of neurite outgrowth in this microenvironment.  
Furthermore, the model can facilitate the pre-clinical drug discovery of small molecules 
which overcome loss of neurite outgrowth specifically induced by Aggrecan in human 
neurites.  
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B C 
D E 
Figure 5-4 Inhibition of neurite outgrowth from neuroprogenitors derived from human stem 
cells grown in Alvetex®Scaffold.   The scaffold was coated with 10 µg/ml Laminin and P-D-L and 
50 µg/ml Aggrecan.  TERA2.cl.SP12 aggregates were differentiated with 0.1 µM EC23 for 21 
days.  Differentiated aggregates were then placed on the scaffold in the presence of mitotic 
inhibitors for a further 10 days, shown schematically in A.  During this time neurites failed formed 
within the scaffold the neural cell bodies remained on top of the scaffold in an aggregate and were 
immuno-positive for TUJ-1. Confocal imaging from the top elevation of Alvetex® (B) demonstrated 
neurite outgrowth on the horizontal plain. The bottom elevation (C) shows neurite outgrowth 
penetrating the scaffold, this is reduced compared to the control (Figure 5-3 C).  Sections (10 µm) 
of wax embedded scaffold were stained with TUJ-1(Green) and DAPI (Blue).  Sections of Alvetex® 
scaffold demonstrated poor 3D neurite outgrowth into Aggrecan coated Alvetex® (D, E).  Dashed 
line indicated approximate top interface of Alvetex®.  Asterisk marks aggregate cell bodies. Arrors 
point to neurites. Scale bars: (B,C) 250 µm, (D,E) 100 µm. n=3.  
* 
* 
* 
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5.3.3 Rescue of neurite inhibition by Aggrecan using small molecules 
 
It is known that manipulation of cell signalling pathways using small molecules can 
control the response of cells to the external environment.  One way cells respond to the 
extracellular environment is via receptor mediated signalling.  Proteins in the ECM can 
bind receptors on the surface of cells such as neurons and activate a conformational change 
in the receptor protein. The conformational change then activates a signalling cascade 
within the cell resulting in a number of downstream responses such as changes in 
cytoskeletal architecture and regulation of gene expression.  One example of this is the 
positive effect of Laminin on neurite outgrowth and neural development, Laminin is 
known to act through heterodimers of integrin receptors and specifically required Integrin 
β1 [287].  
In the 2D environment ECM proteins bind receptors on a single plain in contact with the 
tissue culture plastic, this results in cells having a differential response to the environment 
between the attached surface and the un-attached surface.  Since only one surface of the 
cell is in contact with the ECM there is reduced receptor activation compared to a 3D 
environment.  Therefore, small molecules and proteins that can regulate the signal in 2D 
may be insufficient to do so in 3D due to stronger receptor activation from the 3D ECM. In 
addition compensatory mechanisms which may occur to overcome inhibitory proteins 
affect by the external environment will only be affective on one side in 2D.  Neurites that 
develop in 3D have a number of different responses to their environment.  These responses 
affect the structure of the neuron and growth cone making it more rounded, gene 
expression profiles are different as the environment is more consistent and cells behave 
more like those that would be seen in vivo. The more true-like physiology of neurons that 
develop in 3D makes investigating signalling pathways more relevant when using 3D 
models than traditional 2D culture.  
This section utilises a 3D ECM model of neurite outgrowth to determine how small 
molecule modulators of the signalling cascade induced by Aggrecan can overcome neurite 
inhibition, as was demonstrated in Chapter IV.  The main difference between 2D and 3D in 
this model is the surrounding ECM that neurons in 3D will be responding to which may 
alter the concentration of each small molecule required to induce neurite outgrowth.  
Figure 5-5 is a schematic of the assay used to investigate small molecule modulation of 
Aggrecan induced inhibition of neurite outgrowth in 3D.  Note the descriptions of each 
imaging angle – top elevation is imaged via confocal microscopy on a complete scaffold 
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and will visibly show the aggregate, this is the same for bottom elevation however 
imagining will be of neurites projecting through the scaffold.  Sections of the scaffold 
embedded in paraffin wax were imaged using a fluorescence microscope.  
 
 
 
Figure 5-5 Schematic of the experimental approach used to investigate the small molecule 
modulation of Aggrecan induced human neurite outgrowth inhibition. Neurite outgrowth into 
the scaffold can be inhibited by coating adding 50 µg/ml Aggrecan to the permissive Laminin/P-D-
L coating solution.  This model can be used to investigate recovery of neurite outgrowth from 
inhibited neurites via the addition of bio-active small molecules targeting key cellular pathways 
involved in the modulation of neuritogenesis. 
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As described in Chapter IV the application of 15 µM Y-27632 or 10 µM AC261066 to 
neurites inhibited by Aggrecan resulted in recovery of neurite outgrowth. These 
compounds acted through modulation of known cell signalling pathways. It was unknown 
how the human neurites would respond to Aggrecan if the ECM surface was in 3D around 
the neurites, and if the application of these small molecules to the cell culture media was 
sufficient to recover neurite outgrowth. 
In this section human neurites were grown in 3D using Alvetex®Scaffold coated with 10 
µg/ml Laminin/P-D-L with and without 50 µg/ml Aggrecan.   3D neurite outgrowth was 
demonstrated with the permissive Laminin/P-D-L only substrate; however, the addition of 
Aggrecan significantly reduced the number of neurites that completely penetrated the 
scaffold (Figure 5-6). As was described in Chapter IV the small molecules Y-27632 and 
AC261066 rescue the inhibitory response to Aggrecan.  To investigate this in our 3D 
model Y-27632 and AC261066 were subsequently added to the cell culture media.  
Application of the small molecules to this system resulted in recovery of neurite outgrowth 
to 3D Aggrecan inhibited neurites (Figure 5-6).  The number of neurites that projected 
through the scaffold were imaged by confocal microscopy and given a depth code to make 
individual neurons easier to distinguish. A depth code gives a different false colour to each 
Z-stack section taken by the confocal microscope.  This makes it easier to follow neurites 
to their origin as the lowest and highest levels of the neurite are easily distinguishable. 
Neurons were counted on the bottom elevation under each condition and demonstrated the 
recovery of neurite outgrowth in 3D by both AC261066 and Y-27632. 
In Chapter IV, two other small molecule modulators of neurite outgrowth were assessed; 
these were XAV 939 and PTP IV inhibitor.  Aggregates grown in 3D with and without 
Aggrecan treated with XAV 939 did not attach to the Alvetex®Scaffold/were loosely 
attached and lost during processing making any imaging analysis/ processing incomplete.  
The small molecule PTP IV, however, did induce some neurite outgrowth recovery from 
neurites grown on an Aggrecan rich ECM (Figure 5-7).  3D neurite outgrowth into the 
inhibitory Aggrecan environment was demonstrated after treatment with 1 µM PTP IV for 
10 days.  Neurite outgrowth did not penetrate the complete scaffold, as demonstrated by 
confocal microscopy. However outgrowth was apparent by sectioning the scaffold, no 
outgrowth into the scaffold seen in untreated cultures. Incomplete recovery of neurite 
outgrowth by PTP IV treatment may be due to differences in the optimal concentration of 
between 2D and 3D. Although 1 µM was optimal in 2D, a concentration-response study 
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may demonstrate a shift in the optimal concentration in 3D due to the increase in activated 
PTPσ receptors from the 3D ECM.  
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Figure 5-6 Neurite outgrowth inhibited by Aggrecan can be overcome by Y-27632 or AC261066 
treatment. Alvetex®Scaffold was coated with Laminin and P-D-L (A, E) or Laminin, P-D-L and Aggrecan 
(B, C, D, F, G, H).  Addition of Aggrecan resulted in a significant decrease in the number of neurites 
growing through the scaffold.   Addition of 10 µM Y-27632 (D, H) or AC261066 (C, G) resulted in 
enhanced neurite outgrowth and differentiation on an Aggrecan substrate.  A Z-stack by confocal 
microscopy was used to image TUJ-1 stained neurites and aggregates.  The images were modified using 
depth coding which provides a different false colour to each section of the Z-Stack.  Through depth coding 
individual neurites could be distinguished on the bottom elevation of Alvetex®Scaffold for quantification 
(E-H).  Quantification Demonstrated enhanced neurite outgrowth in the presence of Y-27632 and 
AC261066 (I).  Data represent mean ± SEM, n=3. Scale Bar: (A-D, F, G) 250 µm, (E, H) 100 µm * p≤0.05 
Students paired t-test. 
C 
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A B 
Figure 5-7 Neurite outgrowth inhibition by Aggrecan coated Alvetex®Scaffold can be partially 
overcome by PTPIV inhibition. Aggregates of TERA2.cl.SP12 cells differentiated for 21 days by 
0.1 µM EC23 were placed onto Alvetex®Scaffold coated with 10 µg/ml Laminin, P-D-L and 50 
µg/ml Aggrecan  untreated (A) or with the addition of 1 µM PTP IV inhibitor (B) for 10 days.  
Transverse sections of Alvetex®Scaffold were taken from each condition.  Condition (A) was not 
permissive for neurite outgrowth and resulted in no neural projections in to the scaffold. However, 
condition (B) was permissive to partial neurite outgrowth demonstrating recovery of neuritogenesis 
into a previously inhibitory environment. Arrow marks neurite outgrowth into Scaffold. Dashed 
line indicated approximate top interface of Alvetex®.  Asterisk marks aggregate cell bodies Scale 
bars: 50 µm. n=3.  
 
* 
* 
* 
* 
252 
 
 
 
5.3.4 Recovery of neurite inhibition by chondroitinase ABC treatment of Aggrecan coated 
Alvetex®Scaffold 
 
The enzyme chondroitinase ABC, a bacterial enzyme, is known to cleave 
glycosaminoglycan (GAG) chains from proteoglycans such as CSPGs [161].  It has been 
shown that the major active component of CSPG signalling in neurons is via GAG which 
is a ligand for protein tyrosine phosphatase receptors on the neural membrane [314].  
CSPGs are produced in the spinal cord post injury by activated astrocytes and activate PTP 
receptors [1].  Activation results in growth cone collapse and neurite retraction at the 
neural level and loss of function at the whole animal level due to loss of innervation.  
Sustained loss of innervation results in loss of synapse at the tissue target making speed of 
treatment a major obstacle for neural regeneration [315].   Removal of GAG from 
Aggrecan in our 2D model of neurite outgrowth resulted in recovery axon elongation.  It 
has been demonstrated in published literature that chondroitinase treatment to areas of 
damaged spinal cord can aid neural regeneration and functional recovery.  
In this Chapter a 3D model of Aggrecan induced human neurite inhibition was used to 
assess the basic mechanism by which Chondroitinase ABC treatment may work.  This is 
the first study to utilise synthetically differentiated stem cell derived human neurons and a 
3D model of spinal cord ECM with specific protein composition to assess Chondroitinase 
treatment.  The advantage of this model over animal models is the defined human neural 
process that is occurring and the defined ECM coating of the 3D scaffold. 
In this section Alvetex®Scaffold was coated as described previously with and without 
Aggrecan.  Prior to seeding the differentiated neurospheres, Chondroitinase was added for 
1 hour at 37 °C as described in the methods section.  To control for any effect of the buffer 
used to dissolve the active enzyme on neurite outgrowth controls using the enzyme buffer 
alone were performed.  Figure 5-8 demonstrates pan-CSPG staining (Green) on sections of 
Alvetex®Scaffold coated with and without Aggrecan.  These data demonstrate that there is 
no staining for pan-CSPG in Laminin/P-D-L only coated scaffold (A), however, in both the 
Aggrecan coated and Aggrecan coated plus enzyme buffer a layer of CSPG  - in this case 
Aggrecan, is visible (B,C). Note some areas of the scaffold have a higher intensity staining 
than others indicating a non-homogenous coating procedure, which may account for some 
neurites developing on Aggrecan coated Alvetex®Scaffold, seen previously.  Finally, 
treating the Aggrecan coated scaffold with Chondroitinase ABC resulted in points of high 
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intensity fluorescence (D), where much of the scaffold was negatively stained, this may 
indicate trapping of the GAG side chains in the scaffold after enzymatic cleavage.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8 Chondroitinase digests Aggrecan coated on Alvetex®Scaffold.  Transverse sections 
of Alvetex®Scaffold were stained for a pan-CSPG epitope (Green). Control staining with Laminin 
and P-D-L only (A), Alvetex®Scaffold coated with Aggrecan (B), Alvetex®Scaffold coated with 
Aggrecan and washed with the chondroitinase enzyme buffer for 1 hour (C), coated with Aggrecan 
and washed with chondroitinase in buffer for 1 hour (D). Positive staining was demonstrated in 
each of the Aggrecan coated scaffolds; however, the addition of chondroitinase resulted in less 
homogenous coating of the scaffold and areas of highly concentrated staining. Scale bars: 100 µm. 
n=2.  
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Figure 5-9 Neurite outgrowth inhibition by Aggrecan coated Alvetex®Scaffold can be 
overcome by chondroitinase pre-treatment. Alvetex®Scaffold was coated with 10 µg/ml 
Laminin, P-D-L and 50 µg/ml Aggrecan, creating a 3D environment for neurite outgrowth to be 
investigated.  Scaffolds were then either washed for 1 hour with enzyme buffer (A) or buffer 
containing the enzyme chondroitinase (B).  Aggregates of TERA2.cl.SP12 cells were  
differentiated for 21 days by 0.1 µM EC23 prior to coating the scaffold, after coating and treatment 
the aggregates were placed onto the scaffold.  Aggregates were maintained for 10 days under each 
condition.  Transverse sections of Alvetex®Scaffold were taken and stained for TUJ-1 (green) and 
DAPI (blue).  Condition A was not permissive for neurite outgrowth and resulted in no neural 
projections in to the scaffold. Condition B was permissive to partial neurite outgrowth 
demonstrating recovery of neuritogenesis into a previously inhibitory environment. Dashed line 
indicated approximate top interface of Alvetex®.  Arrow marks neurite outgrowth into Scaffold.  
Asterisk marks aggregate cell bodies. Scale bars: 50 µm. n=3.  
 
* 
* 
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5.3.5 Investigating the effect of Aggrecan on primary neural progenitor differentiation in 
3D 
 
The neural progenitor cells used so far in this study have been derived from the human 
pluripotent stem cells TERA2.cl.SP12 grown in an aggregate and treated with the synthetic 
retinoid EC23.  The neural progenitors that form express a variety of markers specific to 
CNS cells and go through key developmental step to form differentiated neural 
progenitors.   Although this represents a defined model of neurite development the cells are 
derived from a cancer stem-cell line that has some genetic abnormalities, therefore 
throughout this study it has been assumed that they would respond to the various ECM and 
small molecules in a normal way as would be demonstrated in vivo. Since the neural 
developmental process shows normal changes and the neurites that form are 
electrophysiological active the response of the neurites to the environment demonstrated is 
likely physiologically relevant.    The next part of this study was to investigate the effect of 
Aggrecan on the 3D growth of primary mouse and human neural progenitor development 
to determine if the response seen in the stem cell-derived neural progenitors is similar to 
that of primary cells. 
Note that, as was described earlier, one benefit of the stem cell-derived 3D neurite 
outgrowth method was the quantification of neurite outgrowth, the use of primary neurons 
makes quantification of neurite outgrowth much more difficult due to the individual neural 
processes that develop in networks and the lack of directional growth observed.  Again this 
study utilised Alvetex®Scaffold as a scaffold for 3D neurite growth. 
Mouse embryonic cortical cultures 
Embryonic mouse cortical cultures were isolated and cultured in 3D as described in the 
methods section.  Differentiation of the mouse cultures in 3D resulted in aggregates 
consisting of both neural and glial cells as defined by either TUJ-1 expression for axons 
and GFAP for glia.  Figure 5-10 shows images of the differentiated aggregates with the 
Alvetex®Scaffold visible in the background. The cells formed discrete aggregates visible 
on the scaffold (A); the neural tissue could be seen clearly within the aggregate at high 
magnification (B).  In this figure the scaffold was ethanol wet and coated protein coated 
with FBS.  In Figure 5-11 the addition of an Aggrecan coating stem resulted in a visible 
reduction in the number of embryonic mouse cortical cell aggregates.  It is unknown the 
mechanism by which cell aggregates are reduced, however it is likely a toxic effect. In this 
figure only cell bodies stained with DAPI (Blue) and neural processes stained for TUJ-1 
(green) were imaged.  Although this primary model may represent more physiologically 
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relevant cells the biological information that is gained from culturing these cells on 
Aggrecan coated Alvetex® is limited. Note: It was not possible to perform sectioning of the 
scaffold since the scaffold did not contain a sufficient number of cells for processing.  
Furthermore, due to species differences primary human neural progenitor differentiation 
would be more relevant. 
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Figure 5-10 Embryonic mouse cortical cultures differentiated on Alvetex®Scaffold.  Day 14-16 embryonic mouse brains were dissociated and differentiated on 
Alvetex® as described in the Methods section.  The cultures formed aggregates of cells containing axons (TUJ-1, Green) and Glial (GFAP, Red).  Cell nuclei were stained 
with DAPI (Blue). Alvetex® was serum coated prior to cells seeding giving the scaffold a hydrophilic surface. Low magnification image shows aggregates of cells (A).  
High magnification image (B) demonstrates the filamentous TUJ-1 staining and associated GFAP positive cells.  These data demonstrate the 3D differentiation of primary 
mouse neuroprogenitors in to neurons and glial.  These images were taken on an Epi-flourescence microscope (Data generated in collaboration with Dr I Smith and Dr B 
Whalley Reading University). n=3. 
 
A B 
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Figure 5-11 Growth of embryonic mouse primary cortical neuroprogenitors on Aggrecan 
coated Alvetex®Scaffold. Primary mouse cortical neurons were seeded on 96 well 
Alvetex®Scaffold coated with DMEM: F12 + 10 % FBS ± 10 µg/ml Aggrecan. Neurons were 
stained for TUJ-1 (Green) and DAPI (Blue). Images were taken using a confocal microscope (488 
nm and 405 nm). Cells aggregated on both uncoated scaffolds (A) and Aggrecan coated (B) 
scaffolds, however, there was notably less aggregates of cells in the Aggrecan coated Scaffold, 
possibly indicating toxicity of Aggrecan to the cells. Scale bars: 100 µm. n=3. 
A B 
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Normal human neural progenitor culture 
 
Normal human neural progenitor cells (nHNPC) derived from human brain mesencephalon 
were acquired from LONZA (PT-2599).  The cells are cryopreserved and shipped as 
neurospheres, the neurospheres differentiate upon treatment with BDNF into neural and 
glial lineages. Although the nHNPC are commercial and cryopreserved they are a primary 
human model and can be used for drug toxicology, CNS function and electrophysiology 
studies.  The cells are derived from a single donor reducing heterogeneity and are at a 
concentration of 1.2 x 106 cells / vial.  Treatment with BDNF in 2D results in 
differentiation of the progenitors into neural and glial cells (Figure 5-12) for use in the 
above studies.  
To differentiate the nHNP cells in 3D they were seeded onto human serum coated 
Alvetex®Scaffold as described in Section 5.2.13 and maintained in neural maintenance 
media containing FGF and EGF for 5 days.  After 5 days FGF and EGF treatment was 
stopped and the cells were differentiated by treatment with BDNF.  Cells were maintained 
in the 3D environment for 25 days prior to fixation, staining (TUJ-1 and GFAP) and 
imaging using confocal microscopy.  Figure 5-13 shows the 3D differentiation of nHNPC 
in Alvetex®.  Neural processes were demonstrated by TUJ-1 staining (Green) and 
associated GFAP staining demonstrated the presence of Glial cells (Red).  Multi-electrode 
array (MEA) data of the complete Alvetex®Scaffold demonstrated good firing potentials 
on 258 electrodes from the human neurons; note that in 2D human neurons do not induce 
any action potentials measurable by MEA.  The addition of tetrodotoxin toxin (TTX), a 
voltage gated, fast sodium channel blocker and CNQX/DLAP5 AMPA/NDMA 
antagonists, to the control cultures, caused an almost complete inhibition of firing potential 
validating the action potential of the neurons grown in 3D in this model (Figure 5-14).    
To assess the effect of Aggrecan coating on nHNPC differentiation in 3D the scaffold was 
coated with 1 ng/ml or 10 µg/ml Aggrecan overnight prior to human serum coating and 
cell seeding – cells were then differentiated with BDNF for 35 days. Cultures were fixed in 
4 % PFA and stained with TUJ-1.  Confocal imaging demonstrates the effect of Aggrecan 
on the cultures (Figure 5-15).  The control culture demonstrated good neural differentiation 
and neurite outgrowth (A), the addition of 1 ng/ml Aggrecan coating did not result in loss 
of neurite outgrowth and the neurons looked healthy (B).  
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Using a MEA to measure the action potential of neurons grown in the presence of 1 ng/ml 
Aggrecan revealed a significant decrease in firing rate compared to the control (Figure 
5-15).  Since TUJ-1 staining demonstrated good neurite growth on both control and 1 
ng/ml Aggrecan coated Alvetex®  the effect of Aggrecan on the action potential of human 
neurons grown in 3D was not related to neurite outgrowth.  Furthermore, there was a 
significantly higher number of firing events in Aggrecan coated cultures compared to the 
TTX treated control, indicating that although these neurites were not firing they had the 
potential to fire. 
Coating Alvetex® in 10 µg/ml Aggrecan resulted in aggregation and loss of neurite 
outgrowth; the cells had a defined periphery and looked more like mouse cortical cultures 
in Figure 5-11 (C).  No action potential was measured from neurons differentiated in the 
presence of 10 µg/ml Aggrecan using MEA.  
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Figure 5-12 Normal human neural progenitors grown on a 2D MEA.  Tuj-1 positive neurites 
(green), GFAP positive glial cells (red) and cell nuclei (DAPI, blue) form after nHNP are induced 
to differentiate with BDNF.  No action potential is measurable in by MEA from these cultures. 
(Data generated in collaboration Dr I Smith and Dr B Whalley, Reading University). n=3.  
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Figure 5-13 Normal human neural progenitors differentiation in 3D using Alvetex®Scaffold. 
Human neural progenitor cells were induced to differentiate in 3D by the addition of BDNF. The 
cells were cultured as described in the Methods section and expressed TUJ-1 (Green), GFAP 
(Red) and DAPI (Blue) after 25 days culture. Notice that compared to mouse cortical cultures the 
neurites form more in a network that as an aggregate. This image was taken using Epi-
fluorescence, (Data generated in collaboration Dr I Smith and Dr B Whalley, Reading 
University). n=3.  
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Figure 5-14 Action potential of human neural progenitor neurons differentiated in 3D.  
Normal human neural progenitors were differentiated on Alvetex® in the presence of BDNF.  Using 
MEA the action potential from 258 electrodes was recorded.  The firing rate of control neurons was 
1.1 Hz and this could be significantly reduced by the addition of 10 µM TTX.  These data 
demonstrate that the firing that was observed by MEA was the result of a sodium pump in the 
neural membrane.  Paired students t-test  ***P<0.0001 n=258 electrodes.  Error= ±SEM. 
*** 
 
* 
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Figure 5-15 Normal human neural progenitors differentiated in 3D on Aggrecan coated Alvetex®Scaffold.  Normal human neural progenitors were seeded onto 
Alvetex®Scaffold in 96 well plates as described in Methods.  Scaffolds were treated with DMEM: F12 + 10% Ab –ve human serum overnight. Aggrecan scaffolds were 
coated with either 1 ng/ml or 10 µg/ml Aggrecan overnight prior to DMEM: F12 serum treatment.  Neurons were stained for TUJ-1 (Green) and DAPI (Blue). Images were 
taken using a confocal microscope (488 nm and 405 nm). Low concentrations of Aggrecan (1 ng/ml) coating did not have an effect visibly on neurite formation (B), 
however, at much higher concentration (10 µg/ml) coating resulted in an apparent loss of neurite formation and aggregation of neurons.  This demonstrates the regulatory 
ability of Aggrecan on primary human neural progenitor differentiation. Scale bars: (A,B) =50 µm, C=100 µm. n=3. 
A B C 
Control 1 ng/ml Aggrecan 10 µg/ml Aggrecan 
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Figure 5-16 Inhibition of the 3D neural action potential by Aggrecan.   Multi electrode array 
(MEA) analysis was used to measure the action potential in neurons grown in 3D.  The assay 
determined the electrical signal from multiple electrodes in contact with the scaffold.  Addition of 1 
ng/ml Aggrecan to the scaffold resulted in an almost complete loss of firing from the neurites.  
Control n=258 electrodes, Aggrecan n=63 electrodes.  Error bars= ±SEM. Unpaired student’s t-test 
with Welch’s correction ***P<0.0001. 
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Figure 5-17 Control cultures treated with tetrodotoxin (TTX) had a lower firing potential than 
neurons grown on Aggrecan in 3D. Multi electrode array (MEA) analysis was used to measure the 
action potential in neurons grown in 3D.  The assay determined the electrical signal from multiple 
electrodes in contact with the scaffold.  Addition of 1 ng/ml Aggrecan to the scaffold resulted in an 
almost complete loss of firing from the neurites, however, the firing rate was around double that of 
control cultures treated with TTX, indicating potential firing of neurite on Aggrecan treated scaffolds.  
Control n=258 electrodes, Aggrecan n=63 electrodes.  Error bars= ±SEM. Unpaired student’s t-test 
with Welch’s correction * P<0.05.  
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 5.3.6 Enhancing Physiological Relevance: Co-culture of human stem cell derived neurons 
and U118MG astroglioma cell to investigate neurite outgrowth 
 
Within the central nervous system glial cells provide support and protection of neurons 
during embryonic development and adult homeostasis.  The supporting cells of the CNS 
consist of Astrocytes, Oligodendrocytes and Microglia and act to sustain and myelinate 
CNS neurons including the synaptic support and plasticity [316].  The interaction between 
glial and neuronal cells is complex and pathology involving glia often results in loss of 
neural function [317].    
Activation of astrocytes post-CNS injury results in the formation of an ECM that is 
inhibitory to neurite outgrowth. Post-CNS injury, astrocytes are activated by the 
production of high levels of TGF-β and begin to express glial fibrillary acidic protein 
(GFAP) the cells also change shape becoming star-like which are good indicators of 
reactive gliosis post CNS trauma [318].  One of the first indications that astrocytes, 
specifically reactive astrocytes are involved in propagation of the glial scar was through 
their specific location to the injury site after injury forming a visible barrier and periphery 
to the scar.  Further studies revealed that the reactive astrocytes produce ECM proteins that 
help compose the glial scar [319]. 
In this section a 3D model of CNS neural/astrocyte co-culture was developed using the 
human astroglioma cell line U118MG and our human neurite outgrowth mode, as 
described in Chapter IV in 2D.  
Figure 5-18 demonstrates the H & E staining of U118MG cells grown within the scaffold.  
Sections of the scaffold show good cell penetration. Cells appeared viable with large areas 
of cytoplasm characteristic of U118MG cells (A).  Co-culture with human stem cell 
derived neural progenitor aggregates and U118MG cells (B) demonstrated that the 
aggregate remains on top of the scaffold allowing for the potential of axonal projections 
into the scaffold in co-culture with U118MG.  Due to the high cytoplasmic content of 
U118MG culture in 3D it was not possible to determine if neurite outgrowth was present at 
this stage.  
268 
 
 
 
 
Figure 5-18 Co-culture of U118-MG and human stem cell derived neurons using 
Alvetex®Scaffold.  U118MG cells were grown in Alvetex®Scaffold coated with Laminin and P-D-L.  
Cells were grown for 10 days in the presence of mitotic inhibitors; wax embedded sectioned (10 µm) 
and stained with H & E (A). For co-culture U118MG were allowed to settle for 15 minutes at 37 °C 
prior to an aggregate being added to the top of the scaffold (B). Note that the presence of mitotic 
inhibitors or Laminin/P-D-L does not result in loss of U118MG culture. Scale bars: 100 µm. n=3.  
A B 
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To assess the neurite outgrowth potential of human neurons that develop from aggregates 
of neural progenitors when co-cultured with astroglioma cells, sections of 
Alvetex®Scaffold were taken and stained for the neural specific antigen TUJ-1 and DAPI 
(showing U118MG nuclei within the scaffold).  Figure 5-19 demonstrates that no neurites 
developed into the scaffold when co-cultured with U118MG cells, as would be expected 
from the preliminary data described in Chapter IV.    
The physical influence of U118MG cells in 3D would be much greater than in 2D.  In 2D 
neurites can develop between gaps in U118MG cells, however, in 3D a 200 µm confluent 
block of U118MG tissue would make the development of growing neurites much more 
difficult.  Interestingly, the physical barrier of 3D U118MG cells was overcome by ROCK 
inhibition demonstrating a receptor mediated inhibition on neurite outgrowth by U118MG. 
Enhancement of neurite outgrowth was demonstrated in co-culture when the cells were 
treated with the ROCK inhibitor Y-27632, as was described in 2D in Chapter IV. 
It was suggested that ROCK inhibition may induced neural development over U118MG 
and through the scaffold to quantify the enhanced 3D neurite outgrowth neurites would be 
required to develop through the scaffold and to the bottom elevation.  Complete 
penetration would allow for accurate neurite counting on the bottom elevation of Alvetex®.  
As described in Chapter IV that inhibition of neurite outgrowth was likely to be the result 
of the presence of CSPGs on the membrane of U118MG cells.  Figure 5-20, demonstrates 
the top elevation of human neurites alone (A) and co-cultured with U118MG (B), notice 
co-culturing resulted in loss of any horizontal outgrowth from the neural aggregate. 
Neurites in co-culture tended to rap around the aggregate, suggesting inhibition by the 
astroglioma cells.   To quantify the extent of neurite inhibition bottom elevation of 
projecting neurites were counted; Figure 5-20 (C) demonstrates good growth of neurites 
through the scaffold when U118MG cells are not present.  Co-culture with U118MG cells 
resulted in loss of projecting neurites demonstrated by only DAPI staining on the bottom 
elevation (D), as described in Chapter IV neurite outgrowth can be recovered with the 
addition of the ROCK inhibitor of Y-27632, Figure 5-20 (E) indicating a receptor mediated 
interaction between U118MG and neural progenitor development that can be overcome by 
cytoskeletal stabilisation and inhibition of downstream ROCK activation.  These data agree 
with what was demonstrated in Chapter IV.   
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To investigate if U118MG cells expressed GAG motifs on their surface which may 
account for inhibition of neurite outgrowth 10 µM sectioned scaffolds were immuno-
stained by an anti-CSPG antibody specific for a GAG epitope.  Immuno-staining 
demonstrated high levels of CSPG expression indicative of membrane associated CSPG, 
the expression of such molecules may be a feature of the tumorous nature of the cells since 
the CSPG Brevican a CNS restricted CSPG is known to enhance the invasiveness of 
glioma [296]. Interestingly there was an apparent increase in staining intensity when 
U118MG cells were treated with Y-27632, this has been observed in previous studies in 
similar cells and may be representative of the non-selective nature of Y-27632 treatment.  
Enhancement of neurite outgrowth in the presence of Y-27632 and U118MG cells suggests 
the effect of cytoskeletal stabilisation in developing neurons is sufficient to overcome any 
amount of CSPG induced inhibition. 
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Figure 5-19 Inhibition of neurite outgrowth by U118MG co-culture can be overcome by ROCK inhibition. The scaffold was coated in a 10 µg/ml Laminin and P-D-
L solution. U118MG cells colonised Alvetex®Scaffold, after colonisation a TERA2.cl.SP12 cell aggregate differentiated for 21 days with 0.1 µM EC23 was placed on top.  
Cells were then cultured for 10 days either with 15 µM Y-27632 or as an untreated control prior to fixation with 4 % PFA. Alvetex®Scaffold was dehydrated, wax embed , 
sectioned to 10 µm and stained for TUJ-1 (Green) indicating neural tissue (B,E) or DAPI (Blue) indicating U118MG inside the scaffold and the aggregate neural cell 
bodies on top (A,D). Overlay of DAPI and TUJ-1 indicate neurite outgrowth into the Scaffold (C, F). Note an increase in TUJ-1 staining within the scaffold in the Y-27632 
treated culture.  Dashed lines indicate the approximate top side of the Scaffold. Arrow marks neurite formation inside the scaffold. Asterisk marks the aggregate on top of 
Alvetex®. Scale bars: 100 µm. n=3. 
A B C 
D E F 
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Figure 5-20 Inhibition of neurite outgrowth by U118MG co-culture can be overcome by 
ROCK inhibition.   Co-culture with U118MG astroglioma cells resulted in loss of neurite 
outgrowth from the stem cell derived neural progenitors (B and D).  In the absence of U118MG 
cells (A and C) or with the addition of the ROCK inhibitor Y-27632 (E) neurites projected through 
the scaffold.   Neurites and neurospheres were stained with TUJ-1 (Green) and U118MG nuclei 
were stained with DAPI (Blue).  In the presence of U118MG cells, neurites did not extend from the 
neural aggregate (B). Quantification of the number of neurites that project through the 
Alvetex®Scaffold (F). Arrows mark neurites that developed through the scaffold. Data represent 
mean ± SEM, n=3. Scale Bar: 250 µm. 
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Figure 5-21 Chondroitin sulphate proteoglycan expression by U118MG cells.  Sections of 
Alvetex®Scaffold contain U118MG cells were stained using an anti-CSPG antibody (Green) and 
DAPI (Blue).  No evidence of none specific staining of the secondary antibody was demonstrated 
in the no primary antibody control (A).  Some low level CSPG positive staining was detected by 
U118MG cells grown on Laminin/P-D-L (B).  High levels of positive staining was demonstrated 
when U118MG cells were treated with 15 µM Y-27632 (C).   Scale bars: (A) = 100 µm, (B,C) = 50 
µm. n=3.  
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5.3.7 Guidance of neurite outgrowth using physical conduits 
 
The use of nerve conduits to guide axon formation is used in treatments of PNS injury 
allowing for a short length of nerve to regenerate when autograft tissue is not sufficient 
[320].   The use of nerve conduits to guide CNS axon growth is not as feasible for CNS 
injury due to the lack of axonal regenerative potential in the CNS [306].  One treatment for 
CNS injury is a peripheral nerve grafts which can be grown in conduits spanning the glial 
scar in the CNS offering some functional regeneration to the patient, however, due to the 
increased invasive nature of the procedure this is not ideal.  Enhancing the neurite 
outgrowth potential of CNS neurons is an attractive replacement for graft tissue. Guidance 
of regenerating axons will be important for treatment of CNS injury and will likely involve 
a number of stimulatory cues of neurite outgrowth.  Directed neurite outgrowth for use in 
neural graft tissue is a major obstacle for human neural regeneration.  The random 
direction of developing axons may result in incorrect innervation or death of neural tissue 
[96].  The use of chemo attractants, guidance proteins and nerve conduits can facilitate the 
growth of axons in the CNS. 
Multiple studies have demonstrated the use of aligned polymer scaffolds to direct neurite 
outgrowth [118, 121, 321].  In this section polystyrene electrospun scaffolds were used to 
direct human neurite outgrowth from stem cell-derived neuroprogenitor aggregates. The 
aligned scaffold used is not naturally permissive to neurite outgrowth as it does not contain 
any guidance molecules or ECM proteins.  To ensure the scaffold was permissive to 
neurite outgrowth the scaffold was coated in a high concentration of Laminin and P-D-L, 
as described in the methods section of this Chapter. After coating the scaffold with ECM 
protein it was permissive of neurite outgrowth from the human stem cell derived 
neuroprogenitors. Furthermore, the presence of Laminin induced the axon elongation along 
the aligned fibres.  Induction of neurite outgrowth by Laminin is through an Integrin 
receptor binding mechanism [312].  
Figure 5-22 demonstrates the guidance of human neurites developing from aggregates of 
differentiated stem cells.  The neurites developed along the electrospun fibres in both 
directions; no neurites tended to develop perpendicular to the aligned fibres indicating 
either guidance by the ECM proteins Laminin/P-D-L or a stimulatory cue provided by the 
protein coated scaffold [312, 322]. This model can be used to assess the guidance of 
neurites along fibres using different coating ECM proteins.   
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Design of nerve conduits for peripheral nerve regeneration demonstrate that co-culture 
with support cells such as Schwann cells produces more robust axon growth and direction. 
Georgiou M et al (2013) [323], demonstrated using rat DRG that aligned Schwann cells 
can induce directed neurite outgrowth and the conduit can be used to treat a rat sciatic 
nerve injury model. The use of supporting cells in this way could be beneficial for CNS 
regeneration.  Other studies have used electrospun scaffolds to co-culture and align Swann 
cells/Glial cells supporting and guiding the development of rat DRG neurons [324].  
Although these studies utilise peripheral nerves some insight as to how CNS neurons may 
develop can be taken from the work. 
Figure 5-23 demonstrates the effect of co-culturing stem cell-derived human 
neuroprogenitor aggregates (production described in Methods section) with astroglioma 
U118MG cells on Laminin/P-D-L coated aligned scaffold.  Initially 1 x 106 U118MG cells 
were seeded onto the electrospun scaffold and left to adhere for 15 minutes.  After 15 
minutes incubation 5-10 stem cell-derived neural-progenitor aggregates were placed on the 
scaffold in the presence of mitotic inhibitors.  The scaffold was the incubated as described 
in the Methods Section, for 10 days before fixation in 4 % PFA and immunostaining for 
TUJ-1 and DAPI.  The presence of U118MG cells resulted in loss of directed outgrowth 
from neurites growing along the aligned fibres, indicating either a physical or biochemical 
effect from the U118MG cells; however, the presence of the aligned fibres did tend to 
allow for some outgrowth to occur between the U118MG cells but not in any particular 
direction.  The U118MG cells did not line along the scaffold fibres but spanned them in a 
non-polarised manner; this may be due to the tumorous nature of the cells.  More 
physiologically relevant astrocytic cells would likely have a positive effect on neurite 
outgrowth, the opposite to what has been demonstrated in this section. 
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Figure 5-22 Human neurons grow along aligned electrospun fibres.  Electrospun fibres were 
coated with 10 µg/ml Laminin and P-D-L overnight.  Aggregates of TERA2.cl.SP12 cells treated 
with 0.1 µM EC23 for 21 days were placed on the fibres, in cell culture media containing mitotic 
inhibitors for 10 days.  The cultures were fixed in 4 % PFA and stained for TUJ-1 (Green). DAPI 
(Blue) (A, B), Aligned Fibres (Blue) (C, D). Imaging through confocal microscopy demonstrates 
neurites growing along the fibres (arrows).  Fibres fluoresced blue when excited with 458 nm 
light by the confocal microscope. Double ended arrow indicates direction of fibres. These data 
indicate the directed neurite outgrowth of human neurons along an electrospun scaffold. Scale 
bars: (A, B) = 250 µM, (C) = 100 µM, (D) = 50 µM. n=3.  
 
C D C D 
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Figure 5-23 Co culture of human neurons and human astrocytoma cells using electrospun 
scaffold. Aggregates of TERA2.cl.SP12 cells treated with 0.1 µM EC23 for 21 days were placed 
onto aligned electrospun scaffolds coated with 10 µg/ml Laminin/P-D-L. Neurites formed along the 
fibres away from the aggregate TUJ-1 (Green) (A).  The addition of 100,000 U118MG to the media 
resulted in loss of directed outgrowth (B). Arrows demonstrate direction of fibre alignment. TUJ-1 
(Green), DAPI (Blue). Media also contained mitotic inhibitors as described in Methods. Arrow 
marks neurite outgrowth. Double ended arrow marks direction of aligned scaffold fibres.   Scale 
bars: 250 µm. n=3.  
Control + U118MG A 
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5.4 DISCUSSION 
 
Trauma to the CNS often results in some level of paralysis and is common in high impact 
sports such as Rugby or injuries sustained from motor vehicle crashes and stab wounds. 
Although multiple organ systems in the adult shows some regenerative potential such as 
neurons in the peripheral nervous system and the liver, neurons in the CNS do not 
regenerate.  Advances in our understanding of neural subtype, neural development and the 
interaction of neurons and their environment has led to the discovery that CNS neurons do 
have the potential to regenerate like neurons in the PNS.  Differences in the composition of 
the local microenvironment post injury in the CNS and PNS give the neurons differing 
regenerative potential. Investigating the interaction between neurons and the local post 
injury microenvironment is important for developing novel therapeutics.  This Chapter 
focused on using stem cell-derived CNS neural progenitors to investigate in a 
physiologically relevant model of CNS injury the effect of small molecules on specific 
signalling pathway modulators.  
5.4.1 Development of a novel model to study 3D neurite outgrowth in vitro 
 
In this study stem cell-derived neurons were combined with 3D scaffold technology to 
produce a highly neurogenic model of neurite outgrowth, the study utilised a two stage 
process to enhance reproducibility and control over the stages of differentiation.  Human 
stem cells were differentiated into neural progenitors prior to inducing neurite outgrowth in 
3D.  This allowed for a controlled process at each stage, regulating the differentiation of 
stem cells in stage 1 and neurite outgrowth in stage 2.  This two-step process allowed for 
manipulation of the 3D culture environment for controlled differentiation of stem cells and 
modulation of neurite outgrowth in 3D.  Stem cells were differentiated in a 3D aggregate 
model and when combined with the synthetic retinoid EC23 produced highly neurogenic 
and reproducible differentiation.  Neurite outgrowth from the aggregates could then be 
investigated under a number of different matrix conditions by coating Alvetex®Scaffold 
with different ECM proteins.   
Previous studies that have used stem cell-derived neural progenitors in neurite outgrowth 
and differentiation studies in 3D and have completed the differentiation and neurite 
outgrowth process in the same 3D environment, limiting experimental control and 
regulation over the development of the cells.  Ge, D et al (2013) [325]  utilised rat neural 
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stem cells to investigate 3D neural differentiation for use in high throughput studies.  The 
investigation demonstrated the differentiation of rat neural stem cells in a 3D collagen 
matrix.  The project utilised a two-step process of cell proliferation in 3D and then 
differentiation, however, a mixture of cell types developed including neurons, 
oligodendrocytes and astrocytes. The neurons in this study could not be used to investigate 
neurite outgrowth due to the complexity of the culture.   
Other studies have utilised collagen matrix as a biocompatible scaffold to aid neurite 
differentiation and neurite outgrowth studies.  Even though the scaffolds are good at 
inducing 3D neurite differentiation the overall assay is limited in its application due to 
difficulties in quantification of the neural growth in 3D.  Therefore, due to the inherent 
difficulties of neurite growth and quantification, most neurite outgrowth studies are 
performed in 2D. 
Hydrogels that can undergo solution-gelation transitions have been investigated for their 
ability to support neurite formation and outgrowth.  The highly porous gels are permissive 
of neural migration and network formation due to interconnecting pores.  Again, although 
neurite differentiation and outgrowth can be induced in 3D using these scaffolds it is 
difficult to assess any changes in outgrowth under particular conditions.  Furthermore, due 
to the migration of neural progenitors and network formation a lack of neural polarity is 
often demonstrated.  Nisbet, D.R et al (2008) [326] developed a Xyloglucan hydrogel to 
investigate primary mouse cortical neural 3D differentiation. The study demonstrated an 
enhancement of neural network formation when P-D-L was used in conjunction with the 
scaffold. This study described the use of these scaffolds for CNS regeneration; however, 
the neurites that formed were < 150 µm in length and without any directional growth.  It is 
possible that implantation of the scaffold replacing scar tissue may facilitate endogenous 
neural regeneration however, the biocompatibility and sustainability of the gel was not 
investigated.  
3D neural differentiation and outgrowth studies have either been described as an in vitro 
assay for drug toxicity and development studies or as potential conduits to aid endogenous 
CNS regeneration.  Matrigel™ is a commercial gel like scaffold that can be used either to 
coat a 2D substrate or encapsulate cells in a 3D lattice.  The gel comprises of a variety of 
proteins secreted from Engelbreth-Holm-Swarm mouse sarcoma cells and can induce 
neurite differentiation and outgrowth to a greater extent than demonstrated by individual 
ECM proteins such as Collagen [327].  However, again as with other gel based scaffolds 
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control over the composition of the gel and its processing is difficult and not easily applied 
to investigating neurite outgrowth.   
An alternative approach to gel scaffolds is the use of porous membrane that can be 
manipulated either by chemical functionalization of protein coating. The scaffolds are 
much more rigid, however, tend to be easier to process and data more reliable to quantify.  
It was demonstrated by Hayman, M.W et al (2005) [122] that coating a solid polystyrene 
scaffold with a mixture of Laminin and P-D-L proteins could induce neurite outgrowth 
from human stem cell-derived neurons, however, growth into the scaffold was not 
demonstrated and outgrowth was a measure of lateral axon development.  Sectioning of the 
scaffold as was demonstrated in this study may have given a better understanding of the 
3D nature of the neurites that developed. The Alvetex®Scaffold, is highly porous, flexible 
and easy to handle using all processing techniques. Furthermore, due to the 
interconnectivity between pores a true 3D growth of cell tissue can be achieved.  
In this study a 3D model of human neurite outgrowth was developed using ECM coated 
Alvetex®Scaffold and well defined stem cell-derived human neural progenitor aggregates.  
The application of such a model allows for advancing neurobiology in understanding the 
key, early developmental processes that occur during human neurite outgrowth in 3D. 
Furthermore, the model allows for variable protein coating to determine the role of 
different ECM molecules on neurite outgrowth. In addition, co-culture with other cell types 
in possible using our aggregate model due to the sustained aggregate of cell bodies on the 
scaffold surface making individual cell types easier to distinguish.  
As with previous neurite outgrowth models in both 2D and 3D, the use of Laminin and P-
D-L coating was essential to provide a permissive environment for neurite outgrowth as 
has been demonstrated in previous neurite outgrowth studies [102, 234, 322].  It was 
demonstrated in Figure 5-2 no neurites developed into the scaffold without ECM coating. 
The addition of overnight Laminin/ P-D-L coating resulted in a large number of neurites 
developing into the 3D scaffold, leaving cell bodies on the surface. ECM coating of 
Alvetex® resulted in neurites being in contact with Laminin/P-D-L at multiple focal points, 
similar to the ECM in vivo previous studies using similar scaffolds to those used in this 
study suggest that although Laminin was required to induce high levels of neurite 
outgrowth, the addition of P-D-L was necessary to aid cell adhesion [122, 328]. 
Neurites projected through the scaffold, spanning the 200 µm distance and grew on the 
underside. Thicker scaffolds may be necessary to maintain the 3D culture throughout 
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neurite outgrowth; however, this would make quantifying axonal changes much more 
difficult.  Individual neurites can be retrograde traced using viral proteins to determine the 
cell body each developing/regenerating neurite develops from and the gene profile of the 
individual neurite. Overall this section described a proof of concept.  Human neurites could 
be grown in a permissive 3D environment and analysed using immunohistochemistry. This 
model can be used to manipulate the 3D environment to investigate molecular processes 
that occur during spinal cord injury. 
In 2D the use of neural progenitors for investigating neural-matrix interactions and neural 
regeneration have elucidated multiple pathways for potential therapeutics.  The translation 
of these finding is difficult and animal models of spinal cord injury are required to further 
investigate the role of many of these pathways.  Due to ethical and licencing restrictions 
when using animal models and species differences associated with their use developing a 
human physiologically relevant model of the glial scar to investigate some of the key 
molecular events that occur in neurons after traumatic spinal cord injury will become very 
important for translational research in the future. In this thesis the combined use of a 3D 
porous scaffold and human stem cell-derived neural progenitors has provided a 
reproducible in vitro assay to investigate the cell signalling events that may be manipulated 
to overcome CSPG induced neurite inhibition.  Furthermore, due to the composition of the 
scaffold ECM coating to investigate multiple protein-neural interactions is straight forward 
and more routine.    
5.4.2 Modulation of neurite outgrowth in 3D 
 
Studies on the 3D effect of CSPGs on neurite outgrowth have utilised in vivo animal 
models to determine the biological role in CNS regeneration inhibition.  Although these 
systems are important at elucidating the events that occur in neurons post CNS trauma the 
complexity of whole animal model systems means basic biology and signalling events are 
difficult to identify as multiple cell systems are acting.  Compensatory mechanisms, 
immune cell infiltration and angiogenesis are just some of the processes that may cloud the 
basic biology that is occurring shortly after CNS injury or as the scar is more developed. 
Using physiologically relevant 3D model systems of human neurite outgrowth may be a 
necessary bridge between 2D biology and in vivo studies in the future with pressure to 
reduce or move away from animal studies.  As with what was described in Chapter IV, the 
modulation of key molecular signalling pathways during Aggrecan induced neurite 
outgrowth inhibition by synthetic small molecules is a potential therapeutic.  The need for 
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accurate and reproducible models of human neurite outgrowth to investigate these 
pathways is a major challenge in neurobiology.  The lack of human in vivo models and the 
species differences between mouse and human neural development mean that an in vitro 
human model of neurite outgrowth in the CNS is important for accurate predictive 
capability for human clinical trials and in reducing the need for unnecessary animal 
research. Throughout this thesis the characterisation of developing neuronal subtype and 
developmental stage has been a focus since many models do not take developmental stage 
differences into account.  This model of neurite outgrowth can be sustained and functional 
neurites will develop, allowing for more mature neurite outgrowth and regeneration models 
to be developed in the future.  
We have demonstrated that the CSPG-Aggrecan, in a conventional 2D neurite outgrowth 
model inhibits neurite outgrowth, Aggrecan has also been described as an inhibitor of 
neurite regeneration in published literature.  This is the first model to investigate 
synthetically derived human neurite outgrowth into a 3D Aggrecan coated substrate.  
Addition of 50 µg/ml Aggrecan to the coating substrate, which contained the permissive 
proteins Laminin and P-D-L resulted in an almost complete loss of neurite outgrowth from 
the neuroprogenitor aggregate.  Sectioning the scaffold and confocal microscopy revealed 
a much reduced level of outgrowth as would agree with 2D models.  The inhibition of 
neurite outgrowth by Aggrecan was highly potent but did not result in the death of cell 
bodies within the aggregate, making regeneration of neurites feasible.  Specific modulation 
of neurite outgrowth by Aggrecan and its high levels in the glial scar suggest an important 
role for the glycoprotein in neural regeneration.    
It is known that the concentration of Aggrecan, or more precisely the ratio of permissive 
Laminin/P-D-L and Aggrecan protein in the ECM is an important factor that determines if 
neurites will develop [329].  Since a concentration dependent regulation of neurite 
outgrowth by Aggrecan was assessed in Chapter IV it would be necessary to determine if 
there is any difference in the potency of Aggrecan in 3D.  It may be that due to the 3D 
coating a much lower concentration of Aggrecan would induce a significant loss of 
outgrowth. Kofron, C.M et al (2009) [330] performed a study to determine the choice 
characteristics of neurons grown at a 2D/3D interface.  They determined that neurites 
would develop on a Laminin substrate in 2D as opposed to developing in a more complex 
3D Collagen I matrix. However, if neurites were presented with the inhibitory GAG motif 
by CSPG coating, the neurites would develop more into the 3D collagen scaffold. In the 
model in this Chapter a mixture of Laminin/P-D-L and the inhibitory CSPG Aggrecan 
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demonstrated growth in 2D along the top surface of the scaffold as opposed to in the 3D 
environment.  This may suggest that the 2D environment on top of the scaffold provides 
less inhibitory cues to neurite outgrowth than the 3D expression of the same molecules.  
In this section of Chapter V the 3D manipulation of cell signalling in neurons inhibited by 
Aggrecan were investigated.  The molecular events targeted and inhibited were – ROCK 
activation, PTPσ activation, GAG-receptor binding, furthermore, enhancing the RARβ2 
was also investigated as a potential modulator of neurite outgrowth. Below is a discussion 
of each individual pathway and how it affects neurite outgrowth in an inhibitory ECM 
environment. 
Y-27632 (ROCK inhibition) 
Activation of ROCK in neurons is related to neurite retraction and death of the neuron.  
Inhibition of ROCK provides neural protection in normally toxic environment [165]. The 
ROCK effector as has been described previously is involved in the transmission of the 
Aggrecan signal resulting in loss of neurite outgrowth. Many studies have investigated in 
2D neurite outgrowth into a normally inhibitory environment with the addition of the 
synthetic ROCK inhibitor Y-27632 [331]. Furthermore, in vitro models of spinal cord 
injury have also demonstrated the protective effect of Y-27632 on neurites at the injury site 
[239]. A 3D in vitro study showed that rat astrocytes could be cultured in a Collage 
scaffold in a relatively physiologically normal state, treatment of these astrocytes with 
TGF β1 resulted in the production of a number of proteins and small molecules from the 
astrocytes into the 3D matrix, representing reactive gliosis.  The increased production 
consisted of CSPG, high GFAP levels, Vimentin and IL-6. This is the only other study 
where CSPGs are used in a 3D in vitro model but the study does not assess the effects of 
the ECM on neurite outgrowth [332].   
In this Chapter the 3D coating of a scaffold with Aggrecan resulted in an inhibitory 
environment for neurite outgrowth. As has been described in 2D both in this thesis and 
multiple published models treatment with Y-27632 at 15 µM enhanced human neurite 
outgrowth overcoming the inhibitory environment.  This is the first study to describe an in 
vitro human model of neurite outgrowth in an inhibitory 3D environment by Y-27632.  
RARβ2 activation 
The activation of RARβ2 has been shown to enhance neurite outgrowth in a number of 
neurite outgrowth models including rat DRG, cerebellar neurons, PC12 [238]and mouse in 
vivo models [252].  Some evidence also suggests that activation of RAR β2 is involved in 
newt limb regeneration and innervation. Although, this receptor has been demonstrated to 
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have potential for enhancing neurite outgrowth in an inhibitory environment it has only 
been shown to do so in neurites inhibited by MAG [238] or Nogo and again no in vitro 3D 
models were able to demonstrate the effect of RARβ2 on neurite regeneration.  
In the current study the specific effects of RARβ2 on Aggrecan induced neurite inhibition 
of human CNS stem cell-derived neurons demonstrated the enhancement of neurite 
outgrowth, using the highly potent synthetic small molecule agonist AC261066.   This 
model will be able to provide a screen of highly potent RARβ2 small molecules for 
potential therapeutics in spinal cord injury. 
Protein tyrosine phosphatase IV inhibition 
As has been described previously, Aggrecan acts through a protein tyrosine phosphatase σ 
receptor (PTPσR) on the growth cone of developing neurites [1, 333]. Activation of the 
receptor results in the downstream effects describe earlier, resulting in ROCK activation 
and growth cone collapse [334]. Multiple methods have been shown to inhibit the 
downstream response to PTPσR activation; however, few have focussed on inhibiting 
specifically receptor activation.  One benefit of using inhibitors of more upstream 
modulators of the receptor pathway is the increased ligand specificity, which may reduce 
unwanted side effects in treatment.  
In Chapter IV, PTP IV inhibition was shown to overcome 2D Aggrecan induced neurite 
inhibition. In this Chapter these data were translated into a 3D model which is more 
physiologically relevant.  Again inhibition of this receptor enzyme resulted in enhanced 
neurite outgrowth. Research into highly potent PTP inhibitors that are more specific for 
each receptor subtype may be a potential future therapeutic, however, currently no papers 
use this small molecule in models of spinal cord injury.  
Chondroitinase ABC treatment 
Described so far is the modulation of signalling that occurs in neurites after Aggrecan has 
bound and activated the PTPσR.  Activation of the receptor is via the GAG side chains on 
the CSPGs in the glial scar. In this case of this model the GAG side chains are presented to 
developing neurites by Aggrecan on the surface of the scaffold.  GAG side chains can be 
cleaved by the bacterial enzyme Chondroitinase ABC. 
It is known that by cleaving the GAG side chains from CSPGs such as Aggrecan, 
activation of PTPσR does not occur and neurites are not inhibited.  Furthermore, neurite 
regeneration after inhibition has also been observed in animal models of spinal cord injury, 
indicating the potential for therapeutic application [335].  Studies have suggested that 
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Chondroitinase ABC treatment may only induce a recovery of axonal projections and no 
functional recovery is observed [336], however, more recently functional recovery was 
also demonstrated indicating potentially a neural specific response to Chondroitinase ABC 
treatment [337]. 
In this Chapter the treatment of Aggrecan with Chondroitinase ABC prior to neurite 
outgrowth resulted in a permissive environment for neurite outgrowth and development. 
This confirms many of the in vivo animal studies using human stem cell-derived neural 
progenitors.  Furthermore, the application of this to 3D is further enhances the 
physiological relevance of the assay making its translation to treatments more likely to 
succeed. 
Finally, it may be that a synergistic affect is possible with combinations of each of the 
small molecules investigated here as they target different molecular pathways.  It is 
important to keep in mind the side effects for the whole organism if targeted application is 
not possible. 
5.4.3 3D primary mouse and human neural differentiation  
 
To enhance the physiological relevance of the 3D neurite outgrowth model two primary 
neuronal progenitor cultures were grown on Alvetex® as described in Methods section 
5.2.12-5.2.13.  Primary 3D mouse and human neural culture is important for further 
assessing the effect of 3D differentiation of neural structure and function.   
In this section the 3D culture and differentiation of both mouse and human neural 
progenitors was investigated using Alvetex®Scaffold.  Primary cultures of both progenitors 
were demonstrated to grow and differentiate well in 3D.  Primary mouse cortical neural 
progenitors were differentiated into aggregates of TUJ-1 and GFAP positive cells and 
demonstrate that primary mouse embryonic neural progenitors can be grown in 3D using 
Alvetex® to be used as a 3D in vitro neural differentiation model.  Furthermore, primary 
human neural progenitors derived from the brain mesencephalon which are likely to 
represent dopaminergic neurons, were induced to differentiate on Alvetex®. The 3D human 
cultures formed visible TUJ-1 positive neurites with GFAP positive areas of glial cells.  
These data represent a novel model for investigating neural function of tissue explants 
grown in 3D.  
In addition to immuno-staining of the human neurons grown in 3D an MEA was used to 
measure the firing rate of neurons throughout Alvetex®. The MEA uses multiple electrodes 
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to measure firing from many neurons at once, giving a better representation of the neural 
culture compared to individual neural patch electrophysiology.  It is interesting to note at 
this point that human neural progenitors grown on 2D did not have any action potential 
measurable by MEA (Dr I Smith, Reading University). The action potential from 3D 
differentiated nHNP was measured using MEA and could be inhibited by TTX, 
CNQX/DLAP5 treatment indicating a genuine action potential form the cultures. 
5.4.4 Investigating the effect of Aggrecan on primary neural progenitor differentiation in 
3D 
 
Perineuronal nets (PNs) are coatings or lattices that envelope the somata, dendrites and 
axons of neurons in the CNS and are composed of a hyaluronic back bone containing O-
glycosylated CSPGs [338].   
The structures provide a polyanionic microenvironment and are found located to specific 
subsets of neurons [339].  PNs have been associated with synaptic plasticity, development 
and maintenance [340]; furthermore, they are associated with morphological maintenance 
and neuroprotection in the brain [341].  
Aggrecan is a major component of PNs [342, 343], and is thought to be produced by 
neurons in an activity dependent manner. Furthermore, loss of glial cell growth in a model 
of PN formation demonstrated that out of the other major components of the PNs 
(Brevican, tenascin-R and HAPLN1) only Aggrecan and hyaluronan were produced, and 
condensed at the neural membrane forming the characteristic appearance of PNs.  These 
data demonstrate that Aggrecan alone may have a role in neural development and 
maintenance without other structures in the PN [342]. It is known Aggrecan does not affect 
the axonal conduction of an action potential, unlike the CSPG NG2 [291], suggesting the 
effect demonstrated by MEA in this study is an effect on synaptic transmission.   
To assess the effect of Aggrecan on these cultures, Alvetex® was coated in 10 µg/ml 
Aggrecan.  Immunocytochemical staining revealed that in the mouse cortical cultures there 
was a decrease in the number of neural aggregates that formed, which is likely an effect of 
toxicity, few axons were seen in this culture making it a poor model for neurite outgrowth 
studies.   In addition to coating Alvetex® 10 µg/ml, human neurites were also grown and 
differentiated on Alvetex® coated in a low concentration of Aggrecan- 1 ng/ml.  
Immunocytochemical staining for TUJ-1 revealed good neurite outgrowth in cultures 
coated with 1 ng/ml Aggrecan, however, aggregation and loss of neurite outgrowth was 
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seen in cultures grown on 10 µg/ml Aggrecan, indicating a toxic or compartmentalisation 
effect of Aggrecan at high concentration. 
To investigate the structure/function relationship of Aggrecan coated and uncoated 
scaffolds a MEA was used to measure action potential frequency within the cultures.  Data 
demonstrate that there was a massive decrease in action potential in cultures treated with 1 
ng/ml Aggrecan, even though little/no differences were seen in neurite outgrowth. No 
recordings were measured from scaffolds coated with 10 µg/ml Aggrecan, suggesting the 
cells were dead.  Furthermore, treating control cultures with TTX resulted in a lower firing 
rate than that measured in cultures treated with 1 ng/ml Aggrecan suggesting the neurites 
grown at this concentration of Aggrecan have the potential to fire, however, do not. This 
can be related to the role of Aggrecan in PNs in normal physiology.  
Aggrecan and specifically Brevican have been shown to regulate synaptic transmission and 
potassium channels activation in inhibitory neuronal membranes [344]. Therefore, the 
decrease in action potential observed in this model may demonstrate the role of Aggrecan 
at the synapse in the brain.  Furthermore, CSPG sulfation patterns has been shown to 
regulate axonal transmission by inhibiting the action potential, thus effecting plasticity, 
development and survival of neurons, demonstrating a tight control over CSPG PN content 
and axonal firing [345].  
The low concentration effect of Aggrecan on measurable action potential indicates a 
differential role of the CSPG than inhibition of neurite outgrowth. Understanding these 
concentration dependent differences and how alterations in Aggrecan levels in the PNs can 
affect neural plasticity and neuronal firing will be essential for understanding their effect in 
brain pathologies such as Alzheimer’s disease [341, 346].  
5.4.5 Enhancing physiological relevance: co-culture of human stem cell-derived neurons 
and U118MG astroglioma cell to investigate neurite outgrowth 
 
Co-culture of neurons and glia in 2D is confined to the same physiological restraints as 
mono-culture; the interaction between the two cell types is likely not representative of the 
true in vivo situation. The two cell types can grow over each other and often can create 
carpets of highly uniform closely packed cells that do not truly represent the patterning that 
would be typical of in vivo ECM.  Therefore, the interaction between the two cell types 
will be artificial and not representative physiologically.  Neurons and astroglia are often 
closely associated with each other in vivo and there can be many astroglia to each neuron, 
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the role of astroglia is to support neural maintenance and development. Puschmann, T.B et 
al (2013) [347] demonstrated that the 3D culture of astroglial cells resulted in a more 
physiological morphology than in 2D.  Satpute, R.M et al (2006) [348] demonstrated that 
glioblastoma conditioned media could induce neurite outgrowth from PC12 cells. This may 
not be translated into CNS derived neurons since CNS neurons are not stimulated by NGF 
secretion and hence, inhibition of human neurite outgrowth in this thesis may underline 
species and neural subtype differences in vitro.  
Chan, C.C et al (2007) [155] described that ROCK inhibition by Y-27632 increased the 
reactive gliosis of astrocytes increasing CSPG production and GFAP expression. This was 
demonstrated by immunocytochemistry in Figure 5-21, a low level of CSPG expression by 
U118MG cells was demonstrated and provides an explanation for the inhibition of neurite 
outgrowth in co-culture.  Since CSPG levels are enhanced by Y-27632 treatment it may 
seem counter intuitive that Y-27632 treatment also results in neurite outgrowth through the 
cells.  An explanation for this is although CSPG levels are higher in the ECM, the 
inhibition of ROCK in the neurite is sufficient to overcome any level of PTPσR activation 
and hence neurite can develop.  
5.4.6 Guidance of neurite outgrowth using physical conduits 
 
As described earlier the regeneration of functional synapses from neurites is important for 
ensuring correct innervation of tissue, such as muscle.  Since neurite development is 
dependent on a specific interplay between permissive and inhibitory cues it is likely the 
post-trauma ECM would not correctly guide neurites using these cues and the stimulatory 
proteins in the ECM may not be able to correctly guide neurites to their target tissue. 
The development of aligned scaffolds that act as conduits is one method for enhancing the 
functional regeneration and targeted innervation of tissue in the damaged CNS. Guidance 
molecules act to enhance and develop neurites along tracts of specific direction. In this 
study aligned polystyrene scaffolds were used to assess the guidance of stem cell-derived 
human neural progenitors.  The scaffolds were coated with Laminin and it was 
demonstrated that U118MG co-culture resulted in loss of directional neurite outgrowth.  
Although directional growth was demonstrated the number of neurites and length was 
dependent on the diameter and density of the fibres which was not investigated.   Other 
studies have utilised similar methods and investigated the biomaterial properties that can 
produce optimal outgrowth from cultures.  Aligned outgrowth has been demonstrated by 
hydrogels [118] and electrospun nanotubes [121].  Furthermore, functionalization of the 
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conduits using guidance molecules such as NGF, Poly(lactide-co-glycolide) [349], or 
supportive cell types like Schwann cells can be used to enhance the directional growth of 
neurites.  It is likely that transplants of conduits of this sort will be in combination with 
small molecule modulators of neurite outgrowth, Chondrotinase enzymes and survival 
factors.  
5.5 CONCLUSIONS 
 
This Chapter focussed on the translation of a 2D neurite outgrowth assay into a 3D 
physiologically relevant assay that can be used to screen small molecule compounds that 
overcome CSPG induced neurite inhibition to be used in future therapeutics. 
This study built upon previous data describing the use of hEC stem cells and neurite 
outgrowth.  As described in detail in Chapter 4, the neural-progenitors used in this Chapter 
were produced by differentiating human pluripotent stem cells using the well characterised 
synthetic retinoid EC23.  Having described a well-defined 2D model of neurite outgrowth 
the translation of this model to a 3D substrate may provide more physiologically relevant 
data on neurite outgrowth. Using this mode the interaction between developing stem cell-
derived neurites and the 3D extracellular matrix was described, in particular the ECM of 
the glial scar that forms post-spinal cord injury.   
The project described for the first time a human 3D model of Aggrecan induced neurite 
inhibition using stem cell-derived neurons. Furthermore, the model was used to investigate 
molecular signalling pathways and ligand-receptor interactions between the ECM and 
developing human neurites. Furthermore, primary neural data produced in collaboration 
with Reading University demonstrated a functional inhibition of intact neurites that 
develop in the presence of Aggrecan. These data described a robust and well-defined 
model of human neurite outgrowth for use in investigating the molecular processes that 
inhibit neurite outgrowth in the glial scar. 
In addition to neural-ECM interactions described in 3D, the model also demonstrated the 
cellular interaction between the astroglial cell line U118MG and human stem cell-derived 
neurites, in 3D.  This co-culture model demonstrated loss and recovery of neurite 
outgrowth when neurites developed in 3D in the presence of U118MG.  
Although the assay is unlikely to replace animal studies it may be used to pre-screen 
compounds to reduce the number of animals used.  Due to the human nature of the neurons 
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used it would be deemed more likely that positive drug hits in this system are more likely 
to be physiologically relevant in human CNS injury however, due to the simplicity of the 
assay other interacting factors which are found in the whole animal may not be accounted 
for. Multiple assays investigating individual processes may help elucidate those 
mechanisms which are masked by the complexity of whole animal experimentation. 
This study has described a novel 3D model of neurite outgrowth and used the model to 
investigate known and novel small molecule enhancers of neurite outgrowth in an 
inhibitory environment.  Further use of the model may determine clear differences between 
the 2D and 3D environments and the effect on drug screening assays.  Furthermore, the 
model can be adapted to be used to investigate cellular interactions as a co-culture model. 
FUTURE DIRECTION 
 
 Future work should include: 
 As advancements in our understanding of receptor signalling pathways are 
combined with development of small molecules that regulate these pathways 
moved forward it is necessary to investigate these new molecules in biological 
assays for potential therapeutic application.   An aim for future work using the 3D 
model of human neurite outgrowth should be to investigate other small molecule 
modulators of neurite regeneration to aid the structure/function relationship that 
guides development.   Furthermore, combining modulators of separate parts of the 
pathway (for instance combining the PTP IV inhibitor with Chondroitinase ABC) 
may produce a synergistic response in the developing neurites.  
 
 Gene profiling and protein expression of neurites grown in 2D and 3D under the 
permissive, inhibitory or enhanced neurite outgrowth conditions.  A comparison 
between the neurites that develop in 2D and 3D may elucidate further the 
advantages of 3D neurite outgrowth and demonstrate the neurites that develop 
represent more in vivo like expression profiles 
 
 Complex “reactive astrocyte” derived ECM coated scaffold.  The use ECM directly 
derived from the glial scar, or produced in vitro by reactive astrocytes can be used 
to coat the scaffold and investigate more generally the role of this environment in 
neurite outgrowth.   
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 Primary glial and neural co-culture would enhance the power of the co-culture 
model using these human stem cell-derived neurons.  Other primary cells such as 
schwann and astrocytic cells should also be investigated in co-culture.  
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CHAPTER 6 DISCUSSION 
6.1 INTRODUCTION 
 
This thesis aimed to investigate the small molecule modulation of stem cell differentiation 
using a well described in vitro model of neural development.  The model was used to 
investigate the role of metabolism in the action of small molecules; the concentration 
dependant role of small molecules and the induction and maintenance of developmental 
genes.   
Using technologies described throughout this thesis a novel human neurite outgrowth 
model was developed.  The model was used to investigate the role of inhibitory glial scar 
proteins on neural development.  The studies determined that human neurite outgrowth is 
inhibited by the CSPG – Aggrecan and that inhibition can be overcome by targeting 
specific signalling molecules.  In addition the 2D human neurite outgrowth was translated 
into a 3D model of the glial scar and a more physiologically relevant co-culture model with 
astroglioma. 
The work in this thesis has built upon recent advances in the small molecule control over 
cellular development and 3D culture.  The model described will be used in future research 
to further understand the molecular pathways and small molecule modulators of human 
neural regeneration 
6.1.1Synthetic retinoids and stem cell differentiation 
 
Synthetic retinioids are an attractive approach for specifically regulating the pleotropic 
effects induced by retinoic acid receptors.  As has been discussed in Chapter 1, the nuclear 
retinoic acid receptors (RAR) are composed of a number of subtypes and isotypes.  
Retinoic acid receptors act to induce gene transcription by forming heterodimers with 
members of the retinoid X receptors (RXR).  Combinations of each of the RAR-RXR 
subtypes and isotypes provide the many biologically different effects of retinoic acid 
signalling.  Synthetic retinoids that act as agonists for individual retinoic acid receptor 
subtypes is becoming an important tool in understanding their biological effect.  
Furthermore, analogues of all-trans retinoic acid (ATRA) that are pan-RAR agonists 
demonstrate increased potency and stability which is useful in many biological assays. 
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Since EC23 is a stable pan-RAR agonist, investigating the concentration dependent effect 
of RAR activation using EC23 would provide information as to the role of retinoid acid 
receptor activation and biological outcome.  In this thesis the concentration dependent 
initiation of differentiation was investigated using cell surface and genetic markers.  
Changes in the cell surface glycoproteins SSEA3 and TRA-1-60 were measured using flow 
cytometry on differentiating stem cells, furthermore, gene expression analysis of OCT4 
and NANOG were measured.  Data demonstrated that expression of all stem cell markers 
assessed was decreased upon EC23 and ATRA treatment in a concentration dependent way 
and this correlated with previous studies.  In addition the neural specific markers A2B5 
and PAX6 were increased, indicating neural commitment.   Neural commitment of the stem 
cells was concentration dependent and resulted in neurite formation in a monolayer culture.  
A similar study by Christie, V.B (2008) [95] also demonstrated neural commitment by 
stem cells treated with EC23, however, the study did not investigate the lower limit of 
concentration that will induce neural commitment.  
The synthetic retinoic analogue EC23 was shown to be much more potent than its natural 
counterpart ATRA in a model of neural differentiation and again this agrees with previous 
studies [93-95]. Data from this thesis built upon the reason why EC23 is more potent. It 
was unknown if the increased potency was a result of receptor binding affinity or an effect 
of metabolism.  The increased potency demonstrated by this small molecule was shown to 
be the result of increased stability and resistance to oxidation.   Multiple studies have 
demonstrated that metabolism of ATRA can be inhibited by the small molecule Liarozole 
and results in an increased biological activity [66-68].  Using a novel stem cell-based assay 
to investigate the metabolism of ATRA and EC23 it was shown that EC23 unlike ATRA 
was not metabolised and inhibiting the metabolism of ATRA in our model resulted in a 
more EC23 like potency.  This work was taken further to determine if a single pulse of 
EC23 could induce neural commitment and to what exposure do the cells require to induce 
differentiation.  Data agreed with that in the literature for ATRA, where a pulse effect did 
not induce human embryonal carcinoma differentiation [171].  In contrast to this EC23 was 
capable of inducing stem cell differentiation after just a 1 minute pulse at 1 µM. It is 
unknown if these cells would then go on to form functional neurons as this was not 
investigated, however, data from Tonge, P. et al (2010) [171] suggest that with ATRA at 
least, continued RAR activation for 12 days is required for maximal neural differentiation 
of NTERA2.cl.D1 hEC stem cells.  Investigating the effect of pulse and EC23 
concentration on the subtype identity of human neurons may provide insights into the role 
of RAR activation on neural differentiation. 
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Development of novel retinoic acid analogues required understanding of the 
structure/function relationship in different biological systems.  Previous work from our 
group has demonstrated that small structural modifications in retinoids can have large 
biological effects [89, 90].  The structure activity relationship between the stable synthetic 
retinoid EC23 and its para-isomer EC19 were investigated.  EC19 is a similar structure to 
EC23, however, has much lower biological activity in our human stem cell model and is 
thought to induce less or differential retinoic acid receptor activation.   Previous results 
have suggested the addition of a methyl group to the compound may result in a change in 
biological activity or provide a hook for metabolism of the compound [222].  Results from 
this section demonstrated that methylation of EC23 did not change its biological potency 
or metabolism, however, methylation of EC19 resulted in an enhanced biological activity 
and previously inactive concentrations of EC19 induced neural differentiation in our 
model.  These data suggest that methylation of EC19 provided better RAR binding and 
activation compared to the un-methylated version – underlining the structure/function 
relationship in retinoids. 
6.1.2 Concentration dependent effect of retinoids on cellular development 
 
The role of retinoid concentration and biological effect is an important topic of stem cell 
and developmental research.  There are still many mechanisms for the action of retinoic 
acid on development that are to be elucidated.  It is thought that retinoid signalling 
regulates anterior-posterior patterning of the developing embryo and does so through a 
concentration dependent activation of the four HOX gene clusters A,B,C and D [41, 48, 
279].  HOX genes as were described in Chapter 1 are analogous to genes found in the 
developing drosophila.  Furthermore, mouse models and cellular models have 
demonstrated the regulation of cell identity by HOX genes [21, 188].  It is thought that 
regulation of the HOX code which is the combination of HOX genes that are expressed in a 
specific tissue, can determine neural subtype/positional identity.  Retinoids have been 
associated with the regulation of HOX genes that confer anterior identity and these are at 
the 3’ end of the HOX cluster of genes.  The 3’ genes contain RARE and their expression 
is induced by low concentrations of retinoic acid [23, 350].  Expression of genes associated 
with posterior positional identity are determined by 5’ HOX genes. It is thought that 
regulation of 5’ genes is via a co-linear activation by 3’ HOX genes [41, 48, 50].  
In this study the stable synthetic retinoid EC23 was used to investigate the concentration 
dependent regulation of HOX genes both 3’ and 5’ on the clusters A, B and D.  These data 
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build upon that described by Simeone, A et al (1991) [48] which described the direct 
regulation of HOX genes by retinoic acid in the human embryonal carcinoma stem cell line 
NTERA2.cl.D1.  Using the synthetic retinoid EC23 and a sensitive real-time PCR 
technique to measure relative change in HOX gene expression it was demonstrated that 3’ 
HOX genes are expressed earlier and at lower concentrations of retinoic acid receptor 
activation.  Interestingly regulation of 3’ and 5’ HOX genes was dependent on the 
concentration of EC23, where 5’ genes were expressed earlier at higher retinoid 
concentrations.  In this study the co-linear temporal activation of HOX genes was not 
clearly demonstrated and this may be the result of the late time points used.   Earlier time 
points may show the co-linear relationship between genes on the same cluster.   
Interestingly, some of the HOX genes investigated such as HOXD4 showed an optimal 
induction at concentrations lower than the maximal concentration used indicating a 
negative feedback or saturation type effect on the expression.  
Since retinoid and concentration was demonstrated to regulate multiple cell processes and 
data demonstrated EC23 had a concentration dependent effect on neural commitment, it 
was decided to investigate the role of retinoic acid receptor activation and neural subtype 
identity.  To determine if the concentration of retinoic acid used influenced the neural 
subtype identity of ventral progenitors the sonic hedgehog agonist Purmorphamine, was 
added to the culture.  Purmorphamine was added to induce ventral neural subtype identity 
[77].  Real-time PCR was then used to determine if the ventral neural subtype could be 
influenced by retinoic acid concentration.  The motor neuron marker ISL1 and HB9 and the 
interneuron marker NKX2.2 were assessed at 0.1, 1 and 10 µM EC23 or ATRA in the 
presence of Purmorphamine (from day 6).  These data indicate that retinoic acid 
concentration influenced motor neuron and interneuron identity markers. 
Overall Chapter 3 focussed on investigating retinoic acid induced differentiation by the 
stable synthetic retinoid EC23.  Furthermore, there was a focus on retinoid concentration 
and the mechanism behind the increased potency demonstrated in this model by EC23.  
Subsequent Chapters will use EC23 as a replacement of ATRA in neural differentiation 
protocols.  
6.1.3 Human stem cell-derived neurite outgrowth 
 
There are multiple cell lines that are used to investigate neurite outgrowth in vitro. These 
models usually consist of a neural progenitor that can be induced to form neurites upon 
induction by either permissive extracellular matrix proteins or growth factors.  The process 
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of neurite outgrowth can then be investigated and manipulated to determine both positive 
and negative regulation of the process. 
In Chapter 4 a human model of neurite outgrowth was described, TERA2.cl.SP12 human 
EC cells were differentiated by treatment with the synthetic retinoid analogue EC23, the 
novel analogue AH61 and natural ATRA.  A standard operating produce for differentiating 
and inducing neurite outgrowth is described in Figure 6-1. 
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Standard Operating Procedure (SOP) for inducing neurite outgrowth from 
aggregates TERA2.cl.SP12. 
Prior to starting the differentiation procedure ensure: 
 Good stocks of untreated 90 mm Petri Dishes (Fisher Scientific FB51504) 
 At least 200 µl of 0.1 mM EC23(Reinnervate) in molecular biology grade DMSO 
(Sigma Aldrich D8418) 
 1 x 500 ml bottle of DMEM (Lonza BE12-614F) containing 10 % FBS(Sigma 
Aldrich), 5 mM L-glutamine (Lonza BE17-605F) and penicillin/streptomycin 
(Lonza DE17 602F) (DMEMFGP) 
 Access to a class I laminar flow  microbiological safety cabinet 
 0.25 % trypsin/2 mM EDTA (Sigma Aldrich T4049) 
 
To begin the differentiation procedure a single cell suspension of TERA2.cl.SP12 EC cells 
is needed.  A single cell suspension was achieved as described in Chapter 2. Cells were 
counted using a haemocytometer as described in Chapter 2. 
 
For differentiation of cells as aggregate follow the steps blow: 
9. Add 1.5 x 106 TERA2.cl.SP12 EC cells to 20 ml DMEMFGP and leave overnight 
to initiate cell aggregation 
10. After 24 hours aggregation add 20 µl of a 0.1 mM EC23 stock directly to the media 
and gently swirl  
11. After 4 days treatment with a final concentration of 0.1 µM EC23 place the media 
containing aggregates into a 50 ml Falcon tube for 15 minutes allowing the 
aggregates to settle – this must be done in a sterile environment 
12. Using an aspirator, supernatant leaving the pellet of aggregates in the bottom of the 
Falcon tube.  
13. Add 20 ml of DMEMFGP and 20 µl of 0.1 mM EC23.   
14. Gently swirl and place in to a fresh 90 mm untreated bacteriological Petri dish 
15. Repeat steps 3-7 every 3-4 days or when required 
16. After 21 days aggregates are differentiated and capable of forming neurites 
 
 
Figure 6-1 Standard Operating Procedure (SOP) for inducing neurite outgrowth from aggregates 
TERA2.cl.SP12. 
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Previous studies have demonstrated neural differentiation and neurite outgrowth from 
aggregates of human EC cells [111, 270].  The cells were differentiated using retinoic acid 
and neurite outgrowth induced on a Laminin/P-D-L substrate.   This model provided a 
good source of human neurites for investigating neurite outgrowth.  In this section it was 
investigated if replacing ATRA with synthetic retinoid analogues that were more stable 
and potent would influence neurite outgrowth.  Both concentration and temporal 
differentiation was demonstrated to alter the neurite outgrowth potential of progenitors on 
a permissive Laminin/P-D-L substrate.   Differentiating hEC cells with retinoic acid for 14 
days was shown to induce neurite differentiation and neurite outgrowth [85, 111, 351].  
The data in this thesis suggest that increasing the differentiation length to 21 days and 
using highly stable synthetic analogues of ATRA can enhance neurite length and number.   
The aggregate maintained its integrity after 21 days differentiation and made quantification 
of neurite outgrowth reliable and reproducible.  
6.1.4 Spinal cord injury and the glial scar 
 
Traumatic spinal cord injury results in loss of nerve tissue and loss of function.  The 
damage causes localised death of neurons, however, the neurite begin to regenerate 
indicating their potential [129].  Inhibition of neurite regeneration and functional recovery 
as would be seen in the peripheral nervous system is inhibited by the glial scar that forms 
in the injured CNS [324, 352].  After traumatic spinal cord injury a number of activated 
cells within the developing scar begin to produce extracellular matrix proteins [134, 161].  
The proteins that are produced include permissive ECM such as Laminin, Fibronectin and 
Collagen; however, access to these molecules by neurite receptors is hampered by the 
presence of other ECM such as the chondroitin sulphate proteoglycans (CSPG). CSPGs act 
to form a mesh of fibres with the GFAP positive filaments of reactive astrocytes, this mesh 
results in neurites being unable to access growth promoting molecules and permissive 
ECM proteins [132]. Furthermore, receptor activation by CSPGs causes growth cone 
collapse and neurite retraction in regenerating neurites via a rho associated protein kinase 
(ROCK) and collapsing response mediator protein (CRMP) mechanism.  
6.1.5 Aggrecan and the development of a human model of the glial scar 
 
The CSPG Aggrecan is found in the CNS and acts in a normal physiological role to 
modulate neural plasticity and development [291, 353]. Aggrecan is used to model the 
effect of CSPGs on neurite regeneration and neurite outgrowth [1, 160, 314].  Aggrecan 
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contains many of the chondroitin sulphate glycosaminoglycan chains attached to a protein 
back bone making it a potent inhibitor of receptor mediated neurite outgrowth inhibition 
[2].   
The receptors responsible for inducing growth cone collapse, neurite retraction and 
ultimately loss of neural development/regeneration are so far known to be two protein 
tyrosine phosphatase receptors: LAR and PTPσ [1, 150]. In this study the mRNA of both 
of these receptors were shown to be expressed in the developing neural progenitors. 
Furthermore, other receptors and modulators of neurite outgrowth were shown to be 
expressed including NGFβ, NGFβR and RARβ2/4.  The expression of these receptors is 
implicated in neural development of the CNS [354, 355], in addition RARβ2 has been 
demonstrated to have a role in neural differentiation and regeneration making it an 
important target for regenerative therapy [238]. Although expression of NGFβR mRNA 
was demonstrated during differentiation only low levels of its ligand NGFβ mRNA was 
detected.  It is also important to note that there is a link between NGFβ signalling and 
RARβ2 activity [109].  
Gene expression data indicated that the neural progenitor aggregates have up-regulated 
HOXC4 expression and low levels of OTX2 mRNA indicating they are of likely of 
posterior CNS origin [196].  Therefore this model of neurite outgrowth was thought to be a 
promising model to investigate the effect of Aggrecan mediated human neurite inhibition 
and enhancement via receptor modulation. 
As demonstrated in other studies, in this model Aggrecan induced inhibition of neurite 
outgrowth in a concentration dependent manner.  Furthermore, this could be overcome 
through the inhibition of ROCK by Y-27632 [98, 159, 160], making this a good model for 
investigating human neural interactions with Aggrecan in conventional 2D.  Enhancing 
neurite outgrowth on Aggrecan using small molecules may provide knowledge on the 
pathways involved in inhibition or provide novel treatment strategies for overcoming 
inhibition.   
Multiple pathways have been associated with enhancing neurite outgrowth in an inhibitory 
environment or inducing regeneration in damaged CNS neurons. In this thesis a selection 
of highly potent small molecule modulators of these pathways were investigated for their 
ability to enhance human neurite outgrowth on an inhibitory Aggrecan substrate. Data 
demonstrated that as published [4, 238], an agonist of the RARβ2 receptor – AC261066 
was able to induce partial recovery of neurite outgrowth in this model.  Other small 
300 
 
 
molecule modulators i.e. CHIR 99021 a GSK3β pathway inhibitor and XAV 939 a GSK3β 
pathway agonist were shown to influence neurite outgrowth. CHIR 99021 inhibited neurite 
outgrowth on a permissive substrate and XAV 939 enhanced neurite outgrowth on an 
inhibitory substrate, these data agree with previous studies on neurite outgrowth regulation 
by this pathway however, demonstrate this in a defined human model of neurite outgrowth 
[176, 264].    
As described earlier Aggrecan induces neurite inhibition through protein tyrosine 
phosphatase receptors.  Directly targeting the activation of this receptor was investigated as 
a method of overcoming inhibition of neurite outgrowth on an Aggrecan substrate.  The 
bacterial enzyme Chondroitinase ABC is known to cleave the chondroitin sulphate 
glycosaminoglycan (GAG) side chain from Aggrecan [144, 161].  The GAG side chain is 
the major ligand for the PTPσ and LAR receptors.  In this study as has been demonstrated 
by published data, pre-treatment of Aggrecan with Chondroitinase ABC resulted in a more 
permissive substrate for neurite outgrowth in our human model. The use of this enzyme as 
a regenerative therapy is beginning to be realised and its effect on human neurite 
regeneration is an important piece of evidence to suggest its use will be beneficial [293].  
Finally a novel method of inhibiting activation of the PTPσ receptor was investigated.  The 
small molecule inhibitor PTP IV was shown to partially overcome neurite inhibition by 
Aggrecan, its partial effect may be due to it not inhibiting the LAR receptor which would 
still be activated and inhibit outgrowth.  Combinations of treatments will be the best 
approach to ensure correct regeneration of neurites in the injured spinal cord.  
A method to determine the effect of the human astroglioma cell line - U118MG on human 
neurite outgrowth and develop a model for investigating neural-glial co-culture was 
demonstrated.  Data showed an inhibition of neurite outgrowth by the presence of these 
cells and this was overcome by ROCK inhibition which was likely a receptor mediated 
response.  Previous studies have demonstrated the presence of CSPGs on astroglioma cells 
and it is known that brain astrocytes express some of these glycoproteins [295].  In this 
study immunocytochemical staining for Brevican was demonstrated by U118MG 
furthermore, mRNA expression of Brevican was detected suggesting this CSPG at least in 
part regulates the response of the developing neurites to U118MG cells.  
Translating conventional 2D neurite outgrowth into 3D 
Data from this Chapter built upon the use of small molecules to aid stem cell 
differentiation and investigated the ability of synthetic molecules to enhance neurite 
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outgrowth in conventional 2D.  Although this model was easy to use its physiological 
relevance is hampered by the 2D environment experienced by the neurites. Neurons 
experience a 3D extracellular matrix environment during development and regeneration; 
translating the 2D model of neurite outgrowth and Aggrecan induced inhibition was the 
primary aim of the next part of this study.  Chapter 5 investigated the interaction between 
human developing neurites and the 3D extracellular matrix, using the porous polymer 
scaffold Alvetex®. 
Recent studies have described the 3D neurite outgrowth potential of a number of model 
systems including DRG, CGN, PC12 and differentiated hEC stem cells (see Chapter 1).  
Neurite outgrowth can be directed using aligned scaffolds or enhanced using functionalised 
material [349, 356]; furthermore, more 3D studies are investigating the in vitro drug 
discovery potential of 3D models,  making the models more physiologically relevant by 
co-culturing with relevant cell mediators of disease processes [324, 332].  
This thesis demonstrated the 3D neurite outgrowth potential of human stem cell-derived 
neurons.  As described previously the TERA2.cl.SP12 EC cells were differentiated using a 
defined protocol including the synthetic retinoid EC23.  Neurite outgrowth into the 
scaffold was imaged in transverse sections; furthermore, confocal microscopy revealed 
aggregates on the top elevation of the scaffold and projecting neurites on the bottom 
elevation.  Combining permissive ECM proteins with 3D scaffolds has been demonstrated 
previously to promote aggregate adherence and neurite outgrowth similar to this study 
[122].  Manipulating the 3D ECM to investigate other processes such as Aggrecan induced 
inhibition was next investigated.  Aggrecan induced a loss of neurite outgrowth in 3D from 
stem cell-derived neurites.  Fewer neurites were seen on the bottom elevation and little or 
no outgrowth was imaged in transverse sections of the scaffold.  It is important to note that 
many aggregates were lost from the top elevation and this is likely due to a decrease in the 
number of ligands for both Laminin and P-D-L.  Since it is know that P-D-L promotes cell 
adhesion increasing the concentration of this protein may facilitate retention of the 
aggregate without affecting the inhibitory effect of Aggrecan on neurite outgrowth [122].      
Inhibition of human neurite outgrowth in 3D by Aggrecan has not been demonstrated 
previously, furthermore, due to the use of stem cells and EC23 to produce neural 
progenitors this model is ideal to be used as a more physiologically relevant system for 
investigating drugs or small molecules that can overcome CSPG induced neurite inhibition.  
As described previously in conventional 2D, enhancing neurite outgrowth was achieved by 
ROCK inhibition and the RARβ2 agonist AC261066.  The effects of ROCK inhibition and 
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RARβ2 modulation has not been shown in any 3D model of CSPG induced neurite 
inhibition.  Furthermore, this study uses human stem cell-derived neuroprogenitors making 
the 3D model physiologically relevant and useful for drug screening.  
The model also confirmed in 3D the observation that in 2D PTP IV inhibition can enhance 
neurite outgrowth in the inhibitory Aggrecan environment. Small molecule inhibitors of 
protein tyrosine phosphatase (PTP) are an emerging treatment for many diseases.  
Specificity of the small molecules in inhibiting the PTP receptor subtypes is going to be 
key in their therapeutic activity [357].  This section used a commercially available PTPσ 
receptor inhibitor and showed partial neurite outgrowth into a 3D Aggrecan ECM 
environment.  Partial recovery is likely due to the activity of LAR and the low potency and 
poor subtype selectivity of the small molecule PTP IV inhibitor.  
For consistency and to demonstrate the application of this model for investigating methods 
of overcoming neurite outgrowth inhibition by glial scar ECM the Aggrecan coated 
scaffold was pre-treated with the enzyme Chondroitinase ABC.  Pre-treatment for 1 hour at 
37 °C resulted in partial recovery of neurite outgrowth in 3D.   Staining the scaffold for 
chondroitin sulphate GAG side chains before and after Chondrotinase pre-treatment 
demonstrated aggregation of immune-positive staining after Chondroitinase treatment.  
This is likely an effect of the scaffold therefore, increasing the washing procedures may 
enhance recovery of outgrowth by removing the aggregates of GAG side chains.  In vivo 
GAG side chains are likely to be removed by vasculature and likely regulate other 
processes including inflammation and angiogenesis [183].  
This 3D modulation of human neurite outgrowth is a novel method for drug discovery and 
in the future will provide insights into the specific effects of ECM proteins in different 
disease states.  It is important to understand that there are limitations to this method, 
primarily its lack of complexity.  Molecules that regulate neurite outgrowth in vitro may 
not do so in the complex environment of whole system animal models.  However, both 
systems have advantages and should be used in combination to reduce wastage and 
develop key small molecule modulators of neural regeneration.  
To investigate the regulation of primary neurite outgrowth in 3D by Aggrecan mouse 
primary cerebellar cultures and primary human brain cortex neural progenitor cells were 
differentiated in the presence of Aggrecan coated Alvetex®.  In the brain Aggrecan makes 
up specialised ECM structures known as peri-neuronal nets (PNN) [353].  PNNs surround 
synapses and dendritic processes and are implicated in synaptic plasticity and development 
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[358] and alterations in Aggrecan in these structures are associated with Alzheimer’s 
disease [341].  This part of the study demonstrated good growth of both primary mouse 
and primary human neural progenitors, however, the coating the scaffold with a high 
concentration of Aggrecan resulted in a toxic like effect in the mouse cultures and caused 
aggregate like structures to form in the human neural progenitors.  Interestingly a low 
concentration of Aggrecan coating the scaffold did not induce aggregation of human neural 
progenitors; however, electrical signals measured via MEA at Reading University showed 
a complete loss of activity.  These data suggest that Aggrecan alone inhibits the electrical 
activity of human neurites without any obvious structural effect on neurite outgrowth.  
Although it is possible to enhance neurite outgrowth through the glial scar, as we 
understand the environment which the neurites must regenerate it becomes apparent that 
functional recovery and synapse formation will be more difficult to achieve.   Guiding 
neurite regeneration and outgrowth through the scar and to re-connect the complete spinal 
cord will require a more engineering type approach.  Nerve conduits are capable of 
directing neurite outgrowth in a particular polarity and direction.  Methods for directing 
neurite outgrowth in include:  differential ECM coating [349], micro patterning [359] or 
growth factor gradients [123].   
Human neurite guidance and astroglioma co-culture 
To investigate neurite guidance of our stem cell-derived neurons, aligned poly(styrene) 
fibres were produced using electro-spinning.  The fibres were hydrophobic and so would 
not allow for cellular adherence or promote neurite outgrowth.  An ethanol wetting 
procedure was used to make the scaffold hydrophilic and aid the binding or ECM proteins.  
The scaffolds were coated with the permissive Laminin and P-D-L proteins and induced 
neurite outgrowth along the fibres.  This model can be adapted to investigate modulation of 
polarised neurite outgrowth.  Furthermore, it was shown that U118MG co-culture resulted 
in loss of directed neurite outgrowth providing a human model to investigate the 
interaction between the two cell types and neurite guidance.  
To further investigate neural-glial co-culture the 2D assay combining U118MG and human 
stem cell-derived neurons was translated into 3D.  This produced a more physiologically 
relevant system for investigating the interactions between these cell types. U118MG cells 
filled the Laminin/P-D-L coated scaffold and the differentiated stem cell aggregates 
adhered securely to the top elevation.  Both cell populations remained separate as the 
aggregate did not migrate into the scaffold making assessment of neurite outgrowth easier.  
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In the presence of U118MG, as in 2D neurite outgrowth was inhibited and this could be 
overcome by the ROCK inhibitor Y-27632. Treating the co-cultures with Y-27632 resulted 
in enhancement of neurite outgrowth and recovery in the 3D co-culture model.  Staining 
for a pan-CSPG epitope revealed large amounts of positive immunostaining within the 
scaffold, furthermore, staining was enhanced by Y-27632.  This effect has been published 
previously in astrocytes [155] and suggests that U118MG cells in this model may be a 
potential model of reactive astrocytes in the glial scar. Further studies to determine the 
ECM produced by U118MG in 3D may demonstrate more similarities between the two cell 
types.  
6.1.6 Conclusion 
 
In conclusion this thesis has described the genetic and phenotypical effects of synthetic 
retinoid induced neural differentiation and described the mechanism behind the increased 
potency of EC23. Bringing together the known stability and potency of synthetic small 
molecules a highly neurogenic model of neurite outgrowth was developed in conventional 
2D.  This model was then used as a model of the glial scar, by Aggrecan induced neurite 
inhibition.  Furthermore, the role of small molecule signalling and enzymatic degradation 
of CSPGs in enhancing neurite outgrowth was investigated and provided evidence towards 
the use of small molecules modulators for neural regeneration.  Finally, translation of the 
2D glial scar model into 3D model was achieved and used to investigating recovery of 
neurite outgrowth, directed neurite outgrowth and neural-glial co-culture in vitro.  
The work in this thesis have set a good foundation for investigating 3D human neurite 
regeneration in vitro using a potent and reproducible method of human neural 
differentiation and combining this method with enabling Alvetex®Scaffold technology. 
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6.1.7 Future work 
 
 As advancements in our understanding of receptor signalling pathways are 
combined with development of small molecules that regulate these pathways 
moved forward it is necessary to investigate these new molecules in biological 
assays for potential therapeutic application.   An aim for future work using the 3D 
model of human neurite outgrowth should be to investigate other small molecule 
modulators of neurite regeneration to aid the structure/function relationship that 
guides development.   Furthermore, combining modulators of separate parts of the 
pathway (for instance combining the PTP IV inhibitor with Chondroitinase ABC) 
may produce a synergistic response and further enhance neurite outgrowth.  
 
 
 Primary glial and neural co-culture would enhance the power of the co-culture 
model using these human stem cell-derived neurons.  Other primary cells such as 
Schwann and astrocytic cells should also be investigated in co-culture also.  It 
would also be interesting to develop a reactive astrocyte like model using TGFβ 
signalling to investigate the process in a 3D system. 
 
 
 Gene profiling and protein expression of neurites grown in 2D and 3D under the 
permissive, inhibitory or enhanced neurite outgrowth conditions.  A comparison 
between the neurites that develop in 2D and 3D may elucidate further the 
advantages of 3D neurite outgrowth and demonstrate the neurites that develop 
represent more in vivo like expression profiles. 
 
 Other mediators of the inhibitory extracellular matrix of the glial scar should be 
investigated.  Myelin associated glycoprotein (MAG) which has been demonstrated 
to inhibit neurite outgrowth and regeneration binds a well described receptor 
NOGO-66.  Targeting downstream signalling of this receptor is an important target 
for regenerative therapies.  
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